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The CC-1065 and duocarmycin family of compounds are ultrapotent 
antitumour antibiotics which demonstrate activity in the picomolar range. 
These agents exert their biological effect through a sequence selective 
alkylation at the N3 position of adenine resulting in apoptosis. Despite the 
potential of this family to exert themselves as successful chemotherapeutic 
agents, a lack of clinical success has been observed for these compounds. 
This has been attributed to a lack of selectivity resulting in off-target side 
effects and toxicity. For this reason, research now focuses on ways in which 
these alkylating agents could realise their potential using tumour specific, 
targeted delivery strategies.  
Herein, we investigate the use of a duocarmycin SA analogue, functionalised 
for solid phase synthesis, in the design of conjugates for targeted delivery to 
cancerous tissue via the Thomsen-Friedenreich antigen (T-antigen). This 
antigen is overexpressed in 90% of primary human carcinomas, yet is cryptic 
in healthy cells, therefore presenting itself as an ideal moiety for the delivery 
of duocarmycin agents to cancerous tissue.  
The research presented in this thesis will begin with detailing the synthesis of 
the Fmoc-duocarmycin SA analogue along with attempted modifications to 
the synthetic route to try and achieve greater efficiency. Additionally, this 
chapter will detail investigations into alternative protecting group removal 
strategies to improve the effectiveness of this analogues use in solid phase 
synthesis. The chapters subsequent to this will detail the design, synthesis 
and biological evaluation of a series of duocarmycin-based conjugates for 
targeted delivery to the T-antigen. These conjugates involve the use of T-
antigen specific lectins and peptides. Furthermore, the development of a gold 
nanoparticle delivery system involving duocarmycin and a T-antigen specific 
lectin will be detailed. The investigations presented herein provide scope for 
future investigations into the design of clinically successful duocarmycin-





First of all I would like to thank my supervisors, Prof. Mark Searcey and Prof. 
David Russell for all their continued support and advice throughout my PhD 
and also for the opportunity in providing work for such an interesting subject 
area. The ever present ‘anything exciting happened?’ question from Mark has 
always kept me alert and striving for success even if my face would say 
otherwise! 
I would also like to thank my fellow lab members for their advice over the 
past 4 years. A special thanks must go to Dr Andrew Beekman, Dr Ryan 
Tinson, Dr Marco Commineti, Dr Maria Marin and Lučka Bibič who have 
been a continuous support network during my studies. The advice and 
comments (often hilarious and gif-based *cough Lucka cough*) have been 
invaluable for completing this thesis. Additionally, my PhD would not have 
been so fun without a good group of friends who have played a role in 
keeping me sane over the years. I am sure these guys know who they are! 
Without you (and the drinks), this journey would certainly not have been so 
smooth and fun! 
Of course, the people outside of the lab have played as big a role as those 
within the lab. For this, I would like to thank my family and friends who have 
always supported my studies throughout my life and I am sure will continue 
to do so into the future.  
Finally, a special thanks must go to my partner, Nat. You have been with me 
throughout the many highs and lows and always provided a place to allow me 
to ‘switch off’ from science when that was what I needed the most. Your 
constant belief and positivity have been invaluable, especially when I lacked 
belief in myself. I must also thank you for the many hours spent listening to 
my presentations about ‘gold nanoparticles’ and ‘Fmoc/Boc deprotections’. 
Your helpful ‘What are you chattin’ about?’ comments have been a constant 
source of feedback throughout. Should you not take anything else away from 





Abstract .......................................................................................................... 1 
Acknowledgements ........................................................................................ 2 
Contents ......................................................................................................... 3 
List of Figures: ............................................................................................... 7 
List of Schemes: ............................................................................................ 11 
List of Tables: ............................................................................................... 15 
Abbreviations: .............................................................................................. 17 
 - Introduction .................................................................................. 21 Chapter 1
1.1 The War on Cancer.............................................................................. 22 
1.1.1 Chemotherapy – A History ........................................................... 23 
1.1.2 Targeted Chemotherapy ............................................................... 26 
1.2 Antibody Drug Conjugates ................................................................. 28 
1.2.1 First Generation Antibody-Drug Conjugates ............................... 29 
1.2.2 Improved ADC Development ...................................................... 30 
1.2.3 Current Antibody-Drug Conjugates ............................................ 35 
1.3 CC-1065 and the Duocarmycin Family .............................................. 38 
1.3.1 Isolation ........................................................................................ 39 
1.3.2 Biological Activity ........................................................................40 
1.3.3 Clinical Results of the Duocarmycins .......................................... 44 
1.3.4 Alkylating Unit Structures ........................................................... 44 
1.3.5 General Prodrug Strategies .......................................................... 46 
1.3.6 Duocarmycin in ADCs ................................................................. 51 
1.4 Aberrant Glycosylation Patterns in Cancer ........................................ 57 
1.4.1 Targeting Cancer Associated Glycans .......................................... 58 
1.5 Thesis Outline ..................................................................................... 61 
 - Optimisation of the Synthesis of Fmoc-DSA-OH and Chapter 2
Investigations into Alternative Approaches to Benzyl Deprotection ............. 63 
2.1 Introduction ........................................................................................ 64 
2.1.1 Synthetic Routes to Duocarmycin SA and other Members of the 
Family ................................................................................................... 64 
2.2 Aims of the Research Reported in this Chapter ................................ 71 
2.3 Results and Discussion ...................................................................... 72 
2.3.1 Synthesis of Benzyl Protected seco-DSA Substituted for Solid 
Phase Peptide Synthesis ....................................................................... 72 
4 
 
2.3.2 Synthesis of Binding subunit analogue substituted for the solid 
phase ..................................................................................................... 86 
2.3.3 Utilisation of Fmoc-DSA-OH in Solid Phase Peptide Synthesis.
 .............................................................................................................. 89 
2.3.4 Benzyl Deprotection of DSA Containing Peptides ...................... 92 
2.3.5 The use of p-methoxybenzyl as an Alternative Protecting Group 
Strategy for Fmoc-DSA-OH ................................................................. 95 
2.3.6 On Resin Benzyl Deprotection Using Boron Tribromide ......... 102 
2.4 Conclusions ...................................................................................... 104 
2.5 Experimental .................................................................................... 106 
2.5.1 General Procedures .................................................................... 106 
2.5.2 Synthesis of Fmoc-DSA-OH (2.10) ........................................... 107 
2.5.3 Synthesis of Fmoc Substituted Binding Subunit (2.14) ............. 114 
2.5.4 Synthesis of PMB Protected Fmoc-DSA-OH ............................. 116 
2.5.5 Synthesis of PCIB Protected Fmoc-DSA-OH (2.21) ................. 123 
2.5.6 General Benzyl Deprotection Conditions .................................. 131 
 -Investigations into the Conjugation of DSA-based Analogues to Chapter 3
Jacalin for Targeted Delivery to the Thomsen-Friedenreich Antigen .......... 133 
3.1 Introduction ...................................................................................... 134 
3.1.1 The Thomsen-Friedenreich Antigen .......................................... 134 
3.1.2 Jacalin – a T-antigen Selective Lectin ....................................... 136 
3.2 Aims of the Research in this Chapter .............................................. 139 
3.3 Results and Discussion .................................................................... 139 
3.3.1 Mass Spectrometry Analysis of Jacalin ..................................... 139 
3.3.2 EDC/NHS Chemistry ................................................................ 144 
3.3.3 Maleimide/Thiol Conjugation Strategy .................................... 158 
3.3.4 Alkyne-Azide Cycloaddition Click Chemistry ........................... 169 
3.4 Conclusion ........................................................................................ 174 
3.5 Experimental .................................................................................... 175 
3.5.1 General Procedures .................................................................... 175 
3.5.2 Solid Phase Chemistry ................................................................ 177 
3.5.3 Solution Phase Chemistry ......................................................... 184 
3.5.4 Protein bioconjugations ............................................................ 187 
 –The Design and Synthesis of Peptide-duocarmycin Conjugates for Chapter 4
Targeted Delivery to the Thomsen-Friedenreich Antigen ............................ 189 
4.1 Introduction ...................................................................................... 190 
5 
 
4.1.1 Peptides as Targeting Molecules. ............................................... 190 
4.1.2 Peptide-Drug Conjugates ............................................................ 191 
4.2 Aims of the Research in this Chapter .............................................. 193 
4.3 Results and Discussion .................................................................... 194 
4.3.1 Design and Synthesis of Duocarmycin Based PDCs. ................ 194 
4.3.2 Biological Evaluation of T-antigen Targeting PDCs ................ 208 
4.4 Conclusions ...................................................................................... 212 
4.5 Experimental .................................................................................... 213 
4.5.1 General Procedures .................................................................... 213 
4.5.2 Synthesis .................................................................................... 215 
4.5.3 Biological Assays ....................................................................... 222 
 - The Design and Synthesis of Targeted Gold Nanoparticles Chapter 5
Functionalised with a Duocarmycin SA-based Analogue. ............................ 224 
5.1 Introduction ...................................................................................... 225 
5.1.1 Nanoparticles as Drug Delivery Platforms ................................ 225 
5.1.2 Gold Nanoparticles as Drug Delivery Platforms ....................... 226 
5.2 Aims of the Research in this Chapter .............................................. 229 
5.3 Results and Discussion .................................................................... 229 
5.3.1 Initial Design of the Nanoparticle Systems ............................... 229 
5.3.2 Synthesis of 16 nm AuNP Functionalised with PEG, a 
Duocarmycin Peptide and Jacalin ..................................................... 232 
5.3.3 Synthesis of 4 nm AuNP Functionalised with a Mixed Monolayer 
of PEG, a Duocarmycin Peptide and Jacalin ..................................... 236 
5.3.4 Coupling of a DSA Peptide to PEG and Subsequent AuNP 
Conjugate Assembly .......................................................................... 240 
5.3.5 Synthesis of a Duocarmycin-AuNP Construct Containing a 
Cleavable Sequence ............................................................................ 244 
5.3.6 Biological Evaluation of AuNP-PEG-DSA-Jac Conjugates ....... 247 
5.4 Conclusions ...................................................................................... 250 
5.5 Experimental .................................................................................... 252 
5.5.1 General Procedures .................................................................... 252 
5.5.2 AuNP and Peptide Synthesis ..................................................... 253 
5.5.3 Biological Assays ........................................................................ 264 
 - Future Work ............................................................................... 266 Chapter 6
6.1 Fmoc-DSA-OH synthesis ................................................................. 267 
6.2 Duocarmycin Conjugation to Jacalin ..............................................268 
6 
 
6.3 Duocarmycin-peptide conjugates .................................................... 269 
6.4 Duocarmycin based Gold Nanoparticles ......................................... 271 





List of Figures: 
Figure 1.1: demonstration of the difficult journey from the synthesis of lead 
compounds through to commercialisation. This pathway is of particular issue 
in the development of cancer related treatments. .......................................... 22 
Figure 1.2: structures of Chlorambucil and Cyclophosphamide. ................... 24 
Figure 1.3: molecular structures, and growth inhibition data of some of the 
most potent cytotoxic agents. Average (av.) of IC50 values reported for a 
variable number of human cancer cell lines (in brackets).15, 16, 17, 18 ............... 25 
Figure 1.4: schematic representation of the mechanism of drug delivery 
mediated by ADCs.31 ........................................................................................ 29 
Figure 1.5: example of a first generation antibody-drug conjugate. ............... 30 
Figure 1.6: structures of Maytesin and Calcheamicin – commonly employed 
warheads in antibody-drug conjugates. .......................................................... 31 
Figure 1.7: schematic representation of the structure of an antibody. The red 
section depicts the variable region whilst blue depicts the constant region.62
.......................................................................................................................... 34 
Figure 1.8: schematic demonstrating the progression of antibody drug 
conjugates from first generation through to third and also the effect this has 
had on the therapeutic window of ADCs. ........................................................ 36 
Figure 1.9: structures of CC-1065, duocarmycin A, SA, B1, C1, B2, C2 and 
Yatakeymcin .................................................................................................... 39 
Figure 1.10: comparison stick models demonstrating the binding and 
alkylation of the natural (left) and unnatural (right) enantiomers of 
duocarmycin SA. The natural enantiomer binds in the 3’ to 5’ direction while 
the unnatural enantiomer binds 5’ to 3’.55 ......................................................40 
Figure 1.11: structure of duocarmycin SA demonstrating the key subunits 
vital for the binding to and alkylation of DNA. The black region depicts the 
alkylating subunit whilst the blue section depicts the binding subunit. ........ 41 
Figure 1.12: scheme showing a possible mechanism the DNA alkylation by 
the duocarmycin family of compounds - The local acid catalysis and bonding 
driven binding model. ..................................................................................... 42 
Figure 1.13: scheme showing the binding-driven bonding model of DNA 
alkylation by duocarmycin SA. This mechanism is now favoured over 
previously proposed mechanism. .................................................................... 43 
Figure 1.14: structure of the commonly studied alkylation subunit analogues.
.......................................................................................................................... 45 
Figure 1.15: carbamate based prodrug utilising a cleavable peptide sequence.
.......................................................................................................................... 49 
Figure 1.16: example structures of galactoside based prodrugs. .................... 50 
Figure 1.17: structure of a duocarmycin ADC in which the antibody is linked 
to the warhead through the binding subunit. ................................................. 52 
Figure 1.18: example of a duocarmycin ADC which utilises a carbamate based 
prodrug strategy. ............................................................................................. 53 
Figure 1.19: example of a duocarmycin ADC which utilises a phosphate base 
prodrug strategy. The phosphate group on the phenolic oxygen via hydrolysis 
to allow for spircyclisation to form the active duocarmycin warhead. ........... 54 
8 
 
Figure 2.1: Structure of duocarmycin SA alkylating unit suitably substituted 
for use in Fmoc based solid phase peptide chemistry. ................................... 71 
Figure 2.2: Structure of binding subunit indole, suitably substituted for use 
on the solid phase. ........................................................................................... 87 
Figure 3.1: Chemical structure of the Thomsen-Friedenreich antigen (T-
antigen). ......................................................................................................... 134 
Figure 3.2: Biosynthetic pathway towards the T-antigen used to decipher 
possible causes of over exposure of the T-antigen within cancer cells. ........ 135 
Figure 3.3: Chimera generated image of the crystal structure of jacalin-T-
antigen complex (PDB ID 1M26). In red is shown the four α-subunits, in 
yellow are four β- subunits and in green is the T-antigen bound at the α-
subunit based binding site.110 ........................................................................ 137 
Figure 3.4: A: shows the α-subunit of jacalin, B: shows the α‘-subunit of 
jacalin and C: the β-subunit of jacalin. See page 177 for LCMS details. ....... 140 
Figure 3.5: MALDI mass spectrometry spectra conducted in linear mode with 
a laser power of 180 of the α-subunit of jacalin, A: shows the full spectrum 
whilst B: shows the main peak at higher resolution. .................................... 143 
Figure 3.6: structure of compound 3.1 synthesised for the attempted 
conjugation to jacalin. In green is the DNA binding subunit, in red is the 
alkylating subunit and in blue a possible cleavable peptide sequence. ........ 146 
Figure 3.7: structure of peptide 3.2 synthesised to improve the hydrophilicity 
and hence eliminate the issues with peptide precipitation. ......................... 149 
Figure 3.8: MALDI mass spectrometry spectrum of unlabelled BSA in blue 
and BSA-3.2 conjugate in orange. A clear increase in the mass of BSA is 
evident after subjection to the conjugation conditions. N.b. the masses shown 
in the figure are taken from the data points at the apex of the respective peak.
......................................................................................................................... 151 
Figure 3.9: MALDI mass spectrometry results of conjugations to jacalin. In 
Blue is the MALDI spectra of the unlabelled jacalin α-subunit. In orange is 
the MALDI of the respective conjugates post reaction with a; DBCO-NHS b: 
SMCC, c: Biotin-NHS. All reactions show an increase in mass of the α-
subunit with each increase representing around four additions of the NHS 
ester to the jacalin. N.b. the masses shown in the figure are taken from the 
data points at the apex of the respective peak. ............................................. 152 
Figure 3.10: MALDI mass spectrometry result for the reaction of jacalin with 
3.3-NHS. The precipitate from the reaction was removed and resuspended 
in acetonitrile to obtain the above spectrum. In blue is the unlabelled jacalin 
α-subunit and in orange, the labelled α-subunit. N.b. the masses shown in 
the figure are taken from the data points at the apex of the respective peak.
........................................................................................................................ 155 
Figure 3.11: A: MALDI mass spectrometry result for unlabelled α-subunit of 
jacalin. B: MALDI of α-subunit after reaction with 3.4-NHS. What is evident 
here is the shifting of the subunit to a higher mass indicating conjugation 
occurring. The spectrum however of this conjugate is less clear possibly due 
to dissolution issues of the conjugate. N.b. the masses shown in the figure are 
taken from the data points at the apex of the respective peak. .................... 157 
9 
 
Figure 3.12: structure of the clinically approved Adcetris® which utilises a 
strategy where a reduced disulphide on the antibody is coupled to a 
maleimide moiety which is integrated into the MMAE drug payload.181 ..... 160 
Figure 3.13: chemical structure of SMCC. In red is the maleimide moiety, in 
blue is the cyclohexane ring spacer and in green the NHS functionality. .... 160 
Figure 3.14: structure of Kadcyla where mAb = trastuzumab. In blue is the 
SMCC linker with the antibody attached through reaction with the NHS ester 
functionality. In red is the thiol introduced onto the DM1 payload for 
reaction with the maleimide of SMCC. .......................................................... 161 
Figure 3.15: chemical structure of peptide 3.5. In red is shown the cysteine 
residue which was introduced into the sequence on the solid phase. ........... 161 
Figure 3.16: LCMS results of the coupling of jacalin to the SMCC linker. A: 
Results of unlabelled jacalin, B: Results of jacalin labelled with SMCC. See 
page 177 for LCMS method details ................................................................ 163 
Figure 3.17: LC-MS results of A: unlabelled jacalin, b: SMCC labelled jacalin, 
c: jacalin labelled with SMCC and peptide 3.5. See page 177 for LCMS 
method details. .............................................................................................. 164 
Figure 3.18: chemical structure of compound 3.13 containing a maleimide 
functionality ................................................................................................... 167 
Figure 3.19: MALDI mass spectrometry spectrum of unlabelled jacalin (blue) 
and jacalin labelled with 3.10 (orange). N.b. the masses shown in the figure 
are taken from the data points at the apex of the respective peak. .............. 168 
Figure 3.20: work by Zhou et al. used the strain-promoted azide-alkyne 
cycloaddition to from antibody-drug conjugates. ......................................... 170 
Figure 3.21: MALDI mass spectrometry spectrum of unlabelled jacalin (blue) 
and jacalin-DBCO (orange). A clear mass increase in the α-subunit is 
observed for jacalin-DBCO. N.b. the masses shown in the figure are taken 
from the data points at the apex of the respective peak. .............................. 173 
Figure 4.1: Schematic representation of a peptide-drug conjugate and 
descriptions of ideal characteristics of each individual component. ............. 191 
Figure 4.2: chemical structure of the PDC synthesised by Cheng and co-
workers based on a PI3Kβ inhibitor.198 ......................................................... 192 
Figure 4.3: chemical structure of PDC 4.2. T-antigen binding peptide 4.1 
(green) is coupled to the DSA based warhead (red). .................................... 195 
Figure 4.4: analytical HPLC and MALDI of the crude PDC 4.2 isolated 
directly from the resin. Expected mass 2244.98 gmol-1. HPLC - Agilent 
Eclipse XDB-C18 column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % 
TFA], Solvent B: [MeOHand 0.05 % TFA]. Gradient: 0% [B] to 95 % [B], 
from 0 min to 15 mins, 95 % [B] to 0 % [B] from 15to 20 mins. Monitored UV 
254 nm. Flow rate 1 mL/min. Column temperature 40 ºC. ......................... 196 
Figure 4.5: analytical HPLC trace of 4.3 post purification using preparative 
HPLC. Agilent Eclipse XDB-C18 column, 4.8 x 150 mm, 5 μm. Solvent A: 
[Water and 0.05 % TFA], Solvent B: [MeOHand 0.05 % TFA]. Gradient: 0% 
[B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 % [B] from 15 to 20 
mins. Monitored UV 214 nm. Flow rate 1 mL/min. Column temperature 40 
ºC. .................................................................................................................. 198 
10 
 
Figure 4.6: HPLC spectrum of two crude samples taken from the same batch 
of resin-peptide construct. Treatment of the resin with cleavage cocktail gives 
4.2 in red, whilst resin treatment with BBr3 and subsequently cleavage 
cocktail, gives 4.3 in blue. Agilent Eclipse XDB-C18 column, 4.8 x 150 mm, 5 
μm. Solvent A: [Water and 0.05 % TFA], Solvent B: [MeOHand 0.05 % TFA]. 
Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 % [B] 
from 15 to 20 mins. Monitored UV 254 nm. Flow rate 1 mL/min. Column 
temperature 40 ºC. ........................................................................................ 199 
Figure 4.7: chemical structure of peptide 4.4. In red is the DSA unit, in 
orange is the PABA spacer connected to the Cit-Val cleavable linker in green. 
In blue is a lysine residue used elsewhere in this thesis for attachment to 
other moieties. .............................................................................................. 200 
Figure 4.8: HPLC traces of crude 4.4 (in blue) and pure 4.5 (in red). Agilent 
Eclipse XDB-C18 column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % 
TFA], Solvent B: [MeOHand 0.05 % TFA]. Gradient: 0% [B] to 95 % [B], 
from 0 min to 15 mins, 95 % [B] to 0 % [B] from 15 to 20 mins. Monitored 
UV 254 nm. Flow rate 1 mL/min. Column temperature 40 ºC. ................... 201 
Figure 4.9: chemical structure of PDC 4.8. In red is the DSA based warhead 
unit, in blue is the PABA-Cit-Val cleavable sequence obtained from peptides 
4.4 and 4.5 and in green is the T antigen binding peptide, 4.1. .................203 
Figure 4.10: chemical structure of the debenzylated PDC 4.9.................... 204 
Figure 4.11: HPLC chromatogram of a pure sample of PDC 4.9. Agilent 
Eclipse XDB-C18 column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % 
TFA], Solvent B: [MeOHand 0.05 % TFA]. Gradient: 0% [B] to 95 % [B], 
from 0 min to 15 mins, 95 % [B] to 0 % [B] from 15 to 20 mins. Monitored 
UV 214 nm. Flow rate 1 mL/min. Column temperature 40 ºC. ................... 205 
Figure 4.12: chemical structure of 4.1-βAla-FITC, synthesised to study the 
interaction of 4.3 with cell lines used for biological evaluation. .................. 207 
Figure 4.13: HPLC trace of pure 4.1-βAla-FITC. Agilent Eclipse XDB-C18 
column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent B: 
[MeOHand 0.05 % TFA]. Gradient: 0% [B] to 95 % [B], from 0 min to 15 
mins, 95 % [B] to 0 % [B] from 15 to 20 mins. Monitored UV 214 nm. Flow 
rate 1 mL/min. Column temperature 40 ºC. ............................................... 208 
Figure 4.14: fluorescence microscopy images of MCF-7 cells post incubation 
with 4.1-βAla-FITC. ................................................................................... 209 
Figure 5.1: a schematic representation demonstrating how the enhanced 
permeability and retention effect leads to the natural accumulation of 
nanoparticles within tumorous tissue.209 ..................................................... 225 
Figure 5.2: schematic representation of CYT-6091 – An AuNP functionalised 
with TNF-α, PEG chains and a small molecule drug therapeutic. ............... 228 
Figure 5.3: extinction spectrum of AuNP stabilised with citrate (blue) and 
AuNPs functionalised with a monolayer of HS-PEG-COOH (orange). The 
plasmon absorption band at 525 nm of the PEG functionalised particles is 
red shifted in comparison to citrate AuNPs (522 nm). ................................. 233 
Figure 5.4: TEM image of 16 nm AuNP functionalised with a monolayer of 




Figure 5.5: chemical structure of peptide 5.1. In green is the lysine residue, in 
blue is a water soluble sequence and in red is the FITC tag. ........................ 235 
Figure 5.6: chemical structure of peptide 3.5 which contains a thiol residue 
for the formation of a Au-thiol bond. ............................................................ 238 
Figure 5.7: UV-Vis extinction spectrum of 4 nm AuNPs functionalised with 
PEG and DSA peptide 3.5 obtained after reaction of AuCl4·3H2O, NaBH4, 
HS-PEG-COOH and 3.5. .............................................................................. 239 
Figure 5.8: TEM image of AuNP functionalised with a mixed monolayer of 
PEG and peptide 3.5. An average particle size of 3.7 nm was observed for 
these particles. ............................................................................................... 239 
Figure 5.9: chemical structure of peptide 5.2. In red is the FITC unit, in blue 
is the DSA warhead and in green the lysine residue for coupling to PEG prior 
to AuNP synthesis. ........................................................................................ 240 
Figure 5.10: UV-Vis extinction spectrum of AuNP functionalised with PEG-
5.2. Evident is the characteristic band of FITC at 495 nm suggesting 
successful coupling of the peptide onto the particle surface. ....................... 241 
Figure 5.11: UV-Vis spectra of AuNP functionalised with PEG, 5.3 and 
jacalin-FITC. Evident is the FITC peak here, suggesting the successful 
coupling of the jacalin onto the free PEG carboxylic acid. ........................... 242 
Figure 5.12: TEM images of AuNP-PEG-5.3-Jac(FITC) showing an average 
particle size of 4.1 nm. ................................................................................... 242 
Figure 5.13: schematic representation of the synthesised AuNP-PEG-5.4-
Jac conjugate. ............................................................................................... 244 
Figure 5.14: UV-Vis extinction spectrum of AuNP-PEG-5.4-Jac in water.
........................................................................................................................ 244 
Figure 5.15: chemical structure of 4.7 and 4.9. ............................................. 245 
Figure 5.16: schematic representation of the AuNP-PEG-4.7-Jac construct. A 
cleavable sequence is included to test whether efficient release of the DSA 
warhead from the AuNP conjugate results in improved activity. ................. 246 
Figure 5.17: extinction spectrum of AuNP-PEG-4.7-Jac .......................... 247 
Figure 5.18: TEM image of AuNP-PEG-4.7-Jac showing an average particle 
size of 4.4 nm ± 1.3 (n = 50). ......................................................................... 247 
Figure 5.19: fluorescence microscopy images of A: MCF-7 cells incubated 
solely with buffer and B: MCF-7 cells incubated in the presence of AuNP-
PEG-5.3-Jac(FITC). The fluorescence visible within the cells indicates that 
the AuNP construct is being taken up by the cells. ....................................... 249 
 
List of Schemes: 
Scheme 1.1: activation of a protected seco based prodrug to give the 
pharmacologically active cyclohexadienone. .................................................. 47 
Scheme 1.2: activation of Carzelesin to give pharmacologically active U-
76074. .............................................................................................................. 48 
Scheme 1.3: structure and activation of KW-2189. ......................................... 48 
Scheme 1.4: example of a photoactivatable duocarmycin based prodrug and 
its activation. ................................................................................................... 50 
12 
 
Scheme 1.5: scheme showing the activation of an antibody-drug conjugate, 
SYD983, which undergoes a four step mechanism to release the active 
duocarmycin. ................................................................................................... 56 
Scheme 2.1: a: CH(CO2Me)2, NaOCH3, THF, 64% b: NaBH4, EtOH, 71%, c: 
Me2C(OMe)2, TsOH, DMF, 99% d: Pb(OAc)4, CHCl3, 100%, e: pyruvaldehyde 
dimethyl acetal, THF, pH 4 phosphate buffer, 61% f: HCl, MeOH, 91%, g: 
DEAD-Ph3P, THF, 100% h: NH2NH2-EtOH, reflux, then Boc2O, THF 67% i: 
DMSO-pH 4 buffer-dioxane, reflux, 91% j: MnO2, NaCN, HOAc, MeOH, 89%, 
K: 10% Pd/C 25% Aq. HCO2NH4, THF, 77% l: PPh3, CCl4, DCM, 81% m: HCl 
then 5,6,7-trimethoxyindole-2-carboxylic acid, EDCI, NaHCO3,DMF, 61% n: 
NaH, THF, DMF, 87%. .................................................................................... 65 
Scheme 2.2: a: Cl3CC(=NH)OBn, CF3SO3H, cyclohexane-DCM, 52%. b: 
DIBAL, PhMe, 87%. c: LDA, CH3COOBn, THF, 78%. d: Dess-Martin 
periodinane, DCM, 86% e: tBuOK, THF, 86% f: 2-ethyl-2-methyl-1,3-
dioxane, BF3.OEt, DCM, 54% g: Ac2O, pyridine, DCM, 97%. h: H2, 10 %Pd/C, 
EtOAc, 75%. i: DPPA, iso-Pr2NEt, benzene, MeOH, reflux, 69%. j: BBr3, 
DCM, 61%. k: DEAD, PPh3, THF, 90%. l: K2CO3, MeOH, 98%. m: Dess-
Martin periodinane, DCM, then Et3N, DCM, reflux 86%. n: H2, Pd(OH)2, 
MeOH, 96% o: N-piperidyl-CO-N=N-CO-N-piperidyl, nBu3P, THF, 88%, p: 
K2CO3, MeOH, 96% q, NaH, DMF, THF, 74%. ............................................... 66 
Scheme 2.3: Example reaction and conditions used for the 5-exo-trig free 
radical reaction to form the indoline ring. ...................................................... 67 
Scheme 2.4: a: NaNO2, HCl, 5 min, SnCl2, -20 oC 1h, 70%. b: NaOAc, methyl 
pyruvate, MeOH, rt, 16 h, 99% c: PPA, xylene, 120 oC, 18h, 64%. d: AlCl3, 
DCM, rt, 72h, 70% e: BnBr, K2CO3, acetone, 40 oC, 8h, 88%. f: Boc2O, DMAP, 
THF, rt, 1h, 98%. G: Lindlar catalyst, quinolone, EtOAc, H2, rt, 18 h, 91%. h: 
Boc2O, THF, rt, 18 h, 89%. i: NBS, THF, -78 oC, 4 h, 88%. j: NaH, DMF, rt, 30 
mins, (E/Z)-1,3-dichloropropene, rt, 12 h, 92% k: TTMSS, AIBN, benzene, 80 
oC, 3 h, 79% l: 4M HCl/EtOAc, 2 h, rt; TMI-CO2H, EDC, DMF, rt, 18 h, 51% 
m: NH4HCO2, Pd/C, THF, 40 oC, 2 h, 91%. .................................................... 68 
Scheme 2.5: a: BnBr, K2CO3, acetone, reflux, 93%, b: ICI, THF, reflux, 91%, c: 
NaH, MsCl, THF, rt, d: TBAF, THF, rt, 75%, e: methyl propiolate, Pd(PPh3)4, 
ZnBr2, DIPEA, THF, reflux, 56%, f: H2, PtO2, AcOEt, rt, g: NIS, THF, 0 oC, 5 
min, ClCO2Me, DMAP, pyridine, 0 oC, 74% h: propargyl alcohol, CuI, 
PdCl2(PPh3)2, THF, Et3N, 50 oC, 83%, i: H2, Pd-C, quinolone, THF-MeOH, rt, 
j: DEAD, PPh3, THF, rt then K2CO3, MeOH, rt, 99%, k: MCPBA, DCM, 0 oC, 5 
min, then Et3SiH, BF3.OEt2, 0 oC, 42%, l: MsCl, Et3N, DCM, rt, 75%, m: H2, 
Pd(OH)2, MeOH, rt, then K2CO3, MeOH, rt, 83% n: K2CO3, DMF, rt, 53%. .. 69 
Scheme 2.6: a: (S)-glycidyl-3-nosylate, NaH, 92% b: iPrMgCl, CuI-PBu3, 
69%, c: ADDP, PBu3, 62%, .............................................................................. 70 
Scheme 2.7: Synthetic route of Fmoc-DSA-OH as presented by Searcey and 
co-workers ....................................................................................................... 73 
Scheme 2.8: a BnBr, K2CO3, DMF, 3 h, rt, 99% .............................................. 74 
Scheme 2.9: a: b: NIS, H2SO4, DMF, 3 h, rt, 93%. .......................................... 75 
Scheme 2.10: a: methyl propiolate, Pd(PPh3)2Cl2, DIPEA, ZnBr2, DMF, 16 h, 
66 °C, 70%. ...................................................................................................... 76 
13 
 
Scheme 2.11: Proposed mechanism for the Sonogashira style methyl 
propiolate coupling. 1: Ligand displacement to give active Pd(0), 2, Oxidative 
addition of iodoaryl starting material, 3, transmetallation with zinc bromide, 
4, cis/trans isomerisation around central palladium complex, 5, reductive 
elimination to give product and reform Pd(0) active catalyst. ....................... 76 
Scheme 2.12: a: 1 M TBAF in THF, THF, 1 h, reflux, then Boc2O, DMAP, 
DCM, 3 h, rt 16-45% over 2 steps. ................................................................... 77 
Scheme 2.13: Sakamoto et al. proposed mechanism for the TBAF mediated 
ring closure to form the indole. ....................................................................... 78 
Scheme 2.14:  example conditions utilised in a Larock indole synthesis, a: 
Pd(OAc)2, K2CO3, PPh3, LiCl, DMF, 100 °C. ................................................... 79 
Scheme 2.15: proposed mechanism for Larock indole synthesis. 1: reduction 
of the Pd(II) to Pd(0), 2: coordination of the chloride to form a chloride-
ligated zerovalent palladium species, 3: oxidative addition of the aryl iodide 
to Pd(0), 4: coordination of the alkyne to palladium of the resulting 
arylpalladium intermediate and subsequent syn-insertion into the 
arylpalladium bond, 5: nitrogen displacement of the halide to form a six-
membered, heteroatom-containing palladacycle, 6: reductive elimination to 
form the desired indole. .................................................................................. 79 
Scheme 2.16: attempted indole formation through a gold catalyst based 
reaction. Conditions a: NaAuCl4.2H2O, EtOH, N2, 12 h, rt. ........................... 81 
Scheme 2.17: a: zinc powder, NH4Cl, Boc2O, DMAP, water, THF, 12 h, rt, 
then NIS, H2SO4, 3 h, rt, 57% over 2 steps. ..................................................... 82 
Scheme 2.18: a: (E/Z) 1,3-dichloropropene, NaH, DMF, 3 h, rt, 73%, .......... 83 
Scheme 2.19: a: AIBN, TTMSS, toluene, 1 h, reflux, 71%. .............................. 84 
Scheme 2.20: a: LiOH, H2O, MeOH, 3 h, rt, quantitative yield. .................... 85 
Scheme 2.21: a: 4 M HCl in dioxane, 16 h, then, Fmoc-Cl, NaHCO3, THF, 10 
min, rt, 84% over 2 steps. ................................................................................ 86 
Scheme 2.22: Proposed synthetic route to 2.14. ............................................ 87 
Scheme 2.23: Modified proposed route to compound 2.14 involving nitro 
reduction prior to ethyl ester hydrolysis. ....................................................... 88 
Scheme 2.24: General scheme demonstrating the route, using Fmoc SPPS, to 
a desired peptide using subsequent coupling and deprotection steps. ..........90 
Scheme 2.25: deprotection of the benzyl group from a DSA based peptide 
sequence, results in an 'unlocking' of the seco form and hence an ability to 
spirocyclise to form the pharmacologically active agent. ............................... 93 
Scheme 2.26: a: 10% Pd/C, 25% Aq. HCO2NH4, THF/MeOH, rt, 1 h ............ 93 
Scheme 2.27: a: 1 M BBr3, DCM, -78 °C, 1 h, 64% .......................................... 94 
Scheme 2.28: proposed mechanism for benzyl deprotection using boron 
tribromide ........................................................................................................ 95 
Scheme 2.29: Schematic representation of PMB group utilisation on the solid 
phase. It was proposed that treatment of the on resin peptide with acidic 
conditions could lead to combined, resin cleavage and PMB deprotection to 
yield active analogues. ..................................................................................... 97 
Scheme 2.30: preferred route to PMB protected Fmoc-DSA-OH. PMB 
protection post benzyl deprotection was unsuccessful. .................................. 98 
14 
 
Scheme 2.31: final Boc deprotection and Fmoc protection step to give the 
PMB protected Fmoc-DSA-OH unit. ............................................................ 100 
Scheme 2.32: proposed route utilising the PCB protecting group. Synthesis of 
PCB protected Fmoc-DSA-OH followed by conversion to the PMB protected 
unit using a palladium-RockPhos complex. ................................................. 101 
Scheme 2.33: a: RockPhos Pd G3 (5 mol%), RockPhos ligand (5 mol%), 
Cs2CO3, MeOH, N2, 20 h, 60 °C. ................................................................... 102 
Scheme 2.34: Treatment of on resin peptide with boron tribromide could 
result in on resin benzyl deprotection therefore removing the need for post 
cleavage modifications. ................................................................................. 103 
Scheme 3.1: general scheme showing the reaction between an amine and a 
carboxylic acid using EDC. The carboxylic acid reacts with EDC to form an 
active ester intermediate which can go on to react with an amine to form a 
stable amide bond. ......................................................................................... 144 
Scheme 3.2: efficiency of the EDC mediated coupling can be improved 
through the addition of NHS. This forms a more stable NHS ester 
intermediate for reaction with the amine. .................................................... 145 
Scheme 3.3: in-situ EDC/NHS activation of 3.1 was utilised as an initial 
attempt at making the jacalin-duocarmycin conjugates. ............................. 147 
Scheme 3.4: a: DCC, NHS, Anhydrous DMF, 16 h........................................ 153 
Scheme 3.5: a: DCC, NHS, Anhydrous DMF, 16 h. Formation of the NHS 
ester of 3.3 using DCC proceeded successfully. This was proposed to be due 
to the lack of steric hindrance around the C-terminus carboxylic acid. ....... 154 
Scheme 3.6: reaction of 3.3-NHS with jacalin in HEPES buffer gave 
successful conjugation to the jacalin structure albeit with resulting 
precipitation of the jacalin............................................................................. 154 
Scheme 3.7: a: 10% Pd/C, 25% Aq. Ammonium formate, MeOH, 1h, rt b: 
DCC, NHS, anhydrous DMF, 16 h, rt. ........................................................... 156 
Scheme 3.8: attempted NHS ester formation of 3.5 was found to be 
unsuccessful under our previously used conditions. .................................... 158 
Scheme 3.9: the thiol-maleimide coupling reaction is thought to proceed 
through attack of a thiolate anion to the activated alkene of the maleimide.
........................................................................................................................ 159 
Scheme 3.10: a: 10% Pd/C, 25% Aq. Ammonium formate, MeOH, rt, 1 h ... 165 
Scheme 3.11: a: HATU, DIPEA, DMF, rt, 2 h ................................................ 166 
Scheme 3.12: 2-Iminothiolane can be used to introduce sulfhydryl residues 
into proteins via reaction with exposed lysine residues. .............................. 167 
Scheme 3.13: reaction of thiolated Jacalin with compound 3.10 to form a 
jacalin-3.10 conjugate. A: 10 Mm HEPES buffered saline, 2 h, rt. ............... 168 
Scheme 3.14: the Huisgen 1,3-dipolar cycloaddition reaction between an 
azide and an alkyne to form a stable triazole based product. ....................... 169 
Scheme 3.15: a: HATU, DIPEA, DMF, 2 h, rt. ............................................... 171 
Scheme 4.1: benzyl deprotection of PDC 4.2. a: 10% Pd/C, 25% Aq. 
ammonium formate, MeOH, 1 h, rt, 32%...................................................... 197 
Scheme 4.2: benzyl deprotection of peptide 4.4 to give 4.5. a: 10% Pd/C, 
25% aq. Ammonium formate, MeOH, 1 h, rt. ............................................... 201 
15 
 
Scheme 4.3: benzyl deprotection of 4.6 to give 4.7. a: 10% Pd/C, 25% aq. 
Ammonium formate, MeOH, 1 h, rt, 38%. ................................................... 202 
Scheme 4.4: elimination of the FITC module from the N-terminus of a 
peptide sequence during TFA mediated cleavage from the resin. Without a 
spacer after the N-terminal amino acid, this process is likely to occur causing 
a number of unwanted side products within the cleavage mixture. ............ 206 
Scheme 5.1: a schematic representation of the initial strategy envisioned for 
the synthesis of a AuNP-duocarmycin/jacalin conjugate. ............................230 
Scheme 5.2: envisioned synthesis of a 4 nm AuNP core functionalised with a 
mixed monolayer of a DSA peptide and PEG, followed by coupling of jacalin 
to the carboxylic terminated PEG. ................................................................ 231 
Scheme 5.3: schematic representation of a route to a AuNP-DSA-Jac 
conjugate utilising an initial coupling of HS-PEG-COOH to an amine 
containing DSA peptide. ................................................................................ 232 
Scheme 5.4: attempted coupling of PEG-AuNP with peptide 5.1. a: MES 
buffer (pH 5), NHS, EDC, 30min, rt, b: HEPES buffer (pH 7.4), peptide 5.1, 
24 h, rt ............................................................................................................ 235 
Scheme 5.5: Synthesis of a 4 nm AuNP core functionalised with a mixed 
monolayer of SH-PEG-COOH and peptide 3.5. ........................................... 238 
Scheme 5.6: benzyl deprotection of 5.3 to give the biologically active 5.4. a: 
10% Pd/C, 25% Aq. ammonium formate, MeOH, rt, 1 h .............................. 243 
 
List of Tables: 
Table 1.1: commonly employed linker strategies used in antibody-drug 
conjugates broadly classified as cleavable and non-cleavable. The cleavage 
sites are shown in red. ..................................................................................... 33 
Table 1.2: examples of ADCs currently approved or progressing within 
clinical trials.34 ................................................................................................. 37 
Table 1.3: cancer associated glycan epitopes and their respective structures 
expressed in symbol nomenclature. ................................................................ 58 
Table 1.4: examples of cancer targeting lectins alongside their associated 
antigen and cancer cell reactivity. 102, 109, 110, 112 ...............................................60 
Table 2.1: conditions employed in the attempted Larock indole synthesis to 
compound 2.5. ............................................................................................... 80 
Table 2.2: Conditions utilised for the attempted cyclisation of compound 2.4 
to give the central indole unit. ......................................................................... 81 
Table 2.3: Summary of conditions found to give most efficient usage of Fmoc-
DSA-OH on the solid phase. ............................................................................ 91 
Table 2.4: summary of various conditions and their respective results 
attempted to try and achieve Boc deprotection without removal of PMB 
group of 2.18. ................................................................................................. 100 
Table 3.1: standard conditions utilised for MALDI based analysis of jacalin 
and the resulting conjugates. ........................................................................ 142 
Table 3.2: conditions employed for the conjugation of 3.2 to jacalin. The 
conditions were selected based on attempts to reduce the precipitation of the 
jacalin and achieve the desired coupling ...................................................... 150 
16 
 
Table 4.1: IC50 results obtained for compounds 4.5 and 4.7 with MCF-7. HL-







2-Cltrt  2-Chlorotrityl 
αCHCA  α-cyano-4-hydroxycinnamic acid 
ABL    Agaricus bisporus lectin 
ACN    acetonitrile  
ADC    antibody drug conjugate  
AIBN  azobisisobutyronitrile  
AuNP  gold nanoparticle 
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CYP    cytochrome P450 enzyme  
DAR    drug-antibody ratio 
DBCO   dibenzocyclooctyl 
DCC   N,N'-dicyclohexylcarbodiimide 
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DCU    dicyclohexylurea 
DHB    2,5 dihydroxybenzoic acid 
DHFR   dihydrofolate reductase 
DIPEA   N,N-diisopropylethylamine  
DMAP   4-dimethylaminopyridine  
DMF    N,N-dimethylformamide  
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DSA    duocarmycin SA 
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19 
 
MTS   3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-      
(4- sulfophenyl)-2H-tetrazolium  
MTX    methotrexate 
MWCO  molecular weight cut-off 
NaH   sodium hydride  
NHS    N-hydoxysuccinimide 
NIS    N-iodosuccinimide  
PABA   para-aminobenzoic acid 
PBS    phosphate buffered saline 
PI3Kβ   phosphoinositide 3-kinase β 
PCB    para-chlorobenzyl 
PDC    peptide-drug conjugate 
PEG    polyethylene glycol  
PES    phenazine ethosulfate  
PMB    para-methoxybenzyl 
PNA    peanut agglutinin 
PSA    polysialic acid 
PyBop   (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate  
SAMB   N’-succinimidyl 4-N-(2’-acetylthiopropionyl)-N-methyl-4-
aminobutyrate 
sLeA    sialyl Lewis A antigen 
sLeX    sialyl Lewis X  
SMCC   (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate) 
SPOS  solid phase organic synthesis 
SPPS   solid phase peptide synthesis 
T-antigen   Thomsen Friedenreich antigen  
TBAF   tetrabutylammonium fluoride solution  
TEM    transmission electron microscope 
TFA    trifluoroacetic acid  
THF    tetrahydrofuran  
20 
 
TIPS    triisopropylsilane  
TK    tyrosine kinase 
TNF    tumour necrosis factor  















1.1 The War on Cancer 
Despite the ‘war on cancer’ having lasted almost 50 years, the development of 
new anticancer therapeutics remains a major challenge.1 Oncology has one of 
the poorest records for investigational drugs in clinical development, with 
success rates that are more than three times lower than for cardiovascular 
disease (Figure 1.1).2 This difficulty stems from the way in which this 
malignant disease manifests itself within the organism it affects. Cancer 
occurs when a single cell in a tissue is genetically damaged or modified to 
produce cells with the ability to proliferate uncontrollably; leading to the 
formation of tumours. Due to the metastatic nature of cancer, this disease 
can spread to areas distant from the initial site of occurrence, leading to loss 
of function of affected organs or tissues.3 The characteristic that makes 
cancer so difficult to treat is the inherent similarities, in terms of 
biochemistry, that exist between cancer cells and healthy cells. This makes it 
very difficult to achieve selective delivery of drugs to cancer cells rather than 
healthy cells. 
 
Figure 1.1: demonstration of the difficult journey from the synthesis of lead compounds 
through to commercialisation. This pathway is of particular issue in the development of 
cancer related treatments. 
 
The current choice of therapy for cancer depends on the extent to which the 
disease has manifested itself within the body and also the extent to which it 
has metastasised. For example, surgery is a localised treatment – it only 
treats the part of the body operated on and so it may cure cancer that is 
completely contained in one area and has not spread. Usually, the earlier a 
23 
 
cancer is found the easier it is to remove. If the cancer has metastasised to 
other areas of the body however, a systemic therapy involving the 
administration of cytotoxic small molecules into the body is usually utilised. 
This way, the drug does not just localise in one place.4 
Cytotoxic drugs known to man are in abundance. However, the number of 
these drugs that have shown success within clinical trials and animal models 
are comparatively small. This has been put down to a lack of identification of 
unique biochemical aspects of malignancies that could be exploited to target 
tumour cells over healthy living cells.5 More recently, advances within this 
area have been made with Gleevec and Trastuzumab providing just two 
examples of now clinically approved agents which make use of the different 
biochemical properties of the two cell types.6 
Despite this struggle to find ideal clinical candidates from known cytotoxic 
agents, the success in terms of survival rates when it comes to cancer can be 
attributed to the many years of chemotherapy based research. This research 
has laid the foundations for current cancer therapies which have enhanced 
our ability to combat the disease. 
1.1.1 Chemotherapy – A History 
Chemotherapy has been one of the foremost approaches for the treatment of 
cancer for more than half a century and consists of the administration of 
drugs which cause cell death through interference of fundamental steps in 
the cell lifecycle. 
The first cytotoxic compounds to be administered in human patients in the 
late 1940s were the nitrogen mustards, chlorambucil and cyclophosphamide 
(Figure 1.2), which are able to alkylate DNA irreversibly leading to eventual 
cell death.7 Around the same time came the observation that folic acid 
stimulated cancer growth, which prompted the development of folate 







Figure 1.2: structures of Chlorambucil and Cyclophosphamide. 
 
Following on from this early stage rational drug design, the elucidation of the 
structure of DNA brought about the development of nucleoside analogues 
such as thioguanine, 5-fluoruracil and gemcitabine (Figure 1.3) which induce 
apoptosis by blocking the elongation of DNA strands.8 With DNA being vital 
to the normal functioning of a cell as well as being important in allowing cell 
proliferation, DNA represented an attractive target for anticancer agents. 
Soon after, the serendipitously-discovered cytotoxic effects of cisplatin 
(Figure 1.3) gave rise to the biological evaluation of different platinum(II) 
complexes, which are able to crosslink DNA strands by binding to guanine 
and adenine residues.9 The realisation of DNA being a major target for 
chemotherapy was further enforced through the discovery of a class of 
natural products called anthracyclines. Drugs in this family include 
daunorubicin and doxorubicin (Figure 1.3) which are known to cause cell 
death by additional means such as intercalation into DNA, generation of free 
radicals, DNA cross linking and interference with helicase activity.10 Besides 
the use of DNA-interacting agents, significant anticancer effects were 
provided by the administration of inhibitors of repair proteins topoisomerase 
I and II. These proteins are involved in fundamental arrangements of the 
DNA structure, being able to break the single-(topoisomerase I) or double-
strand (topoisomerase II) and then rejoin the DNA ends. Drugs such as 
etoposide, teniposide and camptothecins are able to stabilise DNA-
topoisomerase complexes, thus blocking the progression of the replication 
fork.11 
In addition to DNA and DNA-interacting proteins, microtubules represent a 
validated target in chemotherapy. Vinca alkaloids, e.g. vincristine and 
vinblastine and their derivatives, were initially found to bind tubulin, 
inhibiting the microtubule formation and inducing cell apoptosis.12 The 
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isolation of paclitaxel (Figure 1.3) from the Pacific yew, Taxus brevifolius in 
1971, gave rise to the successful use of taxanes for cancer treatment.13 While 
vinca alkaloids affect the rates of tubulin polymerization, taxanes inhibit 
microtubule depolymerisation and also presented an exciting new class of 
antitumour agents.14 
Figure 1.3: molecular structures, and growth inhibition data of some of the most potent 
cytotoxic agents. Average (av.) of IC50 values reported for a variable number of human 




Due to the presence of preferential targets for cancer treatment in both 
healthy and diseased cells, the antitumour efficacy of these conventional 
chemotherapeutics is limited by their nonspecific action against normal cells, 
especially to rapidly growing cells such as bone marrow, cells of hair follicles 
and mucous membrane cells. As a result, these anticancer agents are 
characterised by a narrow therapeutic window, that is, the quantitative 
relationship between efficacy and safety. Moreover, the ability of low-
molecular weight cytotoxic compounds to reach cancer cells is often impaired 
by different physiological barriers such as, tumour interstitial pressure and 
diffusion through the tumour endothelium or extracellular matrix. 
Degradation processes that convert the anticancer drugs into inactive 
metabolites as well as drug resistance mechanisms present more obstacles to 
the success of these agents.19 
In principle, the treatment efficiency of these compounds can be improved by 
increasing the doses, but this approach commonly results in severe side-
effects. The administration of combinations of anticancer drugs with 
different mechanisms of action and non-overlapping toxicity profiles was one 
of the first strategies to improve the efficacy of conventional 
chemotherapeutics; multidrug therapy became a standard modality for the 
treatment of most cancers. As an additional strategy, anticancer drugs 
derived from natural sources became the object of intense research aimed at 
the discovery of new cytotoxic agents with improved anticancer activity. 
These significant efforts led to the development of a variety of both tubulin-
targeted and DNA-interacting agents with higher antiproliferative activity 
than conventional chemotherapeutics. However, the mere enhancement of 
the cell-killing power of cytotoxic drugs did not result in increased 
therapeutic indices. Indeed, the clinical evaluations of these new cytotoxic 
agents were often discontinued, due to the occurrence of severe side-
toxicities at low administration doses. 
1.1.2 Targeted Chemotherapy 
The fundamental drawbacks of cytotoxic agents discussed above prompted 
the development of targeted therapies. This approach may selectively kill the 
diseased tissue while sparing healthy cells, hence dramatically improving the 
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therapeutic index of existing therapies.20 In 1913, Paul Ehrlich described the 
concept of a ‘magic bullet’ i.e. a medicine that can selectively target specific 
microorganisms, and this concept is now the corner stone of the majority of 
research into this area. Based on the understanding of molecular principles 
of genetic and pathological processes that contribute to tumour growth, a 
large variety of new tumour targeting strategies could be developed.21 For 
example, it was found that the altered activity or the overexpression of key 
tyrosine kinase (TK) proteins in tumours result in the abnormal 
phosphorylation of target effectors that activate signalling pathways and 
drive cancer cell growth. Therefore, the use of selective kinase inhibitors as 
targeted anticancer agents gained popularity amongst the pharmaceutical 
industries.22 Approved by the FDA in 2001, imatinib was the first compound 
of this class to enter the market. This drug is indicated for the treatment of 
chronic myelogenous leukemia patients expressing the BCRABL fusion 
protein, which is the result of an abnormal gene translocation.23 While 
imatinib was the 5th best-selling anticancer drug in 2014, at least 20 other 
receptor TK inhibitors (e.g. sunitinib, erlotinib, crizotinib, axitinib and 
gefitinib) have broken into the market as inhibitors of aberrant 
phosphorylations in various cancers, such as renal cell carcinoma, and non-
small cell lung cancer.24 
Besides the active research on inhibitors of receptor tyrosine kinases, a large 
variety of “targeted” pharmacological approaches still rely on the 
administration of traditional cytotoxic agents, which are chemically modified 
or incorporated within suitable macromolecular structures to improve their 
therapeutic window. For example, anticancer agents have been incorporated 
into nanoparticles (e.g. liposomes, polymers and micelles) to exploit the 
leaky vasculature of several tumour masses.25 Unlike in normal tissues, solid 
tumour vasculature allows the extravasation of these large nanomedicines, 
resulting in a more selective drug accumulation at the tumour site. This is 
termed the enhanced permeability and retention (EPR) effect.26 
Among the known hallmarks of cancer, the EPR effect is arguably the most 
exploited strategy to improve the delivery of cytotoxic agents to tumours and, 
relying on the pathological features of the targeted tissue, is generally 
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classified as a “passive drug targeting” approach. Examples of passively-
targeted nanomedicines that have been approved for clinical use are both 
PEGylated (Doxil®/Caelyx®) and non-PEGylated (Myocet®/, 
Daunoxome®) liposomal anthracyclines, and albumin-based pacitaxel 
(Abraxane®).27 
As an alternative to passive drug targeting approaches, the evidence that 
tumours often express different receptors, enzymes and other proteins in 
higher amounts than normal tissues, gave rise to active drug targeting 
strategies. Here, recognition of tumour cells is made possible by the covalent 
conjugation of cytotoxic agents to targeting vehicles that bind specific tumour 
antigens. Such vehicles have included but are not limited to monoclonal 
antibodies, vitamins, peptides and substrate analogues. These drug delivery 
systems are designed to release the cytotoxic payload only after the ligand 
binding to the target.28 
These active targeting strategies have shown promise for the improvement of 
existing, known chemotherapeutic agents. Of particular success and interest 
has been the development of antibody-drug conjugates.  
 
1.2 Antibody Drug Conjugates 
Antibody-drug conjugates (ADCs) are composed of a recombinant 
monoclonal antibody (mAb) connected via a synthetic linker to a highly 
cytotoxic drug molecule.29 These agents became of interest for the treatment 
of cancer due to the combination of antitumour potency of cytotoxic small-
molecule drugs with the selective targeting properties and advantageous 
pharmacokinetic profile of antibodies. The way in which these agents work 
relies on the delivery of a cytotoxic warhead to a specific location by the 
antibody. The ADC is then taken up by the cell, usually by receptor mediated 
endocytosis, where, upon lysosomal degradation, the active warhead is 




Figure 1.4: schematic representation of the mechanism of drug delivery mediated by ADCs.31 
 
The development of ADCs is not a recent idea with the first use within animal 
models coming in the 1960s.32 Since this date, the interest levels surrounding 
ADCs has risen dramatically due to the potential of these agents to change 
the way we look at chemotherapy. Since the first approval of Mylotarg® in 
2000 and its subsequent withdrawal in the year 2010, the ADC market has 
evolved considerably. In the last eight years, the market has witnessed an 
increasing interest from drug developers and healthcare investors alike. Post 
the commercialisation of brentuximab vedotin (Adcetris®) in 2011 and 
trastuzumab emtanzine (Kadcyla®) in 2013, there was a temporary, but 
evident, decline in the popularity of ADCs.33 This was attributed to the fact 
that no new ADC candidates were approved after 2013 and the focus had 
shifted to other novel therapies. However, the recent approval of Besponsa® 
and re-approval of Mylotarg® has renewed the interest in the domain. This 
is evident when you look at current clinical trials with over 60 ADCs 
undertaking the process.34 
1.2.1 First Generation Antibody-Drug Conjugates 
The development of ADCs was driven by the need to improve the tumour 
selectivity of clinically used anticancer drugs. The limited efficacy of many of 
these drugs can be attributed to their insufficient therapeutic window so 
finding novel ways to overcome this limitation was prerequisite. Despite little 
understanding of which roles antibodies play within cancer, it became clear 
that many mAbs displayed preferential binding to tumour cells. These 
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studies paved a way towards an idea of mAbs being used as delivery vehicles 
for current antitumour agents. Initially the agents of interest included 
doxorubicin, vinblastine and melphalan. In spite of initial focus lying on the 
antibody and cytotoxic drug, it became evident that the linker which connects 
these two components is also of vital importance. With encouraging 
preclinical results, a number of these first generation ADCs moved into phase 
I clinical trials with a doxorubicin based ADC eventually reaching phase II 
clinical trials (Figure 1.5).34 However, all of these initial ADCs failed to 
progress beyond this stage due to a lack of clinically meaningful therapeutic 
activity and poor selectivity profiles. 
 
Figure 1.5: example of a first generation antibody-drug conjugate. 
 
1.2.2 Improved ADC Development  
With this lack of success in clinical trials, it was clear that a more careful 
consideration of each individual component of the ADC was required. It was 
hoped that through this, a more successful outcome within trials could be 
achieved.  
The cytotoxic agent 
With an understanding of the processes involved in cellular uptake of ADCs 
came the realisation that warheads with sub nanomolar activity were needed 
to achieve the potencies required for success within patients. This realisation 
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was achieved through research that suggested the delivery of cytotoxic 
molecules to tumours via an antibody was limited by two factors:  
1. The number of antigen molecules present on the cell surface 
2. Internalisation of cell-surface bound antigen-antibody complex or 
intracellular processing to release the active drug moiety.34  
For this reason, current ADC research focuses on the discovery and 
exploitation of more potent cytotoxic agents. Moreover, with many cytotoxic 
agents being hydrophobic and likely to result in antibody aggregation upon 
conjugation, synthetic strategies to overcome this have been at the forefront 
of much research. Antimitotic agents and DNA interacting agents are two 
broad cytotoxic drug classes which have received an increase in attention for 
research surrounding ADC development. For example, the maytansinoid and 
auristatin families are two drug classifications which are often seen to 
dominate the ADC clinical landscape. This is due to their potent biological 
activity and also their success in previously approved ADCs.35 The antimitotic 
agent maytansine (Figure 1.6), for example, has been adapted for inclusion 
onto an antibody to produce the clinically approved Kadcyla®.36 In terms of 
DNA interacting agents, the calicheamicin (Figure 1.6) family is employed in 
the formation of Besponsa® which is the most recently approved ADC 
available.37 These DNA interacting agents have been some of the most potent 
antitumour agents discovered to date and work through inducing DNA 
cleavage via the formation of diradical based species and subsequent 
hydrogen abstraction from both strands of the duplex DNA. This process 
ultimately leads to cellular death.38 
 





Other DNA damaging agents currently under study for the development of 
ADC like systems include the duocarmycins and pyrrolebenzodiazapines 
which both show activity to the desired picomolar range.39 
The Linker 
The key function of the linker is to provide a stable connection between the 
cytotoxic agent and the antibody, thus allowing for preferential systemic 
circulation and an avoidance of systemic toxicity. Despite the need for this 
stability during circulation, the linker should permit ADC cleavage upon 
internalisation to allow for the targeted cellular release of the potent 
cytotoxic drug. It is therefore of importance that a balance between these two 
factors is achieved and this is seen as one of the main challenges when it 
comes to ADC development.34 
Linkers which are currently employed within approved second and third 
generation ADCs are broadly classified into cleavable and non-cleavable 
varieties (Table 1.1).40 Cleavable linkers can not only be sensitive to lysosomal 
proteases, but also to the acidic pH within the cell and to cellular reducing 
agents such as glutathione. Examples of such linkers include the acid 
sensitive hydrazone linker, the now widely used cathepsin B sensitive valine-
citrulline bond and also a glutathione cleavable disulphide bridge.41 Non-
cleavable linkers are designed to enhance the systemic circulation properties 
and unlike cleavable linkers, rely on the proteolytic degradation of the ADC 
to release the linker-drug moiety attached to the antibody. Examples of non-
cleavable linkers include the thioether linker succinimidyl-4-(N-









Table 1.1: commonly employed linker strategies used in antibody-drug conjugates broadly 
classified as cleavable and non-cleavable. The cleavage sites are shown in red. 
 
A more recently discovered consideration when discussing the linker 
employed for ADCs is the potential for what is known as the by-stander 
effect. Solid tumours often express the target antigen in a heterogeneous 
manner. As a result, ADCs that selectively kill only antigen-positive cells and 
spare neighbouring antigen-negative cancer cells may be ineffective in 
eradicating such tumours. Therefore, ADCs may be designed to kill not only 
antigen-positive cells but also other cells in the vicinity, irrespective of the 
expression of the target antigen.43 This can be achieved by consideration of 
the linker degradation processes.44 For example a combination of a 
disulphide bridge along with a Monomethyl auristatin E (MMAE) payload 
has seen desirable bystander effects since the disulphide bridge can be 
cleaved outside of the cell releasing the neutral MMAE, which is able to cross 
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biomembranes and hence exert its effect on those tumour cells that may not 
display the targeted antigen.45-47 
The Antibody 
Structurally, all antibodies consist of two heavy and two light chains forming 
two Fab arms containing identical domains at either end. This is then 
attached by a flexible hinge region to the stem of the antibody, the Fc domain 
(Figure 1.7).48 The Fab domains consist of two variable and two constant 
domains, with the two variable domains making up the variable fragment 
(Fv), which provides the antigen specificity of the antibody. Each variable 
domain contains three hypervariable loops, known as complementarity 
determining regions (CDRs), evenly distributed between four less variable 
framework (FR) regions. It is the CDRs that provide a specific antigen 
recognition site on the surface of the antibody and the hypervariability of 
these regions enables antibodies to recognise an almost unlimited number of 
antigens.49 
 
Figure 1.7: schematic representation of the structure of an antibody. The red section depicts 
the variable region whilst blue depicts the constant region.62 
 
The key function of the antibody in an ADC is to preferentially bind to 
antigens on the target cell and hence concentrate the cytotoxic agent at the 
desired location. It is therefore important that the target antigen should have 
high expression levels in tumours and little or no expression in normal 
tissues. This ensures that the release of the cytotoxic agent at undesired 
locations is avoided and hence toxicities are reduced. Of similar importance 
is the requirement of the antigen to be accessible to the circulating mAb and 
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also the requirement of the antibody to be efficiently internalised upon 
binding to the antigen. This internalisation usually occurs through receptor-
mediated endocytosis which the efficiency of is often dependent upon the 
nature of the receptor.50  
The discovery of antigens and its antibodies that fit the above criteria is not a 
trivial task. Therefore much research still focuses on this area. The human 
epidermal growth factor receptor 2 (HER2) is currently one of the most 
understood and targeted receptors with the ADC Kadcyla® exerting its 
activity through an interaction with this antigen.36 More recent developments 
when it comes to the antibody employed in ADC systems is the use of a 
biparatopic antibody. A biparatopic antibody is one in which the first 
antigen-binding moiety and the second antigen-binding moiety bind to 
different epitopes on the same antigen. A biparatopic antibody may also bind 
to two epitopes on the same antigen molecule, or it may bind to epitopes on 
two different antigen molecules.51 The use of such a system has shown 
success over current ADC systems employed in the clinic. For example, Coats 
and co-workers showed how a biparatopic based HER2 targeting ADC can 
enhance toxin delivery and induce a greater breadth of tumour killing in 
comparison to trastuzumab emtansine.52 
1.2.3 Current Antibody-Drug Conjugates 
Through careful consideration of the above key parameters, the success of 
ADCs within clinical development has improved dramatically. As previously 
discussed, four ADCs are now approved for clinical use by the FDA and many 
more are in clinical development. Despite second generation antibody drug 
conjugates overcoming many of the hurdles preventing the success of the 
first generation, these agents are still not without remaining challenges. 
These enduring concerns have expedited the introduction of a third 
generation of ADCs which seek to reduce the heterogeneous nature of these 
agents through the introduction of site specific conjugations. This allows for 
defined drug antibody ratios (DARs) (Figure 1.8).53 This is seen as of 
paramount importance for the continuing success of these systems into the 
future. Additionally, to further increase the therapeutic index of ADCs, 
improvements must be made either in the potency of the cytotoxic agent to 
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lower the minimum effective dose or in tumour selectivity to increase the 
maximum tolerated dose.34  Therefore, within ADC research, there remains a 
need to discover and optimise highly efficient and active payloads for use in 
such systems. 
 
Figure 1.8: schematic demonstrating the progression of antibody drug conjugates from first 






Table 1.2: examples of ADCs currently approved or progressing within clinical trials.34 
















CPNMB MMAE Val-Cit 
Depatuxizumab 
mafodotin 
Seattle Genetics Phase II CD19 MMAF Maleimido- 
caproic 
acid 
AGS-16C3F Agensys/Astellas Phase II ENPP3 MMAF Maleimido- 
caproic 
acid 
PSMA ADC Progenics/Seattle 
genetics 
Phase II PSMA MMAE Val-Cit 
Polatuzumab 
vedotin 
Genentech/Roche Phase II CD79b MMAE Val-Cit 
CDX-014 Celldex Phase 
I/II 
TIM1 MMAE Val-Cit 
Enfortumb 
vedotin 
Agensys/Astellas Phase I Nectin 4 MMAE Val-Cit 
Telisotuzumab AbbVie/Pierre 
Fabre 
















ImmunoGen Phase II CD19 DM4 SPDB 
Naratuximab 
emtansine 
ImmunoGen Phase II CD37 DM1 SMCC 
Indatuximab 
ravtansine 
Biotest Phase II CD138 DM4 SPDB 
Anetumab 
ravtansine 
Bayer HealthCare Phase II Mesothelin DM4 SPDB 
SAR408701 Sanofi Phase II CEACAM5 DM4 SPDB 
Gemtuzumab 
ozogamicin 







CD22 CM1 Hydrazone 
PF-06647263 Pfizer/AbbVie Phase I Ephrin A4 CM1 Hydrazone 
Vadastuximab 
talrine 
Seattle Genetics Phase 
III 
CD33 SGD1882 Val-Ala 
















TROP2 SN38 CL2A 
Labetuzumab 
govitecan 
Immunomedics Phase II CEACAM5 SN38 CL2A 




1.3 CC-1065 and the Duocarmycin Family 
CC-1065 and the duocarmycins (Figure 1.9) are a family of ultrapotent, 
antitumour antibiotic natural products isolated from broth cultures of 
Streptomyces species.54, 55 In 1978 the parent member of this family, CC-
1065, was reported by Upjohn company and since then this class of 
compounds have captivated scientists and researchers worldwide.56 This 
interest can be attributed to the impressive potency of these agents which at 
the time of discovery were some of the most potent to be discovered matched 
only by calicheamicin and other enediyne based agents. Following on from 
the isolation of CC-1065 came the discovery of a related set of compounds 
called the duocarmycins.57 With similar potencies and related structures, 
these agents further ignited interest into the class of ultrapotent cytotoxic 
agents. More recently, the discovery and elucidation of the yatakemycin 
structure and its impressive biological activity has kept interest in these 
agents alive.54 
As with many of the cytotoxic, natural product based compounds, the CC-
1065 and duocarmycins have shown little success within clinical trials and 
this has been attributed to a combination of extreme potency and lack of 
selectivity. Despite this, research into these agents has adapted by studying 
ways in which these compounds can be successfully utilised or modified in 
order to improve their therapeutic window. 
The following section will summarise the isolation, biological activity and 
mechanistic details of this exciting class of compounds. Details of recent 
research and strategies to get these compounds to succeed within a clinical 




Figure 1.9: structures of CC-1065, duocarmycin A, SA, B1, C1, B2, C2 and Yatakeymcin 
 
1.3.1 Isolation 
During screening for soil cultures that produced agents with cytotoxic activity 
against L1210 cells in culture and in vivo activity against P388 leukaemia in 
mice, the potent antitumour antibiotic, CC-1065 was isolated from 
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Streptomyces zelensis.58 The production, in vitro biological activity and 
microbiological assays for this agent were all completed and as mentioned, 
resulted in much interest into this compound. Studies into the structure of 
CC-1065 allowed for the derivation of a remarkably curved shape, which had 
charge density allowing for binding into the grooves of the DNA double helix. 
These findings along with the presence of an alkylating moiety led to the 
assumption that CC-1065 exerts its biological activity through a selective 
alkylation of DNA.59 
Further screening studies resulted in the discovery of a class of antibiotics 
which were found to be very similar to CC-1065. The duocarmycins were 
isolated during screening for new antitumour antibiotics from actinomycetes. 
Initially this class of compounds consisted of duocarmycin A, B1, B2, C1 and 
C2; all produced by Streptomyces.57 Later this was added to by duocarmycin 
SA which displayed IC50 values of 10-12 M - 10-9 M on HeLa S3 cells. Upon the 
derivation of the structure of these compounds and the discovered 
similarities which existed between them and CC-1065, it was assumed that 
both share a similar mechanism of biological activity.60 
1.3.2 Biological Activity 
CC-1065 and the duocarmycins share many common structural features of 
known DNA minor groove binders including netropsin and distamycin and 
hence it came as no surprise that these agents also bound to the minor 
groove. This is demonstrated in Figure 1.10, which also shows how the 
opposite enantiomer to the natural product binds in the opposite direction.55 
 
Figure 1.10: comparison stick models demonstrating the binding and alkylation of the 
natural (left) and unnatural (right) enantiomers of duocarmycin SA. The natural enantiomer 
binds in the 3’ to 5’ direction while the unnatural enantiomer binds 5’ to 3’.55 
41 
 
The structures of this family of compounds were derived using NMR and 
other spectroscopic techniques. The CC-1065 and duocarmycins were all 
found to contain two distinct moieties with varying roles (Figure 1.11).61, 62 
 
Figure 1.11: structure of duocarmycin SA demonstrating the key subunits vital for the 
binding to and alkylation of DNA. The black region depicts the alkylating subunit whilst the 
blue section depicts the binding subunit. 
 
The biological effect of the family occurs due to a sequence-selective 
alkylation of DNA. The reversible, stereoelectronically controlled adenine-N3 
addition to the least substituted cyclopropane carbon has been found to 
occur within selected AT rich sites in the minor groove.63 GC rich sequences 
tend to be wider and have more steric hindrance and are hence less favoured. 
This alkylation is thought to instigate a cascade of cellular events leading to 
apoptosis.64 Despite over 40 years of research, the particular events which 
lead to apoptosis are still not universally reported.  Extensive efforts have 
been devoted to determine the origin of the DNA alkylation selectivity, to 
establish the link between DNA alkylation and the resultant biological 
properties and to define the fundamental principles underlying the 
relationships between structure, chemical reactivity, and biological activity.  
As well as their incredible potency, a further intriguing property discovered 
for this class of compounds was their stability. The solvolysis half-life at pH 
7.6 for duocarmycin SA is estimated to be 820 years and when compared to 
the half-life for DNA alkylation (1.2 h) a rate enhancement of 7 x 106 is 
found.65 Further studies found that the solvolysis reactivity of the CC-1065 
and duocarmycin family is increased at acidic pH and this led to the 
assumption and possibility of an acid catalysed reaction occurring.66, 67 
However, this interaction and the mechanism behind it was further 
complicated when it was found that the more solvolytically stable an agent 
Binding Subunit Alkylating Subunit 
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was, the more potent its biological activity exerted. This idea of DNA-
catalysed reactions was not unheard of with other cases being reported for 
platinum adduct formation amongst others. What was unusual however was 
the magnitude of the rate enhancement and a number of mechanisms to 
explain this were proposed. 
The first of these mechanisms to be suggested was the local acid catalysis and 
bonding driven binding model (Figure 1.12). This model suggests that the 
selectivity of this family of compounds for its alkylation of DNA lay only 
within the alkylating subunit and that the binding subunit was necessary only 
for greater affinity binding. This mechanism however did not explain why, 
upon binding to DNA, the CC-1065 and duocarmycins alkylating subunit 
became much more reactive.68 The model was therefore added to by the 
suggestion that local differences in pH on the DNA was resulting in this 
activity. These differences could be due to a protonated phosphodiester on 
the DNA backbone which could interact with the carbonyl of the minor 
groove binder.69 
 
Figure 1.12: scheme showing a possible mechanism the DNA alkylation by the duocarmycin 
family of compounds - The local acid catalysis and bonding driven binding model. 
 
Upon the completion of studies which utilised the comparison between 
synthetic analogues and the natural compounds, it became evident that the 
bonding-driven binding model was unable to explain the true mechanism of 
the duocarmycin family. A mechanism in which an alkylation event occurs 
based upon a non-covalent binding seemed to be more appropriate. These 
Binding subunit solely 
involved with enhanced 
binding affinity and not with 
sequence selectivity 
Acid Catalysis proposed to be via a 
protonated phosphate on DNA 









and not within 
duocarmycin 
structure. 
R = DNA Backbone 
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studies involving the natural product analogues showed that the acid 
catalysis proposal concerning the protonated phosphate backbone 
interaction could not occur since when the carbonyl is alkylated or removed, 
a similar alkylation specificity is achieved. This showed that the carbonyl is 
not involved with sequence selectivity. Furthermore, a subunit which 
contains a carbonyl group which is completely inaccessible to the DNA 
backbone maintains full biological activity of the natural product..69, 70 
These studies described above along with many others led to the proposal of 
the binding-driven bonding model (Figure 1.13) by Boger et al.71 This model 
suggests that upon interaction with the DNA backbone, the duocarmycin 
undergoes a conformational change i.e. a twist in the structure between the 
alkylation and binding subunits. Bound to DNA, the molecule adopts a 
helical conformation where the two subunits are twisted approximately 45º 
with respect to one another. Although the bound agent sustains full amide 
character, the N12 is no longer co-planar with the cyclohexadienone system 
and so the vinylogous amide character is significantly disrupted.  This in turn 
activates the cyclopropane ring to attack by the N3 position of adenine. This 
proposal of a disruption as a result of a conformation change has been 
reinforced by NMR studies involving the duocarmycins bound to the DNA. 
 
 
Figure 1.13: scheme showing the binding-driven bonding model of DNA alkylation by 
duocarmycin SA. This mechanism is now favoured over previously proposed mechanism. 
 
 
DNA Binding induced Conformational 
change leads to disruption to the 
vinylogous amide and consequent 
activation of the cyclopropane ring. 
















1.3.3 Clinical Results of the Duocarmycins 
The potency and broad spectrum of antitumour activity of the CC-1065 and 
duocarmycin family of compounds has demonstrated the potential of these 
agents as clinical candidates. Unfortunately, these agents showed 
unacceptably high toxicities for systemic use, and poor specificity meant they 
never fulfilled their potential as possible chemotherapeutic agents. CC-1065 
showed a delayed death profile due to catastrophic hepatotoxicity in 
experimental animals.72 Similarly, despite showing good stability-activity 
profiles, with no hepatotoxicity, duocarmycin SA was also found to be too 
toxic. This delayed toxicity has been attributed to the degree of reversibility 
of the DNA alkylation and hence to the level of non-covalent binding 
stabilisation of the reversible DNA adduct.73 Regardless of these findings, 
duocarmycin SA remains the most promising starting point for the 
development of this family due to its reduced toxicity and notable potency. 
In order for this class of compounds to fulfil their potential and gain an 
improved therapeutic index it was necessary to fully understand their 
reactivity and structural properties. This would allow for the development of 
compounds that may present improved biological profiles. 
1.3.4 Alkylating Unit Structures 
Despite the clinical failures of these compounds, much interest still existed. 
For instance, some research groups set out to investigate the synthesis and 
biological activity of alkylating pharmacophores and analogues. It was hoped 
that these investigations would allow for a clear relationship between 
structure, reactivity and biological activity. This in turn could enable these 
compounds to be adapted for clinical purposes. 
Within these studies a group of alkylating pharmacophores were produced 
which include the subunits CI, CBI, CBQ and CPzI all of which differ slightly 
from the naturally occurring alkylating subunits found in DSA and CC-1065 
(Figure 1.14). These various analogues of the alkylating subunit are now 





Figure 1.14: structure of the commonly studied alkylation subunit analogues. 
 
What became clear from these structure-activity relationship studies was the 
novel parabolic correlation between the stability of these compounds and 
their potency. The overly reactive species will be nonselective with their 
reactivity to biological nucleophiles, whereas the species which are too 
unreactive will not have the ability to alkylate the DNA. A balance between 
these two properties is of paramount importance and investigations to find 
the peak of this correlation were carried out. It was found that duocarmycin 
SA alkylation subunit (DSA) lies at the peak whereas the CC-1065 subunit for 
example was too reactive and hence did not lie at the optimal position.74, 75 
This again shows that duocarmycin SA presents itself as an ideal starting 
point for further investigations. The CBI subunit (Figure 1.14) has been used 
extensively in SAR and prodrug strategy studies and this can be attributed to 
its chemical stability and ease of synthesis. This particular alkylating subunit 
is now commonly employed in duocarmycin ADCs which are in clinical 
development.  
The extensive nature of the SAR studies, into the CC-1065 and duocarmycin 
family of compounds along with Boger’s mechanistic studies allowed for a 
thorough understanding of the way in which these agents act and behave 
depending on their structures. This laid the seed for the design of strategies 
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such as prodrug formation, which may act to improve the therapeutic index 
of these agents. 
1.3.5 General Prodrug Strategies 
Despite their failure within a clinical setting, the CC-1065 and duocarmycin 
family of compounds still present an opportunity to develop an efficacious 
therapeutic agent. The recognition of a lack of selectivity in this family 
expedited strategies to overcome this flaw. One of the explored strategies has 
been the formation of prodrug analogues. A prodrug is a compound that, 
upon administration into an in vivo setting undergoes chemical conversion, 
often by metabolic processes, into an active pharmacological agent. The 
foundation of this strategy for agents such as the duocarmycins, is that these 
metabolic processes that form the active agent only occur within the vicinity 
of cancerous cells or tissue, thereby leaving healthy cells unharmed. 
The majority of duocarmycin based prodrug strategies have relied on the 
masking of the required cyclopropane ring within the alkylating subunit of 
the active agent. The masking of this part of the molecule has been achieved 
through the formation of what is known as the seco form of the drug (Scheme 
1.1). This involves the formation of a ring-opened derivative of the 
spirocyclopropyl-cyclohexadienone unit in which, a leaving group, commonly 
a halide, is employed. This leaving group can leave upon subsequent 
formation of the cyclohexadienone. In order to prevent this spontaneous 
cyclisation occurring before arrival at a specific in vivo target, a prodrug 
based strategy has been the addition of a group on the phenolic OH. 
Significant research has demonstrated a range of functionalities suitable for 
inclusion at this position to allow for successful chemical conversion to the 




Scheme 1.1: activation of a protected seco based prodrug to give the pharmacologically active 
cyclohexadienone. 
 
What follows is a non-exhaustive list of clinical candidates and chemical 
entities which have employed CC-1065/duocarmycin based prodrug 
strategies. The chosen compounds are those which have seen most success or 
generated most interest.  
Carzelesin (Scheme 1.2) carries a phenyl carbamate unit attached to the 
phenol along with an additional diethylamine unit to increase the solubility 
of the drug. Activation of carzelesin requires two steps, (a) hydrolysis of the 
phenylurethane substituent to form U-76073, followed by (b) ring closure to 
form the cyclopropyl-containing DNA-reactive U-76074 (Scheme 
1.2).76  Although carzelesin was less potent in terms of in vitro cytotoxicity 
and in vivo optimal dosage, it was therapeutically more efficacious against 
mouse L1210 leukemia than was U-76074. Despite this impressive activity 
and demonstration of the utilisation of a carbamate prodrug strategy, 
Carzelesin failed to progress further than phase II trials due to the found 






Scheme 1.2: activation of Carzelesin to give pharmacologically active U-76074. 
 
Similarly, KW-2189 was a prodrug developed based upon an analogue of 
duocarmycin A, DU-86 (Scheme 1.3).78 This agent was developed to be 
activated through enzyme hydrolysis to release DU-86. Despite the presence 
of the deactivating carbamate, KW-2189 was shown to be able to alkylate 
DNA prior to the removal of this moiety.79 This is thought to be due to an 
alternative mechanism. KW-2189 was found to show insufficient antitumour 
activity in patients with malignant melanoma or advanced renal cell 
carcinoma, and hence further studies were not continued. However, KW-
2189 has more recently been shown to be active in patients with 
hepatocellular carcinoma in a phase II clinical trial.80 
 




Further carbamate based prodrug strategies have included the introduction 
of an enzyme cleavable peptide sequence onto the phenolic OH (Figure 1.15). 
The cathepsin B cleavable Cbz-Val-Cit-PAMA was introduced by Venkatesan 
and co-workers, which, upon enzyme cleavage undergoes a self-immolative 
breakdown to deliver the pharmacologically active compound.81 Since the 
cathepsin B enzyme is over expressed within cancerous cells in comparison 
to normal cells, this prodrug strategy presents an ability to introduce 
specificity into these agents. These peptide sequences have shown great 
success within numerous clinical candidates for achieving targeted activation 
at a specific location. Despite this, these sequences are not synthetically 
accessible and hence new routes towards making these amino acid-
duocarmycin based agents would be desirable. 
 
Figure 1.15: carbamate based prodrug utilising a cleavable peptide sequence. 
 
Further strategies utilising the addition of moieties to the phenol of the seco 
form of the alkylating subunits make use of sugar conjugation (Figure 1.16).  
A galactoside protected methyl-seco-CBI analogue has been shown to hold a 
770-fold increase in activity in the presence of galactosidase – an enzyme 
over expressed within cancerous cells (Figure 1.16).82 Analogues of this agent 
with increased water solubility also greatly increased prodrug effectiveness 
demonstrating IC50s which matched the free drug.83 Studies which also took 
this analogue and removed the methyl substituent and introduced a water 
soluble DNA binding unit, further improved activity resulting in a significant 




Figure 1.16: example structures of galactoside based prodrugs. 
 
More recent strategies have employed the development of prodrugs which 
are photoactivatable. This strategy involves the introduction of a moiety, 
again attached to the phenol of the seco form of the active drug, which can be 
removed upon photoirradiation. Tietze and co-workers demonstrated the 
potential of this area (Scheme 1.4). The determination of the in vitro 
cytotoxicity by using an HTCFA-test revealed a QIC50 value of 8200 and the 
prodrug was shown to be more than two million times less cytotoxic than the 
corresponding seco-drug. With the seco-drug displaying an IC50 value of 
about 110 fM this agent warrants more research to further realise its 
potential.85 
 
Scheme 1.4: example of a photoactivatable duocarmycin based prodrug and its activation. 
 
Although incorporating protecting group strategies onto the phenolic oxygen 
has yielded some success in these agents, it can be easily imagined how this 




the lability of the protecting group during systemic circulation. With these 
compounds having the ability to spirocyclise to form the pharmacologically 
active compound, it can be proposed that this process, through deprotection 
of the phenol, could happen prior to arrival at a desired site. This in turn 
would account for the high toxicities that are retained for some of these 
agents despite the protecting strategy being in place.  
Despite prodrug strategies further cementing the potential of the 
duocarmycin family of compounds for possible use as a cancer therapeutic, 
these strategies have yet to lead to the formation of a clinically successful 
candidate. Although this maybe the case, these studies were not without 
fruition. The formation of these compounds demonstrated the success of 
strategies including cleavable peptide sequences, locking compounds into the 
seco form and allowing for in vitro/ in vivo spirocyclisation.  
With this lack of clinical success, trends within duocarmycin based research 
moved onto the use of these agents within antibody-drug conjugate like 
systems. It is thought that these systems could harness the potential of this 
family of compounds, with their ultra-potent activity, to create a clinically 
successful agent.  
1.3.6 Duocarmycin in ADCs 
With little success in the utilisation of other strategies to improve the 
therapeutic window of the duocarmycin family of compounds, focus turned 
onto the application of these agents within antibody-drug conjugate systems. 
With their impressive potency, reaching IC50’s in the picomolar range, these 
compounds make an ideal candidate for introduction into such systems.  
As it stands, the duocarmycins have been introduced into a number of 
conjugates with the marked distinction between these entities coming in the 
way or position at which the duocarmycin is conjugated to the antibody.  
One such way in which this has been achieved is through a linker from the 
antibody to the binding subunit of the duocarmycin. As touched upon in 
Section 1.3.5., it could be that this strategy holds an advantage in that without 
conjugation via the phenolic oxygen, concerns about premature release of the 
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warhead due to the lability of this bond could be reduced. This therefore, 
could yield more desirable biological activities. This was demonstrated by 
ImmunoGen in work in which a CBI analogue was conjugated to an anti-
CD19 or anti-CD56 antibody (Figure 1.17).86 This work shows the use of the 
seco form of the drug molecule, as opposed to the spirocyclised active 
compound, in ADC systems – something which is now common practice. In 
this conjugate an unprotected form of the seco CBI unit was utilised along 
with two indole units, included to act as binding subunits in order to 
maximise biological activity. Prior to conjugation of the CBI analogue, the 
antibody was functionalised with SAMB (N’-succinimidyl 4-N-(2’-
acetylthiopropionyl)-N-methyl-4-aminobutyrate) in order to provide a site of 
addition for the payload. This artificially introduced site was then 
deprotected using hydroxylamine before addition of the CBI based unit. The 
system described, demonstrated potent in vitro activity, in the range of 0.1 
nM, and was shown to be selective for cell lines that expressed the specific 
antigen. The conjugates were also tested in a mouse xenograft model of 
leukaemia and had activity that compared well to commercial 
chemotherapeutics. Despite these positive results, these conjugates were not 
taken forward for further development due to their instability and poor 
aqueous solubility.87 
 
Figure 1.17: structure of a duocarmycin ADC in which the antibody is linked to the warhead 
through the binding subunit. 
 
As a follow on from this initial work came the rationale that prodrug 
strategies such as those described earlier on in this chapter could be utilised 
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alongside the benefit of the targeting capabilities of an antibody. Through 
protection of the phenolic oxygen of the alkylating subunit of duocarmycin 
agents with a labile group, premature spirocyclisation within circulation 
could be prevented thereby further improving the therapeutic window of 
these ADC systems. One example of this is a strategy that utilises a carbamate 
based prodrug of a seco-CBI based payload. MDX-1203, is an ADC that was 
developed by Bristol-Meyers Squibb and reached Phase I clinical trial.88 In 
this example, the payload is constituted by a duocarmycin MA (CBI + binding 
unit) protected as a carbamate (Figure 1.18). This example also demonstrates 
the use of a cleavable peptide sequence, which aims to aid the release of the 
payload from the antibody post arrival at the desired site of activity. The use 
of these cleavable peptide sequences, as discussed in the previous chapter has 
demonstrated a large amount of success in a variety of duocarmycin and non-
duocarmycin based systems. A human monoclonal anti-CD70 antibody was 
chosen to target the CD70 receptor overexpressed in lymphomas but also in a 
number of solid tumours. The bioconjugation was obtained via maleimide-
thiol reaction. The clinical trial highlighted delayed toxicity at the highest 
concentration tested, as observed for other non ADC duocarmycin 
derivatives. This could be as a direct result of early payload release. At the 
same concentration, sensitisation was also observed. Although efficacy is not 
the focus of Phase I clinical trials, it was noted that, depending on the dose 
administered, the best cases were either disease progression at lower doses, 
or stable disease at higher doses.89 The development of this ADC has been 
terminated. 
 





With the solubility of duocarmycin based ADCs being a recurring issue in 
terms of clinical progression, ImmunoGen have reported conjugates (DC4 
and DC44) which employ the use of a CC-1065 analogue with a phosphate 
group introduced onto the phenolic oxygen (Figure 1.19).87 Not only does this 
act with similarities to the carbamate group in terms of hydrolytic release but 
it also aids aqueous solubility and stability. It was also hoped that the use of 
this group could reduce interpatient variability and be more efficient in 
comparison to other analogues. The bifunctional SMCC or SPDB linkers were 
exploited in the preparation of these conjugates. In the case of DC4 and 
DC44 anti-CanAg conjugates, the linker did not affect the biological activity 
or selectivity against CanAg positive COLO 205 cells versus A375, CanAg 
negative. Impressively, in these cell lines it was shown that the ADC is more 
potent than the free drug. This could be attributed to a more efficient delivery 
of the payload to the desired location. In comparison to the CanAg 
conjugates, the efficacy of the anti-CD19 conjugates was reliant on the nature 
of the linker with non-cleavable crosslinks leading to a considerably reduced 
potency. This was consistent for the DC44 conjugate with an SPDB linker, 
whose disulphide is more hindered and hence less labile to reduction 
pathways. It also appeared that Ramos cells, used as CD19 positive models in 
this study, produce slow rates of dephosphorylation which, coupled with a 
slow release of the payload, greatly affected the cytotoxicity of the conjugates 
in this model.  
 
Figure 1.19: example of a duocarmycin ADC which utilises a phosphate base prodrug 
strategy. The phosphate group on the phenolic oxygen via hydrolysis to allow for 




More recently within the field of duocarmycin-based ADCs has been a shift to 
a strategy which employs a conjugation route from duocarmycin to antibody 
via the phenolic oxygen of the duocarmycin. This strategy again combines the 
directing ability of the antibody with a prodrug approach in which the 
cleavage of the payload from the antibody will only result in the liberation of 
the pharmacologically active component. As of today this strategy has 
provided the most clinical success, most notably with Synthons’s ADC, 
SYD985 (Scheme 1.5).90, 91 The preparation of this conjugate involves the use 
of the HER2 targeting antibody, trastuzumab, which has been approved for 
breast cancer treatment in its own right. The conjugate also employs a 
cathepsin B cleavable peptide linker, PABC-Cit-Val, and a self immolative 
unit to release the free duocarmycin payload composed of seco-DUBA and an 




Scheme 1.5: scheme showing the activation of an antibody-drug conjugate, SYD983, which 
undergoes a four step mechanism to release the active duocarmycin. 
 
Promising results were obtained for this conjugate in initial stages of Phase I 
clinical trials. Most noticeably, very high response rates and durable 
responses were observed in patients whose cancers were refractory to HER2-
targeted agents, including trastuzumab and trastuzumab emtansine 
following treatment with SYD985 at doses from 1.2 mg/kg onwards.92 As a 
result of these notable results, SYD985 has been granted fast track 
designation by the FDA. This designation is for the treatment of patients 
diagnosed with HER2-positive metastatic breast cancer who have progressed 
after different HER2-targeting treatment regimens, or have progressed 
during or after treatment with trastuzumab emtansine. 
With these results, it is clear that employing an ADC or targeted delivery 
based system for the duocarmycin family of compounds has the promise to 
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yield real, clinical success for the first time for this class. Despite this, the 
generation and discovery of new antibodies is not trivial. In addition, the 
formation of new ADCs for various forms of cancer would require a number 
of these systems being generated which incorporate different antibodies. This 
again is certainly not a trivial task and hence whilst this area certainly 
provides promise, it could be that other targeting moieties and other 
unexplored targets could present advantages over antibody based delivery 
systems.  
1.4 Aberrant Glycosylation Patterns in Cancer 
The discovery that carbohydrate binding proteins (lectins) selectively 
agglutinate cancer cells gave an initial indication of the presence of certain 
variances between surface expressed carbohydrates in healthy and cancerous 
cells.93, 94 Many carbohydrate patterns have been associated with the 
cancerous phenotype. Some include the over or underexpression of naturally 
occurring glycans, whilst more useful for targeted therapy purposes are those 
that show the novel expression of glycans only found in foetuses.95 These 
provide an ideal target for delivery systems to explore. There are three main 
types of cell surface glycoproteins: asparagine attached N-linked glycans, O-
linked glycans that are attached to serine or threonine residues, and 
glycosaminoglycans that are linked to serine residues. O-linked glycans were 
originally discovered in mucin, a protein found in mucus, and were therefore 
termed mucin-type glycans - many cancer-associated carbohydrates are 
known to be of this type.96 
DNA mutations can lead to the overexpression, underexpression, or deletion 
of many genes resulting in a direct effect on the subsequent products, which 
can therefore be overexpressed, underexpressed or missing, respectively.97 
Altered levels of enzymes responsible for post-transcriptional glycosylation 
can be attributed to many of the glycan variations associated with cancer. A 
frequent change in surface carbohydrates of cancer cells is an increase in the 
amount of branching of N-glycans, which can be a direct consequence of the 
increased activity of the enzyme N-acetylglucosaminyltransferase V (GlcNAc-
TV).98 This enzyme causes branching of β1-6GlcNAc, which are further 
positions for the attachment of terminal sialic acid residues. Increased 
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activity of sialyltransferases causes an overall increase in sialylation of N-
linked glycans, a common development in core carbohydrate structures at 
the surface of cancer cells. Early studies have established the relationship 
between excessive sialylation and increased metastasis. The overexpression 
of glycosyltransferases has also been connected to malignancy, as the 
downstream effect of the activity of these enzymes leads to the 
overexpression of many cancer-associated terminal glycan epitopes.99 These 
include the Thomsen-Friedenreich (T) antigen, the Tn antigen, sialyl-Tn, 
polysialic acid (PSA), Sialyl Lewis A (sLea), Lewis Y (LeY) and Sialyl Lewis X 
(sLeX) (Table 1.3). 
Table 1.3: cancer associated glycan epitopes and their respective structures expressed in 
symbol nomenclature. 
 
With a number of these glycans showing desirable levels of overexpression in 
cancer cells, it is clear that these antigens present themselves as ideal targets 
in addition to those commonly employed in current ADCs. Furthermore, with 
glycan binding often being correlated to improved cellular uptake, these 
relatively unexplored targets warrant greater levels of interest in the field of 
targeted chemotherapy. Of course, in order for this potential to be realised, 
moieties which specifically recognise and bind to these glycans with high 
affinity are required. 
1.4.1 Targeting Cancer Associated Glycans 
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Numerous reports have confirmed the potential of lectins as tumour 
targeting agents, therapeutic agents and adjuvants for current cancer 
treatments. What follows is a non-exhaustive summary of lectins found to 
have cancer targeting and therapeutic properties. Discussed below some 
examples of lectins shown to demonstrate these properties whilst Table 1.4 
provides a more exhaustive list of tumour targeting lectins.  
Mistletoe (Viscum album) extracts have seen widespread use in pre-clinical 
and clinical studies for the treatment of a number of different cancers. The 
active component of mistletoe extracts is a lectin named mistletoe lectin-1 
(ML-1).100 Mistletoe extracts under clinical investigations include Iscador, 
Eurixor, Helixor, Lektinol, Isorel, Abnoba-viscum and recombinant ML-1. 
Phase I and II clinical trials have explored the efficacy of mistletoe extracts in 
the treatment of many different cancers including colorectal carcinoma, 
ovarian cancer, renal cell carcinoma, lung cancer and stomach cancer.101, 102 
These trials have demonstrated an increased quality of life, prolonged 
survival and reduction in the number of side effects in comparison with 
current treatments. The lectin consists of two chains; a cytotoxic enzymatic A 
chain and a sialic acid-binding B chain. The ML-1 displays specificity for 
gangliosides and glycoproteins expressing terminal Neu5Acα2- 6Gal1-
4GlcNAc-, the overexpression of which has been associated with carcinomas. 
The therapeutic effect of ML-1 is a synergistic effect of both its direct 
cytotoxic effects and indirect immunomodulatory effects. The A chain is 
responsible for inducing apoptosis at low femtomolar-picomolar 
concentrations and the lectin can also activate immune cells, such as natural-
killer cells, and heighten their cytotoxicity.103, 104 
Peanut agglutinin (PNA), a further lectin, has been shown to selectively bind 
to the T-antigen but not the sialylated form of the antigen.105 PNA only 
agglutinates human erythrocytes upon neuraminidase treatment, and has 
been shown to bind to MCF-7 and MDA-MB231 breast cancer cells with 
varying affinities.106-108 PNA also binds to the sub-normal, non-tumorigenic 
breast cell line MCF-10A, although it’s affinity is 10-fold lower towards the 
non-immortalised variant cell line MCF-10M. Despite the fact that the lectin 
has also been found to selectively target a variety of colon cancer cell lines, 
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PNA also demonstrates some undesirable activity for therapeutic purposes in 
that it is able to stimulate proliferation of some cells lines such as HT-29.109 
The lectin extracted from Artocarpus integrifolia (jackfruit), jacalin, is also a 
T-antigen specific lectin.110 This lectin has previously been shown to aid in 
both the targeted delivery and uptake of anticancer based therapeutics.111 
With its impressive specificity and selectivity for the cancer associated T-
antigen, jacalin has the potential to impose itself as a validated targeted 
delivery moiety. More details on this lectin along with previous examples of 
targeted delivery using jacalin will be discussed in Chapter 3. 
Table 1.4: examples of cancer targeting lectins alongside their associated antigen and cancer 
cell reactivity. 102, 109, 110, 112 
Owing to their remarkable specificity for a variety of cancer-associated 
carbohydrate based antigens, the lectins described above are proposed to be 
powerful prospective cancer targeting ligands. The specificity of lectins 
towards cancer cells, in addition to the remarkable biological effects that 
lectins can exert, such as apoptosis induction, inhibition of proliferation and 
immunomodulation, make lectins attractive multifunctional candidates for 
the targeted therapy of cancer. 
As well as lectins, a number of peptides and small molecules have also been 
discovered which have demonstrated specific and selective binding to cancer 
associated glycans. It could be therefore that these moieties, like lectins, 




































T antigen Caco-2, HT-29  
Erythrina 
cristagalli lectin  
Erythrina 
cristagalli  
Galβ-1,4GlcNAc Type II antigen Caco-2  
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could provide the desired properties to try and achieve the targeted delivery 
of current cytotoxic agents to cancerous tissue thereby improving their 
therapeutic index. Specifically, it is possible that these agents could present a 
new, unexplored area to achieve the targeted delivery of the duocarmycin 
family of compounds to cancer cells. This, along with what has been learnt 
through prodrug and ADC system development, could help to further realise 
the potential of these compounds as future cancer based therapeutics.  
1.5 Thesis Outline 
The work presented in this thesis focuses on the use of a duocarmycin 
analogue for the design and synthesis of conjugates to target the Thomsen-
Friedenreich antigen expressed on cancer cells. Chapter 2 of this thesis will 
detail the synthesis of a benzyl protected duocarmycin SA analogue that is 
suitably functionalised for Fmoc solid phase synthesis. This chapter will also 
look at attempted modifications made to the synthetic route and structure of 
this unit to try and achieve more efficient use on the solid phase. Finally, 
additional benzyl deprotection strategies to yield active duocarmycin 
conjugates will be addressed. 
Chapter 3 will detail the design and synthesis of a variety of duocarmycin-
lectin conjugates. This chapter will make use of the T-antigen targeting 
lectin, jacalin. A variety of conjugation chemistries will be investigated to 
synthesis these conjugates including EDC/NHS chemistry, Thiol maleimide 
chemistry and azide-alkyne click chemistry.  
Chapter 4 will address the synthesis of a duocarmycin-peptide drug 
conjugate. The peptide utilised in this chapter has been shown to selectively 
bind the T-antigen with affinities comparable to many lectins. The 
incorporation of cleavable sequences into these conjugates will be looked at 
in this chapter as well as the biological evaluation of the peptide-drug 
conjugates synthesised. 
Finally, Chapter 5 will detail the design, synthesis and biological evaluation 
of a gold nanoparticle based system for the targeted delivery of duocarmycin 
conjugates to the T-antigen. These nanoparticles will utilise an active 
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2.1  Introduction 
2.1.1  Synthetic Routes to Duocarmycin SA and other Members of 
the Family 
Since the isolation and determination of the biological activity of the CC-1065 
and duocarmycin family of compounds, the derivation of synthetic routes to 
these agents has been extensive.113 Of particular interest from a synthetic 
organic chemistry perspective was the alkylating unit of these agents, with 
this subunit containing the majority of the key functionalisation. As 
discussed in Chapter 1, structure-activity relationship studies into these 
agents identified the minimum required pharmacophore along with a 
number of other alkylating subunit analogues. These analogues allow for 
accessibility to the potent biological activity of these agents whilst simplifying 
the synthetic routes. Of particular importance in terms of this was the 
discovery of the CBI unit which is now commonly utilised due to its ease of 
synthesis. 
In spite of these new accessible analogues, due to its impressive potency and 
desirable biological activity, duocarmycin SA continued to present an ideal 
pharmacophore for analogue synthesis and studies into this compound 
specifically are also extensive.  
The first total synthesis of duocarmycin SA was reported by Boger et al. 
(Scheme 2.1) in 1992 and was based on a previously reported strategy 
involving sequential regiospecific nucleophilic substitution reactions of 
substituted p-quinone diimines.114 Critically, the synthetic route disclosed 
also allowed for the isolation of both enantiomers of the alkylating unit. This 
would come to aid the understanding of the importance of this particular 




Scheme 2.1: a: CH(CO2Me)2, NaOCH3, THF, 64% b: NaBH4, EtOH, 71%, c: Me2C(OMe)2, 
TsOH, DMF, 99% d: Pb(OAc)4, CHCl3, 100%, e: pyruvaldehyde dimethyl acetal, THF, pH 4 
phosphate buffer, 61% f: HCl, MeOH, 91%, g: DEAD-Ph3P, THF, 100% h: NH2NH2-EtOH, 
reflux, then Boc2O, THF 67% i: DMSO-pH 4 buffer-dioxane, reflux, 91% j: MnO2, NaCN, 
HOAc, MeOH, 89%, K: 10% Pd/C 25% Aq. HCO2NH4, THF, 77% l: PPh3, CCl4, DCM, 81% m: 
HCl then 5,6,7-trimethoxyindole-2-carboxylic acid, EDCI, NaHCO3,DMF, 61% n: NaH, THF, 
DMF, 87%. 
Following on from Boger’s initial total synthesis, Natsume and co-workers 
reported a 12-step total synthesis of duocarmycin SA starting from a pyrrole 
unit and proceeding via a tetrahydroquinolinol derivative (Scheme 2.2).115 
This work was later progressed and built upon through an adaptation of this 
synthesis to provide the first enantioselective route to both the natural and 




Scheme 2.2: a: Cl3CC(=NH)OBn, CF3SO3H, cyclohexane-DCM, 52%. b: DIBAL, PhMe, 87%. 
c: LDA, CH3COOBn, THF, 78%. d: Dess-Martin periodinane, DCM, 86% e: tBuOK, THF, 86% 
f: 2-ethyl-2-methyl-1,3-dioxane, BF3.OEt, DCM, 54% g: Ac2O, pyridine, DCM, 97%. h: H2, 10 
%Pd/C, EtOAc, 75%. i: DPPA, iso-Pr2NEt, benzene, MeOH, reflux, 69%. j: BBr3, DCM, 61%. 
k: DEAD, PPh3, THF, 90%. l: K2CO3, MeOH, 98%. m: Dess-Martin periodinane, DCM, then 
Et3N, DCM, reflux 86%. n: H2, Pd(OH)2, MeOH, 96% o: N-piperidyl-CO-N=N-CO-N-
piperidyl, nBu3P, THF, 88%, p: K2CO3, MeOH, 96% q, NaH, DMF, THF, 74%. 
Subsequent to this initial work, further efforts focused on ways in which 
these syntheses could be streamlined to provide an easier and more 
accessible route to the natural products. Of particular importance within this 
area was the development of a route to the formation of the fused three ring 
system via a 5-exo-trig free radical reaction (Scheme 2.3). This strategy was 
first described by Boger and co-workers in 1995 and utilised a TEMPO-trap 
version to synthesise a seco-CBI based analogue of the natural product.117 
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This route was developed further 2 years later by Patel et al. and involved the 
incorporation of a 3-chloropropene group as the reactive alkene that 
generates the indoline ring system. This ideally set up the seco form ready for 
base catalysed ring closure with the chloromethyl group being in the required 
position.118, 119 With this strategy now being a commonly utilised reaction 
within the synthesis of these natural products and subsequent analogues, 
further modifications have been made which allow for this reaction to be 
completed without the use of the undesirable tributyltin hydride.120 
 
Scheme 2.3: Example reaction and conditions used for the 5-exo-trig free radical reaction to 
form the indoline ring. 
In 2003, an efficient and concise synthesis of duocarmycin SA was presented 
by Tietze and co-workers which made use of this fundamental, commonly 
employed, 5-exo-trig reaction (Scheme 2.4).121 This synthetic strategy also 
utilised many other now commonly employed steps in the synthesis of these 
agents, and was also a first example of using a Fischer indole synthesis for 
duocarmycin SA. This provided an ideal route to the highly functionalised 




Scheme 2.4: a: NaNO2, HCl, 5 min, SnCl2, -20 oC 1h, 70%. b: NaOAc, methyl pyruvate, 
MeOH, rt, 16 h, 99% c: PPA, xylene, 120 oC, 18h, 64%. d: AlCl3, DCM, rt, 72h, 70% e: BnBr, 
K2CO3, acetone, 40 oC, 8h, 88%. f: Boc2O, DMAP, THF, rt, 1h, 98%. G: Lindlar catalyst, 
quinolone, EtOAc, H2, rt, 18 h, 91%. h: Boc2O, THF, rt, 18 h, 89%. i: NBS, THF, -78 oC, 4 h, 
88%. j: NaH, DMF, rt, 30 mins, (E/Z)-1,3-dichloropropene, rt, 12 h, 92% k: TTMSS, AIBN, 
benzene, 80 oC, 3 h, 79% l: 4M HCl/EtOAc, 2 h, rt; TMI-CO2H, EDC, DMF, rt, 18 h, 51% m: 
NH4HCO2, Pd/C, THF, 40 oC, 2 h, 91%. 
Other commonly utilised synthetic approaches to the central indole unit now 
involve a sequential coupling and cyclisation reaction between aryl halides 
and methyl propiolate. This strategy was utilised by Sakamoto and co-
workers for the synthesis of duocarmycin SA and made use of a Negishi 







Scheme 2.5: a: BnBr, K2CO3, acetone, reflux, 93%, b: ICI, THF, reflux, 91%, c: NaH, MsCl, 
THF, rt, d: TBAF, THF, rt, 75%, e: methyl propiolate, Pd(PPh3)4, ZnBr2, DIPEA, THF, reflux, 
56%, f: H2, PtO2, AcOEt, rt, g: NIS, THF, 0 oC, 5 min, ClCO2Me, DMAP, pyridine, 0 oC, 74% 
h: propargyl alcohol, CuI, PdCl2(PPh3)2, THF, Et3N, 50 oC, 83%, i: H2, Pd-C, quinolone, THF-
MeOH, rt, j: DEAD, PPh3, THF, rt then K2CO3, MeOH, rt, 99%, k: MCPBA, DCM, 0 oC, 5 
min, then Et3SiH, BF3.OEt2, 0 oC, 42%, l: MsCl, Et3N, DCM, rt, 75%, m: H2, Pd(OH)2, MeOH, 
rt, then K2CO3, MeOH, rt, 83% n: K2CO3, DMF, rt, 53%. 
Despite the success and common utilisation of the 5-exo-trig radical 
cyclisation reaction, the drawback is that the alkylating subunit formed is 
racemic and hence the enantiomers need separating post synthesis. More 
recently, an alternative approach which led to the asymmetric synthesis of 
duocarmycin SA was presented by Boger and co-workers. (Scheme 2.6).120 In 
this route a ring closing procedure was adopted that involved the use of a 
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Grignard/transmetallation reaction on a stereo-defined glycerol derivative. 
This enabled the generation of a fused six membered pyranose ring which 
upon coupling with a binding subunit, could be closed using ADDP and Bu3P 
in a Mitsunobu activation and subsequent displacement of the secondary 
alcohol to generate the natural stereochemistry in the final product.  
 
Scheme 2.6: a: (S)-glycidyl-3-nosylate, NaH, 92% b: iPrMgCl, CuI-PBu3, 69%, c: ADDP, 
PBu3, 62%,  
In spite of the impressive and imaginative chemical routes employed above 
to achieve the total synthesis of duocarmycin SA, the majority of these 
approaches involve a large number of steps and are not trivial. This makes 
the formation of analogues of this agent using these routes particularly 
difficult. Because of this, further synthetic strategies were required that 
would allow for quick and easy synthesis of analogues of these agents for 
various purposes. This would allow for more efficient investigations into the 
targeted delivery of these agents to cancer cells.  
As can be seen in most of these total syntheses of duocarmycin SA and other 
members of the family, the final step often involves the coupling of the DNA 
binding unit to the more difficult to synthesise alkylating subunit. This has 
been commonly achieved through the use of peptide coupling reagents such 
as EDC. It was this realisation that prompted Searcey and co-workers to 
visualise the structures of these natural compounds as being made by amino 
acid like building blocks. Through this visualisation it could be ascertained 
that these structures could be synthesised through an advantageous solid 
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phase chemistry protocol. This would allow the generation of a large number 
of analogues of varying degrees of complexity with relative ease. In order to 
achieve this, the group set about the synthesis of a duocarmycin SA based 
alkylating subunit, suitably substituted for Fmoc based solid phase synthesis 
(Figure 2.1).123 The route to this unit employed many elements of the 
fundamental chemistry presented in earlier total syntheses of duocarmycin 
SA. As in Tietze’s total synthesis, this alkylating subunit was locked into the 
seco form using benzyl protection of the phenolic oxygen which upon 
removal provided the active agents.  
 
Figure 2.1: Structure of duocarmycin SA alkylating unit suitably substituted for use in Fmoc 
based solid phase peptide chemistry. 
What can also be imagined is the potential use of this analogue of the 
alkylating subunit for the synthesis of potential warheads for conjugation to 
various targeting agents. These could include antibodies, small molecules or 
even nanoparticle based drug delivery moieties. Of particular interest would 
be the ease of incorporation of various functionalities or peptide based 
cleavable sequences into these systems thanks to the solid phase capabilities 
of the alkylating unit. 
2.2 Aims of the Research Reported in this Chapter 
The work in this chapter encompasses efforts towards the total synthesis of a 
duocarmycin SA alkylating subunit suitably substituted for use in Fmoc 
based solid phase chemistry. This was achieved through a 13 step synthesis 
which will be discussed in detail along with various attempted modifications 
to improve the efficiency of the synthesis. To further add to the analogues 
usefulness on the solid phase, the synthesis of a binding subunit, also 
substituted for Fmoc based solid phase synthesis, will be discussed.  
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The chapter will also cover general strategies utilised throughout this body of 
work for the introduction of the duocarmycin SA alkylating unit on to the 
solid phase. This includes the use of specific resins, coupling conditions and 
cleavage conditions. 
As a progression from this, the chapter will also look into attempts made to 
further advance this analogue through the incorporation of different 
orthogonal phenolic protecting groups to replace the benzyl group. This is in 
an attempt to help further realise the potential of this unit for use in solid 
phase peptide chemistry.  
2.3  Results and Discussion 
2.3.1 Synthesis of Benzyl Protected seco-DSA Substituted for Solid 
Phase Peptide Synthesis 
The synthesis of the benzyl protected Fmoc substituted DSA alkylating 
subunit (Fmoc-DSA-OH) was achieved following the route reported by 




Scheme 2.7: Synthetic route of Fmoc-DSA-OH as presented by Searcey and co-workers 
This large scale route was adapted slightly to allow for efficient completion 
within a research laboratory. A 25 g scale was deemed reasonable as a 
starting point for the synthesis to allow for sufficient product to be formed 
but also an ability to complete the route without difficulty using equipment 
available. The reported synthesis provides the monomer for solid phase 
synthesis in a racemic mixture from which the resulting enantiomers can be 
isolated. This was considered acceptable since it allows for formation of a 
protected seco form of the agent in large quantities. Not only does this 
prevent large scale formation of ultra-potent cytotoxic agents in the lab, but 
also fewer steps are required since spirocyclisation post benzyl deprotection 
can be achieved in vivo.  
The synthesis began when the phenolic oxygen of 25 g of 2-amino-5-nitro-
phenol (2.1) was benzyl protected using benzyl bromide and potassium 
carbonate (Scheme 2.8). The benzyl group provides an ideal protecting 
strategy due to its stability which allows it to remain in place throughout the 
total synthesis of 2.10. Purification of the product could be achieved without 
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column chromatography through precipitation on the addition of water. This 
was ideal when working on such large scales. After filtration and product 
drying, the benzyl protected compound, 2.2, was obtained as a pure 
compound in high yield (99%) as a yellow solid.  
 
Scheme 2.8: a BnBr, K2CO3, DMF, 3 h, rt, 99% 
The structure of 2.2 was confirmed through 1H NMR which demonstrated 
the presence of 5 aromatic protons at 7.37-7.48 ppm as a multiplet. The 
presence of the benzylic protons at carbon 8 (see Scheme 2.8 for compound 
numbering) were also evident as a singlet at 5.22 ppm. Evidence of the 
desired benzylic protection of the phenol rather than the amine was 
presented through the appearance of two protons as a broad singlet 
representing the exchangeable hydrogens of the amine. This side reaction, 
although possible, can be seen as less likely due to the amine being para to an 
electron-withdrawing and hence deactivating nitro group. Mass spectrometry 
also confirmed the desired mass of 245.0924 gmol-1. 
The next step in the synthesis was regioselective iodination at the 3 position 
(Scheme 2.9), to allow for the subsequent cross coupling to occur in the 
desired location. This was attained through the use of N-iodosuccinimide and 
catalytic amounts of sulphuric acid. This gave over 50 g of 2.3 with a yield of 
93%. Again, product purification could be realised through precipitation on 




Scheme 2.9: a: b: NIS, H2SO4, DMF, 3 h, rt, 93%. 
The compound was characterised through 1H NMR which showed product 
formation through the absence of a doublet peak with integration 1 
corresponding to the C3 position in 2.2. The preservation of protons at 
positions C4 and C6 and hence the desired reaction regioselectivity was 
demonstrated through the presence of two doublets each with coupling 
values of 2.1 Hz representing long range coupling. The doublet of doublet 
character of the proton at C4 was lost. A shift of the C4 proton downfield 
respective to that seen in 2.2 was also evident which was expected with the 
addition of a deactivating iodine substituent to the aromatic ring. The proton 
at C6 is less affected by this iodine addition due to mesomeric effects. The 
addition of the iodine at the desired C3 position can be explained due to the 
deactivating character of the nitro group to electrophilic aromatic 
substitution at ortho and para positions and activation of the single ortho-
position next to the electron-donating amino group. 
The next step involved a Negishi-Sonogashira style coupling with methyl 
propiolate to give 2.4 (Scheme 2.10), followed by subsequent cyclisation to 
form the central indole unit. Previous work into this step demonstrated that 
the Negishi style coupling using Pd(PPh3)2Cl2, DIPEA, ZnBr2 in DMF at 66 
ºC provided the desired coupled product in a relatively good yield (76%). 
This synthesis was conducted in 5 batches and resulted in the formation of 
over 30 g of the coupled product in a 70% yield. A proposed mechanism for 
this step is shown in Scheme 2.11 with common palladium catalysed 




Scheme 2.10: a: methyl propiolate, Pd(PPh3)2Cl2, DIPEA, ZnBr2, DMF, 16 h, 66 °C, 70%. 
 
 
Scheme 2.11: Proposed mechanism for the Sonogashira style methyl propiolate coupling. 1: 
Ligand displacement to give active Pd(0), 2, Oxidative addition of iodoaryl starting material, 
3, transmetallation with zinc bromide, 4, cis/trans isomerisation around central palladium 
complex, 5, reductive elimination to give product and reform Pd(0) active catalyst. 
Upon column chromatography purification, the resulting orange solid was 
characterised using 1H NMR which showed the presence of a peak 
corresponding to the methyl ester at 3.89 ppm. In addition, removal of the 
iodine was indicated through the upfield shift of the proton at C4. 13C NMR 
also showed the presence of 4 new carbons further indicative of a successful 
coupling. Furthermore, IR presented solid evidence of reaction success 
through formation of a carbonyl peak at 1692 cm-1. 
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Following on from this palladium cross coupling, it was next required to 
cyclise this intermediate to form the central indole unit (Scheme 2.12). This 
was previously achieved through the use of tetrabutylammonium fluoride in 
THF under reflux. In this study, the reaction was conducted on 3 batches and 
the crude was immediately Boc protected at the indole nitrogen using Boc2O 
and DMAP.  
 
Scheme 2.12: a: 1 M TBAF in THF, THF, 1 h, reflux, then Boc2O, DMAP, DCM, 3 h, rt 16-45% 
over 2 steps. 
The product was confirmed through the appearance of a doublet at 7.35 ppm 
representing the proton at the C3 position of the indole (see Scheme 2.12 for 
numbering). With a coupling constant of 2.1 Hz being observed for protons at 
the C3, C4 and C6 position, it is clear that there is long range coupling 
occurring through the π system. In addition, the aniline protons from 2.4 
were removed suggesting ring closure via the amine to form the indole. Also 
present was a singlet which integrated for nine protons at 1.42 ppm 
representing the tert-butyl of the Boc group. 
The mechanism for this TBAF promoted ring closure is not trivial and a 
universally accepted mechanism is currently not available. Sakamoto and co-
workers have studied the details of this reaction and showed two significant 
findings; 1, both a fluoride anion and a tetrabutylammonium cation are 
required for the ring closure and 2, 1H NMR demonstrates the formation of 
NBu3 during the reaction.124 With this in mind a mechanism as depicted in 
Scheme 2.13 was proposed in which initial alkyne activation via 
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tetrabutylammonium coordination leads to polarisation of the bond allowing 
attack via the aniline lone pair.  
 
Scheme 2.13: Sakamoto et al. proposed mechanism for the TBAF mediated ring closure to 
form the indole. 
Despite successful synthesis of the desired indole, the yields for this step 
were erratic, ranging from only 16% up to 50%. It was for this reason that 
further studies were completed in an attempt to achieve improved, more 
consistent yields and also to potentially combine the cross coupling and 
cyclisation steps in one. This would thereby remove a column 
chromatography based purification step. Previous examples of this combined 
step were demonstrated by Sakamoto and co-workers who, upon utilisation 
of a mesylate based protection of the amino group could achieve the cross 
coupling and cyclisation.122 However, with the synthesis conducted here 
being on a much larger scale, the mesylate protecting strategy presents an 
increase in the number of required steps and manipulations to the final 
product – something which we were trying to avoid. With a similar strategy 
without the mesylate protecting groups not allowing for combined cross 
coupling and cyclisation, our attention turned to other possible routes to the 
indole. 
One of the routes explored was the Larock indole synthesis which was 
proposed by Larock in 1991 (Scheme 2.14).125 This heteroannulation reaction 
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proceeds under similar conditions to those employed above with a reaction 
between an iodo aniline agent, an alkyne and a palladium catalyst. In 
addition to these reactants, a potassium carbonate base, PPh3 and LiCl are 
also required. Under these conditions, it has been seen that a cross coupling 
and subsequent cyclisation reaction can occur following a mechanism 
presented in Scheme 2.15. 
 
Scheme 2.14:  example conditions utilised in a Larock indole synthesis, a: Pd(OAc)2, K2CO3, 
PPh3, LiCl, DMF, 100 °C. 
 
Scheme 2.15: proposed mechanism for Larock indole synthesis. 1: reduction of the Pd(II) to 
Pd(0), 2: coordination of the chloride to form a chloride-ligated zerovalent palladium 
species, 3: oxidative addition of the aryl iodide to Pd(0), 4: coordination of the alkyne to 
palladium of the resulting arylpalladium intermediate and subsequent syn-insertion into the 
arylpalladium bond, 5: nitrogen displacement of the halide to form a six-membered, 
heteroatom-containing palladacycle, 6: reductive elimination to form the desired indole. 
A variety of conditions utilising this basic approach were explored for the 
synthesis of our required indole unit. These are summarised in Table 2.1. 
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Table 2.1: conditions employed in the attempted Larock indole synthesis to compound 2.5. 




chloridea,b Time (h) Yield (%)c 
Pd(OAc)2 (5) K2CO3 (4) LiCl 12 0 
Pd(OAc)2 (10) K2CO3 (4) LiCl 12 5 
Pd(OAc)2 (10) K2CO3 (4) LiCl 24 8 
Pd(OAc)2 (10) Na2CO3 (4) LiCl 24 0 
Pd(OAc)2 (10) K2CO3 (4) N-Bu4NCl 24 4 
Pd(OAc)2 (10) K2CO3 (8) LiCl 24 7 
Pd(OAc)2 (10) K2CO3 LiCl (2 
equivalents) 
24 8 
a All molar equivalents are with respect to compound 2.4. b All reactions 
were completed with 1 mol equivalent of chloride unless stated. c Isolated 
yields after column chromatography purification. PPh3 was employed at 5 
mol% in all conditions.  
What was observed from these results was that with 10 mol% of the 
palladium catalyst, K2CO3 employed as a base and LiCl employed as a source 
of chloride, a successful reaction was observed. However with a yield of only 
8%, this was not a viable reaction for the large scale synthesis required. In 
order to improve upon this value additional equivalents of K2CO3 and LiCl 
were employed but this resulted in little improvement. 
With little success in terms of a combined coupling and cyclisation reaction, 
our attention turned to possible improvements to the cyclisation reaction 
with TBAF. With the yields of this step being the bottle-neck of the synthesis, 
alternative literature procedures were sought out. Marinelli and co-workers 
had previously demonstrated the potential of NaAuCl4·2H2O as a catalyst to 
achieve annulation of 2-alkynylanilines in EtOH or EtOH–water mixtures at 
room temperature.126 Particularly promising was the demonstration that 
these conditions have achieved success on substrates with a nitro group para 
to the amine. This is similar to the system employed here in the DSA 
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synthesis and is seen as a potential barrier to these cyclisation reactions 
occurring. For the DSA synthesis, conditions employed involved the reaction 
of compound 2.4 with 0.04 mol equivalents of the gold catalyst (Scheme 
2.16). Reactions were first attempted in ethanol however due to solubility 
issues, THF and DMF were also tested. Despite the promise of this reaction, 
disappointingly, no reaction was seen to arise with only retention of starting 
material occurring.   
 
Scheme 2.16: attempted indole formation through a gold catalyst based reaction. Conditions 
a: NaAuCl4.2H2O, EtOH, N2, 12 h, rt. 
Further attempts to improve this cyclisation steps were made utilising a 
variety of different reagents summarised in Table 2.2. The rationale behind 
the reagents selected was to mimic the properties of tetrabutylammonium 
fluoride and to maybe get an enhancement of these properties to obtain a 
better yield.  
Table 2.2: Conditions utilised for the attempted cyclisation of compound 2.4 to give the 
central indole unit. 
Reagent Conditions Result 
Tetrabutyl ammonium 
chloride 
1 M solution, TFA, 1 h, 
reflux 
indole formation but no 




1 M solution, TFA, 1 h, 
reflux 
Signs of cyclisation but 
reduced yield (6% yield) 
Tetrabutyl ammonium 
iodide 





With no reagents providing a clear advantage over the TBAF, and with the 
required indole unit already in hand it was decided that the synthesis would 
be continued with the existing strategy in order to progress to the final 
product. The majority of the routes explored here require the polarisation of 
the alkyne bond to give a positive charge on the carbon next to the carbonyl 
of the methyl ester. With this carbonyl group already holding a partial 
positive charge on the carbon, it is easy to imagine how this is a particularly 
unfavourable intermediate and hence why it could be hindering this reaction.  
The next step in the synthesis involved the nitro group reduction to the 
amine, subsequent Boc protection of this and then selective iodination in the 
4 position to give 2.6 (Scheme 2.17). Ideally, the synthesis presented by 
Searcey and co-workers allows these steps to be achieved in one pot without 
the need for purification along the way. This is achieved through reduction 
and Boc protection using Zinc powder, NH4Cl, Boc2O and DMAP and then 
subsequent iodination using N-iodosuccinimide and catalytic amounts of 
sulphuric acid. Column chromatography was utilised to isolate 2.6 in a 57% 
yield.  
 
Scheme 2.17: a: zinc powder, NH4Cl, Boc2O, DMAP, water, THF, 12 h, rt, then NIS, H2SO4, 3 
h, rt, 57% over 2 steps. 
The product was confirmed with 1H NMR, which showed a second singlet 
peak integrating for 9 protons at 1.54 ppm demonstrating the presence of the 
further tert-butyl group of the second Boc. Due to the removal of the 
withdrawing nitro group, a large upfield shift is also observed for the proton 
at the C6 position. In addition to this, the aromatic proton at the C4 position 
represented by a doublet in 2.5 was absent suggesting addition of the iodine 
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to the ring in the desired position. Furthermore, the addition of the iodine 
and its deactivating effects are seen in a downfield shift in the proton at C3 to 
7.8 ppm. 
What might be seen as unusual in this system is the lack of iodination at the 
C3 position since this is usually the most nucleophilic site on an indole. 
However, in 2.5, this position is deactivated due to the Boc protection of the 
indole and the vicinal ester in the C2 position.  
The synthesis continued with the alkylation of the Boc protected amine with 
1,3-dichloropropene as a mixture of cis trans isomers to give 2.7 (Scheme 
2.18). The alkylation would form the foundations of the required indoline 
ring. This was achieved using potassium tert-butoxide as a base. However, 
results using this base were often erratic in terms of yield and also a 
competing transesterification reaction occurring. Sodium hydride however, 
was found to be a more reliable base for the alkylation and also providing the 
product in a good yield of 73%. Column chromatography was utilised to 
isolate the resulting mixture of cis-and trans isomers which was 
characterised.  
 
Scheme 2.18: a: (E/Z) 1,3-dichloropropene, NaH, DMF, 3 h, rt, 73%, 
Whilst the E/Z isomer mixture of the 1,3 dicholoropropene used in the 
reaction has no overall effect on the subsequent reactions it does make the 
characterisation of 2.7 more difficult. This is due to the presence of two 
products within the 1H NMR. Mass analysis however, was able to identify a 
successful reaction. 1H NMR also demonstrated the success of the alkylation 
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with the presence of peaks within the alkene region. Presence of new peaks in 
the corresponding region of the 13C NMR spectra provided further evidence 
of a successful alkylation.  
The next step involved the extensively studied 5-exo-trig radical cyclisation 
step presented earlier on in this chapter in section 2.1.1. (Scheme 2.19). This 
was achieved here using AIBN and tristrimethylsilyl silane in toluene at 
reflux. After purification, the three ring fused product (2.8) was obtained as 
a colourless solid in 71% yield.  
 
Scheme 2.19: a: AIBN, TTMSS, toluene, 1 h, reflux, 71%. 
Evidence of the success of the reaction was demonstrated through 1H NMR 
and 13C NMR which suggested ring closure with a simplification of the 
spectra now that the presence of two geometrical isomers had been removed. 
Also, the occurrence of peaks between 3.89 and 4.13 ppm integrating for 5 
protons suggested the formation of the desired 5-membered indoline ring 
with the presence of the protons at C32-C34 (see Scheme 2.19 for compound 
numbering). The splitting of the protons from this region are complex due to 
diastereotopic effects as a result of the introduction of a chiral centre at C33.  
In order to introduce the required carboxylic acid functionality for the solid 
phase peptide synthesis, the methyl ester was then hydrolysed under basic 
conditions using a saturated aqueous solution of LiOH in methanol and THF 
(Scheme 2.20). Subsequent acidification and filtration of the mixture gave 




Scheme 2.20: a: LiOH, H2O, MeOH, 3 h, rt, quantitative yield. 
1H NMR in deuterated DMSO confirmed the presence of 2.9 through a broad 
singlet at 13.46 ppm - the removal of the methyl ester peak at 3.86 ppm was 
also observed. IR confirmed the presence of the carboxylic acid through a 
broad peak at around 3000 cm-1 and a peak representing the carbonyl at 
1694 cm-1. 
The final step of the synthesis required Boc deprotection from the indole and 
indoline nitrogen and subsequent, regioselective Fmoc protection of the 
indoline nitrogen (Scheme 2.21). The Boc deprotection was achieved through 
stirring the starting material in 4 M HCl in dioxane overnight. The desired 
Fmoc protection was then attained through reaction with Fmoc-Cl and 
NaHCO3 in THF. Column chromatography based purification resulted in 




Scheme 2.21: a: 4 M HCl in dioxane, 16 h, then, Fmoc-Cl, NaHCO3, THF, 10 min, rt, 84% 
over 2 steps.  
The structure of 2.10 was confirmed through various characterisation 
techniques. The 1H NMR demonstrated the removal of both of the Boc 
groups indicating the success of this part of the reaction. The rest of the 1H 
NMR spectrum however is more complex and this has been previously 
demonstrated by Searcey and co-workers to be due to the presence of 
rotamers. This has been proposed to occur due to steric clash between the 
Fmoc group and the benzyl group. Accurate mass analysis showed more 
clearly the presence of 2.10 through an observed mass of 578.1245 along 
with the characteristic isotope splitting expected from the chlorine. 
The 13 step synthesis, discussed above was achieved with a final overall yield 
of 3% giving 2.1 g of the final product. This Fmoc substituted, benzyl 
protected seco-DSA alkylating subunit could then be introduced onto the 
solid phase ready for further investigations in to achieving a targeted delivery 
of the cytotoxic agent to cancer cells.  
2.3.2 Synthesis of Binding subunit analogue substituted for the 
solid phase 
In order for 2.10 to fully realise its potential for use on the solid phase it was 
proposed that a compound that could represent the binding unit of the 
natural products would also be ideal. This unit should also be substituted for 
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use in Fmoc-based solid phase synthesis in order for peptide sequences to be 
extended from both the C-terminus and the N-terminus. Previous work on 
the solid phase by Searcey and co-workers utilised a 5-methoxyindole unit 
which capped the N-terminus and hence didn’t provided the ability to grow 
from this end.123 An analogue of this indole containing a primary Fmoc 
protected amine and a carboxylic acid was projected to be a possible 
alternative. The envisioned indole based binding subunit is shown in Figure 
2.2.  
 
Figure 2.2: Structure of binding subunit indole, suitably substituted for use on the solid 
phase. 
The synthesis of this subunit was to start with the commercially available 
ethyl 5-nitroindole-2-carboxylate (2.11) and a proposed route to 2.14 is 
shown in Scheme 2.22. 
 
 
Scheme 2.22: Proposed synthetic route to 2.14. 
The hydrolysis of the ethyl ester of 2.11 was achieved under basic conditions 
with lithium hydroxide. The product was isolated after acidification in 
aqueous solution giving a quantitative yield. The hydrolysis was observed to 
occur with 1H NMR demonstrating the presence of a peak at 12.5 ppm 
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representing the carboxylic acid. Absence of a triplet at 1.33 ppm and a 
quartet at 4.32 ppm also provided evidence of ethyl group removal. 
The reduction of the nitro group was first attempted using 10% palladium on 
carbon along with 25% ammonium formate as a source of hydrogen. After 
hydrogenation, the resulting mixture was filtered directly into a solution of 
Fmoc-Cl in DCM. Despite this process having success with other units within 
our laboratory, attempted purification of the resulting mixture and 
subsequent characterisation showed no presence of the desired Fmoc 
protected subunit. An alternative reduction method was attempted using zinc 
powder, NH4Cl and H2O in THF. With this reduction method showing 
success for the synthesis of 2.10 it was hoped a similar result would be 
obtained here. However, after completing this reaction none of the desired 
product was obtained. The reason for the failure of these reactions was 
proposed to be due to the presence of the carboxylic acid. The formation of 
the desired carboxylic acid and amine makes isolation of the product 
difficult. For this reason, a new synthetic route was proposed which involved 
nitro reduction and protection prior to the ester hydrolysis (Scheme 2.23). A 
Boc protection strategy would be utilised prior to Fmoc protection due to the 
lability of the Fmoc group to basic conditions used for ester hydrolysis. This 
is similar to the strategy used in the synthesis of 2.10. 
 
Scheme 2.23: Modified proposed route to compound 2.14 involving nitro reduction prior to 
ethyl ester hydrolysis. 
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The nitro reduction and subsequent Boc protection of 5-nitroindole-2-
carboxylate (2.11) was achieved in one pot using zinc powder, NH4Cl, water, 
Boc2O and DMAP. Interestingly, despite one equivalent of DMAP being used, 
1H NMR demonstrated that Boc protection of the indolic nitrogen did not 
occur. Despite this, the product after column chromatography was taken 
forward onto the ethyl ester hydrolysis. The reduction of the nitro group also 
resulted in an observed upfield shift of the proton at C4 and C6. This can be 
attributed to the reduction of the electron withdrawing character at position 
C5. 
As in the synthesis of 2.10, the ester hydrolysis of 2.15 was achieved using 
lithium hydroxide. Subsequently, the isolated 2.16 was Boc deprotected 
using 4 M HCl in dioxane before Fmoc protection with Fmoc-Cl and 
NaHCO3. The presence of the desired compound was confirmed through 1H 
NMR, which showed the peaks of the central indole unit and also the 
characteristic peaks of the Fmoc unit in the aromatic region and ay 4.47 ppm 
and 4.31 ppm.  
With an alkylating subunit (2.10) and a binding subunit (2.14) both suitably 
substituted for solid phase synthesis in hand, attempted synthesis of specific 
peptide sequences incorporating these units could be conducted. The 
sequences of interest would be those which aid the formation of conjugates 
between duocarmycin and a targeting moiety. This might include specific 
functionalities or the introduction of cleavable sequences. 
2.3.3 Utilisation of Fmoc-DSA-OH in Solid Phase Peptide 
Synthesis.  
2.3.3.1 Solid Phase Chemistry 
The unique feature of the alkylating unit analogue which makes it such a 
desirable moiety is its ability to be introduced and used within solid phase 
organic synthesis (SPOS). In comparison to its solution phase synthesis 
counterpart, SPOS presents many advantageous features. Most notably of 
these is the removal of tedious purification steps after each chemical 
manipulation. With the desired molecule anchored to a solid support, 
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reagents utilised for reaction can simply be washed from the resin using an 
applicable solvent. Isolation of the final product can then be achieved via 
cleavage from the solid support.127 
SPOS is of particular use in the synthesis of long chain peptides termed solid 
phase peptide synthesis (SPPS) which was brought about by Merrifield in the 
late 1960s.128 Through anchoring a specific amino acid onto a solid support, 
subsequent amino acid couplings could be made without the need for long 
purification steps after each addition. Using orthogonal protecting groups, 
successive coupling and deprotection reactions could be used to build up the 
peptide sequences. It was this work which was fundamental in the awarding 
of the 1983 Nobel Prize for chemistry to Merrifield.129 After originally being 
seen as a flight of fancy, the simplicity and ingenuity of this concept is 
depicted in the popular use of this technique and also in its ability to be 
automated in modern day systems. Particularly popular is the use of Fmoc 
based SPPS (Scheme 2.24).127 This strategy utilises amino acids whose 
primary amine groups are protected with an Fmoc group. This base labile 
group can be removed after each coupling without any effect on the 
anchoring of the peptide to the resin. The linker between resin and peptide is 
often acid labile and so cleavage of the final peptide, along with side chain 
protecting group removal, is commonly achieved through the use of reagents 
such as trifluoroacetic acid (TFA).  
 
Scheme 2.24: General scheme demonstrating the route, using Fmoc SPPS, to a desired 
peptide using subsequent coupling and deprotection steps. 
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2.3.3.2 Strategies Employed for the use of Fmoc-DSA-OH in SPPS. 
With the use of the above units (2.10 and 2.14) on the solid phase being 
present throughout this thesis, what follows is a summary of conditions most 
commonly utilised for the synthesis of specific peptides. Following on from 
this section, where specific peptides are introduced in the subsequent 
chapters, a discussion of the synthesis of these peptides will be brief unless 
anomalous conditions to those introduced here were used.  
Previous work by Searcey and co-workers demonstrated the use of the 
alkylating unit synthesised above, on the solid phase.123 This work, found the 
ideal conditions required to obtain the most efficient use of the subunit. Post 
cleavage HPLC analysis was used to study the purity of the peptide 
synthesised in relation to undesired side products. The conditions studied 
included different types of resin, coupling reagents, and cleavage conditions. 
The results of this study are summarised in Table 2.3. 
Table 2.3: Summary of conditions found to give most efficient usage of Fmoc-DSA-OH on 
the solid phase.  
a Depending on desired functionality at the C-terminus, b Depending on 
chosen resin and amino acids present within sequence.  
SPPS requirement/step Ideal Reagents and conditions 
Resin a 2-chlorotrityl (2-Cltrt) resin or rink 
amide based resin. Resin swelling 
was achieved in dichloromethane 







based couplings.  
Fmoc Deprotection 40% piperidine in DMF 10mins, 
20% piperidine in DMF, 5 min x2 
Cleavage conditions b 2- Cltrt resin – 1% TFA, 10% TIPS, 
DCM, 3 h 
Rink Amide – 95% TFA, 2.5% TIPS, 
2.5% H2O, 3 h 
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2-Cltrt resin was found to be an ideal resin choice for utilising the benzyl 
protected Fmoc-DSA-OH on the solid phase. The 2-Cltrt resin can be cleaved 
only at the desired position and the resulting cation formed is more sterically 
hindered due to the larger linker structure. This means it is less likely to 
interact further with the synthesised structures. Additionally, the 2-Cltrt 
resin can be cleaved in only 1% TFA which reduces any possible acid induced 
degradation of the peptide which may occur in higher TFA concentrations. 
Although this resin demonstrated the most potential, rink amide was also 
shown to be an acceptable substitute should an amide based C-terminus be 
desired.  
In terms of coupling agents, HATU and DIPEA were found to be the most 
ideal. This was in comparison to HBTU, PyBOP, EDC and DIC. In some 
instances in the work disclosed herein, HBTU and HOBt were utilised for 
couplings as an alternative to HATU. 
With these conditions being found to provide the optimal usage of the DSA 
unit on the solid phase, they were mimicked for the majority of the peptides 
synthesised within this body of work. For peptides which were synthesised 
following conditions other than those found in this table, specific conditions 
will be disclosed where applicable.  
2.3.4 Benzyl Deprotection of DSA Containing Peptides 
Upon synthesis and cleavage from the resin, benzyl group deprotection is 
required to provide the active agents. Once the benzyl group has been 
removed from the phenolic oxygen, the seco-form of the duocarmycin 
analogues are no longer in a ‘locked’ conformation and hence are free to 




Scheme 2.25: deprotection of the benzyl group from a DSA based peptide sequence, results 
in an 'unlocking' of the seco form and hence an ability to spirocyclise to form the 
pharmacologically active agent. 
The benzyl deprotection can be achieved through a transfer hydrogenation 
reaction of the starting material with 10% palladium/carbon, with 25% 
ammonium formate as a source of hydrogen.21-23 These conditions were 
utilised for many of the peptides presented in this thesis with a general 
example being demonstrated in Scheme 2.26. The success of the reaction was 
observed via reverse-phase HPLC, which identified a shift in the main 
product peak subsequent to subjection to the reaction conditions. The shift to 
an earlier retention time indicted the formation of a more polar species 
which is consistent with this specific reaction. 1H NMR and various mass 
spectrometry techniques were also used to confirm debenzylation depending 
on the specific species. 
 
Scheme 2.26: a: 10% Pd/C, 25% Aq. HCO2NH4, THF/MeOH, rt, 1 h 
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Despite these conditions presenting a viable option for the debenzylation of a 
number of synthesised peptides in this thesis, it was noted that sometimes 
this reaction does not provide the desired outcome, resulting in either no 
debenzylation or mixtures of products. This has been observed for analogues 
of certain lengths (15+ amino acids) and also on the introduction of certain 
amino acids such as cysteine. The specifics of these findings will be discussed 
in chapters 3 and 4 where applicable. It was for this reason that an 
alternative set of conditions for the debenzylation reactions were sought 
after.  
The debenzylation of various organic compounds using boron tribromide has 
been disclosed on numerous occasions within the literature.130-132 It was 
proposed that these conditions may be useful in the debenzylation of DSA 
based peptide sequences due to the chemoselectivity of the described 
reaction. As an initial attempt, 2.10 was reacted with boron tribromide in 
DCM as a 1 M solution at -78 °C (Scheme 2.27).  
 
Scheme 2.27: a: 1 M BBr3, DCM, -78 °C, 1 h, 64% 
Monitoring of the reaction via reverse-phase HPLC demonstrated complete 
consumption of the starting material and formation of a new major peak. 
Column chromatography was utilised to isolate this peak which upon 
characterisation was found to be the desired debenzylated product. 
Specifically, 1H NMR demonstrated the removal of a multiplet representing 
the benzyl group aromatic protons at 7.47 ppm and mass spectrometry 
analysis showed the desired mass of 488.13. A proposed mechanism for this 
transformation is shown in (Scheme 2.28) and proceeds with an initial 
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formation of an ether adduct followed by the loss of bromide which attacks 
the benzylic methylene of the zwitterionic intermediate. This results in 
cleavage of the C–O bond. Hydrolysis of the penultimate intermediate during 
aqueous workup gives the desired debenzylated compound.133  
 
Scheme 2.28: proposed mechanism for benzyl deprotection using boron tribromide 
Upon attempted mimicking of these conditions with various analogues, the 
boron tribromide debenzylation reaction was found to be applicable. Pleasing 
was the observation that these conditions or those similar, could achieve the 
debenzylation of larger peptide analogues where the Pd/C, HCO2NH4 
reaction was found to be inapplicable. This will be discussed further in 
chapter 3. The discovery of the use of boron tribromide for the debenzylation 
reaction in these systems, helps to further realise the potential of this Fmoc 
substituted alkylating unit in solid phase synthesis. This opens up new doors 
for the use of this particular subunit in the further study of duocarmycin 
based agents.  
2.3.5 The use of p-methoxybenzyl as an Alternative Protecting 
Group Strategy for Fmoc-DSA-OH 
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The benzyl group utilised in the synthesis of Fmoc-DSA-OH holds many 
advantages, mainly due to its lack of lability to the reaction conditions 
employed in the synthesis. However, as mentioned above, the removal of this 
group from the systems formed on the solid phase is not trivial and problems 
have been encountered with this on numerous occasions. In addition to this, 
the benzyl group removal presents an additional step post cleavage from the 
resin which is undesirable and often leads to reduced yields. As a 
consequence, it was proposed that a new protecting group strategy could be 
utilised to get around this. Specifically, in an ideal situation, the protecting 
group used would remain inert to reaction conditions employed in the 
solution and solid phase synthesis but be labile to possible resin cleavage 
conditions. This would mean that pharmacologically active systems could be 
isolated directly from the resin thus eliminating a post cleavage deprotection. 
In turn this could enhance yields and reduce handling of these extremely 
cytotoxic agents.  
One of the protecting groups which caught our attention was the para-
methoxybenzyl group (PMB). The foremost reason for this was its reactivity 
profile, which provided the ideal balance of lability and stability for use in our 
syntheses. The PMB group, like the benzyl group, is relatively stable and is 
able to remain on a phenol group under a wide variety of different 
conditions. Also similar is the way in which the PMB can be removed by 
hydrogenation.134 In addition to this, deprotection of a PMB group has been 
demonstrated using oxidative conditions such as the use of DDQ.135 However, 
the particular property which drew us towards this group was the multiple 
demonstrations of lability towards specific acidic conditions. Examples of 
these conditions include, but are not limited to; MgBr2·Et2O– Me2S,136 
SnCl2·2H2O-EtSH,137 TMSI-TPP,138 AlCl3–Me2NC6H5,139 SnCl4-
benzenethiol140, CeCl3·7H2O–NaI,141 Ce(OTf)3,142 ZrCl4,143 TfOH-N-methyl-p-
toluenesulfonamide or sulfonamide-functionalized (‘‘safety-catch’’) resins,144 
and TfOH-1,3-dimethoxybenzene.145 These conditions have been employed in 
a variety of systems including natural product synthesis. The desirability of 
this particular property lies in the fact that upon cleavage of the resin under 
acidic conditions, the PMB group is likely to also be removed. This would 
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yield pharmacologically active duocarmycin based peptides and remove the 
often troublesome post cleavage deprotection step (Scheme 2.29). 
 
Scheme 2.29: Schematic representation of PMB group utilisation on the solid phase. It was 
proposed that treatment of the on resin peptide with acidic conditions could lead to 
combined, resin cleavage and PMB deprotection to yield active analogues. 
Despite the promising nature of this strategy, it was envisioned that the final, 
Boc deprotection and Fmoc protection step in the Fmoc-DSA-OH synthesis 
could be troublesome for the PMB protected unit. This is due to the acidic 
conditions utilised to remove the Boc group. It was for this reason that initial 
attempts to obtain the desired PMB protected Fmoc-DSA-OH unit (2.18) 
was to begin with the previously synthesised benzyl protected Fmoc-DSA-
OH. It was hoped that benzyl removal and subsequent PMB protection would 




Scheme 2.30: preferred route to PMB protected Fmoc-DSA-OH. PMB protection post benzyl 
deprotection was unsuccessful. 
The deprotection of the benzyl protected Fmoc-DSA-OH unit to give 2.17 
was achieved using the boron tribromide based reaction disclosed in section 
2.3.4. After purification and confirmation of the desired product, the 
compound was then subjected to PMB protection using p-methoxybenzyl 
bromide and a variety of basic conditions. These include K2CO3, NaOH and 
NaH. The bases chosen were done so taking into consideration the presence 
of the base labile Fmoc group on the molecule. By attempting a variety of 
base strengths it was hoped that optimum conditions where the Fmoc stayed 
intact whilst the phenol functionality became nucleophilic enough to undergo 
the SN2 reaction would be obtained. To try and promote the protection of the 
phenol, potassium iodide was also utilised in catalytic quantities. What was 
observed from these conditions was that the desired product was not formed. 
This was proposed to be due to the high functionality of this Fmoc-DSA-OH 
unit, particularly the inherent lability of the Fmoc group to basic conditions. 
It was unlikely that phenol protection would occur without base due to its 
poor nucleophilicity.  
Although this was disappointing to see, the use of the PMB protecting group 
was pursued through starting the synthesis of the PMB protected Fmoc-DSA-
OH unit starting from 2-amino-5-nitro-phenol (see Scheme 2.7 for the 
analogous synthesis using the benzyl protecting group strategy). In spite of 
the possibility of the troublesome penultimate Boc deprotection step, it was 
hoped that some inherent, chemical differences between the Boc and PMB 
group could be utilised to achieve the selective Boc deprotection. As 
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described above, one of the attractive properties of the PMB group was its 
similarities in stability to the benzyl group. It was proposed therefore that the 
majority of the conditions used towards 2.14 could be retained without 
significant modifications. Indeed, this was found to be the case. 
Characterisation of the products from each individual step using conditions 
described in Section 2.3.1. demonstrated the presence of the desired 
compounds. 1H NMR showed the formation of the PMB group in each step 
with an additional singlet for the methoxy CH3 evident at around 4 ppm. In 
addition to this, due to the symmetry of the PMB group aromatic protons, 
two peaks evident as identical multiplets were present in the aromatic 
regions. We were particularly pleased that the iodination reactions within the 
synthetic route (see Scheme 2.9 and Scheme 2.17 for the analogous reactions 
with the benzyl group) were found to occur with the desired regioselectivity. 
It could be imagined how the more reactive PMB group could have interfered 
with these reactions.  
The synthesis proceeded smoothly up until the penultimate step of Boc 
deprotection of 2.19 (Scheme 2.31). Initial attempts using 4 M HCl in 
dioxane as used previously, resulted in what looked like completed 
degradation of the compound as demonstrated by a messy 1H NMR with no 
obvious presence of characteristic peaks of these compounds. This was 
slightly unexpected as it was thought a combined PMB and Boc deprotection 
would be the only side reaction that may occur. With these conditions 
proving inapplicable to this system, investigations into other conditions 
which might be utilised successfully were made. These conditions and the 




Scheme 2.31: final Boc deprotection and Fmoc protection step to give the PMB protected 
Fmoc-DSA-OH unit. 
 
Table 2.4: summary of various conditions and their respective results attempted to try and 
achieve Boc deprotection without removal of PMB group of 2.18. 
a All conditions were tested under various time points. 
The conditions utilised and shown in Table 2.4 were rationally chosen due to 
their previously shown ability to Boc deprotect. It was hoped that in these 
mild or non-acidic conditions they could be useful for achieving the desired 
outcome in our compound.  
With the tested conditions resulting in what looked like degradation/some 
other unknown side reactions or no reaction at all, the literature was further 
consulted to see if there may be a way around this to achieve the synthesis of 
2.18. The literature search returned a potential route by employing a para-
chlorobenzyl (PCB) protecting group. This group has been reported as a more 
stable alternative to the PMB group.146, 147 Jensen and co-workers then 
Conditions a Result 
4 M HCl in dioxane Complete degradation 
2 M HCl in dioxane Partial Boc/PMB deprotection 
1 M HCl in dioxane No reaction 
10% TFA in DCM Partial Boc/PMB deprotection 
5% TFA in DCM No reaction 
SnCl4 in EtOAc Complete degradation 
TBAF in THF (reflux) No reaction 
Water (reflux) No reaction 
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disclosed the conversion of the PCB group to the PMB group through 
utilisation of a palladium-RockPhos ligand complex.148 This route seemed 
ideal for our system as it meant the increased stability to acidic conditions of 
the PCB group could be utilised to synthesise the PCB protected Fmoc-DSA-
OH (2.21). This, according to the literature could then be converted to the 
desired PMB protected Fmoc-DSA-OH (2.18) (Scheme 2.32). 
 
Scheme 2.32: proposed route utilising the PCB protecting group. Synthesis of PCB protected 
Fmoc-DSA-OH followed by conversion to the PMB protected unit using a palladium-
RockPhos complex. 
In order for this strategy to be investigated, the synthesis of 2.21 was carried 
out. Again, due to the advantageous stable nature of this protecting group, 
the conditions utilised for the benzyl protected Fmoc-DSA-OH could be 
mimicked. 1H NMR provided solid evidence of reaction success with the 
presence of the aromatic protons of this group showing at 7.47 ppm as a 
multiplet. In addition, mass spectrometry demonstrated the desired masses 
along with the presence of the characteristic chlorine isotope pattern. 
The increased stability of the PCB group to acidic conditions in comparison 
to the PMB group was demonstrated through a successful Boc deprotection 
and subsequent Fmoc protection to give the desired compound. This Boc 
deprotection was achieved using 4 M HCl in dioxane or with trifluoroacetic 
acid in DCM. Now that the PCB protected Fmoc-DSA-OH was in hand, 
attempts could be made to convert this to 2.18. An initial attempt was made 
following the conditions describe by Jensen and co-workers.148 These are 




Scheme 2.33: a: RockPhos Pd G3 (5 mol%), RockPhos ligand (5 mol%), Cs2CO3, MeOH, N2, 
20 h, 60 °C. 
After the 20 h reaction time course, thin layer chromatography (TLC) 
suggested no reaction occurring and this was confirmed by 1H NMR which 
showed only the presence of starting material. As a progression from this 
initial attempt, alternative bases were investigated including sodium tert-
butoxide, which Jensen and co-workers suggested can provide an ideal 
substitute. However, under these reaction conditions, again no conversion of 
the starting material was observed. Further attempts to push the reaction to 
completion through elevating reaction temperatures and ensuring complete 
exclusion of oxygen to protect the palladium catalyst all proved futile. With 
little success and the observation of starting material retention, it was 
proposed that in this system, oxidative addition of the aryl chloride was 
unfavourable and hence this step was hindering the progress of the PCB to 
PMB conversion.  
2.3.6 On Resin Benzyl Deprotection Using Boron Tribromide 
Despite the disappointing results obtained from the PMB based studies, 
achieving the benzyl deprotection on resin or alongside cleavage was still an 
area worth exploring. This is due to the possibility of improved yields and a 
more robust synthetic route to active duocarmycin based peptides. It was for 
this reason that the boron tribromide reaction discussed in Section 2.3.4. was 
further investigated. The idea was that treatment of a DSA based peptide, still 
on the resin, with BBr3 could result in benzyl deprotection prior to cleavage. 
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Cleavage from the resin would therefore yield active analogues without the 
need for post cleavage manipulations (Scheme 2.34). 
 
Scheme 2.34: Treatment of on resin peptide with boron tribromide could result in on resin 
benzyl deprotection therefore removing the need for post cleavage modifications. 
With these conditions resulting in the formation of hydrogen bromide (HBr) 
as a side product, it was possible that resin cleavage may also be achieved in 
addition to benzyl deprotection. This is due to the acidic nature of HBr. 
Specific examples of the peptides on which this method was utilised will be 
described in Chapters 3 and 4. However, what we were delighted to see from 
these studies was that resin treatment with the BBr3 in DCM for 2 h did result 
in benzyl deprotection. HPLC analysis and post cleavage mass spectrometry 
studies demonstrated the success of these conditions. Especially pleasing, 
was the apparent result of complete benzyl deprotection occurring on the 
resin. This was evident since post cleavage HPLC and mass spectrometry 
showed no signs of the benzyl protected analogue. Although resin cleavage 
was not observed during BBr3 treatment, the work in this thesis using this 
method was completed on a rink amide resin. The increased acid stability of 
this resin is likely to have had a role to play within these results. However, it 
is proposed that the use of the more acid labile 2-Cltrt resin with BBr3 may 
yield results of combined benzyl deprotection and resin cleavage. 
These results further cement the potential of the benzyl protected Fmoc-
DSA-OH unit for use in solid phase peptide synthesis. The benzyl bromide 
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conditions reported here, greatly increase the efficiency of duocarmycin 
based analogue synthesis on the solid phase using this unit. 
2.4 Conclusions 
The aim of the work presented in this chapter was to synthesise a benzyl 
protected duocarmycin SA based analogue which is suitably substituted for 
use in solid phase peptide chemistry. As an extension to this, attempts were 
made to help further realise the potential of this subunit for use in solid 
phase chemistry.  
The synthesis of the duocarmycin SA subunit, substituted for Fmoc based 
solid phase peptide chemistry was completed on a large scale. Efforts were 
made to improve some of the bottle neck steps of the synthesis that had 
shown reduced or erratic yields. Despite various alternative conditions being 
attempted, including a Larock indole synthesis, a lack of improved yields or 
meaningful results led us to continue the synthesis on the original path. The 
final benzyl protected Fmoc-DSA-OH unit was synthesised in 13 steps in an 
overall yield of 3%.  
As an initial attempt to further enhance the utility of this unit on the solid 
phase, the synthesis of a binding subunit like moiety that can also be 
employed on a resin support was investigated. The aim of this subunit was to 
allow attachment to the DSA unit and also peptide chain growth at either the 
C or the N terminus. The synthesis of this unit proceeded from a 
commercially available indole and the final Fmoc, carboxylic acid substituted 
indole was synthesised in 3 steps with an overall yield of 45%. The utility of 
this unit in solid phase peptide synthesis has been established and specific 
examples of peptides incorporating this unit will be presented in the coming 
chapters. 
This chapter also aims to provide details of the ideal conditions established 
for use of the above units on the solid phase. A 2-Cltrt resin has previously 
been described as an ideal resin to incorporate the Fmoc-DSA-OH unit with 
HATU and DIPEA based couplings also showing an ideal level of success. A 
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rink amide resin has been found to be useful for incorporating the DSA unit 
into peptide sequences where an amide functionalised C-terminus is desired.  
Previously, the benzyl group deprotection from the DSA unit has been 
achieved with a transfer hydrogenation reaction using palladium and 
ammonium formate. The body of work presented in this thesis established 
certain examples where these conditions are inapplicable. For this reason 
investigations to find alternative conditions for the benzyl deprotection were 
conducted.  The use of boron tribromide to achieve this manipulation was 
found to be desirable in its capacity to be applicable for a wide variety of DSA 
containing peptides. For peptides where the transfer hydrogenation was 
shown to be unsuccessful, the boron tribromide conditions yielded the 
desired benzyl deprotected, active peptides in reasonable yields. Following on 
from these initial investigations, we were pleased to find that these boron 
tribromide based conditions can be applied to peptides still on the resin. This 
means that benzyl deprotection can be achieved before peptide cleavage. This 
work therefore enhances the use of this analogue on the solid phase since it 
removes the need for post cleavage modifications which have been found to 
greatly reduce the yield of the final peptides. Furthermore, removal of the 
benzyl group before cleavage reduces the need to handle these cytotoxic 
agents in the laboratory.   
Finally, to further improve the efficiency of the Fmoc-DSA-OH compound in 
solid phase peptide chemistry investigations into alternative protecting 
groups for the subunit as opposed to the benzyl group were conducted. This 
was carried out since the benzyl group deprotection has been shown to be 
tricky in specific examples and also requires an additional step to be 
removed. It was proposed that an alternative protecting group could be 
utilised which can be removed during peptide cleavage from the resin under 
acidic conditions. A PMB protecting group was suggested to be a reasonable 
alternative for these studies. The synthesis of the final PMB protected Fmoc-
DSA-OH unit was found to be intractable due to the need to remove Boc 
groups with acidic conditions during the synthesis. This was shown to result 
in either premature PMB deprotection or compound degradation. A PCB 
protecting group was reported in the literature that shows increased acidic 
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stability and can be transformed into the PMB under a single step using a 
palladium catalyst. The synthesis of a PCB protected Fmoc-DSA-OH unit was 
therefore completed. However, conversion of this into the PMB protected 
Fmoc-DSA-OH unit was found to be unsuccessful under a variety of 
conditions. Despite the lack of success with the two protecting groups studied 
here, further protecting groups could be investigated which may allow for 
combined deprotection and resin cleavage. If success could be found within 
this area, a dramatic improvement to the efficiency of using this duocarmycin 
SA analogue on the solid phase would be made.  
2.5 Experimental 
2.5.1 General Procedures 
Reagents and Solvents  
All chemicals were reagent grade and were purchased from Sigma Aldrich, 
Fisher Scientific, Fluorochem and Tokyo Chemical Industry. Anhydrous 
solvents were bought from Sigma Aldrich and assumed to conform to 
specification.  
Physical Characterisation and Spectroscopic Techniques  
1H- and 13C-NMR spectra were recorded on a Bruker spectrometer operating 
at 400 MHz (1H) or 100 MHz (13C) using the specified deuterated solvent. 
The chemical shifts for both 1H- and 13C were recorded in ppm and were 
referenced to the residual solvent peak of CHCl3 at 7.26 ppm (1H) and 77.0 
ppm (13C) or DMSO-d6 at 2.50 ppm (1H) and 39.5 ppm (13C). Multiplicities in 
the NMR spectra are described as s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad, and combinations thereof; coupling 
constants are reported in Hz. Assignments, where conspicuous, have been 
confirmed by appropriate 2D NMR experiments. MALDI was performed on 
Kratos Analytical Axima MALDI-TOF. Low resolution mass spectra were 
recorded using a Shimadzu LCMS 2010EV operated under electrospray 
ionisation mode. Accurate mass spectra were recorded at the EPSRC 
National Mass Spectroscopy Service Centre, Swansea or The John Innes 
Centre, Norwich Research Park. Melting points were recorded using open 
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capillary tubes on a Mel-Temp electrothermal melting point apparatus, 
melting points are uncorrected. Infrared spectra were recorded as neat 
samples using a PerkinElmer Spectrum BX with ATR attachment. 
Chromatographic Techniques  
Thin-layer chromatography was performed on aluminum plates coated with 
0.2 mm silica gel-60 F254. After elution, the TLC plates were visualized under 
UV light. Flash chromatographic separations were performed on silica gel for 
column chromatography (particle size 60 μm). Analytical RP-HPLC was 
performed on an Agilent 1200 using an Agilent eclipse XDB-C18 column, 4.6 
x 150 mm, 5 µM and a flow rate of 1 mL/min. Solvent A = Water + 0.05% 
TFA and Solvent B = MeOH + 0.05% TFA. Gradient 5% B up to 95% B over 
20 minutes. Detection wavelength 214 nm and 254 nm. Semi-preparative 
RP-HPLC was performed on an Agilent 1200 using an Agilent eclipse XDB-
C18 column, 9.4 x 250 mm, 5 µM and a flow rate of 4 mL/min. Solvent A = 
Water + 0.05% TFA and Solvent B = MeOH + 0.05% TFA. Gradient 5% B up 
to 95% B over 20 minutes. Detection wavelength 214 nm and 254 nm. 
Preparative RP-HPLC was performed on an Agilent 1200 using an Agilent 
eclipse XDB-C18 column, 21.2 x 150 mm, 5 µM and a flow rate of 20 mL/min. 
Solvent A = 95% H2O + 5% MeOH + 0.05% TFA and Solvent B = 95% MeOH 
+ 5% H2O + 0.05% TFA. Gradient 5% B up to 95% B over 20 minutes. 
2.5.2 Synthesis of Fmoc-DSA-OH (2.10) 
 
BnBr (21.0 mL, 178 mmol) was added dropwise to a stirring suspension of 2-
amino-5-nitrophenol (25.0 g, 162 mmol) and K2CO3 (49.3 g, 257 mmol) in 
DMF (250 mL) at room temperature. After 3 h, the reaction mixture was 
poured over crushed ice and allowed to rest for 30 minutes. The precipitate 
was collected by filtration and triturated with cold water before drying under 
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vacuum. This yielded 38.98 g of 2.2 as a yellow/brown solid (99 %). Rf 0.17 
(20% ethyl acetate in hexane); mp. 145-146 °C (lit.122 144−145 °C). 1H NMR 
(CDCl3, 400 MHz) δ 7.83 (1H, dd, J = 2.3, 8.7), 7.77 (1H, d, J = 2.3), 
7.37−7.46 (5H, m), 6.65 (1H, d, J = 8.8), 5.15 (2H, s), 4.60 (2H, brs). 13C 
NMR (CDCl3, 100 MHz) δ 144.7, 143.1, 138.9, 135.7, 128.9, 128.6, 127.9, 
119.3, 112.3, 107.3, 70.9. IR (neat) νmax 3480, 3359, 1622, 1579, 1517, 1479, 
1385, 1292, 1222, 1092, 1007, 869, 817, 755, 744, 697 cm−1.  
 
H2SO4 (844 µL, 162 mmol) was added to a stirring solution of 2.2 (39.98 g, 
159 mmol) in DMF (590 mL), followed by portionwise addition of NIS (53.9 
g, 239 mmol) at room temperature. After 2 h the reaction mixture was 
poured over crushed ice and left to rest for 30 minutes. The precipitate was 
collected by filtration and triturated with cold water, followed by cold hexane 
before drying under vacuum. This yielded 54.85 g of 2.3 as a bright yellow 
solid (93%). Rf 0.31 (20% ethyl acetate in hexane); mp 101-102 °C (lit.122 
105−106 °C). 1H NMR (CDCl3, 400 MHz) δ 8.31 (1H, d, J = 2.3), 7.76 (1H, d, 
J = 2.3), 7.41−7.47 (5H, m) 5.18 (2H, s), 5.04 (2H brs). 13C NMR (CDCl3, 100 
MHz) δ 144.0, 143.2, 138.7, 135.2, 128.9, 128.8, 128.2, 128.0, 106.6, 78.4, 
71.4. IR (neat) νmax 3476, 3379, 3358, 2357, 2333, 1606, 1587, 1497, 1451, 




2.3 (10.0 g, 27 mmol) was dissolved in anhydrous DMF (300 mL). The 
resulting solution was degassed with a stream of N2 for 50 minutes prior to 
addition of methyl propiolate (9.0 mL, 108 mmol), Pd(PPh3)2Cl2 (0.95 g, 1.35 
mmol), ZnBr2 (24.29 g, 108 mmol) and DIPEA (19.1 mL, 108 mmol). The 
reaction mixture was then heated to 66 ºC and stirred overnight under N2. 
After cooling to room temperature the reaction was poured over crushed ice, 
and the resulting chocolate colour precipitate collected by filtration. The 
reaction was repeated four times and the precipitates combined prior to 
absorption on to silica. Elution through a silica plug with 50% ethyl acetate 
and hexane afforded 37 g of 2.4 as an orange solid (76%). Rf 0.14 (20% ethyl 
acetate in hexane); mp 130-132 °C (lit.123 136−139 °C). 1H NMR (CDCl3, 400 
MHz) δ 8.05 (1H, d, J = 2.4), 7.76 (1H, d, J = 2.4), 7.40−7.47 (5H, m), 5.35 
(2H, brs), 5.18 (2H, s), 3.87 (3H, s). 13C NMR (CDCl3, 100 MHz) δ 154.0, 
146.6, 144.4, 137.6, 135.1, 128.9, 128.9, 128.0, 122.9, 108.2, 100.9, 87.0, 81.1, 
71.3, 53.0. IR (neat) νmax 3499, 3391, 3354, 3087, 2359, 2042, 2204, 1697, 
1614, 1506, 1300, 1239, 1094, 1002, 886, 740, 731, 696, 612 cm−1.  
 
2.4 (15 g, 48.1 mmol) in anhydrous THF (215 mL) was treated with 1M TBAF 
in THF solution (95.5 mL, 96 mmol) and refluxed at 66ºC for 1 h. After 
cooling to room temperature the THF was removed by rotary evaporation 
under reduced pressure. The residue was dissolved in ethyl acetate (250 mL) 
and washed three times with water (250 mL). Concentration of the ethyl 
acetate followed by co-evaporation of the residue with DCM afforded crude 
2.4a as a dark purple foam. The foam was dissolved in DCM (250 mL) and 
treated with Boc2O (20.9 g, 95 mmol) and DMAP (5.83 g, 4.8 mmol) at room 
temperature for 2 h. Removal of the DCM gave crude 2.5 as a dark foam. The 
reaction was then repeated on the same scale and the foam dry loaded onto 
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silica and purified using column chromatography (10% ethyl acetate in 
hexane). Removal of the solvent gave 6.21 g of 2.5 as a bright yellow solid 
(15%). Rf 0.31 (20% ethyl acetate in hexane); mp 166-168 °C (lit.123 168−171 
°C). 1H NMR (CDCl3, 400 MHz) δ 8.26 (1H, d, J = 1.9), 7.67 (1H, d, J = 1.9), 
7.48−7.44 (2H, m), 7.42−7.35 (3H, m), 7.33 (1H, s) 5.33 (2H, s), 3.94 (3H, s), 
1.47 (9H, s). 13C NMR (CDCl3, 100 MHz) δ 160.4, 149.2, 145.5, 143.5, 135.1, 
130.1, 128.8, 128.6, 128.1, 126.3, 112.6, 112.3, 102.1, 86.4, 71.2, 52.4, 27.8, 
27.2. IR (neat) νmax 3308, 3127, 2981, 2523, 2161, 1765, 1721, 1586, 1511, 
1325, 1251, 1225, 1152, 982, 875, 841, 822, 742, 730, 697, 606 cm−1. 
 
2.5 (6.2 g, 14.4 mmol) was dissolved in THF (260 mL) and treated with zinc 
powder (14.0 g, 215 mmol) NH4Cl (7.7 g, 143.7 mmol), Boc2O (9.36 g, 43.1 
mmol), DMAP (175 mg, 1.4 mmol) and water (25 mL). The resulting 
suspension was stirred vigorously at room temperature overnight. After 
removal of the THF under pressure, the residue was dissolved in Et2O (200 
mL) and washed three times with water (100 mL) and dried with MgSO4. 
Removal of the ether gave crude 2.5a as a yellow foam. Crude 2.5a was 
dissolved in DMF (80 mL) and treated with H2SO4 (76 µL, 1.4 mmol) before 
portionwise addition of NIS (4.9 g, 21.5 mmol). The solution was stirred for 3 
h at room temperature. The reaction was then diluted with Et2O (200 mL) 
and washed once with 50% saturated brine in water (200 mL), twice with 
water (200 mL), and once with saturated brine (200 mL). The first wash was 
back extracted three times with Et2O (100 mL) and washed twice with 
saturated brine (200 mL). All the Et2O was combined and concentrated to 
give a dark red foam. The foam was purified by column chromatography 
(10% ethyl acetate in hexane) to give 2.6 (5.0 g, 57%) as an off white solid. Rf 
0.32 (20% ethyl acetate in hexane); mp 160-161 °C (lit.123 158−161 °C). 1H 
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NMR (CDCl3, 400 MHz) δ 7.78 (1H, brs), 7.49−7.44 (2H, m), 7.29−7.38 (3H, 
m), 7.09 (1H, s), 6.76 (1H, brs), 5.24 (2H, s), 3.91 (3H, s), 1.53 (9H, s), 1.40 
(9H, s). 13C NMR (CDCl3, 100 MHz) δ 160.8, 152.9, 149.7, 146.4, 135.8, 134.5, 
131.4, 128.5, 128.4, 128.2, 127.6, 123.6, 114.4, 102.4, 85.5, 80.9, 70.9, 52.2, 
28.4, 27.1. IR (neat) νmax 3391, 2973, 1764, 1730, 1715, 1615, 1576, 1539, 
1450, 1359, 1232, 1216, 1150, 1076, 982, 878, 843, 723, 693 cm−1. 
 
2.6 (5.0 g, 8 mmol) was dissolved in DMF (85 mL) and treated with t-BuOK 
(1.9 g, 17 mmol) and 1,3-dichloropropene as a mixture of cis and trans 
isomers (3.0 mL, 25 mmol). The resulting solution was stirred for 1.5 h 
submerged in a room temperature water bath. The reaction was then cooled 
to 0 ºC before being quenched with saturated aqueous NH4Cl (4 mL). The 
mixture was then diluted with Et2O (200 mL) and washed twice with 50% 
saturated brine in water (200 mL) and once with saturated brine (200 mL). 
The Et2O was then dried over MgSO4 and concentrated before co-evaporation 
with DCM to give a brown foam. The crude foam was absorbed onto silica 
and purified by silica gel chromatography (5% ethyl acetate in hexane 
increasing up to 10% ethyl acetate until complete elution of the product) to 
give 2.7 as a light brown foam (4.1 g, 73 %). Rf 0.29 (20% ethyl acetate in 
hexane); mp 103-105 °C (lit.123 104−106 °C). 1H NMR (CDCl3, 400 MHz, 
mixture of E/Z isomers) δ 7.28−7.44 (5H, m) 7.18 (1H, s), 6.65−6.47 (1H, m), 
5.80−6.00 (2H, m), 5.17−5.28 (2H, m), 4.46 and 4.18 (1H, m), 4.33 and 3.73 
(1H, m), 3.93 (3H, s), 1.53 (9H, s), 1.29 and 1.27 (9H, s). 13C NMR (CDCl3, 
100 MHz) δ 160.7, 154.1, 149.9, 145.5, 138.6, 138.3 135.8, 132.1, 128.7, 128.3, 
127.95, 127.5, 127.3, 125.3, 121.7, 120.6, 115.1, 109.7 85.8, 83.8, 80.5, 70.6, 
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52.3, 49.3, 46.1, 28.2, 27.2. IR (neat) νmax 2923, 1775, 1735, 1702, 1695, 
1572, 1535, 1463, 1435, 1372, 1299, 1251, 1227, 1077, 978, 845, 784, 764, 739, 
731, 698 cm−1.  
 
2.7 (4.1 g, 5.9 mmol) was dissolved in anhydrous toluene and degassed with 
a stream of nitrogen for 45 minutes prior to addition of AIBN (0.24 g, 1.5 
mmol) and TTMSS (2.0 mL, 6.5 mmol). The resulting solution was refluxed 
at 90ºC under nitrogen for 2 h. The reaction was then left to cool to room 
temperature before being concentrated and subjected directly to silica gel 
column chromatography. 2% ethyl acetate in hexane was initially run before 
increasing up to 5% ethyl acetate until complete elution of the product. 
Removal of the solvent gave 2.8 (2.4 g, 71%) as a colourless foam. Rf 0.35 
(20% ethyl acetate in hexane); mp 116-119 °C (lit.123 115−118 °C). 1H NMR 
(DMSO-d6, 400 MHz) δ 7.69 (1H brs), 7.48−7.29 (6H, m), 5.27 (2H, s), 4.13 
(1H, t, J = 9.7), 4.06−3.89 (4H, m), 3.87 (3H, s), 1.48 (9H, s), 1.38 (9H, s). 13C 
NMR (DMSO-d6, 100 MHz) δ 160.8, 151.9, 150.0, 145.5, 136.6, 128.5, 128.3, 
128.2, 124.0, 113.2, 108.9, 97.4, 85.4, 80.3, 70.2, 52.7, 52.6, 48.0, 40.7 
(obscured by DMSO peak observed by HSQC), 28.4, 27.2, 22.5. IR (neat) 
νmax 2998, 2974, 2921, 1782, 1698, 1593, 1538, 1494, 1439, 1417, 1381, 1343, 




2.8 (2.4 g, 4.2 mmol) was dissolved in a mixture of THF (45 mL) and MeOH 
(30 mL) and treated with a saturated aqueous solution of LiOH (17 mL) 
dropwise. After 4 h the THF and MeOH was removed under reduced 
pressure, and the residue diluted with water (30 mL). Acidification with 5 M 
HCl promoted the precipitation of 2.9 (2.3 g, 100%) as a green foam. Rf 0.46 
(10% MeOH in CH2Cl2); mp 177-180 °C (lit.123 174−178 °C). 1H NMR (DMSO-
d6, 400 MHz) δ 13.45 (1H, brs), 7.66 (1H, brs), 7.47−7.31 (6H, m), 5.26 (2H, 
s), 4.12 (1H, t, J = 9.7), 4.05−3.86 (4H, m), 1.49 (9H, s), 1.37 (9H, s). 13C 
NMR (DMSO-d6, 100 MHz) δ 161.9, 151.7, 149.4, 136.4, 129.9, 128.8, 128.4, 
127.9, 123.8, 123.8, 122.9, 107.9 97.6, 85.0, 80.5, 70.0, 52.6, 47.9, 41.0 
(obscured by DMSO peak observed by HSQC), 28.5, 26.8, 22.5. IR (neat) 
νmax 2972, 2926, 2358, 2321, 1765, 1690, 1682, 1592, 1536, 1495, 1393, 1251, 
1142, 1084, 1015, 942, 747, 695, 669 cm−1.  
 
2.9 (2.4 g, 4.3 mmol) was dissolved in 4 M HCl in dioxane (45 mL) and 
stirred at room temperature overnight. Upon removal of the dioxane under 
reduced pressure, the residue was dissolved in THF (65 mL) and the solution 
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cooled to 0 ºC. The solution was then treated with NaHCO3 (1.08 g, 12.9 
mmol) in H2O (22 mL) followed by Fmoc-Cl (1.11 g, 4.3 mmol) in THF (24 
mL) and left to stir for 5 minutes. After quenching with MeOH (1 mL) the 
THF and MeOH were removed under reduced pressure. The resulting 
mixture was then acidified with 2 M HCl and extracted three times with 2-
MeTHF (100 mL). The organic layer was dried over MgSO4 and the 2-Me-
THF removed under reduced pressure. The crude was dried loaded onto 
silica and purified by silica gel chromatography. 100% DCM was initially run 
gradually increasing up to 5% MeOH in DCM until complete elution of the 
product. Upon removal of the solvent, 2.10 (2.1 g, 84%) was obtained as a 
light green foam. Rf 0.42 (10% MeOH in CH2Cl2); mp 122-125 °C (lit.123 
125−128 °C). 1H NMR (DMSO-d6, 400 MHz) δ 12.97 (1H, brs), 11.90 (1H, s), 
7.90 (2H, d, J = 6.7), 7.74−7.68 (2H, m), 7.67−7.57 (2H, m), 7.53−7.23 (8H, 
m), 7.20 (1H, d, J = 1.8), 5.35−5.84 (2H, brs, [rotameric coalescence 
observed at 333 K, δ 5.17, 2H, s]), 4.74− 4.31 (3H, m, [rotameric coalescence 
observed at 333 K, δ 4.55, 2H, app quin, δ 4.39, 1H, t, J = 6.6]), 4.23−4.14 
(1H, m), 4.10−3.94 (3H, m), 3.93−3.84 (1H, m). 13C NMR (DMSO-d6, 100 
MHz) δ 162.9, 152.0, 146.0, 143.9, 141.2, 137.2, 130.3, 128.6, 128.2, 128.0, 
127.9, 127.6, 126.0, 125.4, 124.1, 120.6, 113.0, 106.2, 95.9, 70.0, 67.0, 51.9, 
47.9, 47.1, 41.5, 34.9. IR (neat) νmax 3031, 2359, 2320, 1733, 1601, 1594, 
1539, 1444, 1417, 1311, 1243, 1218, 1172, 1130, 1056, 827, 753, 737, 667 cm−1. 
HRMS (ES-) calcd. for C34H27N2O5Cl (M - H)-,577.1530; found, 577.1325. 
2.5.3 Synthesis of Fmoc Substituted Binding Subunit (2.14) 
 
Ethyl-5-nitro-indole-2-carboxylate (0.5 g, 2.1 mmol) was dissolved in THF 
(10 mL) and treat with zinc (2.1 g, 31.8 mmol), NH4Cl (1.13 g, 21.2 mmol), 
Boc2O (1.36 g, 6.3 mmol) DMAP (26 mg, 0.2 mmol) and water (3.5 mL). The 
resulting mixture was stirred vigorously overnight at room temperature. 
Upon removal of the THF under reduced pressure the residue was taken up 
in diethyl ether (200 mL) and washed with water (3 x 200 mL). The organic 
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layer was concentrated to give crude 2.15. The reaction was repeated on a 1 g 
scale and the crudes combined before purification by silica gel column 
chromatography (10% ethyl acetate in hexane). Upon removal of the solvent 
2.15 (1.7 g, 88%) was obtained as a colourless solid. Rf 0.35 (20% ethyl 
acetate in hexane); mp 187−188 °C. 1H NMR (DMSO-d6, 400 MHz) δ 11.71 
(1H, s), 9.17 (1H, s), 7.80 (1H, s), 7.23-7.33 (2H, m), 7.05 (1H, d, J = 1.5), 4.32 
(2H, q, J = 6.9), 1.48 (9H, s), 1.33 (3H, t, J = 7.2). 13C NMR (DMSO-d6, 100 
MHz) δ 161.7, 153.6, 134.2, 133.0, 128.1, 127.2, 119.0, 112.9, 110.7, 107.9, 79.0, 
60.8, 28.7, 14.8. IR (neat) νmax 3379, 3339, 2976, 2354, 1702, 1682, 1525, 
1230, 1165, 1050, 1024, 808, 769, cm−1. HRMS (ES-) calcd. for C16H20N2O4 
(M - H)- , 303.1343; found, 303.1365. 
 
2.15 (1.7 g, 5.6 mmol) was dissolved in THF (50 mL), and MeOH (30 mL) 
and treated with a saturated aqueous solution of LiOH (16 mL) dropwise. The 
solution was left to stir at room temperature for 4 h before removal of the 
THF and MeOH under reduced pressure. The residue was diluted with water 
(100 mL) and acidified using 5 M HCl. The resulting precipitate was collected 
using vacuum filtration and recovered from the sinter by dissolution in ethyl 
acetate. Removal of the solvent under reduced pressure gave 2.16 (1.45 g, 
93%) as an off white solid. Rf 0.35 (10% MeOH in CH2Cl2); mp 206-208 °C. 
1H NMR (DMSO-d6, 400 MHz) δ 12.81 (1H, brs), 11.59 (1H, s), 9.15 (1H, s), 
7.77 (1H, s), 7.22-7.31 (2H, m), 6.97 (1H, d, J = 1.5), 1.48 (9H, s). 13C NMR 
(DMSO-d6, 100 MHz) δ 163.2, 153.6, 134.1, 132.8, 129.3, 127.3, 118.5, 112.8, 
110.7, 107.5, 79.0, 28.7. IR (neat) νmax 3352, 2978, 2346, 1697, 1538, 1468, 
1428, 1242, 1201, 1180, 1165, 1050, 1029, 802, 769 cm−1. HRMS (ES-) calcd. 




2.16 (1.4 g, 5.2 mmol) was dissolved in 4 M HCl in dioxane (25 mL) and 
stirred overnight at room temperature. The dioxane was removed under 
reduced pressure and the resulting residue taken up in THF (45 mL). The 
solution was cooled to 0 ºC before being treated with NaHCO3 (1.30 g, 15.5 
mmol) in water (25 mL) followed by Fmoc-Cl (1.34 g, 5.2 mmol) dropwise in 
THF (28 mL). After 5 mins the reaction was quenched with MeOH (1 mL) 
and the THF and MeOH removed under reduced pressure. The remaining 
mixture was acidifed using 2 M HCl and extracted three times with 2-MeTHF 
before being dried over MgSO4. Crude 2.14 was purified by silica gel 
chromatography (100% DCM increasing up to 5% MeOH in DCM until 
complete elution of the product). Upon removal of the solvent, 2.14 (1.07 g, 
55%) was obtained as a colourless solid. Rf 0.38 (10% MeOH in CH2Cl2); mp 
255-257 °C. 1H NMR (DMSO, 400 MHz) δ 12.88 (1H, s), 11.64 (1H, s), 9.56 
(1H, s), 7.91 (2H, d, J = 7.5), 7.73-7.80 (2H, m), 7.39-7.45 (3H, m), 7.29-
2.738 (4H, m), 4.47 (2H, d, J = 6.9), 4.31 (1H, t, J = 6.6). 13C NMR (DMSO-
d6, 100 MHz) δ 163.2, 154.2, 144.3, 141.3, 134.3, 132.3, 129.4, 128.1, 127.6, 
127.3, 125.6, 120.6, 118.7, 113.0, 111.1, 107.6, 65.9, 47.2, 23.0. IR (neat) νmax 
3327, 2962, 2364, 1699, 1670, 1534, 1434, 1293, 1232, 1177, 1293, 1232, 1048, 
741 cm−1. HRMS (ES+) calcd. for C24H18N2O4 (M - H)- , 398.1186; found, 
397.1281. 




4-Methoxybenzyl chloride (12.8 mL, 96.0 mmol) was added dropwise to a 
stirring suspension of 2-amino-5-nitrophenol (15.0 g, 96 mmol) and K2CO3 
(26.5 g, 192 mmol) in DMF (150 mL) at room temperature. After 3 h, the 
reaction mixture was poured over crushed ice and allowed to rest for 30 
minutes. The precipitate was collected by filtration and triturated with cold 
water before drying under vacuum. This yielded 26.53 g of 2.2-PMB as a 
yellow/brown solid (99%). Rf 0.15 (20% ethyl acetate in hexane); mp 132-133 
°C. 1H NMR (CDCl3, 400 MHz) δ 7.82 (1H, dd, J = 2.4, 8.6), 7.78 (1H, d, J = 
2.4), 7.34−7.40 (2H, m), 6.91-6.95 (2H, m), 6.64 (1H, d, J = 8.7), 5.07 (2H, 
s), 3.83 (3H, s). 13C NMR (CDCl3, 100 MHz) δ 144.7, 143.2, 136.2, 134.2, 
129.7, 128.2, 127.7, 119.3, 114.1, 107.3, 70.7, 55.3. IR (neat) νmax 3491, 3352, 
3218, 3188, 2947, 2852, 1625, 1569, 1510, 1482, 1468, 1386, 1282, 1194, 1176, 
1091, 950, 870, 782, 754, 646 cm−1.  
 
H2SO4 (507 µL, 9.60 mmol) was added to a stirring solution of 2.2-PMB 
(26.50 g, 96.0 mmol) in DMF (420 mL), followed by portionwise addition of 
NIS (32.0 g, 144 mmol) at room temperature. After 2 h the reaction mixture 
was poured over crushed ice and left to rest for 30 minutes. The precipitate 
was collected by filtration and triturated with cold water, followed by cold 
hexane before drying under vacuum. This yielded 37.10 g of 2.3-PMB as a 
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bright yellow solid (93%). Rf 0.28 (20% ethyl acetate in hexane); mp 138-140 
°C. 1H NMR (CDCl3, 400 MHz) δ 8.28 (1H, d, J = 2.2), 7.74 (1H, d, J = 2.2), 
7.34−7.48 (2H, m) 6.92-6.97 (2H, m), 5.08 (2H s), 4.99 (2H, brs), 3.84 (3H, 
s). 13C NMR (CDCl3, 100 MHz) δ 160.0, 144.0 143.3, 138.7, 129.8, 128.1, 
127.3, 114.2, 106.6, 78.3, 71.2, 55.4. IR (neat) νmax 3469, 3387, 3242, 3056, 
3045, 2332, 1612, 1569, 1492, 1444, 1282, 1205, 1145, 1032, 869, 849, 810, 
758, 652 cm−1. HRMS (ES-) calcd. for C14H13N2O4I (M - H)- , 398.9841; 
found, 398.9945. 
 
2.3-PMB (15.0 g, 32 mmol) was dissolved in anhydrous DMF (220 mL). The 
resulting solution was degassed with a stream of N2 for 50 minutes prior to 
addition of methyl propiolate (11.38 mL, 128.0 mmol), Pd(PPh3)2Cl2 (1.12 g, 
1.6 mmol), ZnBr2 (28.82 g, 128.0 mmol) and DIPEA (22.29 mL, 128.0 
mmol). The reaction mixture was then heated to 66 ºC and stirred overnight 
under N2. After cooling to room temperature the reaction was poured over 
crushed ice, and the resulting chocolate colour precipitate collected by 
filtration. The precipitate was then absorbed on to silica. Elution through a 
silica plug with 50% ethyl acetate and hexane afforded 6.73 g of 2.4-PMB as 
an orange solid (60%). Rf 0.20 (20% ethyl acetate in hexane); mp 146-147 °C. 
1H NMR (CDCl3, 400 MHz) δ 8.04 (1H, d, J = 2.3), 7.76 (1H, d, J = 2.3), 
7.34−7.38 (2H, m), 6.93-6.97 (2H, m), 5.28 (2H, brs), 5.09 (2H, s), 3.86 (3H, 
s), 2.84 (3H, s). 13C NMR (CDCl3, 100 MHz) δ 160.1, 154.0, 146.7, 144.4, 
137.5, 129.9, 127.1, 122.8, 114.3, 108.1, 100.7, 86.9, 81.1, 71.2, 55.3, 53.0. IR 
(neat) νmax 3488, 3384, 3256, 3101, 3024, 3015, 2902, 2226, 1699, 1608, 
1475, 1398, 1297, 1281, 1230, 1158, 1099, 1010, 882, 749, 735, 690, 650, 620 
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cm−1. HRMS (ES-) calcd. for C18H16N2O6 (M - H)- , 355.0930; found, 
355.0917. 
 
2.4-PMB (7.52 g, 21.1 mmol) in anhydrous THF (110 mL) was treated with 1 
M TBAF in THF solution (47 mL, 47.2 mmol) and refluxed at 66ºC for 1 h. 
After cooling to room temperature the THF was removed by rotary 
evaporation under reduced pressure. The residue was dissolved in ethyl 
acetate (125 mL) and washed three times with water (125 mL). Concentration 
of the ethyl acetate followed by co-evaporation of the residue with DCM 
afforded crude 2.4a-PMB as a dark purple foam. The foam was dissolved in 
DCM (125 mL) and treated with Boc2O (9.17 g, 42.2 mmol) and DMAP (2.58 
g, 21.1 mmol) at room temperature for 2 h. Removal of the DCM gave crude 
2.5-PMB as a dark foam which was dry loaded onto silica and purified using 
column chromatography (10% ethyl acetate in hexane). Removal of the 
solvent gave 5.22 g of 2.5-PMB as a bright yellow solid (54%). Rf 0.37 (20% 
ethyl acetate in hexane); mp 154-156 °C. 1H NMR (CDCl3, 400 MHz) δ 8.25 
(1H, d, J = 1.9), 7.69 (1H, d, J = 1.9), 7.41−7.37 (2H, m), 7.33 (1H, s), 6.92-
6.89 (2H, m) 5.25 (2H, s), 3.93 (3H, s), 3.81 (3H, s), 1.47 (9H, s). 13C NMR 
(CDCl3, 100 MHz) δ 161.0, 149.6, 145.9, 143.8, 135.6, 130.4, 129.2, 128.8, 
128.3, 126.5, 113.1, 113.0, 101.9, 86.7, 71.4, 54.2, 52.6, 27.8, 27.2. IR (neat) 
νmax 3135, 3106, 3092, 2812, 1762, 1715, 1594, 1503, 1399, 1310, 1246, 1178, 




2.5-PMB (5.22 g, 11.4 mmol) was dissolved in THF (110 mL) and treated 
with zinc powder (11.17 g, 171.7 mmol) NH4Cl (6.12 g, 114.3 mmol), Boc2O 
(7.46 g, 34.3 mmol), DMAP (139 mg, 1.14 mmol) and water (21 mL). The 
resulting suspension was stirred vigorously at room temperature overnight. 
After removal of the THF under pressure, the residue was dissolved in Et2O 
(200 mL) and washed three times with water (100 mL) and dried with 
MgSO4. Removal of the ether gave crude 2.5a-PMB as a yellow foam. Crude 
2.5a-PMB was dissolved in DMF (70 mL) and treated with H2SO4 (60 µL, 
1.14 mmol) before portionwise addition of NIS (7.72 g, 34.3 mmol). The 
solution was stirred for 3 h at room temperature. The reaction was then 
diluted with Et2O (200 mL) and washed once with 50% saturated brine in 
water (200 mL), twice with water (200 mL), and once with saturated brine 
(200 mL). The first wash was back extracted three times with Et2O (100 mL) 
and washed twice with saturated brine (200 mL). All the Et2O was combined 
and concentrated to give a dark red foam. The foam was purified by column 
chromatography (10% ethyl acetate in hexane) to give 2.6-PMB (2.43 g, 
33%) as an off white solid. Rf 0.38 (20% ethyl acetate in hexane); mp 110-112 
°C. 1H NMR (CDCl3, 400 MHz) δ 7.79 (1H, brs), 7.41−7.37 (2H, m), 7.08 (1H, 
s), 6.90-6.86 (2H, m), 6.77 (1H, brs), 5.17 (2H, s), 3.90 (3H, s), 3.80 (3H, s), 
1.54 (9H, s), 1.40 (9H, s). 13C NMR (CDCl3, 100 MHz) δ 159.7, 152.9, 149.8, 
146.5, 135.8, 134.5, 131.3, 130.2, 128.0, 127.6, 121.5, 114.4, 113.9, 85.5, 80.9, 
70.7, 55.3, 52.1, 28.4, 27.1. IR (neat) νmax 3355, 2910, 2325, 1755, 1736, 
1702, 1652, 1529, 1485, 1401, 1365, 1312, 1239, 1209, 1172, 1042, 971, 852, 




2.6-PMB (2.43 g, 3.7 mmol) was dissolved in DMF (50 mL) and treated with 
NaH (0.18 g, 7.4 mmol) and 1,3-dichloropropene as a mixture of cis and 
trans isomers (1.03 mL, 11.1 mmol). The resulting solution was stirred for 2 h 
submerged in a room temperature water bath. The reaction was then cooled 
to 0 ºC before being quenched with saturated aqueous NH4Cl (2 mL). The 
mixture was then diluted with Et2O (150 mL) and washed twice with 50% 
saturated brine in water (150 mL) and once with saturated brine (150 mL). 
The Et2O was then dried over MgSO4 and concentrated before co-evaporation 
with DCM to give a brown foam. The crude foam was absorbed onto silica 
and purified by silica gel chromatography (5% ethyl acetate in hexane 
increasing up to 10% ethyl acetate until complete elution of the product) to 
give 2.7-PMB as a light brown foam (1.05 g, 40%). Rf 0.34 (20% ethyl 
acetate in hexane); mp 87-89 °C. 1H NMR (CDCl3, 400 MHz, mixture of E/Z 
isomers) δ 7.41−7.30 (2H, m) 7.17 (1H, s), 6.93−6.83 (2H, m), 5.79−6.46 (1H, 
m), 6.05−5.83 (2H, m), 5.16 (1H, m), 4.52-4.15 (1H, m), 2.94-3.89 (3H, m), 
3.81-3.77 (3H, s), 1.57-1.46 (9H, m), 1.41-1.24 (9H, m). 13C NMR (CDCl3, 100 
MHz) δ 160.7, 159.7, 153.8, 149.6, 145.9, 142.7, 138.4, 135.2, 132.5, 129.3, 
128.7, 128.2, 127.9, 127.8, 127.7, 121.5, 120.4, 115.2, 109.5, 85.9, 83.4, 79.8, 
70.4, 55.3, 52.2, 46.3, 28.2, 27.2. IR (neat) νmax 2984, 1762, 1720, 1699, 
1679, 1571, 1449, 1429, 1413, 1296, 1278, 1162, 1099, 969, 853, 845, 764, 705 





2.7-PMB (1.05 g, 1.5 mmol) was dissolved in anhydrous toluene (10 mL) and 
degassed with a stream of nitrogen for 45 minutes prior to addition of AIBN 
(60 mg, 0.36 mmol) and TTMSS (490 µl, 1.59 mmol). The resulting solution 
was refluxed at 90ºC under nitrogen for 2 h. The reaction was then left to 
cool to room temperature before being concentrated and subjected directly to 
silica gel column chromatography. 2% ethyl acetate in hexane was initially 
run before increasing up to 5% ethyl acetate until complete elution of the 
product. Removal of the solvent gave 2.8-PMB (0.74 g, 55%) as a colourless 
foam. Rf 0.35 (20% ethyl acetate in hexane); mp 108.120 °C. 1H NMR 
(CDCl3, 400 MHz) δ 7.80 (1H, brs), 7.45−7.34 (2H, m), 7.07 (1H, s), 6.91-
6.86 (2H, m), 5.16 (2H, m), 4.01-4.18 (2H, m), 3.89 (3H, s), 3.87-3.81 (2H, 
m), 3.80 (3H, s), 3.50 (1H, t, J = 8.8), 1.56 (9H, s), 1.40 (9H, s). 13C NMR 
(DMSO-d6, 100 MHz) δ 160.9, 159.7, 150.0, 148.2, 145.7, 135.2, 130.1, 130.0, 
129.9, 128.6, 128.0, 124.7, 124.0, 129.9, 114.3, 108.2, 97.0, 85.5, 80.6, 70.1, 
55.6.3, 52.8, 48.1, 40.7, 28.5, 27.2, 22.5. IR (neat) νmax 3016, 2982, 2416, 
1771, 1735, 1703, 1610, 1509, 1482, 1405, 1299, 1254, 1152, 1102, 998, 876, 
749, 736, 705, cm−1. HRMS (ES-) calcd. for C31H37N2O8Cl (M - H)- , 





2.8-PMB (0.47 g, 0.8 mmol) was dissolved in a mixture of THF (5 mL) and 
MeOH (3 mL) and treated with a saturated aqueous solution of LiOH (1.7 
mL) dropwise. After 4 h the THF and MeOH was removed under reduced 
pressure, and the residue diluted with water (10 mL). Acidification with 5 M 
HCl promoted the precipitation of 2.19 (0.46 g, 99%) as a green foam. Rf 
0.52 (10% MeOH in CH2Cl2); mp 158.159 °C. 1H NMR (CDCl3, 400 MHz) δ 
7.81 (1H, brs), 7.42−7.30 (2H, m), 7.18 (1H, brs), 6.90-6.84 (2H, m), 5.14 
(2H, s), 4.17-4.00 (2H, m), 2.89-3.80 (2H, m), 3.79 (3H, m), 3.48 (1H, t, J = 
8.8), 1.56 (9H, s), 1.34 (9H, s) 13C NMR (DMSO-d6, 100 MHz) δ 162.5, 159.6, 
152.1, 150.7, 145.5,  136.2, 130.0, 128.7, 128.0, 127.2, 124.3, 123.4, 122.4, 
114.2, 106.1, 98.3, 84.4, 80.0, 69.9, 55.6, 52.7, 48.1, 40.6, 28.5, 27.3, 22.4. IR 
(neat) νmax 2958, 2912, 2299, 1782, 1683, 1652, 1599, 1515, 1402, 1384, 
1248, 1206, 1165, 969, 912, 758, 705, cm−1. HRMS (ES-) calcd. for 
C30H35O8N2Cl (M - H)-, 585.2009; found, 585.1995. 




4-chlorobenzyl chloride (1.15 g, 7.2 mmol) was added dropwise to a stirring 
suspension of 2-amino-5-nitrophenol (1.0 g, 6.5 mmol) and K2CO3 (1.45 g, 
10.5 mmol) in DMF (10 mL) at room temperature. After 3 h, the reaction 
mixture was poured over crushed ice and allowed to rest for 30 minutes. The 
precipitate was collected by filtration and triturated with cold water before 
drying under vacuum. This yielded 1.8 g of 2.2-PCIB as a yellow/brown 
solid (99%). Rf 0.20 (20% ethyl acetate in hexane); mp 127-128.5 °C. 1H 
NMR (CDCl3, 400 MHz) δ 7.82 (1H, dd, J = 2.3, 8.8), 7.73 (1H, d, J = 2.3), 
7.38 (4H, s), 6.66 (1H, d, J = 8.7), 5.11 (2H, s). 13C NMR (CDCl3, 100 MHz) δ 
144.3, 143.2, 138.7, 134.5, 134.2, 129.2, 129.0, 119.5, 112.2, 107.3, 70.1. IR 
(neat) νmax 3492, 3299, 3124, 3055, 2986, 1682, 1512, 1471, 1399, 1372, 
1284, 1171, 950, 918, 856, 832, 820, 765, 744, 697 cm−1. HRMS (ES-) calcd. 
for C13H11N2O3Cl (M - H)-, 277.0379; found, 277.0385. 
 
H2SO4 (300 µL, 0.65 mmol) was added to a stirring solution of 2.2-PCIB 
(1.8 g, 6.5 mmol) in DMF (20 mL), followed by portionwise addition of NIS 
(2.19 g, 9.8 mmol) at room temperature. After 2 h the reaction mixture was 
poured over crushed ice and left to rest for 30 minutes. The precipitate was 
collected by filtration and triturated with cold water, followed by cold hexane 
before drying under vacuum. This yielded 2.52 g of 2.3-PCIB as a bright 
yellow solid (93%). Rf 0.35 (20% ethyl acetate in hexene); mp 142-143 °C. 1H 
NMR (CDCl3, 400 MHz) δ 8.29 (1H, d, J = 2.3), 7.71 (1H, d, J = 2.3), 
7.42−7.34 (4H, m) 5.12 (2H, s), 5.01 (2H brs). 13C NMR (CDCl3, 100 MHz) δ 
143.9, 142.9, 138.7, 134.7, 133.7, 129.3, 129.1, 128.3, 106.6, 78.5, 70.5. IR 
(neat) νmax 3452, 3265, 3110, 3028, 3002, 2592, 1631, 1592, 1482, 1431, 
1392, 1267, 1241, 1063, 1009, 891, 823, 812, 764 cm−1. HRMS (ES-) calcd. for 




2.3-PCIB (2.52 g, 6.2 mmol) was dissolved in anhydrous DMF (50 mL). The 
resulting solution was degassed with a stream of N2 for 50 minutes prior to 
addition of methyl propiolate (2.2 mL, 24.9 mmol), Pd(PPh3)2Cl2 (0.22 g, 
0.31 mmol), ZnBr2 (5.6 g, 24.9 mmol) and DIPEA (4.3 mL, 24.9 mmol). The 
reaction mixture was then heated to 66 ºC and stirred overnight under N2. 
After cooling to room temperature the reaction was poured over crushed ice, 
and the resulting chocolate colour precipitate collected by filtration. The 
precipitate was then absorbed on to silica. Elution through a silica plug with 
50% ethyl acetate and hexane afforded 1.3 g of 2.4-PCIB as an orange solid 
(58%). Rf 0.19 (20% ethyl acetate in hexane); mp 120-122 °C. 1H NMR 
(CDCl3, 400 MHz) δ 8.06 (1H, d, J = 2.4), 7.73 (1H, d, J = 2.4), 7.41−7.35 
(4H, m), 5.29 (2H, brs), 5.14 (2H, s), 3.86 (3H, s). 13C NMR (CDCl3, 100 
MHz) δ 153.7, 146.3, 144.1, 137.4, 134.8, 129.4, 129.2, 128.6, 123.5, 108.4, 
101.4, 87.2, 81.3, 71.0, 53.4. IR (neat) νmax 3483, 3353, 3120, 3058, 2876, 
2115, 1706, 1626, 1503, 1421, 1403, 1304, 1285, 1198, 1120, 998, 874, 752, 




2.4-PCIB (1.3 g, 3.6 mmol) in anhydrous THF (20 mL) was treated with 1 M 
TBAF in THF solution (7.2 mL, 7.2 mmol) and refluxed at 66ºC for 1 h. After 
cooling to room temperature the THF was removed by rotary evaporation 
under reduced pressure. The residue was dissolved in ethyl acetate (40 mL) 
and washed three times with water (40 mL). Concentration of the ethyl 
acetate followed by co-evaporation of the residue with DCM afforded crude 
2.4a-PCIB as a dark purple foam. The foam was dissolved in DCM (40 mL) 
and treated with Boc2O (1.6 g, 7.2 mmol) and DMAP (441 mg, 3.61 mmol) at 
room temperature for 2 h. Removal of the DCM gave crude 2.5-PCIB as a 
dark foam which was dry loaded onto silica and purified using column 
chromatography (10% ethyl acetate in hexane). Removal of the solvent gave 
0.47 g of 2.5-PCIB as a bright yellow solid (29%). Rf 0.36 (20% ethyl acetate 
in hexane); mp 152-153 °C. 1H NMR (CDCl3, 400 MHz) δ 8.27 (1H, d, J = 
1.8), 7.65 (1H, d, J = 1.8), 7.43−7.35 (4H, m), 7.34 (1H, s), 5.28 (2H, s) 3.90 
(3H, s), 1.48 (9H, s). 13C NMR (CDCl3, 100 MHz) δ 160.1, 148.8, 145.2, 143.1, 
134.9, 130.0, 129.4, 129.0, 128.7, 126.1, 112.2, 112.0, 101.9, 86.3, 71.0, 52.4, 
27.5, 27.0. IR (neat) νmax 3135, 3026, 3012, 1752, 1736, 1592, 1499, 1420, 
1399, 1368, 1301, 1236, 1210, 1105, 1062, 996, 852, 812, 735, 721, 705, 684 
cm−1.  
 
2.5-PCIB (0.47 g, 1.0 mmol) was dissolved in THF (10 mL) and treated with 
zinc powder (1.0 g, 15.3 mmol) NH4Cl (0.55 g, 10 mmol), Boc2O (0.66 g, 3.03 
mmol), DMAP (13 mg, 0.10 mmol) and water (2 mL). The resulting 
suspension was stirred vigorously at room temperature overnight. After 
removal of the THF under pressure, the residue was dissolved in Et2O (20 
mL) and washed three times with water (10 mL) and dried with MgSO4. 
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Removal of the ether gave crude 2.5a-PCIB as a yellow foam. Crude 2.5a-
PCIB was dissolved in DMF (10 mL) and treated with H2SO4 (6 µL, 0.1 
mmol) before portionwise addition of NIS (0.35 g, 1.5 mmol). The solution 
was stirred for 3 h at room temperature. The reaction was then diluted with 
Et2O (20 mL) and washed once with 50% saturated brine in water (20 mL), 
twice with water (20 mL), and once with saturated brine (20 mL). The first 
wash was back extracted three times with Et2O (10 mL) and washed twice 
with saturated brine (20 mL). All the Et2O was combined and concentrated 
to give a dark red foam. The foam was purified by column chromatography 
(10% ethyl acetate in hexane) to give 2.6-PCIB (0.4 g, 60%) as an off white 
solid. Rf 0.32 (15% ethyl acetate in hexane); mp 160-161 °C. 1H NMR (CDCl3, 
400 MHz) δ 7.78 (1H, brs), 7.44−7.40 (2H, m), 7.35−7.31 (2H, m), 7.09 (1H, 
s), 6.79 (1H, brs), 5.21 (2H, s), 3.91 (3H, s), 1.54 (9H, s), 1.43 (9H, s). 13C 
NMR (CDCl3, 100 MHz) δ 161.3, 153.4, 149.5, 146.1, 135.8, 134.2, 131.1, 129.2, 
129.0, 128.9, 128.1, 123.8, 114.5, 103.1, 85.2, 80.6, 70.5, 52.4, 28.3, 27.0. IR 
(neat) νmax 3410, 3001, 2956, 1759, 1731, 1706, 1625, 1590, 1562, 1510, 1382, 
1306, 1249, 1218, 1078, 922, 896, 821, 825, 754, 722 cm−1. HRMS (ES-) calcd. 
for C27H30N2O7Cl (M - H)-, 529.1741; found, 529.1756. 
 
2.6-PCIB (1.3 g, 1.9 mmol) was dissolved in DMF (30 mL) and treated with 
NaH (0.16 g, 3.9 mmol) and 1,3-dichloropropene as a mixture of cis and 
trans isomers (551 µL, 5.94 mmol). The resulting solution was stirred for 2 h 
submerged in a room temperature water bath. The reaction was then cooled 
to 0 ºC before being quenched with saturated aqueous NH4Cl (0.8 mL). The 
mixture was then diluted with Et2O (50 mL) and washed twice with 50% 
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saturated brine in water (50 mL) and once with saturated brine (50 mL). The 
Et2O was then dried over MgSO4 and concentrated before co-evaporation 
with DCM to give a brown foam. The crude foam was absorbed onto silica 
and purified by silica gel chromatography (5% ethyl acetate in hexane 
increasing up to 10% ethyl acetate until complete elution of the product) to 
give 2.7-PCIB as a light brown foam (1.16 g, 80%). Rf 0.35 (20% ethyl 
acetate in hexane); mp 111-113 °C. 1H NMR (CDCl3, 400 MHz, mixture of E/Z 
isomers) δ 7.41−7.38 (4H, m) 7.16 (1H, s), 6.67−6.47 (1H, m), 6.10−5.98 (2H, 
m), 5.22−5.08 (2H, m), 4.56-4.20 (1H, m), 4.32 and 3.75 (1H, m), 3.95 (3H, 
s), 1.61-1.21 (18H, m). 13C NMR (CDCl3, 100 MHz) δ 161.2, 154.6, 150.5, 
145.2, 138.2, 135.5, 132.0, 129.3, 128.9, 128.5, 128.0, 125.0, 121.9, 120.3, 
115.6, 110.0, 86.1, 83.7, 80.3, 70.1, 52.3, 49.5, 46.1, 28.4, 27.2. IR (neat) νmax 
2910, 2905, 1782, 1720, 1699, 1682, 1555, 1502, 1478, 1415, 1381, 1315, 1274, 
1110, 1096, 1052, 946, 876, 836, 819, 720, 702 cm−1. HRMS (ES-) calcd. for 
C30H33N2O7Cl2I (M - H)-, 729.0631; found, 729.0704. 
 
2.7-PCIB (1.14 g, 1.60 mmol) was dissolved in anhydrous toluene (20 mL) 
and degassed with a stream of nitrogen for 45 minutes prior to addition of 
AIBN (64 mg, 0.39 mmol) and TTMSS (543 µl, 1.7 mmol). The resulting 
solution was refluxed at 90ºC under nitrogen for 2 h. The reaction was then 
left to cool to room temperature before being concentrated and subjected 
directly to silica gel column chromatography. 2% ethyl acetate in hexane was 
initially run before increasing up to 5% ethyl acetate until complete elution of 
the product. Removal of the solvent gave 2.8-PCIB (0.81 g, 82%) as a 
colourless foam. Rf 0.33 (20% ethyl acetate in hexane); mp 124-126 °C. 1H 
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NMR (DMSO-d6, 400 MHz) δ 7.67 (1H brs), 7.50−7.43 (5H, m), 5.26 (2H, s), 
4.13 (1H, t, J = 9.7), 4.07−3.89 (4H, m), 3.87 (3H, s), 1.49 (9H, s), 1.38 (9H, 
s). 13C NMR (DMSO-d6, 100 MHz) δ 160.8, 151.1, 149.0, 144.9, 136.0, 128.9, 
128.5, 128.2, 123.1, 113.0, 108.1, 97.1, 84.6, 80.0, 69.3, 52.0, 51.9, 47.5, 40.6 
(obscured by DMSO peak, observed by HSQC), 28.1, 26.8, 22.2. IR (neat) 
νmax 3010, 2986, 2265, 1764, 1699, 1682, 1601, 1582, 1502, 1499, 1399, 
1359, 1321, 1256, 1199, 1136, 1012, 992, 896, 799, 705, 701, 625 cm−1. HRMS 
(ES-) calcd. for C30H34N2O7Cl2 (M - H)-, 603.1665; found, 603.1681. 
 
2.8-PCIB (0.81 g, 1.3 mmol) was dissolved in a mixture of THF (9 mL) and 
MeOH (5 mL) and treated with a saturated aqueous solution of LiOH (2.9 
mL) dropwise. After 4 h the THF and MeOH was removed under reduced 
pressure, and the residue diluted with water (15 mL). Acidification with 5 M 
HCl promoted the precipitation of 2.9-PCIB (0.75 g, 97%) as a green foam. 
Rf 0.45 (10% MeOH in CH2Cl2); mp 177-180 °C. 1H NMR (DMSO-d6, 400 
MHz) δ 13.62 (1H, brs), 7.62 (1H, brs), 7.53−7.41 (4H, m), 7.25 (1H, brs), 5.24 
(2H, s), 4.13 (1H, t, J = 9.7), 4.05−3.85 (4H, m), 1.48 (9H, s), 1.36 (9H, s). 13C 
NMR (DMSO-d6, 100 MHz) δ 161.3, 151.1, 148.7, 135.9, 129.1, 128.9, 128.5, 
128.1, 123.8, 123.7, 122.1, 108.5, 96.8, 84.1, 79.6, 69.2, 52.0, 47.2, 40.4 
(obscured by DMSO peak, observed by HSQC), 28.0, 26.7, 22.2. IR (neat) 
νmax 3002, 2956, 2327, 1771, 1682, 1683, 1545, 1512, 1399, 1372, 1352, 1104, 
1092, 924, 897, 810, 789, 702 cm−1. HRMS (ES-) calcd. for C29H32N2O7Cl2 (M 




2.9-PCIB (0.75 g, 1.3 mmol) was dissolved in 4 M HCl in dioxane (15 mL) 
and stirred at room temperature overnight. Upon removal of the dioxane 
under reduced pressure, the residue was dissolved in THF (21 mL) and the 
solution cooled to 0 ºC. The solution was then treated with NaHCO3 (0.32 g, 
3.8 mmol) in H2O (6 mL) followed by Fmoc-Cl (0.33 g, 1.3 mmol) in THF 
(6.5 mL) and left to stir for 5 minutes. After quenching with MeOH (0.5 mL) 
the THF and MeOH were removed under reduced pressure. The resulting 
mixture was then acidified with 2 M HCl and extracted with 2-MeTHF (3 x 10 
mL). The organic layer was dried over MgSO4 and the 2-Me-THF removed 
under reduced pressure. The crude was dried loaded onto silica and purified 
by silica gel chromatography. 100% DCM was initially run gradually 
increasing up to 5% MeOH in DCM until complete elution of the product. 
Upon removal of the solvent, 2.21 (0.62 g, 78%) was obtained as a light 
green foam. Rf 0.42 (10% MeOH in CH2Cl2); mp 131-135 °C. 1H NMR 
(DMSO-d6, 400 MHz) δ 12.95 (1H, brs), 11.94 (1H, s), 7.91 (2H, d, J = 6.7), 
7.73−7.68 (2H, m), 7.48−7.31 (8H, m), 7.18 (1H, d, J = 1.8), 5.23 (2H, s), 
4.58-4.33 (3H, m), 4.18 (1H, t, J = 6.6), 4.09-3.86 (5H, m). 13C NMR (DMSO-
d6, 100 MHz) δ 162.9, 152.4, 146.1, 144.2, 141.3, 137.3, 130.3, 128.7, 128.2, 
128.1, 127.8, 127.6, 126.0, 125.5, 124.6, 120.7, 110.4, 106.2, 95.9, 69.9, 67.0, 
52.4, 48.1, 47.1, 30.9, 25.6. IR (neat) νmax 2965, 2321, 2306, 1704, 1691, 
1594, 1538, 1436, 1389, 1302, 1265, 1242, 1202, 1106, 1045, 1009, 978, 899, 
814, 730, 624, 613 cm−1. HRMS (ES−) calcd. for C34H26O5N2Cl2 (M − H)−, 




2.10 (20 mg, 0.04 mmol) was suspended in DCM (5 mL) and the mixture 
cooled to -78 ºC. To this, a 1 M solution of BBr3 in DCM (35 µL, 0.04 mmol) 
was added and the resulting suspension stirred under N2 for 1 h. 
Subsequently, the reaction was quenched with crushed ice and the organic 
layer washed with water (3 x 10 mL). The DCM solution was concentrated 
before being subjected directly to silica gel column chromatography (10% 
MeOH in DCM). Removal of the solvent gave 2.17 (11 mg, 64%) as a light 
brown solid. Rf 0.15 (10% MeOH in CH2Cl2); mp 134-136°C. 1H NMR 
(DMSO-d6, 400 MHz) δ 12.84 (1H, brs), 11.36 (1H, s), 7.91 (2H, d, J = 8.3), 
7.76−7.68 (2H, m), 7.43 (2H, t, J = 7.5), 7.38−7.31 (3H, m), 7.09 (1H, s), 
4.55− 4.33 (3H, m), 4.28−4.08 (1H, m), 4.04−3.90 (3H, m), 3.93−3.84 (1H, 
m). δ 13C NMR (DMSO-d6, 100 MHz) δ 162.9, 152.0, 146.0, 137.2, 130.3, 
128.6, 127.6, 126.0, 125.4, 124.1, 120.6, 113.0, 106.2, 95.9, 70.0, 67.0, 51.9, 
47.9, 47.1, 41.5. HRMS (ES−) calcd. for C27H21O5N2Cl (M − H)−, 487.1066; 
found, 487.1068. 
2.5.6 General Benzyl Deprotection Conditions 
1. 10% Pd/C + Ammonium Formate 
The benzyl protected DSA analogue was dissolved in MeOH/THF and the 
resulting solution degassed with a stream of N2 for 45 mins. A slurry of 10% 
palladium on carbon (2 mg per 1 mg of benzyl protected compound) was 
prepared with 25% aqueous ammonium formate (25 µL per 1 mg of 
palladium on carbon) and introduced into the benzyl protected compound 
solution. The resulting heterogeneous reaction was stirred for 1 h under 
nitrogen before the palladium on carbon was removed via filtration through a 
celite plug. The MeOH/THF was removed from the supernatant under 
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reduced pressure. The resulting benzyl deprotected compound was purified 
using reverse-phase preparative HPLC.  
2. BBr3 
The benzyl protected DSA analogue was suspended in DCM (5 mL per 10 mg 
of benzyl protected compound) and the resulting suspension cooled to -78 
ºC. A 1 M solution of BBr3 in DCM (1 equiv.) was added and the reaction 
stirred for 1 h at -78 ºC. The mixture was stirred for a further hour and 
allowed to warm to room temperature before being quenched with crushed 
ice. The solution was then washed with water (3 x 10 mL) before the solvent 
was removed from the organic layer under reduced pressure. The crude 
benzyl deprotected compound was then purified using reverse-phase 
preparative HPLC.  
3. On Resin Benzyl Deprotection Using BBr3 
20 mg of resin, containing the benzyl protected DSA analogue, was 
suspended in DCM (5 mL) and the resulting suspension cooled to -78 ºC. A 1 
M solution of BBr3 in DCM (1 equiv. in relation to resin loading) was added to 
the mixture before being stirred at -78 ºC under N2 for 1 h and then for a 
further hour warming to room temperature. The suspension was then filtered 
and the resin washed with DCM (6 x 10 mL). The crude benzyl deprotected 
peptide was then cleaved from the resin using standard TFA based cleavage 
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3.1.1 The Thomsen-Friedenreich Antigen 
The cancer phenotype is commonly associated with aberrant glycosylation 
patterns. One glycan that is directly linked to cancer is the Thomsen-
Friedenreich antigen (T-antigen) also known as the TF antigen, the core 1 
glycan or CD176.149, 150 The T-antigen is a disaccharide composed of a 
galactose β1-3 N-acetylgalactosamine, O-linked to a glycoprotein through 
serine or threonine residues or more commonly written as Galβ1-3GalNAc-α-
O-ser/thr. A chemical structure of the T antigen is shown in Figure 3.1. 
 
Figure 3.1: Chemical structure of the Thomsen-Friedenreich antigen (T-antigen). 
 
The T-antigen is considered therapeutically attractive due to its oncofetal 
nature. This means that it is usually cryptic in normal cells but shows 
exposure in embryonic and cancer cells.151 In fact, the expression of the T-
antigen has been demonstrated in 90% of primary human carcinomas, 
including in the lung, the breast and the pancreas.95, 152 Additionally, cancer 
initiating cells or cancer stem cells in the lung, liver and colon have been 
found to express the T-antigen, further cementing its potential as a target for 
therapeutic purposes.153 
The reason for the exposure of the T-antigen within cancer cells has been 
attributed to the differing glycosylation mechanisms that are observed 
between healthy cells and cancer cells. Within normal cells, the T-antigen is 
often concealed by sulfate molecules, sialic acid, fucose or N-
acetylglucosamine residues.154 However, within cancer cells, the T-antigen is 
more exposed. The biosynthetic pathway to the T-antigen is shown in Figure 
3.2 and demonstrates how the expression of the T-antigen arises from a 
further cancer associated α-linked N-acetylgalactosamine glycan called the 
Tn-antigen. This conversion from the Tn-antigen to the T-antigen is 
mediated by the enzyme core 1 β3- galactose transferase.155 Deficiencies in 
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β3-galactose transferase activity are suggested to be responsible for the 
exposure of the Tn-antigen and hence a possible route to the exposure of the 
T-antigen. In addition to an increase in the T-antigen exposure, colon cancer 
cells have also shown a decrease in the expression of the core 3 glycan.156 
Decreased synthesis of core 3 glycans in colon cancer cells has been 
attributed to a marked decrease in core 3 β3-N-acetylglucosamine 
transferase activity, leading to the prevalence of T-antigen synthesis. 
 
Figure 3.2: Biosynthetic pathway towards the T-antigen used to decipher possible causes of 
over exposure of the T-antigen within cancer cells. 
 
Further proposals for the increased expression of the T-antigen in cancer 
cells have included a link to the decreased expression of carbohydrate 
sulfotransferases.151 These enzymes are responsible for concealing the T-
antigen through sulfation and hence a lack of activity could lead to its 
exposure. Furthermore, in breast and colorectal cancer cells, T antigen 
expression was found to be highly dependent on the pH of the Golgi 
apparatus. An increase of ca. 0.2 pH units in the Golgi apparatus was 
sufficient to elevate the expression of the T antigen.151, 157 
The role of the T-antigen within cancer cells has been proposed to be 
significant in metastasis and cell adhesion. This is due to the existence of T-
antigen-mediated adhesion of highly metastatic murine lymphoma cells and 
hepatocytes.158 In addition, the participation of the T-antigen in human 
breast carcinoma cell adhesion to the endothelium has been discovered and 
Galβ3GalNAc-α-
(Core 1, T-antigen) 
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this process has been found to be critical in early stages of cancer 
metastasis.159 Despite these revelations, more research is required to develop 
and further understand the molecular underpinnings of the T-antigen within 
cancer. This in turn may aid in the potential use of this target within the 
therapeutic world.   
Although the expression patterns of the T-antigen make it an ideal target for 
therapeutic purposes, the biosynthetic pathway demonstrates the intricate 
discrepancies that exist between the T-antigen and other related, non-cancer 
associated antigens. Highly selective and specific targeting ligands are 
therefore required for these targets to be useful for therapeutic purposes.  
3.1.2 Jacalin – a T-antigen Selective Lectin 
Jacalin is a plant based lectin which is derived from the seeds of the Jack 
fruit (Artocarpus heterophyllus) and was isolated towards the end of the 
1970s.160 This lectin has been shown to selectively bind to the T-antigen and 
hence presents itself as an ideal agent for targeted delivery to tumour cells.161  
Structurally, jacalin consists of two chains termed the α-chain and the β-
chain. The α-chain is much larger with a molecular weight of around 14.5 
kDa whilst the β-chain has a molecular weight of 2.1 kDa. The total molecular 
mass of jacalin has been reported to be between 65-66 kDa suggesting that 
the quaternary structure of this lectin comprises a tetramer composed of four 




Figure 3.3: Chimera generated image of the crystal structure of jacalin-T-antigen complex 
(PDB ID 1M26). In red is shown the four α-subunits, in yellow are four β- subunits and in 
green is the T-antigen bound at the α-subunit based binding site.110 
Whilst other T-antigen specific lectins exist, jacalin separates itself from 
others in the biological response it elicits upon binding. Whilst lectins such as 
peanut agglutinin increase cell proliferation through an interaction with c-
Met and mitogen-activated protein kinase, jacalin has been shown to inhibit 
cell proliferation upon binding. This was demonstrated in HT-29 colon 
cancer cells with the inhibition shown to be reversible and non-toxic.109, 163 In 
the same cell line, jacalin was shown to bind to the T-antigen with a 
dissociation constant (Kd) of 500 ± 50 nM, reaching maximum binding in 20 
minutes at 4 °C.112 
The ability of jacalin to specifically recognise and bind to the T-antigen was 
demonstrated by Kumar and co-workers who used it to detect the antigen on 
precancerous and cancerous colonic tissue.164 Histological examination of T-
antigen expression was made using a comparison of jacalin, an anti-T antigen 
antibody and the galactose oxidase-Schiff (GOS) reaction. The latter is a 
reaction which colourimetrically labels tissue expressing the T antigen, 
following oxidation of the terminal galactose residue of the disaccharide and 
treatment with Schiff’s reagent. Although jacalin didn’t show the highest 
specificity of these agents, the results showed that jacalin had the highest 
sensitivity of 84.3% for cancerous and precancerous tissue, as compared to 
the GOS reaction (75.7%) and immunostaining (50%). Although, the reduced 
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specificity towards the T-antigen may at first seem detrimental for targeted 
delivery, an 80% selectivity can be viewed as impressively high. This is due to 
the fact the other 20% is likely to be caused by jacalin’s ability to also 
recognise the cancer associated sialylated version of the T-antigen albeit with 
a much lower binding affinity.165  
The use of lectins in targeted drug delivery has been reported on numerous 
occasions. Gabor and co-workers demonstrated the use of wheat germ 
agglutinin for the targeted delivery of doxorubicin to caco-2 cell lines.166 
Additionally, Ohkohchi and co-workers utilised a recombinant bacterial C-
type lectin (rBC2LC-N) to successfully deliver a bacterial exotoxin to a 
human PDAC cell line (Capan-1).167 Despite this, the use of jacalin to achieve 
targeted delivery of cytotoxic payloads to cancer cells has been relatively 
scarce although some do exist. One such study completed by Russell and co-
workers involved the formation of jacalin capped nanoparticles 
functionalised with a photosensitiser.111 The group found that in comparison 
to non-jacalin capped nanoparticles, the jacalin nanoparticles were delivered 
and taken up much more readily by HT-29 colon cancer cells through a 
specific interaction with the T-antigen. This was demonstrated by an increase 
in cell death post irradiation, from 8% up to 95% when the particles were 
conjugated with jacalin in comparison to when they were not.  This specific 
interaction was confirmed using inhibition studies with and asialofetuin 
which has been shown to express the T-antigen on its surface.  
Following on from this study, Anbazhagan and co-workers utilised jacalin in 
the formation of silver nanoparticles carrying the anticancer phytomolecules, 
acetylshikonin and β,β-dimethylacrylshikonin.168 Again, improved 
cytotoxicity’s were demonstrated for the drugs loaded onto jacalin capped 
silver nanoparticles. The acetylshikonin attached to the jacalin capped 
particle showed induced maximum cytotoxicity effects on human chronic 
myeloid leukaemia (CML) cell line, K562 at 100 nM, whereas for a similar 
effect about 500 nM of pure acetylshiknin was required. This can be 
attributed to the ability of jacalin to recognise the T-antigen expressed on the 




With evidence that jacalin shows desirable specificity and sensitivity for the 
T-antigen and also a proven ability to enhance the delivery of cytotoxic 
warheads, further research is warranted to establish the potential use of this 
lectin in antibody-drug like systems. It could be that jacalin provides the 
necessary properties that may help to achieve the targeted delivery of a 
duocarmycin based analogue and hence help this family of agents realise 
their potential as therapeutic agents.  
3.2 Aims of the Research in this Chapter 
The aim of the research in this chapter is to introduce investigations carried 
out to attach a duocarmycin based analogue, synthesised on the solid phase, 
to jacalin.  
The chapter will begin with a brief overview of the mass spectrometry 
analysis of jacalin which was completed to aid characterisation of the 
conjugates. The use of LC-MS and MALDI mass spectrometry were 
investigated as tools to try and decipher whether conjugation had occurred 
within our system and also to measure the degree of conjugation. 
Following on from this initial section, the chapter will then move to focus on 
the various conjugation strategies employed in order to achieve the desired 
conjugates. These strategies are broadly classified into EDC/NHS chemistry, 
maleimide/thiol chemistry and click chemistry.  
3.3 Results and Discussion 
3.3.1 Mass Spectrometry Analysis of Jacalin 
For the work carried out in this chapter, a method of deducing the level of 
conjugation obtained to the jacalin structure was required. Mass 
spectrometry presented an ideal way to deduce this characteristic and is used 
frequently for similar purposes within ADC like systems. For this reason, 
investigations to decipher the most efficient way to study jacalin using the 
mass spectrometry equipment available were conducted. 
As an initial strategy the use of liquid chromatography-mass spectrometry 
(LC-MS) was explored. Figure 3.4 shows the results of the LC-MS which were 






















From Figure 3.4, the three characteristic subunits of jacalin are evident. 
Figure 3.4A represents the α-subunit. What is also evident from the peak 
observed for this subunit is a series of masses with subsequent additions of 
162 Da. This indicates some glycosylation caused by additions of hexose 
moieties. Figure 3.4B represents the α’-chain of jacalin. The α and α’-
uea000249oc
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Figure 3.4: A: shows the α-subunit of jacalin, B: shows the α‘-subunit of jacalin and C: the β-
subunit of jacalin. See page 177 for LCMS details. 
 
α-SUBUNIT 
 Calcd. Mass = 14662.5610 
 Observed Mass = 14662.694 
N.B. Addition of 162 Da caused by 
glycosylation with hexose residues.  
β-SUBUNIT 
 Calcd. Mass = 2062.2474 
 Observed Mass = 
2061.9871 (not labelled) 
α’-SUBUNIT 
 Calcd. Mass = 15802.0808 
 Observed Mass = 15801.6221 
 
N.B. Addition of 162 Da caused by 




subunits, existing in a 1:3 ratio, are almost identical in their primary amino 
acid sequence except for one valine for isoleucine substitution.169 Although 
the α-chain shows some evidence of hexose glycosylation, the extent of 
glycosylation in the α'-chain is much greater than that in the α-subunit. In 
the α'-polypeptide, all molecules contain an N-linked oligosaccharide at 
position 74 and some contain a sugar at position 43 as verified by threonine 
resonance in the 1H-NMR spectrum of the jacalin glycopeptide.170 Figure 
3.4C shows the smaller β-subunit at around 2.1 kDa. This subunit is 
composed of 20 amino acids and is bound in a non-covalent manner to the α-
subunits.169 
The presence of the 162 Da increments in the mass spectrum of the jacalin α-
subunit was expected given the numerous literature reports demonstarting 
the binding of jacalin to a number of hexose units.169 The presence of these 
increments in the jacalin mass spectrum however does raise the question as 
to whether the jacalin used in this body of work will still readily bind the T-
antigen given that it is clearly interacting with some other hexose units. 
However, it has been reported that jacalin is able to recognise the GalNAc 
moiety in the T-antigen structure more extensively that for example a Gal 
moiety.170 As such, this inferred that the jacalin used here would still 
demonstrate some binding towards the T-antigen. Despite this, the above 
was still a consideration to take forward for later experiments in this body of 
work. 
The LC-MS results above present an ideal way to analyse conjugation to the 
jacalin structure. The majority of the conjugation strategies attempted as part 
of this thesis utilised a route via the lysine residues of the jacalin. With the α-
subunit containing the majority of the lysine residues, an increase in mass to 
this subunit, depending on the duocarmycin peptide analogue used, would 
represent conjugation occurring. 
Whilst the LC-MS results present an accurate method of establishing 
conjugation, due to time constraints and equipment availability, the use of 
matrix assisted laser desorption ionisation (MALDI) was also explored for 
analysing conjugates. MALDI mass spectrometry presents itself as an ideal 
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method for analysing protein mass due to its mild ionisation technique.171 In 
addition, the method itself is relatively easy and time efficient.  
One of the most crucial aspects for a successful MALDI analysis is the choice 
of matrix. This can greatly affect the level of ionisation of the sample and 
hence the quality of the resulting spectra.172 In order to find the best MALDI 
matrix for jacalin, a variety of matrices were studied. These were α-cyano-4-
hydroxycinnamic acid (αCHCA), trans-ferulic acid, sinapinic acid, 2,5 
dihydroxybenzoic acid (DHB) and picolinic acid. It was found that trans-
ferulic acid was able to give the clearest and sharpest spectra for jacalin, 
especially in the α-subunit mass range. In addition to the matrix, other 
features which were found to greatly affect the spectra quality were matrix 
solvent system, sample buffer desalting, TFA introduction and sample 
preparation. Details of these key components are shown in Table 3.1 along 
with an example MALDI spectra using the discovered, ideal conditions in 
Figure 3.5.  
Table 3.1: standard conditions utilised for MALDI based analysis of jacalin and the resulting 
conjugates. 
MALDI variable Ideal conditions 
Matrix Trans-ferulic acid shown to give best 
ionisation. Sinapinic acid also shown to be 
a good alternative. 
Matrix solvent 70:30 mixture of acetonitrile (ACN) to H2O 
shown to give the best results. 
Mode A linear mode on the MALDI was used for 
all samples. 
Sample desalting All samples in buffer were desalted prior to 
sample plating using Dowex® MB Mixed 
Ion Exchange Resin. 
TFA introduction Introduction of 0.1% TFA to matrix 
solution was made for all samples. 
Sample preparation A ‘sandwich’ technique was utilised for all 
sample preparations. This involved spotting 
the matrix onto the plate and allowing it to 
dry. The sample was then spotted before 







Figure 3.5A demonstrates the sharp peak of the jacalin α-subunit under the 
investigated conditions. The presence of a 2M peak at around 34 kDa is also 
evident. Figure 3.5B presents a higher resolution version of this α-subunit 
peak. Similar to the LC-MS, a shoulder off this main peak is likely to be 
caused by the presence of the glycosylated α’-subunit. Although the main α-
subunit peak is sharp, slight broadening maybe present due to glycosylation 
of 162 Da as seen in the LC-MS data presented in Figure 3.4.  
It should be noted however that a relatively large difference (~ 1.2 kDa) exists 
between the mass of the α-subunit and the α’-submit found in MALDI mass 
spectrometry in comparison with that found via electrospray ionisation in the 
LCMS spectra (see Figure 3.4). This also constitutes a mass difference of 1.4 
kDa between the calculated mass of the α-subunit and that obtained using 
MALDI mass spectrometry. The reason for such a large difference is 
unknown. However, this may be due to the MALDI mass spectrometer not 
functioning at optimal capacity and failing to be sufficiently calibrated. 
However, since the purpose of obtaining the mass of the jacalin α- and α’-
subunits in this chapter was to observe any increase in the mass of said 
subunits, it was decided that the MALDI spectrometer still provided an ideal 
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Figure 3.5: MALDI mass spectrometry spectra conducted in linear mode with a laser 
power of 180 of the α-subunit of jacalin, A: shows the full spectrum whilst B: shows the 
main peak at higher resolution. 
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should be fully appreciated that in order to obtain a more concrete picture of 
any conjugations observed using the MALDI mass spectrometer, a more 
accurate mass analysis would be required.  
With two methods of analysis optimised and in hand for assessing the level of 
conjugation to the jacalin structure, work could begin on attempting to 
achieve the desired conjugation. The next sections will detail the various 
strategies utilised in order to achieve this. 
3.3.2 EDC/NHS Chemistry 
The carbodiimide, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC), is the most commonly used coupling agent for 
achieving conjugation between an amine and a carboxylic acid. The reason 
for this popularity stems from the water soluble nature of this reagent and 
also of the isourea by-product. This feature means that post reaction, these 
impurities can be removed with relative ease using techniques such as 
dialysis.173 A general route to the stable amide linkage formed from an EDC 
mediated reaction is demonstrated in Scheme 3.1. 
 
Scheme 3.1: general scheme showing the reaction between an amine and a carboxylic acid 
using EDC. The carboxylic acid reacts with EDC to form an active ester intermediate which 
can go on to react with an amine to form a stable amide bond. 
 
Whilst there is no doubt about the utility of this reaction for achieving 
conjugations, it also has a number of drawbacks. Firstly, EDC itself is 
particularly labile in the presence of water and hence decomposition of the 
reagent prior to reaction is not uncommon. In order to avoid this, optimal pH 
ranges for the reaction have been established.174 A more detrimental 
drawback for this reaction however, is the instability of the o-acylisoura 
active intermediate (Scheme 3.1). This intermediate can hydrolyse in aqueous 
solutions with rate constants of only a few seconds.27 Therefore, if the relative 
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concentrations of the intermediate and amine are not optimised for the 
coupling to occur, the resulting reaction is likely to be hindered leading to 
greatly reduced yields. This is a particular problem when reagents are in low 
concentration compared to water which is often the case for protein 
conjugations.  
In order to avoid these problems, it was discovered that the addition of N-
hydroxysuccinimde (NHS) to an EDC mediated reaction can greatly increase 
yields.175 The addition of NHS pushes the reaction via an active NHS ester 
intermediate which has been shown to react rapidly with amines. 
Additionally, this NHS ester intermediate shows improved stability in 
aqueous solutions in comparison to the o-acylisourea intermediate. This is 
particularly the case when the pH is ~ 5. A scheme representing this NHS 
based EDC coupling is demonstrated in Scheme 3.2.  
 
Scheme 3.2: efficiency of the EDC mediated coupling can be improved through the addition 
of NHS. This forms a more stable NHS ester intermediate for reaction with the amine.  
 
3.3.2.1 In-situ EDC/NHS Activation 
With this reaction showing great applicability and with literature procedures 
being extensive, it was chosen as a first strategy for the conjugation between 
jacalin and a duocarmycin based analogue. What was also ideal about this 
reaction is the abundance of amine containing lysine residues on the jacalin 
α-subunit. These can be utilised in the reaction with a carboxylic acid. As 
mentioned in Chapter 2, the use of 2-cltrt resin with the DSA unit has shown 
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advantageous results. This is also ideal in this situation since cleavage from 
this resin results in the formation of a carboxylic acid at the C-terminus of 
the peptide sequence. The required amine and carboxylic acid functionalities 
would therefore be in hand without significant chemical manipulation. 
For the synthesis of the duocarmycin peptide, it was decided that a cleavable 
peptide sequence would be incorporated. This would allow for cleavage of the 
duocarmycin moiety from the jacalin upon cellular internalisation. From a 
brief literature search, a Phe-Leu sequence was found which has 
demonstrated cleavage by cellular enzymes.176, 177 This sequence was 
desirable since it would be easy to incorporate using SPPS. Compound 3.1 
shown in Figure 3.6 was therefore synthesised. 
 
Figure 3.6: structure of compound 3.1 synthesised for the attempted conjugation to jacalin. 
In green is the DNA binding subunit, in red is the alkylating subunit and in blue a possible 
cleavable peptide sequence.  
 
Following the general solid phase conditions presented in Chapter 2, Section 
2.3.3.2, the above peptide was successfully synthesised. Subsequent to 
cleavage from the resin, the peptide was purified using preparative high 
performance liquid chromatography (HPLC). Post purification, analytical 
HPLC demonstrated >95% purity of 3.1 and an overall yield of 48% was 
obtained. MALDI was used to confirm the desired molecular weight of 3.1. 
For the initial conjugation investigation it was decided to leave the benzyl 




Now that a duocarmycin based peptide containing a carboxylic acid 
functionality was in hand, attempts could be made to conjugate this to the 
lysine residues of jacalin. Initial attempts focused on an in-situ based 
EDC/NHS activation method using a one pot mixture of jacalin, 3.1, EDC 
and NHS. This method is advantageous in that since jacalin, and hence the 
amine residues are present within the mixture, rapid reaction with the NHS 
ester intermediate of 3.1 should proceed.  
Notable during the development of these reactions was the insolubility of 3.1 
in aqueous solutions. For this reason, stock solutions of 3.1 were made in 
DMSO before dilution into the specific reaction buffer being used. A relative 
concentration of 20 molar equivalents of 3.1 was selected as an initial 
starting point in the reaction since it was known there were 8 lysine residues 
per α-subunit in jacalin and hence 32 overall. Since a drug-jacalin ratio of 
around 4 was targeted, this concentration ratio of 3.1 to jacalin was deemed 
an acceptable starting point.  
The reaction buffer chosen for the conjugation presented above was HEPES 
buffer saline at pH 6.5. This was chosen for two reasons. Firstly, HEPES 
buffer saline pH 7.4 was recommended by the company from which the 
jacalin was purchased and hence deviation from this buffer system was 
undesirable. Secondly, slightly acidic pH’s promote the formation of the NHS 
ester and also reduce the likelihood of hydrolysis.174  Scheme 3.3 
demonstrates the reaction undertaken as described above. 
 
Scheme 3.3: in-situ EDC/NHS activation of 3.1 was utilised as an initial attempt at making 




Upon leaving the mixture to react for between 2 and 12 h, the reaction was 
purified using dialysis to remove the small molecule components. Using a 
specific molecular weight cut off (MWCO), the conjugated jacalin or any 
unlabelled jacalin should remain as the sole component. After this procedure, 
the solution was analysed using the mass spectrometry strategies presented 
in Section 3.3.1. What was observed here was no conjugation occurring with 
the masses obtained being identical to that of the unlabelled jacalin. One 
possibility for the lack of reaction came from the observation that a 
precipitate had formed during the reaction. After analysis of the precipitate 
through HPLC and MALDI mass spectrometry, it was found that 3.1 was 
precipitating from the reaction buffer, this could therefore be preventing the 
formation of the conjugate. Secondly, since EDC and NHS are included in the 
presence of the jacalin, it is possible that jacalin cross-linking may occur. 
This is because of the presence of exposed amine residues (lysine) and 
carboxylic acid residues (glutamic/aspartic acid) on the jacalin structure. 
EDC/NHS based activation of the carboxylic functionality of the 
glutamic/aspartic acid could therefore occur which in turn could react with 
the lysine residues. Although these cross-linked structures were absent from 
the MALDI spectra, this was expected since ionisation and hence detection of 
these can be difficult. 
In order to address the issue surrounding the hydrophobicity of 3.1, a further 
duocarmycin analogue was synthesised that contained more hydrophilic 
amino acid residues. The chosen residues were arginine amino acids and the 
structure of this peptide (3.2) is shown in Figure 3.7. For the ease and speed 
of synthesis, the DNA binding subunit and the cleavable sequence were 
omitted from this analogue. The removal of the DNA binding unit has 
previously been shown to have some effect on the biological activity of 
analogues although for these early stage conjugation investigations it was 




Figure 3.7: structure of peptide 3.2 synthesised to improve the hydrophilicity and hence 
eliminate the issues with peptide precipitation. 
 
The water soluble compound, 3.2, was included in the in-situ EDC/NHS 
reaction with jacalin. Again, upon purification, mass analysis demonstrated 
no conjugation occurring. With the issue of peptide solubility now 
eliminated, it appeared that possible jacalin cross-linking might be 
preventing the desired reaction from occurring. In order to address this 
issue, the EDC/NHS molar ratios were adjusted. This has been shown in 
previous work to have an effect on promoting the intermolecular reaction as 
opposed to protein cross-linking in conjugation reactions.178 Additionally, the 
utilisation of sulfo-N-hydroxysuccinimide (sulfo-NHS) was attempted in our 
system as this analogue of NHS has demonstrated effects on conjugation 
efficiencies.175 A summary of the attempted conditions to promote 
conjugation using the in-situ EDC/NHS activation method are demonstrated 









Table 3.2: conditions employed for the conjugation of 3.2 to jacalin. The conditions were 














2 mg/mL 20 20 NHS - 25 Precipitation and no 
conjugation 
1 mg/mL 20 20 NHS - 20 Precipitation and no 
conjugation 
1 mg/mL 10 10 NHS - 10 Less precipitation 
and no conjugation 
1 mg/mL 20 20 sulfo-NHS - 25 Precipitation and no 
conjugation 
1 mg/mL 10 10 sulfo-NHS - 10 Less precipitation 
but no conjugation 
 
a concentration within a 10 mM HEPES buffer b molar equivalents in relation to jacalin c 
type of NHS ester (NHS or sulfo-NHS) 
Since a lack of conjugation was still being observed it was decided to 
investigate whether the issues were jacalin or peptide specific. Bovine serum 
albumin (BSA) is a model protein that is relatively inexpensive and available 
in reasonable quantities. Also, the molecular weight of BSA is very similar to 
that of jacalin so it was hoped that results could be applicable to both species. 
3.2 was reacted with BSA in the presence of EDC (0.1 mg per mg of protein). 
NHS was omitted and a 0.1 M MES buffer at pH 5 was used. After reacting 
for 90 minutes at room temperature, the BSA was purified through a 7K 
MWCO spin column and analysed by MALDI mass spectrometry. The 
resulting spectrum demonstrated a mass increase of around 3200 Da which 
suggest a conjugation of around four units of 3.2 to the BSA structure 




Figure 3.8: MALDI mass spectrometry spectrum of unlabelled BSA in blue and BSA-3.2 
conjugate in orange. A clear increase in the mass of BSA is evident after subjection to the 
conjugation conditions. N.b. the masses shown in the figure are taken from the data points at 
the apex of the respective peak.  
 
This result suggested there was no issue occurring with the EDC activation of 
our duocarmycin peptides. When the above conditions were repeated with 
jacalin however, no conjugation upon mass analysis was visible. It is possible 
that the lysine residues on the jacalin structure could be more concealed and 
hence less likely to react with the activated esters formed in-situ before they 
hydrolyse.  
3.3.2.2 Ex-situ NHS Ester Formation of Duocarmycin Analogues 
Since attempts using the in situ activation of duocarmycin peptides with 
EDC/NHS were unsuccessful, attention turned to an ex-situ formation of 
duocarmycin-based NHS esters. These esters could then be added into a 
buffer containing jacalin in order to achieve conjugation. This strategy would 
allow for greater control over the degree of conjugation to jacalin since 
specific molar ratios of the active NHS esters could be added. Additionally, 
with EDC and NHS being absent from the reaction mixture, any problems 
due to jacalin crosslinking could be avoided.  
The utility of this strategy for conjugation to jacalin was first demonstrated 
using a number of commercially available NHS esters. For these reactions, 
jacalin in HEPES buffer at pH 7.4, was reacted with 20 molar equivalents of 
the NHS esters. The MALDI results of these conjugations are demonstrated 





Figure 3.9: MALDI mass spectrometry results of conjugations to jacalin. In Blue is the MALDI 
spectra of the unlabelled jacalin α-subunit. In orange is the MALDI of the respective conjugates 
post reaction with a; DBCO-NHS b: SMCC, c: Biotin-NHS. All reactions show an increase in 
mass of the α-subunit with each increase representing around four additions of the NHS ester 
to the jacalin. N.b. the masses shown in the figure are taken from the data points at the apex of 






What can be seen from the above figure is that an increase in mass to the α-
subunit of the jacalin is achieved through reaction with a pre-made NHS 
ester. These results therefore confirm that this strategy is a viable option to 
achieve conjugation to the structure of jacalin. Some of the conjugates 
formed in these reactions precipitated from the solution and were 
resuspended in acetonitrile and water in order to generate the MALDI 
results. This suggested that the precipitation of the jacalin upon conjugation 
was a general phenomenon and not necessarily associated just with 
duocarmycin conjugation  
Following on from the above model reaction, the synthesis of the NHS ester 
of peptide 3.1 was attempted. This was carried out using N,N'-
dicyclohexylcarbodiimide (DCC) and NHS. The conditions utilised for this 












Scheme 3.4: a: DCC, NHS, Anhydrous DMF, 16 h 
Post reaction, MALDI mass spectrometry showed a mass representing only 
3.1 rather than 3.1-NHS, which suggested that the reaction had been 
unsuccessful. To assess the presence of the NHS ester the proposed 3.1-NHS 
was reacted with N,N-dimethylaminopropylamine. However, HPLC and 
MALDI analysis demonstrated no coupling reaction occurring suggesting, 
again, that the NHS formation had been unsuccessful. These findings 
coincided with the observation that no dicyclohexylurea (DCU) had 
precipitated during the reaction. DCU is the by-product from the DCC based 
coupling reactions and is insoluble in DMF. Therefore, a sign of the reaction 
proceeding is the precipitation of DCU as a colourless solid.173  
A possible reason for the lack of reactivity of 3.1 was the steric hindrance 
around the C-terminus carboxylic acid caused by the phenylalanine amino 
acid. This could prevent the formation of the active O-acylisourea 
intermediate and therefore stop the reaction from occurring. In order to test 
this theory compound 3.3 was made. For ease of synthesis the binding-
subunit and cleavable sequence were again removed and a short β-alanine 
sized linker was introduced. It was proposed that with less steric hindrance 
around the C-terminus carboxylic acid, the DCC based coupling reaction with 




Scheme 3.5: a: DCC, NHS, Anhydrous DMF, 16 h. Formation of the NHS ester of 3.3 using 
DCC proceeded successfully. This was proposed to be due to the lack of steric hindrance 
around the C-terminus carboxylic acid.  
 
Although compound 3.3-NHS (Scheme 3.5) was not isolated, the presence 
of the NHS ester was confirmed using LC-MS which showed a peak indicative 
of the desired mass. Additionally, upon reaction of 3.3-NHS with N,N-
dimethylaminopropylamine, HPLC and MALDI mass spectrometry showed 
coupling had occurred which was further indicative of the NHS ester being 
formed. These findings were consistent with the observation that in this 
reaction, DCU did precipitate. 
For the conjugation of 3.3-NHS to jacalin, 3.3-NHS was prepared freshly in 
anhydrous DMF. The resulting DCU was removed by centrifugation and the 
DMF evaporated. 3.3-NHS was then resuspended in DMSO before being 
added to jacalin in HEPES buffer at 20 molar excess (Scheme 3.6). This 
followed the conditions utilised for the results in Figure 3.9.  
 
Scheme 3.6: reaction of 3.3-NHS with jacalin in HEPES buffer gave successful conjugation 
to the jacalin structure albeit with resulting precipitation of the jacalin. 
 
During the reaction, it was again observed that a precipitate was forming. 
After the required reaction time, the precipitate was removed via 
centrifugation and resuspended in acetonitrile and water and analysed using 




Figure 3.10: MALDI mass spectrometry result for the reaction of jacalin with 3.3-NHS. The 
precipitate from the reaction was removed and resuspended in acetonitrile to obtain the 
above spectrum. In blue is the unlabelled jacalin α-subunit and in orange, the labelled α-
subunit. N.b. the masses shown in the figure are taken from the data points at the apex of the 
respective peak. 
 
The precipitate from the reaction was the labelled jacalin species, as 
demonstrated in orange in the above MALDI spectrum. The mass increase of 
around 1500 Da suggested the addition of between 3 and 4 molecules of 3.3 
to the jacalin α-subunit. The precipitation of jacalin which had been observed 
on multiple occasions was a concern due to potential issues with the 
quaternary structure of the protein and potential effects on biological assays. 
In addition, the precipitation made the characterisation of the conjugates 
difficult as it was observed that mass spectral analysis of the conjugate 
following precipitation was problematic. It could be that the masking of the 
lysine residues (a point of possible ionisation during MALDI) via the 
conjugation of 3.3 could be hindering the characterisation process.  
Benzyl deprotection of 3.3 would give the active duocarmycin which could be 
converted to the NHS ester for conjugation to the jacalin. Benzyl 
deprotection of 3.3 was achieved using transfer hydrogenation with 10% 
palladium on carbon and ammonium formate as detailed in Chapter 2, 
Section 2.3.4. The resulting active duocarmycin unit, 3.4, was then reacted 






Scheme 3.7: a: 10% Pd/C, 25% Aq. Ammonium formate, MeOH, 1h, rt b: DCC, NHS, 
anhydrous DMF, 16 h, rt. 
 
Crude 3.4-NHS was redissolved in DMSO and reacted with jacalin in a 20 
molar excess. Precipitation was again observed during the reaction time 
course. After 20 h, the precipitate was collected and resuspended in 
acetonitrile and water. It was noted this time that it was harder to get the 
precipitate back into solution. Despite this, the precipitate was analysed via 
MALDI mass spectrometry ( 
Figure 3.11). The spectra obtained for this conjugate were less clear, possibly 
due to the dissolution issues, but did seem to suggest conjugation occurring 




Figure 3.11: A: MALDI mass spectrometry result for unlabelled α-subunit of jacalin. B: 
MALDI of α-subunit after reaction with 3.4-NHS. What is evident here is the shifting of the 
subunit to a higher mass indicating conjugation occurring. The spectrum however of this 
conjugate is less clear possibly due to dissolution issues of the conjugate. N.b. the masses 
shown in the figure are taken from the data points at the apex of the respective peak. 
 
The addition of duocarmycin based units onto antibodies and proteins has 
previously been described as difficult due to problems with precipitation.87 
This is likely to be due to the unfavourable covering of the protein surface 
with hydrophobic units in aqueous conditions. It was this reason which drove 
ImmunoGen to investigate the use of phosphate groups to aid dissolution.87 
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particularly prone to precipitation, even in the model reactions described 
above. Attempts to reduce precipitation by controlling the levels of 
conjugation occurring to the jacalin structure by reducing the molar 
equivalents of the NHS-esters were unsuccessful. Addition of hydrophilic 
amino acids into the sequence could potentially prevent precipitation. 
Peptide 3.5 was synthesised using SPPS, however, the formation of 3.5-
NHS was unsuccessful (Scheme 3.8). It seems likely that the basicity of the 
arginine unit may affect the DCC/NHS reaction preventing formation of the 
reactive ester.  
 
Scheme 3.8: attempted NHS ester formation of 3.5 was found to be unsuccessful under our 
previously used conditions.  
 
Although the use of the EDC/NHS route was successful in forming a 
protected jacalin-DSA conjugate (jacalin-3.3) and an active analogue (jacalin-
3.4), issues with precipitation and the lack of solubility of these conjugates 
suggested that alternative methods for conjugation might be more 
appropriate and, as such, investigations into the potential of the 
maleimide/thiol conjugation route were initiated.    
3.3.3 Maleimide/Thiol Conjugation Strategy 
The reaction between a thiol and maleimide has been studied extensively for 
use within protein bioconjugation reactions as a non-cleavable linkage.173 The 
reaction involves a Michael type addition of a thiol to the activated alkene of 
a maleimide (Scheme 3.9). The activation of this position is a direct result of 
the electron-withdrawing ability of the adjacent carbonyl groups. Release of 
ring strain also contributes to the driving force of this reaction. The efficiency 
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and ease of this manipulation has contributed to its classification as a click 
chemistry reaction.179 
 
Scheme 3.9: the thiol-maleimide coupling reaction is thought to proceed through attack of a 
thiolate anion to the activated alkene of the maleimide. 
 
It is this efficiency that has led to the utilisation of this reaction in the 
bioconjugation field. Cysteine residues on proteins can be utilised for the 
reaction with maleimides introduced onto small molecules. Mixing of the two 
species within an appropriate buffer system was shown to give favourable 
conjugation results.173 The use of this technique has more recently been 
utilised in ADC like systems since selective disulfide bridge reduction on 
antibodies can allow for selective conjugations to these sites.180 This in turn 
gives some control over the resulting drug-antibody ratio and hence a move 
to more homogenous product mixtures. This strategy was utilised in the 




Figure 3.12: structure of the clinically approved Adcetris® which utilises a strategy where a 
reduced disulphide on the antibody is coupled to a maleimide moiety which is integrated 
into the MMAE drug payload.181 
 
In the reverse manner, the formation of linkers that allow the 
functionalisation of a protein with a maleimide have also been introduced. 
This allows thiol containing small molecules to be conjugated to these sites. 
One such linker which has been used extensively within ADC development 
and bioconjugation reactions is succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) (Figure 3.13).182 This 
bifunctional linker contains a NHS ester functionality and a maleimide 
functionality. These are held apart by a cyclohexane ring which has been 
shown to confer added stability to the linker. 
 
Figure 3.13: chemical structure of SMCC. In red is the maleimide moiety, in blue is the 
cyclohexane ring spacer and in green the NHS functionality.  
 
Careful control over pH can ensure that thiol addition occurs selectively at 
the maleimide (pH 6.5-7.5) whilst amine residues react with the NHS ester 
functionality (pH 7-9).173 This strategy is utilised in the formation of 




Figure 3.14: structure of Kadcyla where mAb = trastuzumab. In blue is the SMCC linker with 
the antibody attached through reaction with the NHS ester functionality. In red is the thiol 
introduced onto the DM1 payload for reaction with the maleimide of SMCC.  
 
The use of the SMCC linker within our system can be seen as favourable for a 
number of reasons. Firstly, jacalin does not contain any cysteine residues in 
its primary amino acid sequence.169 This means that regioselective reactions 
of the SMCC with jacalin can be achieved as only lysine residues are available 
for reaction with the NHS ester of the linker. This results in jacalin being 
functionalised with a maleimide moiety. In addition to this, with the DSA 
system being utilised on the solid phase, the introduction of a cysteine 
residue, and hence a thiol, into a specific peptide sequence should proceed 
with relative ease. This means that both components of the desired click 
reaction should be simple to synthesise.  
In order to attempt this conjugation, the solid phase synthesis of a 
duocarmycin peptide containing a thiol functionality was completed. The 
peptide was based on peptide 3.1 from earlier but with a cysteine residue 
introduced. This gives 3.5 as shown in Figure 3.15. 
 
Figure 3.15: chemical structure of peptide 3.5. In red is shown the cysteine residue which 




Peptide 3.5 was synthesised on a 2-Cltrt resin. Typically, cysteine residues 
utilised in Fmoc based SPSS contain a trityl protecting group on the thiol. 
However, this group requires high TFA concentrations for removal so a 
methoxytrityl thiol protecting group, which can be removed in only 1% TFA, 
was utilised.183 The synthetic strategy employed for this peptide was very 
similar to those described in Chapter 2, Section 2.3.3.2. However, one 
difference is within the cleavage cocktail utilised - for peptide 3.5, 
ethanedithiol (EDT) at 2.5% was introduced. EDT has been shown to aid in 
the cleavage of peptides containing cysteine residues since it acts as an ideal 
scavenger for the trityl and methoxytrityl groups as well as a reducing agent 
to avoid intermolecular disulphide bond formation.184 Evidence of the 
successful synthesis of 3.5 was provided by MALDI with the expected mass 
being clearly shown. Preparative HPLC was used to purify the peptide and a 
reasonable purity of 92% was found post purification using analytical HPLC. 
It was decided that for a proof of concept reaction, the benzyl group would be 
left in to reduce handling of the highly cytotoxic analogues.  
It was then necessary to attempt the maleimide functionalisation of the 
jacalin lectin. For this, the lyophilized protein was reconstituted into HEPES 
buffer saline at pH 7.4 at a 2 mg/mL concentration. A 2 mg/mL solution of 
SMCC in DMSO was then made and added to the jacalin to give a 20 molar 
excess of the linker. After 2 h, the functionalised jacalin was purified through 
a 7K MWCO spin column and the resulting solution analysed by LC-MS. The 



























From these results it is evident that the coupling of the SMCC linker has 
occurred with the addition of up to four linkers per α-subunit. The 
complexity of the labelled jacalin spectrum is a result of the glycosylation of 
the jacalin structure and the various levels of conjugation present in the 
mixture. However, thorough deconvolution and analysis can show that each 
peak is shifted by 220 Da (up to four times) which is consistent with the 
addition of an SMCC linker. The data provided in the table of Figure 3.16 
relates to the jacalin α-subunit without any addition of a hexose moiety. The 
other peaks present in the spectrum relate to the masses of the jacalin α-
subunit with differing levels of hexose conjugation. Also noteworthy here is 
the lack of precipitation upon SMCC conjugation. It could be the smaller size 
of this unit aids in keeping this jacalin conjugate in solution.  
With the maleimide functionalised jacalin now in hand. Attempts could be 
made to react this with peptide 3.5. For this, the SMCC functionalised jacalin 
Figure 3.16: LCMS results of the coupling of jacalin to the SMCC linker. A: Results of 







was mixed with 20 molar equivalents of 3.5 in HEPES buffer. After 2 h, a 
precipitate was evident within the reaction mixture. This was removed and 
the resulting supernatant passed through a spin column. Both the precipitate 
and the supernatant were then analysed through LC-MS. Whilst the 
supernatant seemed to contain only jacalin and SMCC labelled jacalin, the 
LC-MS result of the precipitate which was dissolved in DMSO/Buffer showed 
a more promising result (Figure 3.17).   
 
Figure 3.17: LC-MS results of A: unlabelled jacalin, b: SMCC labelled jacalin, c: jacalin 
labelled with SMCC and peptide 3.5. See page 177 for LCMS method details.  
 
The above results show that the precipitate from the reaction mixture 






subunit. This was pleasing since a DAR of between 3 and 4 has previously 
been shown to be desirable in ADC like systems.185 Precipitation was again 
observed and the effect this could have on the potential of the conjugates as 
targeted agents was of some concern.  
To investigate the conjugation reaction with the benzyl deprotected, active 
form of peptide 3.5, Initial studies involved the transfer hydrogenation 
reaction using palladium and ammonium formate introduced in Chapter 2 
(Scheme 3.10). 
 
Scheme 3.10: a: 10% Pd/C, 25% Aq. Ammonium formate, MeOH, rt, 1 h 
 
HPLC analysis after 1 h showed that no reaction had occurred via the 
presence of the starting material peak. For this reason, the reaction was left 
for an extended amount of time. When HPLC still presented no reaction 
occurring, further additions of palladium and ammonium formate were made 
but no reaction occurred. Other Palladium based catalysts for the transfer 
hydrogenation also returned no favourable results.  
This lack of reactivity could be due to the poisoning of the palladium catalyst 
via the sulphur of the cysteine residue. This process has previously been 
shown to occur in a number of reaction conditions.186, 187  
Benzyl deprotection was also attempted using aluminium chloride and BBr3 
(see Chapter 2, Section 2.3.4.), which has also shown promise in previous 
studies.131 However, neither of these conditions returned the desired product.  
As an alternative approach, peptide 3.1 could again be synthesised and 
benzyl deprotected. Following on from this, a thiol moiety could be added via 
the C-terminus carboxylic acid which could then be used for maleimide 
coupling. For this it was decided cysteamine could act as an ideal bifunctional 
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linker for the system. Cysteamine was coupled to the benzyl deprotected form 
of 3.1, numbered here as 3.7 (Scheme 3.11).   
 
Scheme 3.11: a: HATU, DIPEA, DMF, rt, 2 h 
 
Post reaction HPLC demonstrated the presence of two main peaks in the 
reaction mixture and these were identified using mass spectrometry as 3.8 
and also 3.8 but with cysteamine as a disulphide. Both of the peaks were 
isolated and could be utilised in parallel as within the reaction buffer during 
the conjugation to the maleimide jacalin, TCEP would be included to reduce 
the disulphide to give solely 3.8.188 However, when this was attempted and 
the resulting conjugate analysed by LC-MS, only SMCC labelled jacalin was 
evident, indicating that 3.8 had not reacted with the maleimide. As an 
alternative approach, prior to jacalin conjugation, the 3.8 mixture was 
passed through a TCEP containing resin- the resulting eluent then added 
directly into the jacalin SMCC containing buffer. However, post reaction LC-
MS again indicated that no coupling had occurred.  
An alternative approach involved the reversal of the reactivity employed 
above i.e. introduce a maleimide functionality onto a duocarmycin agent and 
a thiol onto the protein. Since jacalin does not contain a cysteine residue, 
artificial introduction of a thiol moiety is required. The use of 2-
iminothiolane, also known as Traut’s reagent, (Scheme 3.12) provides a 
simple, one step conversion of amines to sulfhydryl’s and is therefore ideal 
for the introduction of thiols onto lysine resides of jacalin.173 A further 
advantage of this reagent is that it maintains the charge properties of the 
original lysine residue and should therefore not result in any solubility issues 




Scheme 3.12: 2-Iminothiolane can be used to introduce sulfhydryl residues into proteins via 
reaction with exposed lysine residues.  
 
For this reaction, jacalin was dissolved in HEPES buffer at pH 7.4 and 
treated with 2-iminothiolane at a 20 molar excess. After 2 h, the reaction 
mixture was purified to remove excess 2-iminothiolane. This was achieved by 
spinning the mixture through a 7K MWCO spin column. In order to confirm 
the presence of thiols on jacalin, an Ellman’s assay was completed. The 
observed colour change from colourless to yellow upon introduction of the 
Ellman’s reagent provided evidence of a successful reaction.189 
Compound 3.9 (Figure 3.18) represents a duocarmycin analogue containing 
a maleimide moiety. The DNA binding subunit is not present and the peptide 
was synthesised on a rink amide resin to cap the C-terminus with an amide. 
A maleimide functionality was introduced onto the N-terminus through use 
of N-ε-maleimidocaproic acid.  
 
Figure 3.18: chemical structure of compound 3.13 containing a maleimide functionality 
 
Upon the successful synthesis of crude 3.9 as determined by mass 
spectrometry the benzyl deprotection of 3.9 was realised. For this 
manipulation, the BBr3 benzyl deprotection conditions were used as opposed 
to the transfer hydrogenation reactions to avoid reduction of the required 
maleimide functionality. 1H NMR confirmed the formation of 3.10 (Scheme 
3.13) via the absence of peaks representing the benzyl group. Mass 
spectrometry also confirmed the formation of 3.10. 
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What remained now was for 3.10 to be reacted with the thiolated jacalin. 
This was done using a 20 molar excess of 3.10 to the jacalin (Scheme 3.13).  
 
Scheme 3.13: reaction of thiolated Jacalin with compound 3.10 to form a jacalin-3.10 
conjugate. A: 10 Mm HEPES buffered saline, 2 h, rt. 
 
After the 2 h reaction time, a precipitate was again evident within the 
reaction mixture which was in turn removed by centrifugation and analysed 
via MALDI mass spectrometry (Figure 3.19).  
 
Figure 3.19: MALDI mass spectrometry spectrum of unlabelled jacalin (blue) and jacalin 
labelled with 3.10 (orange). N.b. the masses shown in the figure are taken from the data 
points at the apex of the respective peak. 
 
Again this precipitate was difficult to get back into solution and hence 







spectrum however, did indicate a mass increase suggesting the addition of 
between two and three 3.10 units per jacalin α-subunit. With this conjugate 
only re-dissolving in large quantities of DMSO, investigations into its use as a 
possible active conjugate for our studies were discontinued.  
After the promising results obtained for the coupling of 3.5 to jacalin 
functionalised with SMCC, it was particularly disappointing that troubles 
with the subsequent benzyl deprotection and thiol introduction were 
encountered. Despite this, it is worth noting that this conjugation strategy 
along with the reverse reactivity strategy had also promoted the precipitation 
of jacalin. It maybe that therefore, this conjugation route was also going to 
result in issues when it came to the biological analysis of these conjugates. 
The work in this section therefore further supports those findings from 
Section 3.3.2 of this chapter in that jacalin may be very difficult to conjugate 
with small molecules without causing its precipitation and hence an 
alteration to its quaternary structure. To further confirm whether this is the 
case a further conjugation strategy was explored.  
3.3.4 Alkyne-Azide Cycloaddition Click Chemistry 
The Huisgen 1,3-dipolar cycloaddition reaction, also termed the [3 + 2] 
azide-alkyne cycloaddition has manifested itself as the most popular click 
reaction founded to date.173 This reaction involves the formation of five-
membered triazole-based heterocycles, from the reaction between an azide 
and an alkyne (Scheme 3.14). 
 
Scheme 3.14: the Huisgen 1,3-dipolar cycloaddition reaction between an azide and an alkyne 
to form a stable triazole based product.  
 
Whilst most commonly used within the area of organic synthesis and drug 
discovery, this click reaction has found multiple uses within bioconjugation 
chemistry.173 The popularity in this area can be attributed to a number of 
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factors. Firstly, the azide moiety is absent in almost all naturally existing 
compounds, and lacks reactivity with natural biomolecules. This means, that 
the azide itself can be used for highly selective bioconjugation reactions. In 
addition to this, the click chemistry reaction allows for mild reaction 
conditions, high yields, simple work-ups and specificity, all of which are ideal 
in bioconjugation. These advantages for bioconjugation reactions were 
brought about by the realisation that a Cu(I) catalyst could lower the 
activation energy to reaction between the azide and alkyne and therefore 
both speed up the reaction and allow for more mild conditions. This is of 
course vital when using biomolecules such as proteins. In addition to this, the 
Cu(I) catalyst was also found to promote the formation of 1,4-disubstituted 
1,2,3-triazole products therefore improving the selectivity of the reaction.173  
More recently, the utility of the azide-alkyne click reaction has been 
broadened through the development of strain-promoted azide-alkyne 
cycloaddition.190 This reaction uses a highly strained alkyne which allows the 
reaction to proceed without the need for a copper catalyst. This is particularly 
advantageous within living systems where the toxicity of the copper catalyst 
can cause issues. Not only this, but the simplicity of the strained promoted 
click reaction, in that the two reagents simply need to be mixed, means it 
presents itself as a good tool within bioconjugation reactions.  
The utility of this reaction within ADC like systems has been demonstrated 
by Zhou et al. who conjugated azide functionalised sulfonate agents to 
monoclonal antibodies via a strained dibenzocyclooctyl (DBCO) alkyne 
(Figure 3.20).191 
 
Figure 3.20: work by Zhou et al. used the strain-promoted azide-alkyne cycloaddition to 
from antibody-drug conjugates.  
 
As an initial start point for the jacalin-duocarmycin based system it was 
expected that a duocarmycin-based peptide containing an azide moiety could 
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be made with relative ease. An alkyne-NHS compound could then be utilised 
to functionalise jacalin following conditions previously employed. The two 
moieties could then be coupled together under copper catalyst conditions. A 
copper catalyst promoted reaction formed the initial investigation since 
protocols using this technique were extensive within the literature.  
When considering the formation of the duocarmycin based peptide 
containing an azide, a more hydrophilic compound could be useful to reduce 
the precipitation of jacalin previously observed. Azide 3.11 (Scheme 3.15) 
contained an amine moiety connected to an azide via a PEG chain. This 
linker combines a hydrophilic PEG chain and an amine which can be coupled 
to the C-terminus of the duocarmycin-based peptides. Coupling of azide 3.11 
to peptide 3.12 (a simplified version of 3.1 for speed and ease of synthesis) 
via a stable amide bond was achieved in good yield (Scheme 3.15). 
 
Scheme 3.15: a: HATU, DIPEA, DMF, 2 h, rt. 
 
The successful synthesis of 3.13 was confirmed via MALDI which 
demonstrated M+Na and M+K adducts of 3.13. Analytical HPLC also 
demonstrated a purity of >90% which was adequate for the proof of concept 
coupling reactions. As previously, the click reactions were investigated with 
the benzyl protected 3.13 so as to reduce the handling of potentially cytotoxic 
agents.  
Jacalin functionalisation with an alkyne utilised propargyl-N-
hydroxysuccinimidyl ester. This was reacted with jacalin in HEPES buffer at 
room temperature for 2 h. After this, excess alkyne was removed from the 
reaction mixture. Successful coupling of the alkyne to the jacalin was 
demonstrated through MALDI which showed a clear increase in the mass of 
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the α-subunit. This increase suggested the coupling of around four alkynes 
per α-subunit.  
With both components now in hand, the click reaction between the two could 
be attempted. For the required Cu(I) catalyst a mixture of CuSO4 and sodium 
ascorbate was utilised. The ascorbate is able to reduce the Cu(II) to Cu(I) in 
situ.173 This is desirable since the direct use of Cu(I) can cause the reaction to 
be extremely susceptible to oxygen, which in turn can dramatically reduce 
the yield. The azide and jacalin-alkyne conjugate were mixed in HEPES 
buffer before addition of the CuSO4-ascorbate mixture. Following a protocol 
published by Weil and co-workers the reaction was left to proceed for four 
days at room temperature.192 After this time course, a precipitate was evident 
within the reaction mixture. This precipitate was removed before being 
analysed by MALDI. The resulting spectrum suggested that no conjugation 
had occurred with a peak similar to that of the jacalin-alkyne being observed. 
The MALDI spectrum of the supernatant also seemed to present no 
indication of a successful coupling. To further investigate this click chemistry 
reaction, an alternative catalyst was employed which has previously shown 
success in click reactions within our laboratory. Cu(MeCN)4.PF6 and DIPEA 
were used within a repeated reaction but again, no coupling occurred. 
What was different with this reaction was that the jacalin precipitation was 
occurring without actual coupling to its structure. This suggested that the 
lectin was unstable within the reaction conditions utilised. This could be as a 
result of a pH change that may occur within the buffer system with the 
specific reaction components utilised here. For this reason a brief 
investigation of the strain-promoted click reaction was carried out. In theory, 
the azide and alkyne can simply be mixed together simplifying the reaction 
conditions and hence hopefully maintaining the jacalin within solution.  
For this alternative the coupling of dibenzocyclooctyl-NHS (DBCO-NHS) to 
the jacalin was attempted. From this reaction a precipitate was obtained but 
it was easily re-dissolved in a H2O/ACN mixture. This allowed us to easily 




Figure 3.21: MALDI mass spectrometry spectrum of unlabelled jacalin (blue) and jacalin-
DBCO (orange). A clear mass increase in the α-subunit is observed for jacalin-DBCO. N.b. 
the masses shown in the figure are taken from the data points at the apex of the respective 
peak. 
 
The precipitation of jacalin in this reaction was unsurprising due to the large, 
hydrophobic nature of DBCO. However, upon analysis of the MALDI 
spectrum it can be seen that an addition of two DBCO units per α-subunit 
was enough to cause this precipitation. This was more surprising since it was 
not expected that this would be enough to cause the instability or aggregation 
of the jacalin within the aqueous solution. 
The coupling of jacalin-DBCO to 3.13 was attempted by simply mixing the 
two reactants in HEPES buffer/ACN mixture and allowing the reaction to 
proceed for four days. After the reaction time course, the mixture was 
analysed by MALDI mass spectrometry. Disappointingly, this spectrum 
suggested that no coupling of the azide of 3.13 had occurred to the DBCO. 
Whilst this was disheartening, it can be seen as unsurprising since the 
reaction of DBCO with azides has previously been described as challenging 
and nontrivial. This has been proposed to be due to low yields, a lack of 
reactivity and extended reaction times.173  
With these results further backing up our proposition of jacalin being a 
difficult lectin to conjugate to, it was decided to spend no further time 





is a lectin that is extremely sensitive to additions to its surface. This has been 
observed here on numerous occasions with a variety of ligands. Even with 
careful control over the level of conjugation being made, the precipitation of 
the lectin is observed. This property of jacalin therefore means that it does 
not suit itself for use within ADC like systems, where surface modifications 
are required. This of course could be solely attributed to the hydrophobic 
nature of the duocarmycin unit employed within the conjugations, however 
the precipitation has also been observed with various other NHS esters used 
within this body of work.  
It is for this reason a further route to achieve the targeted delivery of 
duocarmycin agents to cancer cells via the Thomsen-Friedenreich T-antigen 
was investigated. With this antigen presenting itself as a viable and 
potentially efficacious moiety to achieve targeted delivery, further research 
was warranted.  The following chapter presents an alternative method to 
achieve this.  
3.4 Conclusion 
The aim of the research within this chapter was to investigate the conjugation 
of duocarmycin based moieties to the T-antigen binding lectin, jacalin. An 
exploration into various methods of conjugation, often mimicking those 
utilised in approved ADCs, was proposed to ascertain which was the most 
advantageous for our specific system. 
As an initial method the commonly employed EDC/NHS chemistry was 
utilised. The coupling of the exposed lysine residues of jacalin with the C-
terminus carboxylic acid of our duocarmycin analogues was attempted. Both 
in-situ and ex-situ formation of the NHS ester of our duocarmycin analogues 
was investigated. Whilst the ex-situ NHS formation gave the most consistent 
results, jacalin precipitation with these conditions was common and occurred 
on numerous occasions. This was potentially concerning due to the possible 
alterations to the jacalin quaternary that led to aggregation and precipitation 
from the buffer system. 
As an additional attempt to achieve the conjugation, thiol/maleimide 
chemistry was investigated. Initial attempts involved the formation of a 
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maleimide functionalised jacalin and a duocarmycin analogue containing a 
cysteine residue. The coupling of these two proceeded with ease. However, it 
became clear that the benzyl deprotection of the thiol containing 
duocarmycin analogues was difficult and was not successful. The reverse of 
this chemical reactivity whereby the jacalin was functionalised with a thiol 
and a duocarmycin-maleimide analogue was synthesised demonstrated an 
ability to conjugate the two species together. However, precipitation and 
difficulties with re-dissolution of the conjugate again suggested that jacalin 
may be sensitive to surface modification with the duocarmycin based units 
utilised within this body of work. 
As a final conjugation strategy the azide-alkyne click reaction was attempted. 
Jacalin was functionalised with an alkyne, and an azide containing 
duocarmycin analogue was synthesised. However, the coupling of the two 
using a copper catalyst demonstrated no conjugation. As a further attempt, 
DBCO was utilised to try a strain promoted click reaction. Jacalin was 
functionalised with DBCO and reacted with our azide-duocarmycin unit. 
Under these conditions, no conjugation was observed. 
What was common throughout all the above strategies was the precipitation 
of jacalin upon conjugation or within the reaction conditions employed. This 
has been attributed to both the sensitivity of the lectin to certain conditions 
and also the sensitivity to surface modifications. This can be seen as a 
particular problem due to the hydrophobic nature of the DSA units employed 
within this chapter. It is for this reason that we concluded that jacalin may 
not be suitable for investigations within ADC like systems incorporating our 
duocarmycin analogues. However, the directed targeting to the T-antigen is 
an area which warrants further research.  
3.5 Experimental 
3.5.1 General Procedures 
Reagents and Solvents  
All chemicals were reagent grade and were purchased from Sigma Aldrich, 
Fisher Scientific and Tokyo Chemical Industry. Fmoc-amino acids and 
coupling reagents were purchased from Novabiochem, Fluorochem or AGTC 
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Bioproducts. Anhydrous solvents were bought from Sigma Aldrich and 
assumed to conform to specification. Jacalin was purchased from Vector 
laboratories. Zeba™ spin desalting columns (7K MWCO, 0.5 mL) were 
purchased from Fisher scientific. 
Physical Characterisation and Spectroscopic Techniques  
1H- and 13C-NMR spectra were recorded on a Bruker spectrometer operating 
at 400 MHz (1H) or 100 MHz (13C) using the specified deuterated solvent. 
The chemical shifts for both 1H- and 13C were recorded in ppm and were 
referenced to the residual solvent peak of DMSO at 2.50 ppm (1H) and 39.7 
ppm (13C). Multiplicities in the NMR spectra are described as s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, and combinations 
thereof; coupling constants are reported in Hz. Low resolution mass spectra 
were recorded using a Shimadzu LCMS 2010EV operated under electrospray 
ionisation in positive (ES+) mode. Accurate mass spectra were recorded at 
the EPSRC National Mass Spectroscopy Service Centre, Swansea or The John 
Innes Centre, Norwich Research Park. Melting points were recorded using 
open capillary tubes on a Mel-Temp electrothermal melting point apparatus, 
melting points are uncorrected. Infrared spectra were recorded using a 
PerkinElmer Spectrum BX with ATR attachment.  
Chromatographic Techniques  
Analytical RP-HPLC was performed on an Agilent 1200 using an Agilent 
eclipse XDB-C18 column, 4.6 x 150 mm, 5 µM and a flow rate of 1 mL/min. 
Solvent A = Water + 0.05% TFA and Solvent B = MeOH + 0.05% TFA. 
Gradient 5% B up to 95% B over 20 minutes. Detection wavelength 214 nm 
and 254 nm. Semi-preparative RP-HPLC was performed on an Agilent 1200 
using an Agilent eclipse XDB-C18 column, 9.4 x 250 mm, 5 µM and a flow 
rate of 4 mL/min. Solvent A = Water + 0.05% TFA and Solvent B = MeOH + 
0.05% TFA. Gradient 5% B up to 95% B over 20 minutes. Detection 
wavelength 214 nm and 254 nm. Preparative RP-HPLC was performed on an 
Agilent 1200 using an Agilent eclipse XDB-C18 column, 21.2 x 150 mm, 5 µM 
and a flow rate of 20 mL/min. Solvent A = 95% H2O + 5% MeOH + 0.05% 
TFA and Solvent B = 95% MeOH + 5% H2O + 0.05% TFA. Gradient 5% B up 
to 95% B over 20 minutes. 
Protein MALDI Mass Spectrometry 
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MALDI mass spectrometry of proteins and peptides was performed on 
Kratos Analytical Axima MALDI-TOF. For peptides, α-cyano-4-
hydroxycinnamic acid was utilised as a matrix and for proteins, trans-ferulic 
acid was used. MALDI sample preparation for jacalin/BSA MALDI involved a 
sandwich method where matrix was first applied to the plate followed by a 
desalted sample of protein followed by a further layer of matrix. MALDI mass 
spectrometry profiles were recorded in linear mode with a laser power 
between 150 and 180 for jacalin and BSA. Reflectron mode was used for the 
obtainment of MALDI spectra for peptides.  
Protein LCMS 
Samples were injected onto a ProSwift reversed phase RP-1S column (4.6 × 
50 mm; Thermo Scientific) at 25 °C using an UltiMate 3000 HPLC system 
(Dionex). Gradient elution was performed at a flow rate of 0.2 mL/min using 
a linear gradient (15 min) from 2 to 100% (vol/vol) acetonitrile and 0.1% 
(vol/vol) formic acid. The eluent was continuously infused into a Bruker 
micrOTOF-QIII mass spectrometer running Hystar (Bruker Daltonics) using 
positive mode ESI. The mass spectrometer was calibrated with ESI-L tuning 
mix (Agilent Technologies). MS acquisition parameters were as follows: dry 
gas flow of 8 L/min, nebulizer gas pressure of 1.8 Bar, dry gas at 240 °C, 
capillary voltage of 4,500 V, offset of 500 V, and collision RF of 650 Vpp. 
Processing and analysis of MS experimental data were carried out using 
Compass DataAnalysis, version 4.1 (Bruker Daltonik). Neutral mass spectra 
were generated using the ESI Compass, version 1.3 Maximum Entropy 
deconvolution algorithm over a mass range of 2,000–30,000 Da for the α-
subunit. Exact masses are reported from peak centroids representing the 
isotope average neutral mass. 
 




H-Phe-2ClTrt resin (100 mg, 0.09 mmol, [manufacturer’s resin loading 0.9 
mmol/g]) was prepared for coupling by swelling in DCM for 30 mins 
followed by DMF for 30 mins. Fmoc-Val-OH (152 mg, 0.45 mmol) was 
dissolved in 2 mL of DMF and treated with HATU (171 mg, 0.45 mmol) and 
DIPEA (156 µL, 0.90 mmol). After 10 secs the resulting solution was added to 
the resin and the mixture shaken for 1 h. Subsequently, the resin was washed 
with DMF (6 x 10 mL) and the coupling repeated. The resin was washed 6 
times with DMF (10 mL) before removal of the valine Fmoc using piperidine 
in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following Fmoc 
deprotection, the resin was washed with DMF (6 x 10 mL). Next, 2.10 (78 
mg, 0.14 mmol) was dissolved in 2 mL of DMF and treated with HATU (51 
mg, 0.14 mmol) and DIPEA (47 µL, 0.27 mmol). After 10 secs the resulting 
solution was added to the resin and the mixture shaken overnight. The resin 
was subsequently washed with DMF (6 x 10 mL) before the Fmoc group on 
the indoline nitrogen of 2.10 removed using piperidine in DMF (6 mL 40% 
10 mins, 6 mL 20% 5 mins twice). The resin was then washed again with 
DMF (6 x 10 mL) before being treated with 2.14 (143 mg, 0.36 mmol) HATU 
(136 mg, 0.36 mmol) and DIPEA (125 µL, 0.72 mmol). The mixture was 
shaken for 6 h before the resin was with DMF (6 x 10 mL) and the coupling 
repeated. The resin was then washed with DMF (6 x 10 mL) before the Fmoc 
group of 2.14 was removed using piperidine in DMF (6 mL 40% 10 mins, 6 
mL 20% 5 mins twice). Upon washing of the resin with DMF (6 x 10 mL) the 
resin was treated with AcCl (32 µL, 0.45 mmol) and DIPEA (156 µL, 0.9 
mmol) in DMF (2 mL). After shaking for 1 h the resin was washed with DMF 
(6 x 10 mL) followed by DCM (6 x 10 mL). Cleavage of 3.1 from the resin was 
affected by addition of a solution of 2% TFA, 10% TIPS in DCM (10 mL). 
After 3 h of shaking the cleavage mixture was filtered. The resin was rinsed 
with DCM (2 x 3 mL) and the combined filtrates were concentrated to 
dryness by rotary evaporation under vacuum. Crude 3.1 was then analysed 
via analytical RP-HPLC (RT = 18.2 min) and HRMS (ES+) calcd. for 
C45H45ClN6O7 (M + H)+, 317.3111; found, 317.3112. Crude 3.1 (10 mg, 0.01 
mmol) was dissolved in MeOH (1 mL) and the resulting solution degassed 
with a gentle stream of N2 for 30 mins. To this solution was added a slurry of 
10% Pd/C (20 mg) in 25% aq. Ammonium formate (500 µL) and the 
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resulting suspension stirred under N2 for 1 h. The reaction mixture was then 
filtered through a pad of celite before the MeOH was removed under reduced 
pressure. Crude 3.11 was then purified using preparative HPLC to give pure 
3.11 (4.1 mg, 47%) as a light brown solid which was analysed via RP-HPLC 
(RT + 16.5 min) and HRMS (ES+) calcd. for C38H39ClN6O7 (M + H)+, 
727.2642; found, 727.2639. 
 
H-Arg(Pbf)-2ClTrt resin (100 mg, 0.067 mmol, [manufacturer’s resin loading 
0.67 mmol/g]) was prepared for coupling by swelling in DCM for 30 mins 
followed by DMF for 30 mins. Fmoc-Arg(Pbf)-OH (217 mg, 0.34 mmol) was 
dissolved in 2 mL of DMF and treated with HATU (127 mg, 0.34 mmol) and 
DIPEA (116 µL, 0.67 mmol). After 10 secs the resulting solution was added to 
the resin and the mixture shaken for 1 h. Subsequently, the resin was washed 
with DMF (6 x 10 mL) and the coupling repeated. The resin was washed with 
DMF (6 x 10 mL) before removal of the arginine Fmoc using piperidine in 
DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following Fmoc 
deprotection, the resin was washed with DMF (6 x 10 mL). Next, Fmoc-Gly-
OH (99 mg, 0.34 mmol) was dissolved in 2 mL of DMF and treated with 
HATU (127 mg, 0.34 mmol) and DIPEA (116 µL, 0.67 mmol). After 10 secs 
the resulting solution was added to the resin and the mixture shaken for 1 h 
before being washed with DMF (6 x 10 mL) and the coupling with Fmoc-Gly-
OH repeated. The resin was subsequently washed with DMF (6 x 10 mL) 
before the Fmoc group on the glycine was removed using piperidine in DMF 
(6 mL 40% 10 mins, 6 mL 20% 5 mins twice). The resin was then washed 
again with DMF (6 x 10 mL) before being treated with 2.10 (57 mg, 0.1 
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mmol) HATU (38 mg, 0.1 mmol) and DIPEA (34 µL, 0.2 mmol). The mixture 
was shaken overnight before the resin was with DMF (6 x 10 mL). The 
indoline Fmoc group of 2.10 was removed using piperidine in DMF (6 mL 
40% 10 mins, 6 mL 20% 5 mins twice). Upon washing with DMF (6 x 10 mL), 
the resin was treated with AcCl (23 µL, 0.34 mmol) and DIPEA (116 µL, 0.67 
mmol) in DMF (2 mL). After shaking for 1 h the resin was washed with DMF 
(6 x 10 mL) followed by DCM (6 x 10 mL). Cleavage of 3.2 from the resin was 
affected by addition of a solution of 47% TFA, 10% TIPS in DCM (10 mL). 
After 3 h of shaking the cleavage mixture was filtered. The resin was rinsed 
with DCM (2 x 3 mL) and the combined filtrates were concentrated to 
dryness by rotary evaporation under vacuum to give 3.2 which was analysed 
using reverse phase HPLC (RT = 14.3 min) and HRMS (ES+) calcd. for 
C36H48ClN11O7 (M + Na)+, 804.3324; found, 804.3336.  
 
H-Phe-2ClTrt resin (100 mg, 0.09 mmol, [manufacturer’s resin loading 0.9 
mmol/g]) was prepared for coupling by swelling in DCM for 30 mins 
followed by DMF for 30 mins. Fmoc-Leu-OH (152 mg, 0.45 mmol) was 
dissolved in 2 mL of DMF and treated with HATU (171 mg, 0.45 mmol) and 
DIPEA (156 µL, 0.9 mmol). After 10 secs the resulting solution was added to 
the resin and the mixture shaken for 1 h. Subsequently, the resin was washed 
with DMF (6 x 10 mL) and the coupling repeated. The resin was washed 6 
times with DMF (10 mL) before removal of the leucine Fmoc using piperidine 
in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following Fmoc 
deprotection the resin was washed with DMF (6 x 10 mL). Next, 2.10 (78 mg, 
0.14 mmol) was dissolved in 2 mL of DMF and treated with HATU (51 mg, 
0.135 mmol) and DIPEA (47 µL, 0.27 mmol). After 10 secs the resulting 
solution was added to the resin and the mixture shaken overnight. The resin 
was subsequently washed with DMF (6 x 10 mL) before the Fmoc group on 
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the indoline nitrogen of 2.10 removed using piperidine in DMF (6 mL 40% 
10 mins, 6 mL 20% 5 mins twice). The resin was then washed again with 
DMF (6 x 10 mL) before being treated with 2.14 (143 mg, 0.36 mmol) HATU 
(136 mg, 0.36 mmol) and DIPEA (125 µL, 0.72 mmol). The mixture was 
shaken for 6 h before the resin was with DMF (6 x 10 mL) and the coupling 
repeated. The resin was then washed with DMF (6 x 10 mL) before the Fmoc 
group of 2.14 was removed using piperidine in DMF (6 mL 40% 10 mins, 6 
mL 20% 5 mins twice). Upon washing of the resin with DMF (6 x 10 mL) The 
resin was treated with Fmoc-Cys(mtt)-OH (269 mg, 0.45 mmol), HATU (171 
mg, 0.45 mmol) and DIPEA (156 µL, 0.9 mmol) in DMF (2 mL). After 10 
seconds, the solution was added to the resin and the mixture shaken for 1 h. 
Subsequently the resin was washed with DMF (6 x 10 mL) and the Fmoc-
Cys(mtt)-OH coupling repeated. The resin was then again washed with DMF 
(6 x 10 mL) and the cysteine Fmoc group removed using piperidine in DMF 
(6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following washing of the resin 
with DMF (6 x 10 mL), the resin was treated with AcCl (32 µL, 0.45 mmol) 
and DIPEA (156 µL, 0.9 mmol) in DMF (2 mL). After shaking for 1 h the 
resin was washed with DMF (6 x 10 mL) followed by DCM (6 x 10 mL). 
Cleavage of 3.5 from the resin was affected by addition of a solution of 2% 
TFA, 10% TIPS in DCM (10 mL). After 3 h of shaking the cleavage mixture 
was filtered. The resin was rinsed with DCM (2 x 3 mL) and the combined 
filtrates were concentrated to dryness by rotary evaporation under vacuum. 
Crude 3.5 was then purified using prep-HPLC to give 3.5 (2.1 mg, 42%) as a 
light brown solid which was analysed using reversed phase HPLC (RT = 18.6 
min) and HRMS (ES-) calcd. for C48H50ClN7O8S (M - H)-, 918.3034; found, 
918.3057. 
 
H-β-Ala-2ClTrt resin (100 mg, 0.075 mmol, [manufacturer’s resin loading 
0.75 mmol/g]) was prepared for coupling by swelling in DCM for 30 mins 
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followed by DMF for a further 30 mins. 2.10 (65 mg, 0.11 mmol) was 
dissolved in 2 mL of DMF and treated with HATU (42 mg, 0.11 mmol) and 
DIPEA (39 µL, 0.22 mmol). After 10 secs the resulting solution was added to 
the resin and the mixture shaken overnight. The resin was with DMF (6 x 10 
mL) and removal of the Fmoc group from the indoline nitrogen of 2.10 
affected with piperidine in DMF (3 mL 40% 10 mins, 3 mL 20% 5 mins 
twice). Following Fmoc deprotection the resin was washed with DMF (6 x 10 
mL) before being treated with anhydrous DMF (2 mL), DIPEA (130 µL, 0.75 
mmol), and AcCl (26 µL, 0.375 mmol). After 1 h of shaking the resin was 
washed with DMF (6 x 10 mL) and the acetylation repeated. Subsequently 
the resin was washed with DMF (6 x 10 mL) and then DCM (6 x 10 mL). 
Cleavage was affected by addition of a solution of 1% TFA, 10% TIPS in DCM 
(10 mL). After 2 h of shaking the cleavage mixture was filtered. The resin was 
rinsed 3 times with DCM (3 mL) and the combined filtrates were evaporated 
to dryness under reduced pressure to give crude 3.3. Crude 3.3 (10 mg, 0.02 
mmol) was dissolved in MeOH (1 mL) and the resulting degassed with a 
gentle stream of N2 for 30 mins. To this solution was added a slurry of 10% 
Pd/C (20 mg) in 25% aq. ammonium formate (500 µL) and the resulting 
suspension stirred under N2 for 1 h. The reaction mixture was then filtered 
through a pad of celite before the MeOH was removed under reduced 
pressure. Crude 3.4 was then purified using preparative HPLC to give 3.4 
(3.2 mg, 38%) as a light brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 12.29 
(1H, brs), 11.18 (1H, s), 9.68 (1H, s), 8.46 (1H, brs), 7.66 (1H, s), 7.09 (1H, s), 
4.30−4.25 (1H, m), 4.11−4.00 (3H, m), 3.87−3.81 (1H, m), 3.48 (2H, m), 2.53 
(2H, obscured by DMSO peak, observed by HSQC and COSY), 2.11 (3H, s). 
HRMS (ES+) calcd. for C17H19ClN3O5 (M + H)+, 380.1008; found, 380.1010. 
 
H-Phe-2ClTrt resin (100 mg, 0.09 mmol, [manufacturer’s resin loading 0.9 
mmol/g]) was prepared for coupling by swelling in DCM for 30 mins 
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followed by DMF for 30 mins. Fmoc-Val-OH (152 mg, 0.45 mmol) was 
dissolved in 2 mL of DMF and treated with HATU (171 mg, 0.45 mmol) and 
DIPEA (156 µL, 0.90 mmol). After 10 secs the resulting solution was added to 
the resin and the mixture shaken for 1 h. Subsequently, the resin was washed 
with DMF (6 x 10 mL) and the coupling repeated. The resin was washed 6 
times with DMF (10 mL) before removal of the valine Fmoc using piperidine 
in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following Fmoc 
deprotection the resin was washed with DMF (6 x 10 mL). Next, 2.10 (78 mg, 
0.14 mmol) was dissolved in 2 mL of DMF and treated with HATU (51 mg, 
0.14 mmol) and DIPEA (47 µL, 0.28 mmol). After 10 secs the resulting 
solution was added to the resin and the mixture shaken overnight. The resin 
was subsequently washed with DMF (6 x 10 mL) before the Fmoc group on 
the indoline nitrogen of 2.10 removed using piperidine in DMF (6 mL 40% 
10 mins, 6 mL 20% 5 mins twice). Upon washing with DMF (6 x 10 mL) the 
resin was treated with AcCl (32 µL, 0.45 mmol) and DIPEA (156 µL, 0.9 
mmol) in DMF (2 mL). After shaking for 1 h the resin was washed with DMF 
(6 x 10 mL) followed by DCM (6 x 10 mL). Cleavage of 3.12 from the resin 
was affected by addition of a solution of 2% TFA, 10% TIPS in DCM (10 mL). 
After 3 h of shaking the cleavage mixture was filtered. The resin was rinsed 
with DCM (2 x 3 mL) and the combined filtrates were concentrated to 
dryness by rotary evaporation under vacuum. 3.12 was then analysed using 
reversed phase HPLC (RT = 14.8 min) and MALDI mass spectrometry for 
3.12 (M + H)+, 659.2730. 
        
NovaPEG Rink Amide resin (100 mg, 0.049 mmol [manufacturer’s resin 
loading 0.49 mmol/g]) was prepared for coupling by swelling in DMF for 30 
mins. 2.10 (42 mg, 0.0735 mmol) was dissolved in 2 mL of DMF and treated 
with HATU (27 mg, 0.0735 mmol) and DIPEA (25 µL, 0.147 mmol). After 10 
secs the resulting solution was added to the resin and the mixture shaken 
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overnight. The resin was washed 6 with DMF (6 x 10 mL) and removal of the 
Fmoc group from the indoline nitrogen of 2.10 affected with piperidine in 
DMF (3 mL 40% 10 mins, 3 mL 20% 5 mins twice). Following Fmoc 
deprotection the resin was washed with DMF (6 x 10 mL) before being 
treated with N-ε-maleimidocaproic acid (51 mg, 0.245 mmol), HATU (93 mg, 
0.245 mmol) and DIPEA (85 µL, 0.49 mmol) in DMF. The resin was shaken 
for 6 h before being washed and the coupling with N-ε-
maleimidocaproic acid repeated. Subsequently, the resin was washed with 
DMF (6 x 10 mL) and then DCM (6 x 10 mL). Cleavage was affected by 
addition of a solution of 47% TFA, 10% TIPS in DCM (10 mL). After 2 h of 
shaking, the cleavage mixture was filtered. The resin was rinsed 3 times with 
DCM (3 mL) and the combined filtrates were concentrated to dryness by 
rotary evaporation under vacuum to give crude 3.9. Crude 3.9 (10 mg, 0.018 
mmol) was dissolved in MeOH (1 mL) and the resulting degassed with a 
gentle stream of N2 for 30 mins. To this solution was added a slurry of 10% 
Pd/C (20 mg) in 25% aq. ammonium formate (500 µL) and the resulting 
suspension stirred under N2 for 1 h. The reaction mixture was then filtered 
through a pad of celite before the MeOH was removed under reduced 
pressure. Crude 3.10 was then purified using preparative HPLC to give 3.10 
(3.7 mg, 45%) as a light brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 11.09 
(1H, s), 7.72 (1H, s), 7.39 (2H, brs), 7.12 (2H, s), 6.99 (1H, d, J = 2.1), 
4.30−4.25 (1H, m), 4.11−4.00 (3H, m), 3.87−3.81 (1H, m), 3.37 (2H, t, J = 
6.8), 2.17 (2H, t, J = 7.2), 1.52-1.43 (4H, m), 1.16-1.24 (2H, m). HRMS (ES-) 
calcd. for C22H23ClN4O5 (M - H)-, 457.1279; found, 457.1281. 
3.5.3 Solution Phase Chemistry 




3.3 (2 mg, 0.004 mmol) was dissolved in anhydrous DMF (200 µL) and 
treated with DCC (1 mg, 0.005 mmol) and NHS (0.7 mg, 0.006 mmol). The 
resulting reaction was allowed to stir overnight at room temperature. 
Subsequently, the precipitated DCU was removed from the mixture by 
centrifugation at 14,000 rpm for 10 mins. The supernatant containing 3.3-
NHS was then evaporated to dryness under reduced pressure and washed 
with diethyl ether (3 x 5 mL). The presence of the NHS ester was then 
confirmed via reaction with 3-(dimethylamino)-1-propylamine and 
subsequent HPLC and Mass spectrometry.  
 
3.4 (2 mg, 0.005 mmol) was dissolved in anhydrous DMF (200 µL) and 
treated with DCC (1.3 mg, 0.006 mmol) and NHS (0.8 mg, 0.007 mmol). The 
resulting reaction was allowed to stir overnight at room temperature. 
Subsequently, the precipitated DCU was removed from the mixture by 
centrifugation at 14,000 rpm for 10 mins. The supernatant containing crude 
3.4-NHS was then evaporated to dryness under reduced pressure and 
washed with diethyl ether (3 x 5 mL). The presence of the NHS ester was 
then confirmed via reaction with 3-(dimethylamino)-1-propylamine and 
subsequent HPLC and Mass spectrometry.  
NHS Presence Confirmation Using 3-(dimethylamino)-1-
propylamine Coupling 
Presence of the NHS on 3.3-NHS and 3.4-NHS was confirmed via reaction 
with 3-(dimethylamino)-1-propylamine and subsequent analysis via MALDI 
mass spectrometry and analytical HPLC. Briefly, crude 3.3-NHS/3.4-NHS 
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(2 mg) was dissolved in anhydrous DMF (200 µL) and treated with 3-
(dimethylamino)-1-propylamine (1 equiv.). The reaction was left to stir for 1 h 
at room temperature. Subsequently, the DMF was removed under reduced 
pressure and the resulting solid dissolved in MeOH (1 mL) and analysed via 
analytical HPLC and MALDI mass spectrometry. 3.3-Amino tail RT = 15.2 
min, MALDI for 3.3-Amino tail (M - H)-, 552.35. 3.4-Amino tail RT = 
13.8 min, MALDI for 3.4-Amino tail (M - H)-, 463.32. 
Off Resin C-terminus Couplings 
 
 
3.7 (4 mg, 0.007 mmol) was dissolved in DMF (200 µL) and treated with 
HATU (2.6 mg, 0.007 mmol) and DIPEA (2 µL, 0.014 mmol). After stirring 
for 10 secs, cysteamine (1 mg, 0.014 mmol) was added and the resulting 
solution left to stir for 2 h at room temperature. Subsequently, the reaction 
mixture was diluted with MeOH (5 mL) and subjected directly to reverse 
phase Prep-HPLC where 3.8 (2.2 mg, 37%) was isolated as a mixture of 
disulphide and non-disulfide products as analysed via analytical HPLC (RT = 
16.8 min and 17.1 min) and MALDI mass spectrometry for 3.8 (M + Na)+, 
808.35. 
 
3.12 (10 mg, 0.015 mmol) was dissolved in DMF (300 µL) and treated with 
HATU (6 mg, 0.015 mmol) and DIPEA (5 µL, 0.03 mmol). After stirring for 
10 secs, 11-Azido-3,6,9-trioxaundecan-1-amine (3.11) (6 µL, 0.03 mmol) was 
added and the resulting solution left to stir for 2 h at room temperature. 
Subsequently, the reaction mixture was diluted with MeOH (5 mL) and 
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subjected directly to reverse phase Prep-HPLC where 3.13 (5.1 mg, 39%) was 
isolated as a light brown solid. 3.13 was subsequently analysed using reverse 
phase HPLC (RT = 13.7 min) and MALDI mass spectrometry for 3.13 (M + 
Na)+, 881.2789. 
3.5.4 Protein bioconjugations 
Jacalin-NHS Ester Conjugations; 
The following experimental relates to the conjugation of jacalin to the 
following NHS esters; succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (SMCC), dibenzocyclooctyne-N-hydroxysuccinimidyl ester 
(DBCO), propargyl-N-hydroxysuccinimidyl ester, (+)-biotin N-
hydroxysuccinimide ester, 3.3-NHS and 3.4-NHS. 
Jacalin (2 mg/mL) was reconstituted in 10 mM HEPES buffered saline (pH 
7.4, 150 mM NaCl, 100 µM CaCl2) and treated with a solution of the 
respective NHS-ester (1 mg/mL, 20 equiv.) in DMSO. The resulting solution 
was left to react for 1 h at room temperature and then for a further 1 h at 4 °C. 
Any precipitate was removed from the solution via centrifugation at 1,000 
rpm for 5 mins at 4 °C. The resulting supernatant was then transferred to 
equilibrated Zeba™ spin desalting columns (7K MWCO, 0.5 mL) and 
centrifuged at 1500 xg for 2 min at 4 °C. For MALDI mass spectrometry, the 
centrifuged pellet was resuspended in ACN/H2O and the purified 
supernatant analysed directly from water. Resulting conjugates were stored 
frozen at -20 °C.  
Coupling of Peptide 3.5 to Jac-SMCC 
To a solution of Jac-SMCC (1 mL, 2mg/mL) in 10 mM HEPES buffered saline 
(pH 7.4, 150 mM NaCl, 100 µM CaCl2) was added peptide 3.5 (0.5 mg, 0.54 
µmol) in DMSO (100 µL). The resulting reaction was incubated for 2 h at 4 
ºC. Subsequently, the formed precipitate was removed from the solution via 
centrifugation (3000 xg, 3 min, 4 ºC).  Excess 3.5 was then removed from 
the supernatant through spinning the mixture through an equilibrated 
Zeba™ spin desalting columns (7K MWCO, 0.5 mL) at 1500 xg for 2 min at 4 
°C. The precipitated pellet was then resuspended in 50% ACN:H2O and 
analysed via LCMS along with the purified supernatant.  
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Functionalisation of Jacalin with 2-Iminothiolane 
Jacalin (1 mL, 2mg/mL) was reconstituted in 10 mM HEPES buffered saline 
(pH 7.4, 150 mM NaCl, 100 µM CaCl2, 5 mM EDTA) and treated with 2-
Iminothiolane (22 µL, 14 mM) in water. The resulting solution was incubated 
for 1 h at room temperature before being transferred to Zeba™ spin desalting 
columns (7K MWCO, 0.5 mL) and centrifuged at 1500 xg for 2 min at 4 °C. 
The thiol functionalised jacalin was subjected to Ellmans reagent assay 
conditions to confirm the presence of the thiol on the protein. The thiol 
functionalised jacalin was stored frozen at -20 °C until required for reaction.  
Conjugation of 3.2 to Bovine Serum Albumin (BSA) 
Bovine serum albumin (3 mg) was reconstituted in MES buffer (0.1 M, pH 5). 
To this was added 3.2 (0.8 mg, 0.001 mmol) and EDC (25 µL, 10 mg/mL) 
and the resulting mixture incubated at room temperature for 90 min. 
Subsequently, the reaction mixture was transferred to an equilibrated Zeba™ 
spin desalting columns (7K MWCO, 0.5 mL) and centrifuged at 1500 xg for 2 
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4.1.1 Peptides as Targeting Molecules. 
Whilst ADCs have dominated the targeted therapeutic landscape over 
previous years, this strategy does not come without significant drawbacks. 
For example, the synthetic routes to these agents are very difficult, 
increasingly so when the need for homogenous product mixtures has been 
identified.34 Being able to create ADCs with constant and repeatable drug-
antibody ratios (DARs) has been identified as non-trivial on numerous 
occasions.34 This lack of synthetic accessibility has therefore led to many 
setbacks within a clinical trial setting for ADCs. In addition to this, the 
development or discovery of antibodies to target particular antigens is also 
not a trivial process and difficulties within this area have been a continuous 
hindrance within the area of ADCs. Finally, for ADCs to show significant 
efficacy in solid tumour models, it has been recognised that they must be able 
to successfully penetrate the tumour.42 Due to the large size of the antibody 
employed within ADCs, this has been shown to be difficult and, as a result, 
poor efficacies within these models are not uncommon.  
It is these disadvantages of ADCs that have expedited the search for 
alternative strategies to achieve the targeted delivery of cytotoxic agents to 
cancer cells. One such strategy is the use of peptides rather than antibodies. 
The rationale behind this approach is that due to the smaller size of peptides, 
the penetration into solid tumours will be improved, resulting in enhanced 
efficacies. This improved penetration has been established for numerous 
targeting peptides.193 In addition to this, the design, synthesis and 
characterisation of peptides used for targeting purposes is much easier than 
for antibodies. Synthetic methodologies to generate peptides are well 
established and automated systems have been developed. In relation to this, 
the coupling of drug molecules to peptides also allows for complete control 
over the drug ratio within the resulting conjugates and their full structural 
characterisation. This in turn allows for more homogenous product mixtures 
to be made in comparison to ADC systems. Not only this, but due to their 
smaller size, the purification of these systems is more accessible with 
preparative HPLC systems being commonly utilised. Finally, and of 
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particular importance for the development of peptides for therapeutic 
purposes, comes the advantage that a greater ease of modification to peptides 
in relation to antibodies can be obtained. These modifications can be to add 
functionality for conjugation purposes or for imparting improved 
physiochemical properties into the peptide sequence. For example, the 
incorporation of specific amino acids into a targeting sequence can be 
utilised to improve stability or water solubility.194 These advantages of 
peptide based systems has meant that research into their use for therapeutic 
purposes has increased significantly over recent years and this has led to over 
60 of these systems now being approved by the FDA with many more in 
clinical development.195  
4.1.2 Peptide-Drug Conjugates 
As alluded to in the previous section, the use of peptides for therapeutic 
purposes and hence their potential use in peptide-drug conjugates (PDCs) 
could hold many advantages. PDCs combine the cytotoxic activity of a drug 
warhead with the targeting ability of a specific peptide sequence.194 As in 
ADC systems, linker technologies between the cytotoxic drug and the peptide 
can be employed to allow for efficient release of the warhead once at the 
desired site of action whilst ensuring stability during circulation. 
Additionally, the individual components of a PDC must hold certain 
properties in order for the overall system to achieve success within a clinical 
setting. These are summarised briefly in Figure 4.1. 
 
Figure 4.1: Schematic representation of a peptide-drug conjugate and descriptions of ideal 
characteristics of each individual component.  
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Taking the above into consideration, a number of PDCs have been developed. 
One example involves a doxorubicin payload and was designed by Cui and 
co-workers.196 In this work, various numbers of doxorubicin-based units 
were coupled to a cell penetrating Tat peptide via a cathepsin B cleavable 
linker. The group showed that the number of doxorubicin units utilised in the 
peptide had an effect on the rate of drug release from the PDC and that a 
balance of these two factors was vital. In their system, two doxorubicin units 
was found to give the most desirable results with this PDC showing 
favourable accumulation and drug release. 
In another study, Mezo and co-workers utilised peptides containing the 
asparagine-glycine-arginine (NGR) motif that is recognised by CD13 receptor 
isoforms that are selectively overexpressed in tumour neovasculature.197 A 
daunomycin warhead was conjugated to these peptides in a variety of 
different orientations and the resulting conjugates tested for their biological 
activity. The results of the study showed low micromolar activity in some of 
the structural analogues and a lack of activity in others. This demonstrates 
the importance of the drug positioning within a peptide sequence. Improved 
activity of the PDCs within CD13 positive cell lines in relation to CD13 
negative cell lines was also obtained demonstrating the targeting ability of 
the conjugates synthesised in this study. 
PDCs to combat prostate cancer have also been established. Cheng and co-
workers synthesised a PDC based on a highly potent phosphoinositide 3-
kinase β (PI3Kβ) inhibitor (TGX-D1) which has previously shown cytotoxicity 
in prostate cancer cell lines (Figure 4.2).198  
 





In order to improve the poor solubility and lack of specificity, which limit its 
therapeutic applications, the group conjugated this warhead to a HER2 
targeting peptide via a cleavable linker. The results from the study showed 
significantly higher cellular uptake of the PDC in prostate cancer cells 
compared to the parent drug. In addition, both the PDC and its cleaved 
products demonstrated comparable cytotoxic activity to the parent drug.  
These studies highlight the potential of PDCs to help improve upon some of 
the drawbacks of current cytotoxic agents. Therefore, it is possible that the 
use of such a system implementing a duocarmycin unit could potentially 
allow for an improved therapeutic index of this cytotoxic warhead. In 
addition to this, with the more favourable synthetic accessibility of PDCs, it is 
possible that a number of the issues addressed within Chapter 3 of this thesis 
could be overcome. 
4.2 Aims of the Research in this Chapter 
The aim of the research presented in this chapter was to investigate the 
design and synthesis of a duocarmycin based peptide-drug conjugate. The 
synthesis of this conjugate could aid in overcoming many of the issues faced 
with the attachment of duocarmycin to jacalin as presented in Chapter 3 of 
this thesis. In addition to this, it was expected that the advantages brought 
about by peptide based therapeutics would help realise the potential of 
duocarmycin as a possible future clinical candidate.  
The chapter will begin by addressing the synthesis of a number of peptide 
conjugates which incorporate a T-antigen binding peptide sequence and a 
duocarmycin warhead. The incorporation of a cleavable sequence into the 
conjugate is also discussed. 
Following on from this, the chapter provides a comparison between the 
biological activities of these peptide conjugates including analysis of their T-
antigen binding properties and also their cytotoxicity within T-antigen 





4.3 Results and Discussion 
4.3.1 Design and Synthesis of Duocarmycin Based PDCs. 
4.3.1.1 T-antigen Binding Peptides 
A series of peptides have been shown to specifically bind the Thomsen-
Friedenreich antigen.199 Quinn and co-workers established these peptides 
from a 15 amino acid random peptide bacteriophage display library and 
characterised them for their binding affinities and specificities. The group 
found that synthetic peptides identified from the bacteriophage display 
library had reasonable affinities (Kd ~ 1 µM) and specificities for human 
tumour cells that present the T-antigen on their surface. Sequence analysis of 
these peptides revealed that many of them shared homology with sugar 
recognition sites in several carbohydrate-binding proteins. A comparison of 
the affinity selected sequences from the libraries also yielded a common 
motif (W-Y-A-W/F-S-P) rich in aromatic amino acids.200 The group also 
demonstrated the importance of tyrosine within these sequences after an 
iodination of this residue was shown to greatly reduce the affinity of the 
peptides to the T-antigen. The ability and significance of the peptides 
disclosed by Quinn and co-workers is evidenced by their ability to inhibit 
melanoma cell aggregation in vitro, which has previously been shown to have 
a direct relationship to T-antigen expression.159 Additionally, the ability of 
these peptides to compete with peanut lectin for binding to the T-antigen 
displayed on the surface of MDA-MB-435 breast carcinoma cells in situ was 
observed.199  
One of the major attractions to the investigation of a PDC based system as 
part of this work was the fact that the duocarmycin unit (Fmoc-DSA-OH or 
2.10 from Chapter 2) was already functionalised for solid phase peptide 
synthesis. Thus, the synthesis of conjugates could proceed without any 
functional group modifications to the duocarmycin unit for its coupling to the 
peptide. In addition to this, it is possible that with the Fmoc-DSA-OH unit in 
hand, numerous additions of this warhead could be incorporated into the 
peptide sequence in order to achieve optimised cytotoxic activity. The 
combination of these two factors indicated that the synthesis of a conjugate 
should be attempted. 
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4.3.1.2 Synthesis of PDC 4.3 
The literature by Quinn and co-workers disclosed a peptide (4.1) capable of 
binding the T antigen and competing with the T-antigen specific peanut 
lectin (Figure 4.3).199, 200Also of note was the fact that this peptide had been 
used in consequent studies by the group to further investigate the roles of the 
T-antigen within cancer.159 It was proposed therefore that this peptide would 
provide a good starting point for the synthesis of a PDC. As an initial 
strategy, it was proposed that PDC 4.2 (Figure 4.3) could be synthesised.  
 
Figure 4.3: chemical structure of PDC 4.2. T-antigen binding peptide 4.1 (green) is coupled 
to the DSA based warhead (red).  
 
For the ease of synthesis of this PDC, it was proposed that a single 
duocarmycin alkylating subunit could be coupled directly to the peptide 
without a linker. It was proposed that an analogue of this PDC containing a 
cleavable linker between the peptide and warhead could be synthesised for 
comparative purposes and this will be discussed later in this chapter. The 
synthesis of 4.2 started with automated SPPS of peptide 4.1. This was 
completed using a rink amide resin and HOBt/HBTU couplings. Following 
on from the successful formation of the 15 amino acid sequence, as 
deciphered by a test cleavage and mass analysis, the duocarmycin unit was 
coupled manually using HATU/DIPEA, and the N-terminus capped with an 
196 
 
acetyl group. After cleavage from the resin, analytical HPLC indicated the 
presence of one major product peak indicating a clean synthesis (Figure 4.4). 
MALDI mass spectrometry of crude 4.2 also suggested successful synthesis 
of the PDC with the desired mass being found. 
 
 
Figure 4.4: analytical HPLC and MALDI of the crude PDC 4.2 isolated directly from the 
resin. Expected mass 2244.98 gmol-1. HPLC - Agilent Eclipse XDB-C18 column, 4.8 x 150 
mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent B: [MeOHand 0.05 % TFA]. 
Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 % [B] from 15to 20 mins. 
Monitored UV 254 nm. Flow rate 1 mL/min. Column temperature 40 ºC. 
 
In order to undertake the biological studies and evaluate the cytotoxicity of 
PDC 4.2, it was necessary to achieve the benzyl deprotection of the 
duocarmycin warhead within the sequence to give PDC 4.3 (Scheme 4.1). 
Initial attempts to achieve this manipulation were made using transfer 
hydrogenation reaction involving Pd/C and ammonium formate as 
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Scheme 4.1: benzyl deprotection of PDC 4.2. a: 10% Pd/C, 25% Aq. ammonium formate, 
MeOH, 1 h, rt, 32%. 
 
After the specified time, the reaction was analysed by HPLC and MALDI 
mass spectrometry. The HPLC of the reaction mixture showed the presence 
of new peaks but also clear retention of the starting material peak. Similarly, 
MALDI mass spectrometry indicated retention of the starting material yet no 
evidence of 4.3. After prolonging the reaction times and adding further 
equivalents of Pd/C and ammonium formate, the required manipulation was 
still not obtained. It was proposed that under these reaction conditions, the 
possible positions for the Pd to insert itself/bind are extensive and hence 




As a further attempt to obtain PDC 4.3, the BBr3 conditions introduced 
during Chapter 2, Section 2.3.4. were employed. Compound 4.2 was 
suspended in dichloromethane (DCM) and treated with a 1 M solution of 
BBr3 at -78 °C. After the 1 h reaction time, the mixture was analysed via 
HPLC which showed the presence of a new peak and also evidence of existing 
starting material. For this reason, the reaction time was extended for a 
further hour and the solution allowed to warm to room temperature. 
Subsequent to this, analytical HPLC was again used to analyse the reaction 
progress which this time showed complete consumption of the starting 
material and evidence of a new major peak at an earlier retention time. This 
was promising since such a shift in retention time is expected for a benzyl 
deprotection reaction. Following on from this, the product was purified using 
preparative HPLC and analysed through MALDI mass spectrometry. Evident 
from the MALDI spectrum was a clear peak representing the mass of 4.3. 
Post purification analytical HPLC also demonstrated a purity of >90% for the 
PDC (Figure 4.5). These results meant that investigations into the 
cytotoxicity of the PDC within cell lines could be made.  
 
Figure 4.5: analytical HPLC trace of 4.3 post purification using preparative HPLC. Agilent 
Eclipse XDB-C18 column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent 
B: [MeOHand 0.05 % TFA]. Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] 
to 0 % [B] from 15 to 20 mins. Monitored UV 214 nm. Flow rate 1 mL/min. Column 
temperature 40 ºC. 
 
A clear advantage for the synthesis of duocarmycin/peptide hybrids on solid 
phase would be the ability to remove the benzyl group on the resin so that on 
cleavage, the active compound is obtained, as noted in Chapter 2, Section 
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2.3.6. For this reaction, the resin containing PDC 4.2 was suspended in DCM 
and treated with a 1 M solution of BBr3 at -78 °C. The reaction was left for 2 h 
and allowed to warm to room temperature. The peptide was cleaved from the 
resin and the resulting product analysed via analytical HPLC (Figure 4.6 - 
blue) and MALDI mass spectrometry. Evident from this analysis was the 
presence of 4.3.  
 
Figure 4.6: HPLC spectrum of two crude samples taken from the same batch of resin-peptide 
construct. Treatment of the resin with cleavage cocktail gives 4.2 in red, whilst resin 
treatment with BBr3 and subsequently cleavage cocktail, gives 4.3 in blue. Agilent Eclipse 
XDB-C18 column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent B: 
[MeOHand 0.05 % TFA]. Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 
% [B] from 15 to 20 mins. Monitored UV 254 nm. Flow rate 1 mL/min. Column temperature 
40 ºC.    
 
Notable was the synthetic simplicity of the on resin benzyl deprotection 
strategy, in comparison to the post cleavage benzyl deprotection route. This 
also reduced handling of the cytotoxic 4.3 as simple cleavage and removal of 
the solvent under reduced pressure yielded the active PDC for biological 
evaluation. 
4.3.1.3 Introduction of a Cleavable Sequence into PDC 4.3 
As part of this work a comparison between PDCs which include a cleavable 
linkage and those which do not was proposed. Previously within this thesis 
(see Chapter 3), a Phe-Leu peptide sequence has been used that has shown to 
act as a cleavable linker.177 More recently however, the use of a citrulline-
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valine (Cit-Val) cleavable sequence has become far more common and has 
shown desirable stability-lability profiles for use as a linker in targeted 
delivery systems.201 This includes within duocarmycin based systems, and for 
this reason the incorporation of this unit within a PDC system was 
explored.90 The Cit-Val unit is often accompanied by a benzyl group spacer to 
allow for efficient cleavage via a cathepsin B enzyme. This cleavage occurs 
between the benzyl group spacer and the citrulline residue. With cathepsin B 
also being overexpressed within cancer cells, this cleavable sequence further 
presents itself as an ideal linker strategy in targeted delivery systems.202 In 
order to test the suitability of the Cit-Val sequence in the duocarmycin based 
PDC system, the synthesis of a short peptide (4.4 - Figure 4.7) was proposed 
which incorporates the duocarmycin unit, a p-aminobenzoic acid spacer and 
a Cit-Val sequence. A lysine residue at the C-terminus was also included in 
order to add a possible conjugation point for other systems synthesised in 
this body of work (see Chapter 5).  
 
Figure 4.7: chemical structure of peptide 4.4. In red is the DSA unit, in orange is the PABA 
spacer connected to the Cit-Val cleavable linker in green. In blue is a lysine residue used 
elsewhere in this thesis for attachment to other moieties. 
 
Peptide 4.4 was synthesised on rink amide which was initially loaded with 
the Fmoc-DSA-OH unit (2.10) synthesised in Chapter 2. This placed the unit 
at the C-terminus to allow the PABA unit to be introduced before addition of 
the citrulline, valine and lysine, finally capping the N-terminus with an acetyl 
group. Cleavage of 4.4 from the resin was achieved using 47% TFA, 10% 
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TIPS in DCM. Post cleavage HPLC of the crude material demonstrated one 
sharp major peak and MALDI mass spectrometry analysis showed the 
desired mass of 4.4. This indicated that the PABA-Cit-Val linker was 
applicable to the synthetic conditions used with the duocarmycin unit. 
Subsequent to this it was necessary to remove the benzyl group from 4.4 to 
give 4.5 (Scheme 4.2). This would yield an active species that could be 
analysed biologically to see what cytotoxicity could be obtained. The benzyl 
deprotection of 4.4 was shown to proceed smoothly under the standard 
transfer hydrogenation conditions. The resulting peptide 4.5 was purified 
using preparative HPLC to give a pure compound ready to be tested (Figure 
4.8). 
 
Scheme 4.2: benzyl deprotection of peptide 4.4 to give 4.5. a: 10% Pd/C, 25% aq. 
Ammonium formate, MeOH, 1 h, rt. 
 
Figure 4.8: HPLC traces of crude 4.4 (in blue) and pure 4.5 (in red). Agilent Eclipse XDB-
C18 column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent B: [MeOHand 
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0.05 % TFA]. Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 % [B] from 
15 to 20 mins. Monitored UV 254 nm. Flow rate 1 mL/min. Column temperature 40 ºC. 
 
As a control, the cathepsin B cleavage product of 4.5 was also synthesised. 
This would give an indication of the activity expected when this DSA-PABA-
Cit-Val unit is utilised within our PDC systems and subjected to cellular 
conditions. Compound 4.6 (Scheme 4.3) was synthesised following 
conditions utilised for the synthesis of 4.4. Following cleavage from the 
resin, 4.6 was benzyl deprotected, also using transfer hydrogenation 
conditions to give 4.7 (Scheme 4.3). 
 
Scheme 4.3: benzyl deprotection of 4.6 to give 4.7. a: 10% Pd/C, 25% aq. Ammonium 
formate, MeOH, 1 h, rt, 38%.  
 
The desired benzyl deprotection was confirmed using high resolution mass 
spectrometry and also 1H NMR. The smaller molecule size of 4.7 allowed for 
easy analysis via 1H NMR where removal of the 5 aromatic protons and also 
the benzylic CH2 was evident. 
In order to further investigate the potential of this duocarmycin-cleavable 
sequence combination, a cathepsin B cleavage assay was completed following 
a procedure reported by LaBelle and co-workers.203 This would help to 
confirm that the sequence in 4.5 is indeed cleaved by the enzyme to release 
compound 4.7. For this assay, a stock solution of 4.5 was dissolved in DMSO 
and diluted into a cathepsin B activation buffer (0.25 μM HEPES in PBS (pH 
5) with 0.25 µM DTT) which mimics the environment of the lysosome where 
the cathepsin B is found. To this solution, cathepsin B from human liver was 
added before the reaction was incubated at 37 °C for 72 h. After this time 
course, the reaction was diluted with methanol to precipitate the protein 
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which was then removed. The resulting mixture was then analysed via 
analytical HPLC and MALDI mass spectrometry. The HPLC trace indicated 
complete consumption of 4.5. The new peak formed had a shorter retention 
time but only by a marginal time difference. It was discovered however, that 
the retention times of 4.5 and 4.7 are very similar and so this small retention 
time difference was expected. MALDI mass spectrometry also suggested 
complete consumption of 4.5 with no peak for this mass being observed. A 
peak suggesting the formation of 4.7 was however identified providing 
further evidence of successful cleavage of 4.5 by the cathepsin B.  
For a comparison between PDC 4.3, which does not contain a cleavable 
linker, and a PDC which does contain a cleavable linker, the synthesis of PDC 
4.8 was proposed (Figure 4.9). This PDC makes use of the cleavable 
sequence found in 4.5. With the DSA unit now on the C-terminus and the 
Cit-Val cleavable sequence being towards the N-terminus, a shift in the 
positioning of the targeting peptide 4.1 was required in the design of the 
PDC. This is to ensure that that cleavable sequence acts to separate the 
duocarmycin unit from the targeting peptide moiety.  
 
Figure 4.9: chemical structure of PDC 4.8. In red is the DSA based warhead unit, in blue is 
the PABA-Cit-Val cleavable sequence obtained from peptides 4.4 and 4.5 and in green is the 
T antigen binding peptide, 4.1. 
 
The synthesis of PDC 4.8 began with the manual synthesis of the DSA-
PABA-Cit-Val sequence as above in 4.5. The Fmoc-DSA-OH unit was first 
loaded onto a rink amide resin using HATU/DIPEA chemistry and the 
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subsequent couplings of the PABA, Cit and Val proceeded in the same 
manner. Upon removal of the Fmoc group from the valine unit, the 
remaining peptide 4.1 sequence was synthesised on the automatic peptide 
synthesiser using HOBt/HBTU coupling chemistries. The final histidine unit 
was then capped using an acetyl group. Upon cleavage from the resin, crude 
PDC 4.8 was treated with BBr3 in order to achieve the required benzyl 
deprotection to give PDC 4.9 (Figure 4.10).  
 
Figure 4.10: chemical structure of the debenzylated PDC 4.9. 
 
After 2 h, the mixture was analysed by HPLC which suggested the required 
benzyl deprotection had occurred. Subsequently, the mixture was purified 
and again analysed by HPLC and MALDI mass spectrometry to confirm the 




Figure 4.11: HPLC chromatogram of a pure sample of PDC 4.9. Agilent Eclipse XDB-C18 
column, 4.8 x 150 mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent B: [MeOHand 
0.05 % TFA]. Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 % [B] from 
15 to 20 mins. Monitored UV 214 nm. Flow rate 1 mL/min. Column temperature 40 ºC. 
 
The formation of 4.9 meant that two PDC constructs had now been 
successfully synthesised to allow a direct comparison between the two. This 
in turn would provide an analysis on the requirement of a cleavable linker 
between warhead and peptide in these conjugates.  
To further establish the biological activity of this PDC construct, a cathepsin 
B cleavage assay was again completed. It was hoped that after reaction with 
the cathepsin B a clear release of the 4.7 would be observed. The conditions 
by LaBelle and co-workers discussed earlier were repeated but this time on 
PDC 4.9. After 72 hours analytical HPLC and MALDI mass spectrometry 
were used to analyse the data. This time however, there was no observed 
degradation of 4.9 to release 4.7. Efforts are currently ongoing to optimise 
this assay in order to try and observe the release of 4.7.  
4.3.1.4 Synthesis of a Fluorescent Analogue of Peptide 4.1. 
 
A fluorescein isothiocyanate (FITC) analogue based on 4.1 would allow for 
assessment of the binding of this peptide to the T-antigen expressed on cell 
lines during biological evaluation. For this 4.1-FITC analogue, peptide 4.1 
was again synthesised on the automated peptide synthesiser. To this peptide, 
FITC isomer I was directly coupled onto the final histidine residue using 
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pyridine in DMF/DCM. Post cleavage HPLC of 4.1-FITC demonstrated a 
number of signals on the chromatogram suggesting a problem specifically 
with the FITC coupling since the synthesis of 4.1 had been shown to proceed 
smoothly previously. It is not uncommon for the FITC and the terminal 
amino acid residue to undergo an elimination reaction under the acidic 
conditions utilised during cleavage (Scheme 4.4).204 In order to avoid this 
issue, it has been suggested that a spacer should be utilised between the N-
terminal amino acid and the FITC.  
 
Scheme 4.4: elimination of the FITC module from the N-terminus of a peptide sequence 
during TFA mediated cleavage from the resin. Without a spacer after the N-terminal amino 
acid, this process is likely to occur causing a number of unwanted side products within the 
cleavage mixture.  
 
For this reason, peptide 4.1 was synthesised incorporating a β-alanine unit 
after the final histidine residue. Subsequently, FITC was coupled onto the β-




Figure 4.12: chemical structure of 4.1-βAla-FITC, synthesised to study the interaction of 
4.3 with cell lines used for biological evaluation. 
 
HPLC and MALDI mass spectrometry analysis of the resulting cleavage 
product demonstrated the successful synthesis of 4.1-βAla-FITC. The HPLC 
indicated a major product peak (Figure 4.13) and the MALDI mass spectrum 
showed the expected mass for the peptide. With this analogue in hand, 
investigations into the interaction of this peptide with T-antigen expressing 





Figure 4.13: HPLC trace of pure 4.1-βAla-FITC. Agilent Eclipse XDB-C18 column, 4.8 x 150 
mm, 5 μm. Solvent A: [Water and 0.05 % TFA], Solvent B: [MeOHand 0.05 % TFA]. 
Gradient: 0% [B] to 95 % [B], from 0 min to 15 mins, 95 % [B] to 0 % [B] from 15 to 20 mins. 
Monitored UV 214 nm. Flow rate 1 mL/min. Column temperature 40 ºC.  
 
4.3.2 Biological Evaluation of T-antigen Targeting PDCs 
4.3.2.1 βAla-FITC Cell Binding Assays 
As a starting point for the biological analysis of the synthesised peptide 
conjugates, investigations into the interaction of the T-antigen binding 
peptide (4.1) with a cell line which has previously been shown to express the 
antigen were proposed. The MCF-7 human breast cancer cell line has 
previously been shown to demonstrate high levels of T-antigen expression 
and hence were used within these studies.151 For this work 4.1-βAla-FITC 
was utilised. As an initial investigation, MCF-7 cells were incubated with 4.1-
βAla-FITC for 4 h, after which, the cells were visualised using fluorescence 




Figure 4.14: fluorescence microscopy images of MCF-7 cells post incubation with 4.1-βAla-
FITC. 
 
The above microscopy images demonstrate the localisation of 4.1-βAla-
FITC on the MCF-7 cell line. This is presumed to be due to the interaction of 
peptide 4.1 with the T-antigen expressed on these cells. This result indicates 
that the delivery of the DSA unit in the synthesised conjugates to the cancer 
cell lines should occur. Of course, further studies would be required to 
determine the selectivity of this delivery.   
4.3.2.2 Cell Viability Assays 
As an initial screen for activity of 4.3, it was decided to investigate the 
viability of MCF-7 human breast cancer cells post exposure to this PDC. The 
MCF-7 cells were treated with PDC 4.3 at final concentrations of 100 µM, 10 
µM and 1 µM and incubated for 72 h. Post incubation, an MTS assay was 
used to deduce the levels of cell death within the wells. Disappointingly, it 
was evident from the results of this assay that no cell death had occurred 
even at the highest concentration of 4.3. Whilst we have found in our 
laboratory that MCF-7 cells can be relatively resistant to cell death, it was still 
expected that with the active duocarmycin unit present, and at the 
concentrations examined, biological activity of some sort would be observed.  
With this lack of biological activity being obtained within the MCF-7 cell line, 
it was suggested that the lack of a cleavable sequence between peptide 4.1 
and the duocarmycin unit could have been the cause. With the duocarmycin 
warhead having a specific site of action within the cell nucleus, it can be 
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envisioned how when the unit is attached to a large peptide such as 4.1, 
accessibility to the DNA could be an issue. Although cellular degradation of 
the peptide via proteolysis may be expected, this may not occur at a great 
enough extent to achieve the desired release of the duocarmycin unit and 
hence biological activity. With peptide 4.5 and a PDC incorporating this 
cleavable sequence, 4.9, in hand, a comparison of the biological activities of 
these to PDC 4.3 could be made in order to confirm the above as a possible 
reason for the inactivity observed. 
Initially, an assessment of the biological activity of 4.5 and 4.7 was proposed 
to establish whether these units themselves hold any activity and hence may 
demonstrate cytotoxicity when utilised alongside the T-antigen targeting 
peptide 4.1. For activity screening purposes, a set of T-antigen expressing 
cell lines commonly used within the laboratory were chosen.149, 151 The cells 
were treated with 4.5 and 4.7 for 72 h before an MTS assay was used to 
assess cell viability. Table 4.1 gives a summary of the cell lines studied along 
with the respective IC50’s obtained for 4.5 and 4.7. 
Table 4.1: IC50 results obtained for compounds 4.5 and 4.7 with MCF-7. HL-60 and HCT116 
cell lines. 
Cell Lines 4.5 IC50 (µM) 4.7 IC50 (µM) 
MCF-7 0.784 0.178 
HL-60 4.384 0.059 
HCT116 0.343 0.032 
 
The nanomolar IC50’s obtained within these investigations were some of the 
lowest that have been observed for the particular duocarmycin unit used 
within this thesis. This was somewhat surprising considering the lack of a 
binding subunit on these molecules which has been shown previously to 
cause a reduction in the activity obtained for duocarmycin units.205 However, 
it could be that the PABA group present is acting in a similar way to a binding 
subunit and hence could be a key component in achieving these biological 
results. 
Although peptide 4.5 should be cleaved by cathepsin B to give 4.7, quite 
different IC50’s were obtained here, with 4.5 showing a reduced biological 
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activity. However, this could be explained by a reduced cellular uptake of the 
larger 4.5 unit by the cell lines. Alternatively, incomplete cathepsin B 
cleavage of 4.5 may mean that the concentration of 4.7 obtained in vitro 
may be smaller than that used in the assays where the cells were directly 
exposed to 4.7. Despite this slight discrepancy, the activity of 4.5 was still 
relatively high. Therefore, these studies demonstrated that this cleavable 
sequence unit has potential to obtain high activities when incorporated into a 
duocarmycin based sequence and hence warranted further investigation. 
Also worth noting here is the applicability of the 4.5 unit to be introduced 
into a variety of systems for various targeted therapeutic purposes.  
Biological analysis of the whole PDC construct containing this cleavable 
sequence (4.9) was completed in order to determine its cytotoxic activity. 
MCF-7 cells were treated with 8 different concentrations of PDC 4.9 and 
incubated for 72 h. Post incubation, cells were treated with MTS to assess cell 
viability. The results from this assay provided an IC50 of 2 µM for PDC 4.9. 
Importantly, the inactive, protected PDC 4.8 demonstrated no activity at 100 
µM confirming that the activity observed in 4.9 is due to the active 
duocarmycin unit. This result indicates that 4.9 provides a promising 
starting point for the generation of a successful duocarmycin-based PDC. 
Despite this promising result, further investigations are required to help fully 
realise the potential of this PDC construct. Foremost, a thorough assessment 
of the selectivity of the duocarmycin warhead delivery is required. This would 
ensure that the T-antigen binding peptide, 4.1, is successfully delivering the 
duocarmycin warhead to cancerous, T-antigen expressing cells.  
What can be deduced from this comparative assessment of biological activity 
is the advantage of including a cleavable sequence between the duocarmycin 
unit and 4.1. Little activity was obtained for the PDC without a cleavable 
sequence (4.3) yet with a cleavable sequence, low micromolar activity was 
obtained. This suggests that release of the duocarmycin unit from the PDC 
construct is required for this warhead to exert its biological activity. Of 
course, these PDC constructs differ in the positioning of the duocarmycin 
unit (N terminus in 4.3 and C terminus in 4.9) and so this could also be 




The aim of the research within this chapter was to develop a duocarmycin-
based peptide-drug conjugate for targeted delivery to cancer cells via the T-
antigen.  
The discovery of a 15 amino acid peptide sequence (4.1) which has been 
shown to selectively and specifically bind the T-antigen provided an ideal 
starting point for the formation of this PDC construct. The binding of this 
peptide sequence to the T-antigen on MCF-7 cells was confirmed through the 
synthesis of a fluorescent analogue of this peptide. 4.1-βAla-FITC was 
shown, using fluorescence microscopy studies, to bind to MCF-7 cells which 
have been previously reported to express the T-antigen.  
Following on from this, two PDCs based on 4.1 were synthesised. One PDC 
(4.3) was synthesised without a cleavable sequence between peptide and 
duocarmycin warhead and the other PDC (4.9) was synthesised containing a 
cathepsin B cleavable PABA-Cit-Val sequence. Biological analysis of the 
cathepsin B cleavable sequence (4.5) and its respective cleavage product 
(4.7) demonstrated the potential of this unit after IC50s in the low to mid 
nanomolar range in MCF-7, HL60 and HCT116 cell lines were obtained. The 
design and synthesis of this DSA-PABA-Cit-Val sequence also provides scope 
for further studies involving targeted delivery due to its ease of synthesis on 
the solid phase, and its applicability in terms of incorporation into numerous 
other targeting systems. To confirm the cleavage of PDC 4.9 and therefore 
release of 4.7, the PDC was subjected to cathepsin B cleavage assay 
conditions. Unfortunately, whilst 4.7 was observed to be released from 4.5, 
no signs of this occurring from 4.9 were observed. However, efforts to 
optimise this assay for the 4.9 system are on-going.  
During biological analysis, PDC 4.3 demonstrated no cytotoxic activity at 
concentrations of 100 µM and lower in MCF-7 cell lines. This was assumed to 
be due to the lack of cellular degradation of the PDC construct thereby 
preventing the duocarmycin warhead from exerting its DNA alkylation based 
activity. On the other hand, PDC 4.9, containing the cleavable sequence, 
demonstrated an IC50 of 2 µM. This dramatic improvement in activity is 
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assumed to be due to the addition of the cleavable sequence which allows the 
duocarmycin unit to be released. Release of 4.7 specifically from the 
construct is thought to be desirable since the PABA unit in this compound 
may act in a similar way to a DNA binding subunit. This could explain the 
low nanomolar activity obtained for 4.7 in cellular assays.  
Investigations are now required to establish the potential of this promising 
PDC construct (4.9). Studies which aim to ascertain whether this PDC can 
selectively target and hence show greater efficacies in cell lines which show 
an elevated level of T-antigen expression are essential. The literature reports 
a number of cells lines that show a reduced T-antigen expression which these 
studies could be completed with. Additionally, scrambling of the T-antigen 
peptide 4.1, and specifically the aromatic region thought to be essential for 
T-antigen binding, could be used to establish whether the targeting 
capabilities of 4.1 are enabling the activity of PDC construct 4.9. Should the 
scrambled sequence PDC show a lower cytotoxicity, then this would suggest 
that the binding of 4.1 to the T-antigen is crucial for the observed activity 
within 4.9.  The literature surrounding the use of 4.1 also describes how a 
simple iodination of the tyrosine residue can result in complete loss of 
binding to the T-antigen. This strategy could therefore also be employed to 
further investigate the behaviour of 4.9.  
Following on from studies which aid in understanding the binding and 
targeting behaviour of 4.9, investigations which aim to improve upon the 
current cytotoxic activity of this PDC could be made. Of particular interest 
here would be additions of further duocarmycin units into the PDC sequence. 
By adding additional warheads, a greater level of DNA alkylation may be 
achieved which in turn could result in greater cytotoxicity. This strategy has 
shown success within other unpublished analogues from our laboratory and 
so may also prove successful within this system.  
4.5 Experimental 
4.5.1 General Procedures 
Reagents and Solvents  
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All chemicals were reagent grade and were purchased from Sigma Aldrich, 
Fisher Scientific, FluoroChem and Tokyo Chemical Industry. Fmoc-amino 
acids and coupling reagents were purchased from Novabiochem or AGTC 
Bioproducts. Anhydrous solvents were bought from Sigma Aldrich and 
assumed to conform to specification.  
Physical Characterisation and Spectroscopic Techniques  
1H- and 13C-NMR spectra were recorded on a Bruker spectrometer operating 
at 400 MHz (1H) or 100 MHz (13C) using the specified deuterated solvent. 
The chemical shifts for both 1H- and 13C were recorded in ppm and were 
referenced to the residual solvent peak of DMSO at 2.50 ppm (1H) and 39.52 
ppm (13C). Multiplicities in the NMR spectra are described as s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, and combinations 
thereof; coupling constants are reported in Hz. MALDI was performed on 
Kratos Analytical Axima MALDI-TOF using α-cyano-4-hydroxycinnamic acid 
as a matrix. Low resolution mass spectra were recorded using a Shimadzu 
LCMS 2010EV operated under electrospray ionisation in positive (ES+) 
mode. Accurate mass spectra were recorded at the EPSRC National Mass 
Spectroscopy Service Centre, Swansea or at The John Innes Centre, Norwich 
Research Park.  
Chromatographic Techniques  
Analytical RP-HPLC was performed on an Agilent 1200 using an Agilent 
eclipse XDB-C18 column, 4.6 x 150 mm, 5 µM and a flow rate of 1 mL/min. 
Solvent A = Water + 0.05% TFA and Solvent B = MeOH + 0.05% TFA. 
Gradient 5% B up to 95% B over 20 minutes. Detection wavelength 214 nm 
and 254 nm. Semi-preparative RP-HPLC was performed on an Agilent 1200 
using an Agilent eclipse XDB-C18 column, 9.4 x 250 mm, 5 µM and a flow 
rate of 4 mL/min. Solvent A = water + 0.05% TFA and Solvent B = MeOH + 
0.05% TFA. Gradient 5% B up to 95% B over 20 minutes. Detection 
wavelength 214 nm and 254 nm. Preparative RP-HPLC was performed on an 
Agilent 1200 using an Agilent eclipse XDB-C18 column, 21.2 x 150 mm, 5 µM 
and a flow rate of 20 mL/min. Solvent A = 95% H2O + 5% MeOH + 0.05% 
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TFA and Solvent B = 95% MeOH + 5% H2O + 0.05% TFA. Gradient 5% B up 
to 95% B over 20 minutes. 
4.5.2 Synthesis 
Synthesis of PDC-4.2 
 
The 15 amino acid T-antigen binding peptide 4.1 (HGRFILPWWYAFSPS) 
was synthesised on NovaPEG Rink amide resin (resin loading 0.49 mmol/g) 
using an automated peptide synthesiser. 100 mg of NovaPEG Rink Amide 
resin (0.049 mmol) was suspended in DMF (2 mL) and was allowed to swell 
for 30 minutes. The DMF was drained from the peptide vessel and the resin 
was treated with a solution of Fmoc-Ser(tBu)-OH (4 equiv. compared to resin 
loading), to which HBTU (3.9 equiv.), HOBt (4 equiv.) and DIPEA (8 equiv.) 
in DMF were added. The mixture was then vortexed for 30 min. The vessel 
was drained and the resin washed with DMF (3 x 2 mL). The coupling 
reaction was then repeated followed by Fmoc deprotection (2 x 2 mL 40% 
piperidine in DMF, 10 min) and finally the resin was washed with DMF. 
Subsequent amino acids were coupled in an identical fashion. After the final 
amino acid coupling reaction (histidine) and Fmoc deprotection, the resin 
was treated with 2.10 (1.5 equiv.), HATU (1.5 equiv.) and DIPEA (3 equiv.) 
and reacted overnight. Subsequent Fmoc deprotection (3 mL 40% piperidine 
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in DMF, 10 min, 3 mL 20% piperidine in DMF, 5 min x 2) was followed by 
coupling with AcCl (5 equiv.) and DIPEA (10 equiv.) in DMF for 1 h. The 
resin was washed with DMF (6 x 10 mL) followed by DCM (6 x 10 mL). The 
peptide was cleaved from the resin using 47% TFA, 10% TIPS in DCM (10 
mL) and shaken for 3 h after which the cleavage cocktail was drained into a 
round bottom flask. The resin was washed with TFA (x 3) and the solutions 
combined and concentrated under reduced pressure. The peptide was 
precipitated using cold diethyl ether and filtered. PDC 4.2 was purified using 
automated reversed phase Prep HPLC and lyophilised from water to yield a 
brown solid. This was subsequently analysed using RP-HPLC (RT = 17.6 
min) and MALDI mass spectrometry  for 4.2 (M + H)+, 2244.46. 
Synthesis of PDC - 4.3 
 
PDC 4.2 (10.0 mg, 0.004 mmol) was suspended in anhydrous DCM (5 mL) 
and cooled to -78 °C under an atmosphere of N2. To this was added a 1 M 
solution of BBr3 in DCM (9 µL, 0.009 mmol) and the resulting reaction 
stirred at –78 °C for 1 h. Subsequently, the reaction was allowed to warm to 
room temperature and stir for a further 1 h before being quenched with 
crushed ice. The mixture was then evaporated to dryness under reduced 
pressure before being resuspended in MeOH (5 mL) for purification by 
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reverse-phase Prep HPLC. This yielded PDC 4.3, (3.1 mg, 32%) as a light 
brown solid which was analysed via using RP-HPLC (RT = 16.5 min) and 
MALDI mass spectrometry for 4.3 (M + H)+, 2152.56. 
On Resin Benzyl Deprotection of PDC – 4.2 
The resin-4.2 construct (30 mg, 0.015 mmol as determined from resin 
loading) was washed with DCM (6 x 5 mL) and suspended in anhydrous 
DCM (5 mL) under an atmosphere of N2. The resulting mixture was cooled to 
-78 °C and treated with a 1 M solution of BBr3 in DCM (28 µL, 0.028 mmol) 
before stirring for 1 h at -78 °C. The mixture was allowed to warm to room 
temperature and then stirred for a further 1 h. Subsequently, the reaction was 
quenched with crushed ice and the resin filtered off and washed with DCM (5 
x 5 mL). The benzyl deprotected PDC, 4.3, was cleaved from the resin 
through treatment with 47% TFA, 10% TIPS in DCM for 3 h, after which the 
cleavage cocktail was drained into a round bottom flask. The resin was 
washed with TFA (x 3) and the solutions combined and evaporated to 
dryness under reduced pressure. The peptide was precipitated using cold 
diethyl ether and filtered. PDC 4.3 was purified using automated reversed 
phase Prep-HPLC and lyophilised from water to yield a light brown solid. 
This was subsequently analysed using RP-HPLC (RT = 16.5 min) and MALDI 
mass spectrometry for 4.3 (M + H)+, 2152.68). 
Synthesis of Peptide 4.4 and 4.5 
 
NovaPEG Rink Amide resin (150 mg, 0.0735 mmol, [manufacturer’s resin 
loading 0.49 mmol/g]) was prepared for coupling by swelling in 
dichloromethane (DCM) for 30 mins followed by N,N-dimethylformamide 
(DMF) for 30 mins. 2.10 (64 mg, 0.11 mmol) was dissolved in 2 mL of DMF 
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and treated with HATU (42 mg, 0.11 mmol) and DIPEA (39 µL, 0.22 mmol). 
After 10 secs the resulting solution was added to the resin and the mixture 
shaken overnight. Subsequently, the resin was washed with DMF (6 x 10 mL) 
before removal of the indoline Fmoc using piperidine in DMF (6 mL 40% 10 
mins, 6 mL 20% 5 mins twice). Following Fmoc deprotection the resin was 
washed with DMF (6 x 10 mL). Next, Fmoc-PABA-OH (132 mg, 0.368 mmol) 
was dissolved in 2 mL of DMF and treated with HATU (140 mg, 0.368 mmol) 
and DIPEA (129 µL, 0.735 mmol). After 10 secs the resulting solution was 
added to the resin and the mixture shaken for 2 h. The resin was 
subsequently washed with DMF (6 x 10 mL) and the coupling with Fmoc-
PABA-OH repeated. Next, the Fmoc group on the PABA was removed using 
piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). The resin 
was then washed again with DMF (6 x 10 mL) before being treated with 
Fmoc-Cit-OH (146 mg, 0.368 mmol) HATU (140 mg, 0.368 mmol) and 
DIPEA (129 µL, 0.735 mmol). The mixture was shaken for 2 h before the 
resin was washed with DMF (6 x 10 mL). The citrulline Fmoc group was 
removed using piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins 
twice). Upon washing of the resin with DMF (6 x 10 mL), the resin was 
treated with Fmoc-Val-OH (125 mg, 0.368 mmol), HATU (140 mg, 0.368 
mmol) and DIPEA (129 µL, 0.735 mmol) and shaken for 2 h. Upon Fmoc 
deprotection of the valine residue with piperidine (6 mL 40% 10 mins, 6 mL 
20% 5 mins twice), the resin was treated with Fmoc-Lys(Boc)-OH (172 mg, 
0.368 mmol) HATU (140 mg, 0.368 mmol) and DIPEA (129 µL, 0.735 mmol) 
and left to react for 2 h. Subsequently the resin was washed with DMF (6 x 10 
mL) and the lysine Fmoc group removed using piperidine in DMF (6 mL 40% 
10 mins, 6 mL 20% 5 mins twice). Following on from this, the resin was 
washed with DMF (6 x 10 mL) and treated with AcCl (26 µL, 0.37 mmol) and 
DIPEA (129 µL, 0.735 mmol) in DMF (2 mL) for 2 h. Subsequently, the resin 
was washed with DMF (6 x 10 mL) and the AcCl coupling conditions 
repeated. The resin was washed with DMF (6 x 10 mL) and then DCM (6 x 10 
mL). Cleavage of 4.4 from the resin was affected by addition of a solution of 
47% TFA, 10% TIPS in DCM (10 mL). After 3 h of shaking, the cleavage 
mixture was filtered. The resin was rinsed with DCM (2 x 3 mL) and the 
combined filtrates were evaporated to dryness under reduced pressure to 
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give crude 4.4 which was analysed using RP-HPLC (RT = 15.9 min) and 
MALDI mass spectrometry for 4.4 (M + H)+, 901.50). Crude 4.4 (10 mg, 
0.011 mmol) was dissolved in MeOH (1 mL) and treated with a slurry of 10% 
Pd/C (20 mg) in a 25% aq. ammonium formate (500 µL) under N2. After 1 h 
the Pd/C was removed by filtering through a plug of celite. Purification by 
Prep-HPLC yielded 4.5 (4.1 mg, 45%) as a light brown solid which was 
analysed by RP-HPLC (RT = 13.7 min) and HRMS (ES+) calcd. for 
C38H51ClN10O8 (M + H)+, 811.3658; found, 811.3652).  
Synthesis of 4.6 and 4.7 
 
NovaPEG Rink Amide resin (150.0 mg, 0.0735 mmol, [manufacturer’s resin 
loading 0.49 mmol/g]) was prepared for coupling by swelling in 
dichloromethane (DCM) for 30 mins followed by N,N-dimethylformamide 
(DMF) for 30 mins. 2.10 (64 mg, 0.11 mmol) was dissolved in 2 mL of DMF 
and treated with HATU (42 mg, 0.11 mmol) and DIPEA (39 µL, 0.22 mmol). 
After 10 secs the resulting solution was added to the resin and the mixture 
shaken overnight. Subsequently, the resin was washed with DMF (6 x 10 mL) 
before removal of the indoline Fmoc using piperidine in DMF (6 mL 40% 10 
mins, 6 mL 20% 5 mins twice). Following Fmoc deprotection the resin was 
washed with DMF (6 x 10 mL). Next, Fmoc-PABA-OH (132 mg, 0.368 mmol) 
was dissolved in 2 mL of DMF and treated with HATU (140 mg, 0.368 mmol) 
and DIPEA (129 µL, 0.735 mmol). After 10 secs the resulting solution was 
added to the resin and the mixture shaken for 2 h. The resin was 
subsequently washed with DMF (6 x 10 mL) and the coupling with Fmoc-
PABA-OH repeated. Next, the Fmoc group on the PABA was removed using 
piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). The resin 
was then washed again with DMF (6 x 10 mL) and then with DCM (6 x 10 
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mL) before cleavage from the resin using 47% TFA, 10% TIPS in DCM (10 
mL) for 3 h. 4.6 was isolated via filtration of the cleavage mixture and 
subsequent washing of the resin with DCM (3 x 5 mL). The combined filtrates 
were evaporated to dryness under reduced pressure to give crude 4.6 as a 
dark green solid. Crude 4.6 (10 mg, 0.021 mmol) was dissolved in MeOH (1 
mL) and treated with a slurry of 10% Pd/C (20 mg) in a 25% aq. ammonium 
formate (500 µL) under N2. After 1 h the Pd/C was removed by filtering 
through a plug of celite. Purification by Prep-HPLC yielded 4.7 (3.1 mg, 38%) 
as a light brown solid. RP-HPLC (RT = 11.9 min). 1H NMR (DMSO-d6, 400 
MHz) δ 11.12 (1H, s), 7.85 (1H, s), 7.33 (2H, d, J = 8.1), 7.26 (1H, s), 7.14 (1H, 
s), 7.00 (1H, s), 6.64 (2H, s, J = 8.2), 4.33-4.24 (1H, m), 4.01-3.93 (3H, m), 
4.87-3.81 (1H, m). HRMS (ES+) calcd. for C19H17O3N4Cl (M + H)+, 385.1067; 
found, 385.1058. 
Synthesis of PDC – 4.8 
 
The synthesis of PDC 4.8 began with a repeat synthesis of peptide 4.4. This 
was completed on 100 mg (0.049 mmol substitution) NovaPEG Rink Amide 
resin (resin loading 0.49 mmol/g). Unlike in peptide 4.4, following on from 
the coupling of the valine unit and subsequent Fmoc deprotection, the resin 
was transferred to the automated peptide synthesiser where peptide 4.1 was 
built on the valine unit following the same method above, as synthesised in 
PDC 4.2. Upon completion of the final amino acid coupling in peptide 4.1 
(histidine) and subsequent Fmoc deprotection, the N-terminus was capped 
via a coupling with AcCl (5 equiv.) and DIPEA (10 equiv.) in DMF (2 mL). 
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The resin was washed with DMF (6 x 10 mL) followed by DCM (6 x 10 mL). 
The peptide was cleaved from the resin using 47% TFA, 10% TIPS in DCM 
(10 mL) and shaken for 3 h after which the cleavage cocktail was drained into 
a round bottom flask. The resin was washed with TFA (3 x 3 mL) and the 
solutions combined and concentrated under reduced pressure. The peptide 
was precipitated using cold diethyl ether and filtered. PDC 4.8 was purified 
using automated reversed phase Prep-HPLC and lyophilised from water to 
yield a brown solid. This was subsequently analysed using RP-HPLC (RT = 
17.1 min) and MALDI mass spectrometry for 4.2 (M + H)+, found, 2618.50). 
Synthesis of PDC – 4.9 
 
PDC 4.8 (10 mg, 0.0038 mmol) was suspended in anhydrous DCM (5 mL) 
and cooled to -78 °C under an atmosphere of N2. To this was added a 1 M 
solution of BBr3 in DCM (8 µL, 0.007 mmol) and the resulting reaction 
stirred at – 78 °C for 1 h. Subsequently, the reaction was allowed to warm to 
room temperature and stir for a further 1 h before being quenched with 
crushed ice. The mixture was then evaporated to dryness under reduced 
pressure before being resuspended in MeOH (5 mL) for purification by 
reverse-phase Prep HPLC. This yielded PDC 4.9, 4.1 mg (43%) as a light 
brown solid which was analysed via using RP-HPLC (RT = 16.1 min) and 





Synthesis of 4.1-βAla-FITC 
 
The 15 amino acid T-antigen binding peptide 4.1 (HGRFILPWWYAFSPS) 
was synthesised as above for PDC 4.2. After the final amino acid coupling 
reaction (histidine) and Fmoc deprotection, the resin was this time treated 
with Fmoc-βAla-OH (5 equiv.), HATU (5 equiv.) and DIPEA (10 equiv.) and 
reacted for 2 h. Subsequent Fmoc deprotection (3 mL 40% piperidine in 
DMF, 10 min, 3 mL 20% piperidine in DMF, 5 min x 2) was followed by 
coupling with FITC isomer I (1.1 equiv.) in pyridine:DMF:DCM (2.4:1.4:1) 
overnight in the dark. The resin was washed with DMF (6 x 10 mL) followed 
by DCM (6 x 10 mL). The peptide was cleaved from the resin using 47% TFA, 
10% TIPS in DCM (10 mL) and shaken for 3 h after which the cleavage 
cocktail was drained into a round bottom flask. The resin was washed with 
TFA (x 3) and the solutions combined and concentrated under reduced 
pressure. The peptide was precipitated using cold diethyl ether and filtered. 
Peptide 4.1-βAla-FITC was purified using automated reversed phase Prep-
HPLC and lyophilised from water to yield a yellow solid. This was 
subsequently analysed using RP-HPLC (RT = 17.6 min) and MALDI mass 
spectrometry  for 4.1-βAla-FITC (M + Na)+, found, 2245.08). 
4.5.3 Biological Assays 
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Cell culture: The HL60, MCF-7 and HCT116 cell lines was purchased from 
ECACC (Porton Down, UK). Cells were cultured in RPMI 1640 medium 
supplemented with 10% foetal calf serum and 2 mM L-glutamine. HL-60, 
MCF-7 and HCT116 cells were passaged twice weekly and maintained 
between 1-9 x 105 cells/mL at 37 °C and 5% CO2.  
4.1-βAla-FITC Fluorescent Microscopy Binding Assay 
MCF-7 human breast cancer cells were seeded in clear 96- well plates at 5 x 
103 cells/well and treated with a 10 mM stock of 4.1-βAla-FITC and 
incubated for 4 h at 37 °C. The cells were subsequently washed three times 
with PBS and fluorescence microscopy was used to examine cells and 
pictures taken with an inverted Leica DMII fluorescence microscope at 10x 
magnification. 
Antiproliferative Assays 
Antiproliferative assay: Antiproliferative activity was determined by MTS 
assay using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(Promega) and following the manufacturer’s instructions. Briefly, HL-60, 
MCF-7 and HCT116 cells (3 x 104 /100 µL) were seeded in 96-well plates and 
left untreated or treated with DMSO (vehicle control), duocarmycins, or 
doxorubicin hydrochloride in triplicate for 72 h at 37 °C with 5% CO2. 
Following this, MTS assay reagent was added for 4 h and the absorbance 
measured at 490 nm using the Polarstar Optima microplate reader (BMG 
Labtech). IC50 values were calculated using GraphPad Prism Version 5.0 
software. Concentrations tested: Compound 4.3 in MCF-7 cells (100 µM, 10 
µM, 1 µM). Compounds 4.5 and 4.7 in MCF-7, HL60 and HCT116 cell lines 
(100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 µM, 0.001 µM, 0.0001 µM, 0.00001 µM) 
and 4.8 and 4.9 in MCF-7 cells (100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 µM, 
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5.1.1 Nanoparticles as Drug Delivery Platforms 
Despite a century of continuous discovery and development, current 
formulations leave many drugs with poor pharmacokinetic profiles and 
incapable of localising specifically at sites of interest. Drug molecules simply 
diffuse and distribute freely throughout the body, resulting in undesirable 
side effects and a lack of efficacious responses. This inability to reach target 
sites contributes to exceptionally high attrition rates of new chemical entities 
across all therapeutic areas.1  
Nanoparticle-based drug delivery platforms have emerged as suitable 
vehicles for overcoming some of the pharmacokinetic limitations associated 
with conventional drug formulations. Nanoparticles have proven 
advantageous at solubilising therapeutic cargos and substantially prolonging 
their circulation lifetimes. In addition to this, high drug loading within or on 
the surface of nanoparticles has shown great potential for improving the 
efficacy of drugs.206-208 Maeda and co-workers, with their discovery of the 
enhanced permeability and retention (EPR) effect, demonstrated the 
potential for increased accumulation of long-circulating macromolecules by 
extravasation through fenestrated blood vessels in tumours (Figure 5.1).26 
Consequently, over the past two decades, this characteristic of solid tumours 
has been a major motivation for extensive research efforts aimed at applying 
nanoparticles to chemotherapy.  
 
Figure 5.1: a schematic representation demonstrating how the enhanced permeability and 
retention effect leads to the natural accumulation of nanoparticles within tumorous tissue.209 
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The safety and tolerability of nanoparticle-formulated drugs are largely 
improved due to their ability to localise at disease sites.210 This is best shown 
by the reduced cardiotoxicity observed in patients after administration of 
liposomal doxorubicin compared to that of those undergoing treatment with 
the conventional formulation.211 These improvements in patient morbidity 
led to the FDA approval of liposomal doxorubicin (Doxil®) for the treatment 
of Kaposi’s sarcoma in 1995 as well as approval of nanoparticle albumin-
bound paclitaxel (Abraxane®) 10 years later.212 
Whilst the EPR effect presents itself as a successful passive targeting strategy 
for nanoparticle systems, the ability to actively target these nanoparticles to 
specific disease locations is also possible. This is achieved through the 
functionalisation of nanoparticles with targeting moieties such as antibodies, 
proteins and small molecules. These agents are able to specifically recognise 
antigens on the surface of cancerous tissues allowing the nanoparticles to 
accumulate in these regions. This strategy has also been shown to improve 
cellular uptake, thereby further increasing the systems efficacy within 
studies.213 This active targeting approach has been demonstrated using 
liposome nanoparticles conjugated to folic acid for the targeted delivery of 
doxorubicin to folate expressing tumour cells.214, 215 Not only did these 
particles show improved tumour accumulation in comparison to free 
doxorubicin but they also showed evidence of evading multidrug-resistance 
efflux pumps. 
5.1.2 Gold Nanoparticles as Drug Delivery Platforms 
Among the many nanomaterials being developed for nanomedicine 
applications, gold nanoparticles (AuNPs) have shown potential as tumour 
sensors and drug delivery agents.216-218 The use of AuNPs gained popularity in 
these areas of research for several reasons. Firstly, AuNPs are considered to 
be relatively biologically non-reactive and therefore suitable for in vivo 
applications compared to the very toxic cadmium and silver NPs.219 Other 
advantageous qualities include the strong optical properties of AuNPs due to 
localised surface plasmon resonance (LSPR), easily controllable surface 
chemistry, and also, the ease of control over particle size and shape during 
synthesis.217 AuNPs may be considered to be fully multifunctional, with the 
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possibility of combining different desired functionalities in one molecular-
sized package.  
A prominent application of AuNPs is their use as vehicles for the delivery of 
molecules into cells; AuNPs have been described as “promising nanocarriers 
for therapeutics”.220 However, as with other drug delivery systems such as 
ADCs, various factors need to be considered in designing an effective 
nanoparticle drug delivery system. The properties of AuNPs such as their 
size, charge and surface chemistry have been shown to affect their uptake 
into cells as well as their subsequent intracellular fate and pharmacokinetic 
profiles.221 
If AuNPs are used solely as carriers into cells, it is critical to monitor any 
toxic effects of residual materials in the cell after delivery; a biodegradable 
nanoparticle vector whose lifespan is limited to the therapeutic window of 
the drug would be ideal. If the nanoparticle vector is cleared from the system 
once its purpose is reached, it will reduce exposure and limit its toxic effects 
in the body. Another area of concern is the penetration rate of AuNPs into 
tumours and their specificity for target sites. This issue is dependent on the 
choice of targeting moiety used within active targeting strategies and also on 
the receptor being targeted.   
As with ADC systems, drug attachment and release from nanoparticles is 
another challenging area. While the ease of surface modification is what 
makes AuNPs attractive for drug delivery, the strength of drug attachment 
and timing of the release needs to be suitably controlled to produce the 
highest therapeutic efficacy. Foremost, the method of release, if necessary, at 
the tumour site is dependent on how the drug is attached to the AuNP, 
whether covalently or non-covalently.  
Despite the potential of AuNP drug delivery systems, an agent of this kind 
has yet to be approved for use within the clinic. However, there have been 
several reports that have demonstrated the potential of these agents for this 
purpose. The effects of AuNPs conjugated with methotrexate (MTX) for 
inducing cytotoxicity in vitro and anti-tumorigenic effects in vivo have been 
reported.222 It was observed that accumulation of Au-MTX in tumour cells 
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occurred more rapidly and at higher concentrations than those treated with 
free MTX. As a result, enhanced cytotoxic effects were also present in several 
tumour cell lines compared with an identical dosage of free MTX. These 
results warrant further investigation as they suggest that the conjugation of 
AuNPs with a chemotherapeutic drug such as MTX is more efficacious than 
the administration of free drug alone. In addition, with this study only 
relying on a passive targeting strategy, an active targeting strategy could 
further improve the efficacy of this system.  
In another study, a phase I clinical trial on a PEGylated colloidal gold–
tumour necrosis factor (TNF) construct (CYT-6091) conducted in patients 
with advanced stage solid cancers has shown potential (Figure 5.2).223 The 
CYT-6091 complex was well-tolerated in this first clinical trial on human 
subjects. What was also evident was that the AuNP-TNF construct produced 
less adverse reactions than the TNF alone even at the highest drug-AuNP 
concentrations in the pre-clinical findings. AuNPs were found in the tumour 
as well as in the liver biopsies but no toxic adverse effects were observed. The 
authors concluded that the clinical results correlated well with the preclinical 
data, which bodes well for future translational studies for AuNPs. This 
nanoparticle construct has now been involved in studies where the central 
CYT-6091 unit has been functionalised with small molecule drugs such as 
paclitaxel for anticancer treatment.224 
 
Figure 5.2: schematic representation of CYT-6091 – An AuNP functionalised with TNF-α, 
PEG chains and a small molecule drug therapeutic.  
What is evident from the above brief summary, is the ability of AuNP systems 
to dramatically improve the pharmacokinetic and toxicity profiles of known 
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cytotoxic agents. The nanoparticle based systems have shown improved 
solubility, cellular uptake, selectivity and circulatory properties in 
comparison to the free drug. Since these issues have been attributed to the 
lack of success for the duocarmycin family of compounds, it could be that the 
nanoparticle based systems hold the ability to help this family realise their 
potential as clinically successful antitumour agents.  
5.2 Aims of the Research in this Chapter 
The work presented in this chapter encompasses efforts towards the 
synthesis of a gold nanoparticle system functionalised with a cytotoxic 
duocarmycin-based analogue. The design of this system, along with various 
strategies employed to functionalise the gold nanoparticle with the 
duocarmycin analogue will be discussed. Efforts towards the characterisation 
of these gold nanoparticle-duocarmycin conjugates will then be addressed.  
The chapter will also look at attempts to further advance the nanoparticle 
system via an active targeting strategy utilising the jacalin lectin introduced 
in Chapter 3. This was made to allow these gold nanoparticles to specifically 
bind to the T-antigen disaccharide and hence achieve targeted delivery to 
cancerous tissues.  
Finally, the biological assessment of these nanoparticles within various cell 
lines will be addressed which provides considerations for future work.  
5.3 Results and Discussion 
5.3.1 Initial Design of the Nanoparticle Systems 
One of the vital considerations when designing a gold nanoparticle drug 
delivery system is the size of the nanoparticle core. The importance of this 
has been discussed in great detail within the literature and has been shown to 
have a great effect on pharmacokinetic and distribution parameters.221 
Additionally, the functionalisation of the nanoparticle with various molecules 
has also been shown to have an impact on these parameters.225 Thus, the 




In a study by De Jong and co-workers, AuNPs of various size were detected in 
various bodily locations after intravenous injection of male rats with different 
sized AuNPs.226 After 24 h, the highest amount of Au was detected in the 
blood, liver and spleen with lower amounts in the lungs, kidneys, testis, 
thymus, heart and brain. When AuNPs are functionalised with PEG, different 
trends are observed; after tail vein injection of white rats, the accumulation 
of Au in the liver and spleen appears to decrease with decreasing 
nanoparticle size from 50 to 15 nm.227 Conversely, the blood showed the 
greatest amount of Au after 24 h when 15-nm PEG–AuNPs were 
administered. Having a higher concentration in the blood, the 15-nm 
nanoparticles have a greater probability of recirculating and accumulating 
into the reticuloendothelial system, as well as inflamed and/or malignant 
disease sites.  
It was these findings that led to an initial proposed synthesis of a 
duocarmycin-AuNP conjugate involving a 16 nm gold nanoparticle core 
functionalised with PEG. A PEG monolayer on the particle, which is 
functionalised with a terminal carboxylic acid, can be coupled to an amine on 
a duocarmycin peptide. Additionally, the carboxylic acid functionality can be 
utilised for an active targeting strategy whereby jacalin is coupled onto this 
position via a lysine residue yielding AuNP-duocarmycin/jacalin conjugates. 
This strategy is outlined in Scheme 5.1. 
 
Scheme 5.1: a schematic representation of the initial strategy envisioned for the synthesis of 
a AuNP-duocarmycin/jacalin conjugate. 
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Russell and co-workers have utilised 4 nm AuNPs to target phthalocyanine 
analogues to tumours in the development of agents for photodynamic 
therapy.111 As these have shown promising cellular activity, a second set of 
compounds were designed using 4 nm AuNPs conjugated to DSA and to 
jacalin. The proposed structures and routes to these compounds were: 
a) A 4 nm AuNP with DSA directly attached to the AuNP and targeted by 
jacalin attached to PEG (Scheme 5.2). 
 
Scheme 5.2: envisioned synthesis of a 4 nm AuNP core functionalised with a mixed 
monolayer of a DSA peptide and PEG, followed by coupling of jacalin to the carboxylic 
terminated PEG.   
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b) A DSA peptide attached to PEG and then incorporated into the 4 nm 
AuNP conjugate (Scheme 5.3). 
 
Scheme 5.3: schematic representation of a route to a AuNP-DSA-Jac conjugate utilising an 
initial coupling of HS-PEG-COOH to an amine containing DSA peptide. 
c) A cleavable DSA peptide sequence attached to PEG and then 
incorporated into the 4 nm AuNP conjugate.  
The synthesis of these four systems are described below. 
5.3.2 Synthesis of 16 nm AuNP Functionalised with PEG, a 
Duocarmycin Peptide and Jacalin 
The synthesis of the AuNP conjugate began with the 16 nm central AuNP 
core, which has been disclosed in the literature and proceeds via the 
reduction of gold tetrachloride trihydrate using sodium citrate.228 The citrate 
also acts as a stabiliser of the gold core preventing the formation of 
aggregates. The success of this step was demonstrated through 
characterisation via Ultraviolet–visible spectroscopy (UV-Vis) (Figure 5.3). 
The 16 nm AuNPs have previously been shown to display a surface plasmon 
absorption band at 523 nm and this value was also obtained for the particles 
synthesised here.228 Additionally, the deep red colour of the nanoparticles in 
solution suggested a successful synthesis of particles of the desired size. The 
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citrate-reduced gold nanoparticles were then decorated with a monolayer of 
PEG (3000 Da). The PEG utilised here was functionalised at one end with a 
thiol, for attachment to the gold nanoparticle core, and with a carboxylic acid 
at the other end to allow further functionalisation. For this, the citrate AuNPs 
were stirred with the HS-PEG-COOH in water prior to removal of excess PEG 
via passing the solution through a 100K MWCO spin column. The 
functionalisation of the gold nanoparticle core was confirmed via UV-Vis, 
which demonstrated the expected 3 nm red-shift in the plasmon absorption 
band of the nanoparticles post functionalisation (Figure 5.3). 
 
Figure 5.3: extinction spectrum of AuNP stabilised with citrate (blue) and AuNPs 
functionalised with a monolayer of HS-PEG-COOH (orange). The plasmon absorption band 
at 525 nm of the PEG functionalised particles is red shifted in comparison to citrate AuNPs 
(522 nm).  
In order to further confirm that the correctly sized PEG functionalised 
AuNPs had been synthesised, transmission electron microscopy (TEM) was 
utilised. The images produced confirmed the particles had an average size of 
























Figure 5.4: TEM image of 16 nm AuNP functionalised with a monolayer of HS-PEG-COOH. 
An average particle size of 15.7 nm was observed for these particles. 
 
Next, investigations turned to the coupling of a peptide to the carboxylic acid 
residue of the PEG chain. It was projected that this could be achieved via the 
activation of the carboxylic acid of the PEG with EDC/NHS and then 
subsequent coupling with an amine residue on the peptide. In order to test 
this strategy, a short peptide sequence was synthesised containing a lysine 
residue – peptide 5.1 (Figure 5.5). Arginine residues were included in the 
sequence to aid the water solubility of this peptide since the nanoparticles are 
soluble, and stable, in water. A fluorescein isothiocyanate (FITC) tag was also 
included in the sequence as it was hoped this would help us to confirm the 
presence of the peptide on the AuNP using UV-Vis spectroscopy. For this 
early stage proof of concept study, and to reduce the use of the Fmoc-DSA-





Figure 5.5: chemical structure of peptide 5.1. In green is the lysine residue, in blue is a water 
soluble sequence and in red is the FITC tag.  
The successful synthesis of this peptide sequence, following the standard 
SPPS conditions discussed in Chapter 2, Section 2.3.3.2 was confirmed using 
MALDI mass spectrometry and HPLC. The purity obtained for this peptide 
(>80%) was deemed acceptable for this initial investigation. With the amine 
containing peptide and the PEG functionalised AuNPs in hand, 
investigations began into the coupling of the two via an amide bond. For this, 
the 16 nm AuNP-PEG were suspended in MES buffer pH 5 and treated with 
EDC and NHS. After 30 mins, excess EDC and NHS were removed, and NHS 
activated particles resuspended in HEPES buffer at pH 7.4. Peptide 5.1 in 
water, was then added into the solution and the mixture stirred overnight 
(Scheme 5.4). 
 
Scheme 5.4: attempted coupling of PEG-AuNP with peptide 5.1. a: MES buffer (pH 5), NHS, 
EDC, 30min, rt, b: HEPES buffer (pH 7.4), peptide 5.1, 24 h, rt 
236 
 
It was observed that a dark precipitate had formed in the reaction mixture 
and this was attributed to the aggregation of the gold nanoparticles. This 
suggested that the particles were either unstable within the HEPES buffer or 
were unstable to the coupling of 5.1. After confirming that the HEPES buffer 
was not the cause of this instability, it appeared that the coupling, or 
interaction of the particles with 5.1 was undesirable. Despite this, the 
aggregate was removed and the supernatant was characterised to see if any of 
the AuNP-PEG-5.1 conjugates remained in solution. Upon running the UV-
Vis spectrum, it was evident that the concentration of particles remaining in 
solution was very low suggesting the amount of aggregation occurring was 
substantial. Additionally, it was apparent that the 16 nm particles presented 
another issue; the characteristic plasmon absorption band of 16 nm particles 
lies in the same region as the absorption of FITC (495 nm). Due to the 
intensity of the extinction from the particles, the peak from the FITC was 
masked and hence it was very difficult to characterise the coupling of the 
peptide to the particle surface. Without the FITC tag, the absorption of the 
peptide sequence itself, even with the duocarmycin unit is also likely to be 
masked by the particles extinction in the region below 300 nm. As a result, 
further characterisation techniques to confirm the presence of 5.1 on the gold 
nanoparticle were attempted. Both NMR and MALDI mass spectrometry 
however, returned inconclusive results.  
The observed aggregation and characterisation issues presented here 
indicated that this initial strategy employed for the synthesis of a 
duocarmycin-AuNP conjugate may not be appropriate. Whilst further efforts, 
with other fluorescent tags with differing absorptions, such as those beyond 
530 nm, may have resulted in a successful way to characterise these 
conjugates an alternative nanoparticle construct was investigated.   
5.3.3 Synthesis of 4 nm AuNP Functionalised with a Mixed 
Monolayer of PEG, a Duocarmycin Peptide and Jacalin 
It is possible that 4 nm AuNPs could present themselves as an advantageous 
alternative for the desired duocarmycin-AuNP system. This was the case for 
various reasons. Firstly, the synthesis of functionalised 4 nm particles has 
been completed within organic solutions.111 This is ideal for a duocarmycin-
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based construct since duocarmycin based peptides are often very 
hydrophobic and so an organic based synthetic procedure would aid in the 
solubility and stability of these agents during the particle assembly. 
Additionally, the characteristic UV-Vis extinction spectrum of 4 nm AuNPs 
does not show a strong plasmon absorption band at a wavelength similar to 
FITC unlike 16 nm particles.111 This means that a FITC tagging strategy could 
be used to easily confirm the successful coupling of ligands onto the particle 
surface. These factors prompted the design of a strategy for the synthesis of a 
4 nm AuNP-duocarmycin conjugate. Whilst the pharmacokinetic profile of 
these smaller particles may not be fully understood, this size would allow for 
the formation of workable system, which could then be scaled accordingly to 
achieve a desired set of properties. Additionally, with previous successful 
cellular studies being completed by other groups, the 4 nm systems 
presented themselves as an attractive alternative to a 16 nm core.  
Following a procedure reported by Russell and co-workers, it was proposed 
that a 4nm AuNP core could be functionalised with a mixed monolayer of 
duocarmycin and PEG.111 The PEG could then be used to couple jacalin for 
the active targeting to the T-antigen disaccharide. For this, Gold tetrachloride 
trihydrate can be reduced using sodium borohydride in the presence of HS-
PEG-COOH and a thiol containing DSA peptide. This gives a mixed 
monolayer on a central 4 nm AuNP core. A thiol is required on the 
duocarmycin peptide to allow for formation of a Au-S bond and therefore 
functionalisation of the core. In a separate step, jacalin is then coupled onto 
the exposed carboxylic acid of the PEG via the lysine residue on the lectin. 
In order for this strategy to be attempted, peptide 3.5 (Figure 5.6) was 
utilised, the synthesis and characterisation of which was discussed in Chapter 




Figure 5.6: chemical structure of peptide 3.5 which contains a thiol residue for the formation 
of a Au-thiol bond.  
This peptide was chosen as a proof of concept approach to the use of a 
cysteine-labelled duocarmycin analogue to build the nanoparticle. As noted 
in chapter 3, removal of the benzyl group from this system could prove 
problematic, but this was a not a consideration at this point.  
The synthesis of the 4 nm AuNP conjugates containing PEG and DSA peptide 
proceeded via the reduction of gold tetrachloride trihydrate with sodium 
borohydride in water and THF. The stronger reducing agent used here, in 
comparison to sodium citrate, allows for the formation of smaller gold 
nanoparticles.229 This reduction was performed in the presence of a 1:1 ratio 
of HS-PEG-COOH and 3.5 ligands that also help to stabilise the particles 
from aggregation (Scheme 5.5).  
 
Scheme 5.5: Synthesis of a 4 nm AuNP core functionalised with a mixed monolayer of SH-
PEG-COOH and peptide 3.5. 
 
Upon completion of this step, excess ligands were removed from the solution 
by spinning through a 100K MWCO spin column and a UV-Vis extinction 
spectrum obtained for characterisation (Figure 5.7). The less intense surface 
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plasmon absorption band observed in the UV-Vis spectrum suggested a 
much smaller particle size than those synthesised in Section 5.3.2. In 
addition to the UV-Vis, TEM images showed that a mean particle diameter of 
3.7 ± 1.2 nm (n = 45) had been synthesised (Figure 5.8). 
 
Figure 5.7: UV-Vis extinction spectrum of 4 nm AuNPs functionalised with PEG and DSA 
peptide 3.5 obtained after reaction of AuCl4·3H2O, NaBH4, HS-PEG-COOH and 3.5. 
 
Figure 5.8: TEM image of AuNP functionalised with a mixed monolayer of PEG and peptide 
3.5. An average particle size of 3.7 nm was observed for these particles. 
The unusual shaped band at 300 nm suggested a possible coupling of 3.5 to 
the surface of the AuNP. Further evidence was required to indicate whether 
peptide 3.5 was coupled onto the surface of the nanoparticle. However, the 
attachment of the DSA peptide directly to the gold core, within a matrix of 
PEG, could prove to be problematic as this may restrict access to, for 




















target of the DSA. On this basis, coupled with the problematic nature of the 
benzyl deprotection of the thiol-containing DSA system, a second PEG-DSA 4 
nm particle was designed.   
5.3.4 Coupling of a DSA Peptide to PEG and Subsequent AuNP 
Conjugate Assembly 
The new design involved the direct coupling of a DSA peptide to HS-PEG-
COOH via an amide bond strategy and utilisation of this DSA-PEG conjugate 
and free HS-PEG-COOH in the assembly of the 4 nm AuNP. This would give 
a nanoparticle that was decorated with both DSA and free carboxylic acids for 
derivatisation to a targeting protein or peptide (such as jacalin).   
Peptide 5.2 (Figure 5.9) was synthesised with a lysine residue for coupling to 
the carboxylic acid of the PEG and a FITC unit for confirmation of 
attachment to the particle surface. For the initial AuNP assembly, the benzyl 
protection of the DSA unit was kept in place to reduce handling of the 
cytotoxic agents.  
 
Figure 5.9: chemical structure of peptide 5.2. In red is the FITC unit, in blue is the DSA 
warhead and in green the lysine residue for coupling to PEG prior to AuNP synthesis.  
Following the conditions outlined in Chapter 2, Section 2.3.3.2, peptide 5.2 
was successfully synthesised and characterised using MALDI mass 
spectrometry and HPLC. Following on from this, the peptide was coupled 
onto the HS-PEG-COOH using HATU/DIPEA coupling chemistry. A MALDI 
of the PEG was run post reaction, which showed a visible increase in the 
mass indicating a successful coupling to give the PEG-DSA conjugate (PEG-
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5.2). Subsequently, AuCl4·3H2O, in the presence of NaBH4, was reacted with 
PEG-5.2 along with HS-PEG-COOH in a 1:1 ratio. This reaction mixture was 
stirred overnight in the dark. Upon removal of excess ligand by 
centrifugation through a 100K MWCO spin column, the particles, in water, 
were characterised via UV-Vis spectroscopy. The resulting spectrum showed 
the characteristic shape of a 4 nm particle along with the presence of a band 
characteristic of FITC at 495 nm (Figure 5.10). This provided an indication 
that peptide 5.2 was present on the AuNP core.  
 
Figure 5.10: UV-Vis extinction spectrum of AuNP functionalised with PEG-5.2. Evident is 
the characteristic band of FITC at 495 nm suggesting successful coupling of the peptide onto 
the particle surface. 
The next step was to test whether the jacalin could be coupled onto the free 
PEG that was also included in the reaction mixture. In order to do this, the 
synthesis was repeated with peptide 5.3 (Scheme 5.6), whose structure 
resembles 5.2 but without the FITC unit. This was so that a jacalin-FITC 
analogue could be used in the synthesis of the construct to ascertain whether 
the lectin had coupled onto the free PEG. The jacalin-FITC was synthesised 
through the stirring of jacalin in HEPES buffer with 20 equivalents of FITC 
isomer I. After 2 h, the excess FITC was removed through a 7K MWCO spin 
column and the presence of FITC on the jacalin surface confirmed using UV-
Vis spectroscopy. Once the synthesis of the AuNP-PEG-5.3 conjugate had 
been completed, the carboxylic acid of the PEG chains was activated with 
EDC and NHS. Subsequently, the jacalin-FITC was added into the solution 




















jacalin by passing the reaction mixture through a 100K MWCO spin column, 
the AuNP-PEG-5.3-Jac(FITC) conjugate was characterised through UV-
Vis spectroscopy and TEM. Evident here was the presence of the FITC band 
at 495 nm within the spectrum (Figure 5.11). Additionally, TEM (Figure 5.12) 
showed that an average particle size of 4.1 nm ± 1.4 (n = 50) had been 
obtained. This indicated the successful coupling of jacalin to the nanoparticle 
and hence suggested that the entire desired nanoparticle system had been 
synthesised. 
 
Figure 5.11: UV-Vis spectra of AuNP functionalised with PEG, 5.3 and jacalin-FITC. Evident 
is the FITC peak here, suggesting the successful coupling of the jacalin onto the free PEG 
carboxylic acid.  
 
Figure 5.12: TEM images of AuNP-PEG-5.3-Jac(FITC) showing an average particle size of 4.1 
nm. 
With a method for building the entire construct in hand, it was next required 




















This would provide the active AuNP conjugates for biological evaluation. The 
benzyl deprotection was achieved via the standard palladium on carbon, 
aqueous ammonium formate route introduced in Chapter 2, Section 2.3.4. 
(Scheme 5.6). 
 
Scheme 5.6: benzyl deprotection of 5.3 to give the biologically active 5.4. a: 10% Pd/C, 25% 
Aq. ammonium formate, MeOH, rt, 1 h 
With this deprotection proceeding successfully as determined by the 
obtainment of the desired mass of 650.28 (calcd. (M+H)+, 650.27) for 5.4, 
the repetition of the synthesis of the AuNP construct above could be 
completed. Peptide 5.4 was coupled onto the PEG unit and MALDI mass 
spectrometry again confirmed the increase in mass to the polymer backbone. 
The AuNP core was then synthesised as previously using PEG and PEG-5.4 
at a 1:1 ratio, before jacalin was coupled onto the free PEG carboxylic acid 
groups. This gave an overall structure termed here AuNP-PEG-5.4-Jac, as 
presented schematically in Figure 5.13 along with the UV-Vis extinction 




Figure 5.13: schematic representation of the synthesised AuNP-PEG-5.4-Jac conjugate. 
 
Figure 5.14: UV-Vis extinction spectrum of AuNP-PEG-5.4-Jac in water. 
 
5.3.5 Synthesis of a Duocarmycin-AuNP Construct Containing a 
Cleavable Sequence 
As a final AuNP construct for investigation, it was proposed that a cleavable 






















Upon cellular internalisation, it was projected that the cleavable sequence 
could be used to release the duocarmycin unit from the AuNP more 
efficiently, allowing it to enter the nucleus and alkylate the DNA. This could 
in turn demonstrate improved cellular activity in comparison to the AuNP-
PEG-5.4-Jac construct. It was this proposition that led to investigations 
into peptide 4.7 (Figure 5.15) as a potential peptide for introduction into the 
AuNP construct. This peptide was introduced in Chapter 4, Section 4.3.1.3 of 
this thesis where its design, synthesis and characterisation were discussed in 
detail.  
 
Figure 5.15: chemical structure of 4.7 and 4.9. 
In Chapter 4, the biological activity of 4.7 along with its cleavage product 
(4.9) was presented. It was this activity that prompted investigations into 
this peptide within an AuNP construct. The possibility that the activity of 4.7 
might be lower than expected due to poorer cellular internalisation in 
comparison to its cleavage product (4.9) was previously discussed. However, 
with proven ability to be taken up by the cells, it could be that the AuNP 
construct could help this peptide show more potent activity than that 
observed in Chapter 4. Peptide 4.7 also contains the required amine handle 
on the lysine residue to be attached to the PEG prior to AuNP assembly.  
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With 4.7 in hand, the assembly of the AuNP construct, in the same manner 
as detailed in Section 5.3.4, was completed to give AuNP-PEG-4.7-Jac 
(Figure 5.16).  
 
Figure 5.16: schematic representation of the AuNP-PEG-4.7-Jac construct. A cleavable 
sequence is included to test whether efficient release of the DSA warhead from the AuNP 
conjugate results in improved activity.  
 
The UV-vis extinction spectrum and TEM images of these particles are 




Figure 5.17: extinction spectrum of AuNP-PEG-4.7-Jac 
 
Figure 5.18: TEM image of AuNP-PEG-4.7-Jac showing an average particle size of 4.4 nm 
± 1.3 (n = 50). 
5.3.6 Biological Evaluation of AuNP-PEG-DSA-Jac Conjugates 
5.3.6.1 Biological Evaluation of AuNP-PEG-5.4-Jac   
For these studies the AuNP-PEG-5.4-Jac were tested on an MCF-7 human 
breast cancer cell line due to its high T-antigen expressing properties.149, 151 It 
was also decided that the same nanoparticle construct but without the jacalin 
unit attached would be assessed here to see if any differing activity was 
obtained.  
The concentration of a stock solution of particles was determined using the 
particle UV-Vis extinction absorption at 450 nm and an extinction coefficient 






















Dilutions of this stock were then made to give final well concentrations of 
18.2 nM, 1.82 nM, and 0.182 nM. 
The MCF-7 cells were incubated for 72 h after treatment with AuNP-PEG-
5.4-Jac and AuNP-PEG-5.4. AuNP-PEG and AuNP-PEG-Jac were also 
synthesised and included in the assay as controls. Following the incubation 
period, the cell viability was analysed via an MTS assay. Upon analysis, it 
became evident that none of the nanoparticle constructs tested in the assay 
had caused cell death, even at the highest concentrations. The lack of activity 
obtained was attributed to two possible factors. Firstly, it could be that the 
particles themselves were not able to enter the cells and hence the 
duocarmycin warhead was unable to reach the nucleus to exert its biological 
activity. Alternatively, it could be that since the duocarmycin warhead is 
attached to the AuNP construct via a stable, non-cleavable amide linkage, 
once internalised within the cell, it might be unable to again access the 
nucleus to exert its activity on the DNA.  
In order to test the former possibility, the FITC analogues of the AuNP 
construct discussed in Section 5.3.4 of this chapter were used to obtain 
fluorescent microscopy images of the cells lines after treatment with the 
particles. It was hoped this would identify whether the particles were 
entering the cell or not. For these studies, MCF-7 cells were incubated with a 
16.4 nM solution of AuNP-PEG-5.3-Jac(FITC) for 4 h after which time, 





Figure 5.19: fluorescence microscopy images of A: MCF-7 cells incubated solely with buffer 
and B: MCF-7 cells incubated in the presence of AuNP-PEG-5.3-Jac(FITC). The 
fluorescence visible within the cells indicates that the AuNP construct is being taken up by 
the cells. 
The above images demonstrate that the nanoparticle construct containing 
peptide 5.3 and jacalin are taken up by the cell line and hence the lack of 
activity is unlikely to be caused by a lack of cellular uptake. For this reason, 
attention turned to the possibility that the lack of activity could be due to the 
non-cleavable nature of the linker between the active duocarmycin unit and 
the AuNP which is preventing the warhead from exerting its desired effect. 
5.3.6.2 Biological Evaluation of AuNP-PEG-4.7-Jac  
  
The biological evaluation of AuNP-PEG-4.7-Jac was completed in a variety 
of cell lines in a similar manner to that in Section 5.3.6.1. This time however, 
MCF-7 human breast cancer cells, HL60 human leukaemia cells and HCT116 
human colon carcinoma cell lines were used to analyse the activity of the 
AuNPs at 19.4 nM, 1.94 nM and 0.194 nM final well concentrations. 
Disappointingly, MTS analysis of this construct within the various cell lines 
demonstrated no evidence of cell death. With high activity being obtained for 
peptide 4.7 in previous studies, this result came as a surprise.  
These were preliminary studies of this system and, due to time constraints, 
they were not pursued further. Studies that confirm the cleavage of the 
duocarmycin ligand from the nanoparticle core are critical as the next step 
for research into this AuNP construct. Since the cellular uptake of these 




inability of the duocarmycin to reach the DNA to exert its activity could be a 
cause for the lack of activity observed. It is possible that the cathepsin B 
enzyme, required to cleave the PABA-Cit-Val sequence, is unable, sterically, 
to reach the peptide substrate on the AuNP. This in turn would result in lack 
of cleavage of the active drug from the AuNP system and therefore a lack of 
biological activity.  
Following these studies, it will be important to ascertain the amount of 
jacalin functionalised onto the surface of these constructs. In similar systems 
with antibodies, it has been shown that this variable is vital in achieving a 
desired activity.231 Specifically, there is an optimum amount of protein that is 
required on the outer surface of the particle. Additionally, a more thorough 
evaluation of the concentration of drug loaded onto the particle surface may 
help to understand the reason for the lack of activity. Higher concentrations 
of particles or a higher loading value might be required in order to see the 
desired activity within the various cell lines. Whilst the FITC peak within the 
UV-Vis spectra can be used to provide a rough indication of the level of drug 
loading, the accuracy of this approach is low. This is because of the FITC 
absorption band (495 nm) being close to, and hence likely to interact with, 
the region used to determine the particle concentration (450 nm). A more 
robust method to determine this information would be helpful to gain a 
better understanding of the biological analysis conducted here.  
5.4 Conclusions 
The aim of the research in this chapter was to design, synthesise and 
biologically evaluate a duocarmycin gold nanoparticle conjugate. The 
conjugate was also to be functionalised with jacalin to allow for an active 
targeting strategy of the particles to the T-antigen disaccharide and hence 
cancerous tissue.  
A 16 nm AuNP core was originally investigated for the synthesis of this 
conjugate constructs. However, due to issues regarding ligand attachment 
characterisation to the particle and also the need for an aqueous synthetic 
procedure, investigations into this area were discontinued. 
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A 4 nm core was found to be a more advantageous alternative due to the 
ability to synthesise these conjugates in organic media. Additionally, their 
characteristic UV-Vis spectrum allows for a FITC tagging strategy to be 
utilised to characterise ligand attachment to the central nanoparticle core. 
Various strategies were attempted to form the 4 nm particle conjugates but it 
was one in which a duocarmycin peptide was coupled to PEG prior to 
nanoparticle assembly that showed most success.  
Originally a non-cleavable amide linkage was employed to attach the 
duocarmycin to the PEG. However, with this construct showing no activity 
but proven cellular internalisation, a peptide sequence containing a PABA-
Cit-Val cleavable sequence was investigated. This was introduced into the 
AuNP construct but again no activity was observed across a variety of cell 
lines.  
Despite the lack of activity seen within this construct, the potential of AuNP 
systems in helping to achieve the targeted delivery of duocarmycin based 
analogues to cancerous tissue means future work into this area is warranted. 
Of particular interest would be further investigations into determining the 
optimum concentrations of jacalin and duocarmycin ligands attached to the 
central nanoparticle core. A greater understanding and control over these 
variables may aid in the formation of an active construct. Despite these 
variables being of considerable importance, one of the inherent difficulties 
with gold nanoparticle systems is how hard it can be to define the level of 
functionalisation occurring to their surface. This is especially a problem 
when the ligand, like duocarmycin, does not contain any intense 
characteristic UV-Vis bands above 300 nm.  
Once the reason for a lack of activity has been identified within this system, 
the construct itself lends itself well to being modified with various targeting 
moieties. With antibodies and small molecules already having shown good 
activity in nanoparticle systems these could also be used within this AuNP-
duocarmycin conjugate to get targeted delivery to other desirable disease 





5.5.1 General Procedures 
Reagents and Solvents  
All chemicals were reagent grade and were purchased from Sigma Aldrich, 
Fisher Scientific and Tokyo Chemical Industry. Fmoc-amino acids and 
coupling reagents were purchased from Novabiochem, Fluorochem or AGTC 
Bioproducts. Anhydrous solvents were bought from Sigma Aldrich and 
assumed to conform to specification. Vivaspin™ 500 (100 kDa MWCO; PES 
membrane) centrifuge columns were purchased from Sartorius Stedim 
Biotech (UK). The α-thio-ω-carboxy polyethylene glycol (3,000 Da; PEG) 
was purchased from Iris Biotech GmbH (Germany). Jacalin was purchased 
from Vector laboratories (UK).  
Physical Characterisation and Spectroscopic Techniques  
1H- and 13C-NMR spectra were recorded on a Bruker spectrometer operating 
at 400 MHz (1H) or 100 MHz (13C) using the specified deuterated solvent. 
The chemical shifts for both 1H- and 13C were recorded in ppm and were 
referenced to the residual solvent peak of DMSO at 2.50 ppm (1H) and 39.5 
ppm (13C). Multiplicities in the NMR spectra are described as s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, and combinations 
thereof; coupling constants are reported in Hz. MALDI mass spectrometry 
was performed on Kratos Analytical Axima MALDI-TOF. Low resolution 
mass spectra were recorded using a Shimadzu LCMS 2010EV operated under 
electrospray ionisation in positive (ES+) mode. Accurate mass spectra were 
recorded at the EPSRC National Mass Spectroscopy Service Centre, Swansea. 
UV-vis spectra of the samples were recorded using a Hitachi U-300 
spectrophotometer at room temperature. Quartz cuvettes with a 1 cm path 
length were used. 
Chromatographic Techniques  
Analytical RP-HPLC was performed on an Agilent 1200 using an Agilent 
eclipse XDB-C18 column, 4.6 x 150 mm, 5 µM and a flow rate of 1 mL/min. 
Solvent A = Water + 0.05% TFA and Solvent B = MeOH + 0.05% TFA. 
Gradient 5% B up to 95% B over 20 minutes. Detection wavelength 214 nm 
and 254 nm. Semi-preparative RP-HPLC was performed on an Agilent 1200 
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using an Agilent eclipse XDB-C18 column, 9.4 x 250 mm, 5 µM and a flow 
rate of 4 mL/min. Solvent A = Water + 0.05% TFA and Solvent B = MeOH + 
0.05% TFA. Gradient 5% B up to 95% B over 20 minutes. Detection 
wavelength 214 nm and 254 nm. Preparative RP-HPLC was performed on an 
Agilent 1200 using an Agilent eclipse XDB-C18 column, 21.2 x 150 mm, 5 µM 
and a flow rate of 20 mL/min. Solvent A = 95% H2O + 5% MeOH + 0.05% 
TFA and Solvent B = 95% MeOH + 5% H2O + 0.05% TFA. Gradient 5% B up 
to 95% B over 20 minutes. 
TEM imaging 
For TEM imaging, an aliquot of PEG modified gold nanoparticles (500 μL) 
was centrifuged in a Vivaspin™ 500 (100 kDa MWCO, PES) tube at 14,300 
xg at 4 °C for 30 min. The concentrated sample (10 µL) was then spotted onto 
Holey Carbon Film 300 Mesh Cu (50) TEM grid (Agar Scientific) on top of 
adsorbent filter paper. The nanoparticle sample was imaged using a JEOL 
2000EX TEM operating at 200 kV accelerating voltage. The assistance of Dr 
Colin MacDonald (School of Chemistry, University of East Anglia) during the 
TEM imaging is gratefully acknowledged. 
 
5.5.2 AuNP and Peptide Synthesis 
Synthesis of Citrate Capped Gold Nanoparticles 
Aqueous solutions of trisodium citrate (50 mL, 1.3 mM) and gold (III) 
chloride trihydrate (HAuCl4, 100 mL, 0.2 mM) were prepared. The solutions 
were heated to 60 °C, combined with rigorous stirring and heated to 85 °C 
for 2.5 h. Once cooled to room temperature, the nanoparticle solution was 
filtered using sterile syringe driven filter units (0.22 μm polyethersulfone 
(PES), Millipore; MillexTM) to remove aggregates and stored at 4°C. 
Functionalisation of 16 nm Citrate Particles with PEG 
PEG (32.7 mg, 1 mM, 3,274 Da) was self-assembled for 15 h onto citrate 
capped gold nanoparticles (10 mL, ca. 19 nM). Following self-assembly, 
unbound PEG was removed from the sample by 4 repeated ultrafiltrations in 
Vivaspin™ 500 tubes (100 kDa MWCO, PES) by centrifuging at 14,000 rpm 
at 4 °C for 20 min. Following every centrifugation, the PEG modified gold 
nanoparticles were redispersed in an equal volume of 2-(N-
morpholino)ethanesulfonic acid buffer (MES, 50 mM, pH 5.5; Sigma-
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Aldrich). The PEG modified gold nanoparticles were then characterised using 
UV-visible spectroscopy and transmission electron microscopy (TEM) 
imaging. 
Peptide 5.1 Synthesis 
 
H-Arg(Pbf)-2ClTrt resin (100 mg, 0.067 mmol, [manufacturer’s resin loading 
0.67 mmol/g]) was prepared for coupling by swelling in dichloromethane 
(DCM) for 30 mins followed by N,N-dimethylformamide (DMF) for 30 mins. 
Fmoc-Lys(Boc)-OH (156 mg, 0.335 mmol) was dissolved in 2 mL of DMF and 
treated with HATU (127 mg, 0.335 mmol) and DIPEA (116 µL, 0.67 mmol). 
After 10 secs the resulting solution was added to the resin and the mixture 
shaken for 2 h. Subsequently, the resin was washed with DMF (6 x 10 mL) 
and the coupling repeated. The resin was washed 6 times with DMF (10 mL) 
before removal of the lysine Fmoc using piperidine in DMF (6 mL 40% 10 
mins, 6 mL 20% 5 mins twice). Following Fmoc deprotection the resin was 
washed with DMF (6 x 10 mL). Next, Fmoc-Gly-OH (99 mg, 0.335 mmol) 
was dissolved in 2 mL of DMF and treated with HATU (127 mg, 0.335 mmol) 
and DIPEA (116 µL, 0.67 mmol). After 10 secs the resulting solution was 
added to the resin and the mixture shaken for 2 h. The resin was 
subsequently washed with DMF (6 x 10 mL) before the Fmoc group on the 
glycine removed using piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 
mins twice). The resin was then washed again with DMF (6 x 10 mL) before 
being treated with Fmoc-Arg(pbf)-OH (217 mg, 0.335 mmol) HATU (127 mg, 
0.335 mmol) and DIPEA (116 µL, 0.67 mmol). The mixture was shaken for 2 
h before the resin was washed with DMF (6 x 10 mL). The arginine Fmoc 
group was removed using piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 
5 mins twice). Upon washing of the resin with DMF (6 x 10 mL), the resin 
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was treated again with Fmoc-Arg(Pbf)-OH, HATU and DIPEA in the same 
quantities as previously. Upon Fmoc deprotection of the second arginine 
residue with piperidine (6 mL 40% 10 mins, 6 mL 20% 5 mins twice) the 
resin was treated with Fmoc-βAla-OH (104 mg, 0.335 mmol) HATU (127 mg, 
0.335 mmol) and DIPEA (116 µL, 0.67 mmol) and left to react for 2 h. 
Subsequently the resin was washed with DMF (6 x 10 mL) and the β-alanine 
Fmoc group removed using piperidine in DMF (6 mL 40% 10 mins, 6 mL 
20% 5 mins twice). Following on from this, the resin was washed with DMF 
(6 x 10 mL) and treated with fluorescein isothiocyanate isomer I (29 mg, 
0.074 mmol), in pyridine (500 µL), DMF (292 µL) and DCM (208 µL) and 
left to react overnight in the dark. Following overnight shaking, the resin was 
washed with DMF (6 x 10 mL) and then DCM (6 x 10 mL). Cleavage of 5.1 
from the resin was affected by addition of a solution of 47% TFA, 10% TIPS in 
DCM (10 mL). After 3 h of shaking the cleavage mixture was filtered. The 
resin was rinsed with DCM (2 x 3 mL) and the combined filtrates were 
evaporated to dryness under reduced pressure and analysed using RP-HPLC 
(RT = 10.3 min) and MALDI mass spectrometry for 5.1 (M + H)+, found, 
1133.64). 
 
Coupling of Peptide 5.1 to 16 nm AuNP-PEG 
5.1 was conjugated to the PEG on the surface of the 16 nm AuNPs via the 
terminal carboxyl groups in the PEG ligand using a previously reported 
method but with modifications.228 The conjugation was performed via an 
amide linkage through N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) coupling. 16 nm PEG 
functionalised AuNPs (2 mL, 29 nM) in water were treated with EDC (0.8 µL, 
0.005 mmol) and NHS (1.2 mg, 0.01 mmol) and left to stir for 30 mins at 
room temperature. Excess EDC/NHS was removed by ultrafiltration in 
Vivaspin™ 500 columns (100 kDa MWCO) at 14,000 rpm for 30 min at 4 °C. 
The NHS-ester functionalised AuNP-PEG were redispersed in water (2 mL) 
and added to with 5.1 in DMF (1 mg, 0.8 µmol). The solution was stirred 
overnight at room temperature in the dark. Following overnight incubation, 
the precipitated particles were removed by centrifugation (14,000 rpm, 10 
mins, 4 °C) and any unbound 5.1 removed by ultrafiltration in Vivaspin™ 
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500 columns (100 kDa MWCO) by centrifuging at 14,000 rpm for 30 min at 
4 °C. The resulting AuNP pellet was redispersed in ddH2O and analysed 
using UV-vis spectroscopy before being stored at 4 °C. 
 
Synthesis of 3.5 
 
For details of the synthesis and characterisation of peptide 3.5, please refer 
back to Chapter 3, Section 3.5.2.  
 
Synthesis of 4 nm AuNP Functionalised with a Mixed Monolayer 
of 3.5 and PEG 
Gold nanoparticles (ca. 4 nm diameter) were synthesised in DMF and 
stabilised with a mixed monolayer of 3.5 and PEG. 3.5 (0.7 mg, 7 µmol) was 
dissolved in tetrahydrofuran (THF, 1 mL). The PEG (7.5 mg, 2 µmol) was 
dissolved in DMF (2 mL) and then stirred with the 3.5 solution for 5 min. 
Gold (III) chloride trihydrate (1.2 mg, 3 µmol) was dissolved in DMF (1.2 
mL) and combined with the 3.5 and PEG solution and stirred for a further 5 
min. A fresh solution of sodium borohydride (1.5 mg, 0.04 mmol) in DMF 
(1.2 mL) was prepared and rapidly added to the solution of the gold chloride, 
3.5 and PEG under vigorous stirring. The reaction was stirred overnight at 
room temperature. Following overnight incubation, the mixture was 
evaporated to dryness under reduced pressure and resuspended in dH2O (10 
mL) to precipitate excess 3.5 which was subsequently removed via 
centrifugation (14,000 rpm, 10 min, 4 °C). The remaining aqueous solution 
was transferred to Vivaspin™ 500 (100 kDa MWCO) columns and 
centrifuged at 14,000 rpm for 10 min at 4 °C. The remaining functionalised 
AuNPs were then resuspended in ddH2O and analysed using UV-vis 




Synthesis of 5.2 
 
H-Arg(pbf)-2ClTrt resin (50 mg, 0.034 mmol, [manufacturer’s resin loading 
0.68 mmol/g]) was prepared for coupling by swelling in DCM for 30 mins 
followed DMF for 30 mins. Fmoc-Lys(mtt)-OH (106 mg, 0.17 mmol) was 
dissolved in 2 mL of DMF and treated with HATU (65 mg, 0.17 mmol) and 
DIPEA (60 µL, 0.34 mmol). After 10 secs the resulting solution was added to 
the resin and the mixture shaken for 2 h. Subsequently, the resin was washed 
with DMF (6 x 10 mL) and the coupling repeated. The resin was washed 6 
times with DMF (10 mL) before removal of the lysine Fmoc using piperidine 
in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following Fmoc 
deprotection the resin was washed with DMF (6 x 10 mL). Next, Fmoc-Gly-
OH (50 mg, 0.17 mmol) was dissolved in 2 mL of DMF and treated with 
HATU (65 mg, 0.17 mmol) and DIPEA (60 µL, 0.34 mmol). After 10 secs the 
resulting solution was added to the resin and the mixture shaken for 2 h. The 
resin was subsequently washed with DMF (6 x 10 mL) before the Fmoc group 
of the glycine removed using piperidine in DMF (6 mL 40% 10 mins, 6 mL 
20% 5 mins twice). The resin was then washed again with DMF (6 x 10 mL) 
before being treated with 2.10 (30 mg, 0.05 mmol), HATU (19 mg, 0.05 
mmol) and DIPEA (18 µL, 0.10 mmol) in DMF (2 mL) and the mixture 
shaken overnight. The resin was subsequently washed with DMF (6 x 10 mL) 
before the Fmoc group on the indoline nitrogen of 2.10 removed using 
piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). The resin 
was then washed again with DMF (6 x 10 mL) before being treated with 
Fmoc-βAla-OH (53 mg, 0.17 mmol) which had been reacted for 10 secs with 
HATU (65 mg, 0.17 mmol) and DIPEA (60 µL, 0.14 mmol) in DMF (2 mL). 
The resulting mixture was left to react for 2 h. Subsequently the resin was 
washed with DMF (6 x 10 mL) and the β-alanine Fmoc group removed using 
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piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following 
on from this, the resin was washed with DMF (6 x 10 mL) and treated with 
fluorescein isothiocyanate isomer I (15 mg, 0.04 mmol), in pyridine (500 
µL), DMF (291 µL) and DCM (209 µL) and left to react overnight in the dark. 
Following overnight shaking, the resin was washed with DMF (6 x 10 mL) 
and then DCM (6 x 10 mL). Cleavage of 5.2 from the resin was affected by 
addition of a solution of 47% TFA, 10% TIPS in DCM (10 mL). After 3 h of 
shaking the cleavage mixture was filtered. The resin was rinsed with DCM (2 
x 3 mL) and the combined filtrates were evaporated to dryness under 
reduced pressure and analysed using RP-HPLC (RT = 15.4 min) and MALDI 
mass spectrometry  for 5.2 (M + H)+, 1159.56). 
 
Synthesis of PEG-DSA peptide conjugates 
PEG (7.5 mg, 2.29 µmol) was dissolved in DMF (300 µL) and treated with 
HATU (0.87 mg, 2.29 µmol) and DIPEA (3.98 µL, 22.9 µmol). After 10 s, the 
amine containing DSA peptide (22.9 µmol, 10 equiv.) was added and the 
resulting reaction stirred overnight at room temperature. Subsequently, the 
reaction was evaporated to dryness under reduced pressure and the PEG-
DSA conjugate washed with diethyl ether (5 mL). The crude PEG-DSA 
conjugated was then analysed using MALDI mass spectrometry before being 
utilised in the respective AuNP assembly. 
 
Assembly of AuNP-PEG-5.2 
PEG-5.2 (7.5 mg; 5 μmol) and PEG (7.5 mg, 4.9 µmol) were dissolved in 
dH2O (15 mL) and left to stir at room temperature. Then, HAuCl4∙3H2O (1.2 
mg; 3 μmol) was dissolved in THF (1.2 mL), added to the PEG-5.2/PEG 
solution and stirred at room temperature for 5 min. A fresh solution of 
NaBH4 (1.5 mg; 39 μmol) in dH2O (0.5 mL) was prepared and added to the 
PEG-HAuCl4 mixture. The reaction was stirred for 4 h at room temperature. 
Purification of the AuNPs was then performed. Firstly, the THF was 
evaporated by rotary evaporation under reduced pressure. The resulting 
aqueous solution was transferred to Vivaspin™ 500 (100 kDa MWCO) 
columns and centrifuged at 14,000 rpm for 10 min at 4 °C. The AuNP-PEG-
5.2 were resuspended in MES buffer (16.7 mL) and filtered through a Millex 
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GP syringe driven filter unit (0.22 μm). The UV-vis extinction spectrum was 
recorded between 250-800 nm. AuNP-PEG-5.2 were stored at 4 °C. 
 
Synthesis of 5.3 and 5.4 
           
H-Arg(pbf)-2ClTrt resin (100 mg, 0.068 mmol, [manufacturer’s resin 
loading 0.68 mmol/g]) was prepared for coupling by swelling in DCM for 30 
mins followed DMF for 30 mins. Fmoc-Lys(mtt)-OH (212 mg, 0.34 mmol) 
was dissolved in 2 mL of DMF and treated with HATU (129 mg, 0.34 mmol) 
and DIPEA (119 µL, 0.68 mmol). After 10 secs the resulting solution was 
added to the resin and the mixture shaken for 2 h. Subsequently, the resin 
was washed with DMF (6 x 10 mL) and the coupling repeated. The resin was 
washed 6 times with DMF (10 mL) before removal of the lysine Fmoc using 
piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). Following 
Fmoc deprotection the resin was washed with DMF (6 x 10 mL). Next, Fmoc-
Gly-OH (101 mg, 0.34 mmol) was dissolved in 2 mL of DMF and treated with 
HATU (129 mg, 0.34 mmol) and DIPEA (119 µL, 0.68 mmol). After 10 secs 
the resulting solution was added to the resin and the mixture shaken for 2 h. 
The resin was subsequently washed with DMF (6 x 10 mL) before the Fmoc 
group of the glycine removed using piperidine in DMF (6 mL 40% 10 mins, 6 
mL 20% 5 mins twice). The resin was then washed again with DMF (6 x 10 
mL) before being treated with 2.10 (59 mg, 0.10 mmol), HATU (39 mg, 0.10 
mmol) and DIPEA (37 µL, 0.20 mmol) in DMF (2 mL) and the mixture 
shaken overnight. The resin was subsequently washed with DMF (6 x 10 mL) 
before the Fmoc group on the indoline nitrogen of 2.10 removed using 
piperidine in DMF (6 mL 40% 10 mins, 6 mL 20% 5 mins twice). The resin 
was then washed again with DMF (6 x 10 mL) before being treated with AcCl 
(30 µL, 0.34 mmol) and DIPEA (119 µL, 0.68 mmol) in DMF (2 mL). After 
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shaking for 1 h the resin was washed with DMF (6 x 10 mL) followed by DCM 
(6 x 10 mL). Cleavage of 5.3 from the resin was affected by addition of a 
solution of 47% TFA, 10% TIPS in DCM (10 mL). After 3 h of shaking the 
cleavage mixture was filtered. The resin was rinsed with DCM (2 x 3 mL) and 
the combined filtrates were evaporated to dryness under reduced pressure 
analysed using RP-HPLC (RT = 14.1 min) and MALDI mass spectrometry  for 
5.3 (M + Na)+, 762.39). 5.3 (10 mg, 0.01 mmol) was dissolved in MeOH (1 
mL) and the resulting solution degassed with a gentle stream of nitrogen for 
30 mins. A slurry of 10% Pd/C (20 mg) in 25% aq. Ammonium formate (500 
µL) was then made and added into the solution of 5.3. The reaction was 
stirred vigorously for 1 h at room temperature before being filtered through a 
pad of celite. The celite was subsequently washed with MeOH (3 x 5 mL) and 
the combined MeOH filtrates evaporated to dryness under reduced pressure. 
Reverse-phase Prep-HPLC and lyophilisation afforded 5.4 (3.0 mg, 33%) as 
a brown solid. RP-HPLC (RT = 14.1 min) and HRMS (ES+) calcd. for 
C28H40ClN9O7 (M + H)+, 650.2817; found, 650.2823) 
 
Synthesis of 4 nm AuNP-PEG-5.3  
PEG-5.3 (7.5 mg; 5 μmol) and PEG (7.5 mg, 5 µmol) were dissolved in dH2O 
(15 mL) and left to stir at room temperature. Then, HAuCl4∙3H2O (1.2 mg; 
3.0 μmol) was dissolved in THF (1.2 mL), added to the PEG-5.3/PEG 
solution and stirred at room temperature for 5 min. A fresh solution of 
NaBH4 (1.5 mg; 39.6 μmol) in dH2O (0.5 mL) was prepared and added to the 
PEG-HAuCl4 mixture. The reaction was stirred for 4 h at room temperature. 
Purification of the AuNPs was then performed. Firstly, the THF was 
evaporated by rotary evaporation under reduced pressure. The resulting 
aqueous solution was transferred to Vivaspin™ 500 (100 kDa MWCO) 
columns and centrifuged at 14,000 rpm for 10 min at 4 °C. The AuNP-PEG-
5.3 were resuspended in MES buffer (16.7 mL) and filtered through a Millex 
GP syringe driven filter unit (0.22 μm). The UV-vis extinction spectrum was 
recorded between 250-800 nm. AuNP-PEG-5.3 were stored at 4 °C. 
 
Synthesis of Jacalin-FITC 
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Jacalin (2 mg, 66 kDa) was dissolved in 10 mM HEPES buffered saline (1 mL, 
pH 7.4, 150 mM NaCl, 100 µM CaCl2) and treated with FITC isomer I (12 µL, 
10 mg/mL in DMSO). The resulting reaction was stirred at room temperature 
for 1 h before being transferred to Zeba spin desalting columns (7K MWCO, 
0.5 mL) and centrifuged at 1500 xg for 2 min at 4 °C. The jacalin-FITC 
solution was characterised by UV-Vis spectroscopy and stored at -20 °C. 
 
Functionalisation of AuNP-PEG-5.3 with Jacalin-FITC 
Jacalin-FITC was conjugated to the PEG on the surface of the AuNPs via 
the terminal carboxyl groups in the PEG ligand using a previously reported 
method but with modifications.111 The conjugation was performed via an 
amide linkage through EDC and NHS coupling. EDC (1.4 mg) and NHS (1.2 
mg) were added to the AuNP-PEG-5.3 in MES buffer (1 mL) and stirred for 
30 min at room temperature. Excess EDC/NHS was removed by 
ultrafiltration in Vivaspin™ 500 columns (100 kDa MWCO) at 14,000 rpm 
for 30 min at 4 °C. The NHS-ester functionalised AuNP-PEG-5.3 were 
redispersed in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM NaCl, 
100 µM CaCl2) and treated with jacalin-FITC (100 μL; 1 mg/mL). The 
solution was stirred overnight at room temperature in the dark. Following 
overnight incubation, unbound jacalin-FITC was removed by ultrafiltration 
in Vivaspin™ 500 columns (100 kDa MWCO) by centrifuging at 14,000 rpm 
for 30 min at 4 °C. The washes at the bottom of the Vivaspin™ 500 columns 
were removed and the AuNPs pellets retained in the Vivaspin™ 500 columns 
were resuspended in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM 
NaCl, 100 µM CaCl2). This purification step was repeated until no more 
unbound Jacalin-FITC was left as determined by the UV-vis absorbance of 
the washes between 200-800 nm. The final AuNP-PEG-5.3-Jac(FITC) 
pellets were redispersed in ddH2O and stored at 4 °C. 
 
Synthesis of 4 nm AuNP-PEG-5.4-Jac 
PEG-5.4 (7.5 mg; 5 μmol) and PEG (7.5 mg, 5 µmol) were dissolved in dH2O 
(15 mL) and left to stir at room temperature. Then, HAuCl4∙3H2O (1.2 mg; 
3.0 μmol) was dissolved in THF (1.2 mL), added to the PEG-5.4/PEG 
solution and stirred at room temperature for 5 min. A fresh solution of 
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NaBH4 (1.5 mg; 39.65 μmol) in dH2O (0.5 mL) was prepared and added to 
the PEG-HAuCl4 mixture. The reaction was stirred for 4 h at room 
temperature. Purification of the AuNPs was then performed. Firstly, the THF 
was evaporated by rotary evaporation under reduced pressure. The resulting 
aqueous solution was transferred to Vivaspin™ 500 (100 kDa MWCO) 
columns and centrifuged at 14,000 rpm for 10 min at 4 °C. AuNP-PEG-5.4 
was resuspended in MES buffer (16.7 mL) and treated with EDC (1.4 mg) and 
NHS (1.2 mg) for 30 min at room temperature. Excess EDC/NHS was 
removed by ultrafiltration in Vivaspin™ 500 columns (100 kDa MWCO) at 
14,000 rpm for 30 min at 4 °C. The NHS-ester functionalised AuNP-PEG-
5.4 were redispersed in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 
mM NaCl, 100 µM CaCl2) and treated with jacalin (100 μL; 1 mg/mL). The 
solution was stirred overnight at room temperature in the dark. Following 
overnight incubation, unbound jacalin was removed by ultrafiltration in 
Vivaspin™ 500 columns (100 kDa MWCO) by centrifuging at 14,000 rpm for 
30 min at 4 °C. The washes at the bottom of the Vivaspin™ 500 columns 
were removed and the AuNPs pellets retained in the Vivaspin™ 500 columns 
were resuspended in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM 
NaCl, 100 µM CaCl2). This purification step was repeated until no more 
unbound jacalin was left as determined by the UV-vis absorbance of the 
washes between 200-800 nm. The final AuNP-PEG-5.4-Jac pellets were 
redispersed in ddH2O and stored at 4 °C. 
 
Synthesis of AuNP-PEG 
The synthesis of AuNPs (ca. 4 nm) functionalised with PEG (AuNP-PEG) 
was performed. PEG (15 mg; 5 μmol) was dissolved in dH2O (15 mL) and left 
to stir at room temperature. Then, HAuCl4∙3H2O (1.2 mg; 3.0 μmol) was 
dissolved in THF (1.2 mL), added to the PEG solution and stirred at room 
temperature for 5 min. A fresh solution of NaBH4 (1.5 mg; 39.6 μmol) in 
dH2O (0.5 mL) was prepared and added to the PEG-HAuCl4 mixture. The 
reaction was stirred for 6 h at room temperature. Purification of the AuNPs 
was then performed. Firstly, the THF was evaporated under reduced 
pressure. The aqueous solution was transferred to Vivaspin™ 500 columns 
(100 kDa MWCO) and centrifuged at 14,000 rpm for 10 min. The AuNP-PEG 
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were resuspended in ddH2O or MES buffer (15 mL) and filtered through a 
Millex GP syringe driven filter unit (0.22 μm). The UV-vis extinction 
spectrum was recorded between 250-800 nm. The AuNP-PEG were stored 
at 4 °C. 
 
Synthesis of AuNP-PEG-Jac 
Jacalin was conjugated to the PEG on the surface of the AuNPs via the 
terminal carboxyl groups in the PEG ligand using a previously reported 
method but with modifications. The conjugation was performed via an amide 
linkage through EDC and NHS coupling. EDC (1.4 mg) and NHS (1.2 mg) 
were added to the AuNP-PEG in MES buffer (1 mL) and stirred for 30 min 
at room temperature. Subsequently, excess EDC/NHS was removed by 
ultrafiltration in Vivaspin™ 500 columns (100 kDa MWCO) at 14,000 rpm 
for 30 min at 4 °C. The NHS-ester functionalised AuNP-PEG were 
redispersed in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM NaCl, 
100 µM CaCl2) and treated with jacalin (100 μL; 1 mg/mL). The solution was 
stirred overnight at room temperature. Following overnight incubation, 
unbound jacalin was removed by ultrafiltration in Vivaspin™ 500 columns 
(100 kDa MWCO) by centrifuging at 14,000 rpm for 30 min at 4 °C. The 
washes at the bottom of the Vivaspin™ 500 columns were removed and the 
AuNPs pellets retained in the Vivaspin™ 500 columns were resuspended in 
10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM NaCl, 100 µM 
CaCl2). This purification step was repeated until no more unbound jacalin 
was left as determined by the UV-vis absorbance of the washes between 200- 
800 nm. The final AuNPs pellets were redispersed in ddH2O and stored at 4 
°C. 
 




For details of the synthesis and characterisation of peptide 4.5, refer back to 
Chapter 4, Section 4.5.2. 
 
Synthesis of AuNP-PEG-4.5-Jac 
PEG-4.5 (7.5 mg; 5 μmol) and PEG (7.5 mg, 5 µmol) were dissolved in dH2O 
(15 mL) and left to stir at room temperature. Then, HAuCl4∙3H2O (1.2 mg; 
3.0 μmol) was dissolved in THF (1.2 mL), added to the PEG-4.7/PEG 
solution and stirred at room temperature for 5 min. A fresh solution of 
NaBH4 (1.5 mg; 39.6 μmol) in dH2O (0.5 mL) was prepared and added to the 
PEG-HAuCl4 mixture. The reaction was stirred for 4 h at room temperature. 
Purification of the AuNPs was then performed. Firstly, the THF was 
evaporated under reduced pressure. The resulting aqueous solution was 
transferred to Vivaspin™ 500 (100 kDa MWCO) columns and centrifuged at 
14,000 rpm for 10 min at 4 °C. The AuNP-PEG-4.5 particles were 
resuspended in MES buffer (16.7 mL) and treated with EDC (1.4 mg) and 
NHS (1.2 mg) for 30 min at room temperature. Excess EDC/NHS was 
removed by ultrafiltration in Vivaspin™ 500 columns (100 kDa MWCO) at 
14,000 rpm for 30 min at 4 °C. The NHS-ester functionalised AuNP-PEG-4.5 
were redispersed in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM 
NaCl, 100 µM CaCl2) and treated with jacalin (100 μL; 1 mg/mL). The 
solution was stirred overnight at room temperature in the dark. Following 
overnight incubation, unbound jacalin was removed by ultrafiltration in 
Vivaspin™ 500 columns (100 kDa MWCO) by centrifuging at 14,000 rpm for 
30 min at 4 °C. The washes at the bottom of the Vivaspin™ 500 columns 
were removed and the AuNPs pellets retained in the Vivaspin™ 500 columns 
were resuspended in 10 mM HEPES buffered saline (0.5 mL, pH 7.4, 150 mM 
NaCl, 100 µM CaCl2). This purification step was repeated until no more 
unbound jacalin was left as determined by the UV-vis absorbance of the 
washes between 200-800 nm. The final AuNP-PEG-4.5-Jac pellets were 
redispersed in ddH2O and stored at 4 °C. 
 




Cell culture: The HL60, MCF-7 and HCT116 cell lines was purchased from 
ECACC (Porton Down, UK). Cells were cultured in RPMI 1640 medium 
supplemented with 10% foetal calf serum and 2 mM L-glutamine. HL-60, 
MCF-7 and HCT116 cells were passaged twice weekly and maintained 
between 1-9 x 105 cells/mL at 37 °C and 5% CO2.  
Antiproliferative assay: Antiproliferative activity was determined by MTS 
assay using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(Promega) and following the manufacturer’s instructions. Briefly, HL-60, 
MCF-7 and HCT116 cells (3 x 104 /100 µL) were seeded in 96-well plates and 
left untreated or treated with H2O (vehicle control), AuNP-PEG (control), 
AuNP-PEG-Jac (control), AuNP-PEG-5.4, AuNP-PEG-5.4-Jac, AuNP-
PEG-4.5-Jac or doxorubicin hydrochloride in triplicate for 72 h at 37 °C 
with 5% CO2. Following this, MTS assay reagent was added for 4 h and the 
absorbance measured at 490 nm using the Polarstar Optima microplate 
reader (BMG Labtech). Concentrations tested: AuNP-PEG-5.4-Jac and 
AuNP-PEG-5.4 in MCF-7 cells (18.2 nM, 1.82 nM, 0.182 nM). AuNP-PEG-
4.5-Jac in MCF-7, HCT116 and HL60 cell lines (19.4 nM, 1.94 nM, 0.194 
nM). 
Fluorescence Microscopy Imaging 
MCF-7 human breast cancer cells were seeded in clear 96- well plates at 5 x 
103 cells/well and treated with a 16.4 nM stock of AuNP-PEG-5.3-
Jac(FITC) and incubated for 4 h at 37 °C. The cells were subsequently 
washed three times with PBS and fluorescence microscopy was used to 
examine cells and pictures taken with an inverted Leica DMII fluorescence 
















6.1 Fmoc-DSA-OH synthesis 
As a follow on from the work presented in Chapter 2 of this thesis, future 
work should aim to establish a synthetic method which would allow for the 
simple and efficient formation of the central indole unit which is found in all 
compounds in the CC-1065 and duocarmycin family. At present, it is the 
cyclisation step to form this central indole unit which is the bottle neck of the 
present synthesis leading to erratic and often low yields. Whilst a variety of 
conditions were attempted in order to achieve an improved reaction in this 
regard, we were unable to establish an ideal set of reaction conditions for this 
transformation. Of course, should further conditions beyond the presently 
used TBAF catalysed reaction be unsuccessful in forming the central indole 
ring efficiently starting from compound 2.4, it may be that further reaction 
strategies to from the central indole unit are investigated.   
Unfortunately, due to time constraints, the provision of a new protecting 
group strategy for the protection of the phenolic oxygen on the Fmoc-DSA-
OH unit was not established. The optimisation of such a protecting group 
strategy in is sure to improve the efficiency of the use of the unit in solid 
phase peptide chemistry. As such, future work should aim to investigate 
further protecting groups which may be suitable in this position. Such a 
protecting group should be stable to conditions used in the synthesis of the 
duocarmycin unit as well as to conditions employed in the building of peptide 
chains, whilst being labile to conditions used to remove peptides from solid 
phase resins. A recent development in the area of solid phase peptide 
synthesis is the development of resins which can be cleaved under UV-light 
conditions. As such, an orthogonal protecting group in this regard could be 
investigated for the Fmoc-DSA-OH unit and may provide an enhancement to 
its utility is SPPS. 
A further, more extensive expansion to this work would be to investigate the 
use of the artificial amino acid strategy used in this work, i.e. the 
incorporation of Fmoc and carboxylic acid functionality, with other members 
of the CC-1065 and duocarmycin family. With yatakemycin demonstrating 
impressive potencies in recent studies, and a structure similar to that of 
duocarmycin SA, this compound represents an attractive starting point for 
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this area of work. Should an analogue of this kind be successfully 
synthesised, solid phase peptide synthesis will provide an ideal strategy for 
the development of further analogues which may display improved biological 
activity.  
6.2 Duocarmycin Conjugation to Jacalin 
Within chapter 3 of this thesis, an investigation into the coupling of a variety 
of duocarmycin-peptide analogues to jacalin was investigated. The 
investigations within this chapter of work led to a variety of conjugation 
chemistries being attempted. These included EDC/NHS chemistry, thiol 
maleimide chemistry and azide-alkyne click chemistry. Upon analysis of the 
conjugates synthesised using these methodologies it became apparent that all 
appeared to successfully result in the formation of a conjugate with the 
jacalin structure. These conjugates was analysed through both LCMS and 
MALDI mass spectrometry. Whilst LCMS was able to give conclusive 
evidence of conjugation occurring to the jacalin structure, the MALDI mass 
spectrometry data presented in this chapter was only capable of providing a 
qualitative indication of whether the mass of the α-subunit of jacalin was 
increasing. As such, it is imperative that for the work in this chapter to take 
on greater meaning, the mass analysis is repeated with more reliable 
equipment. Ideally, a more consistent method of analysing the conjugates 
using LCMS would be established in order to provide a clearer understanding 
of the number of drug additions occurring to jacalin during the conjugation 
reaction. Should such an understanding be obtained, it may then be possible 
to control the number of duocarmycin units becoming conjugated to the 
jacalin in order to give ideal drug-protein ratios.  
The LCMS analysis of jacalin in this chapter also identified a series of 162 Da 
additions to the surface of jacalin. Such additions can be attributed to the 
addition of hexose moieties to the jacalin structure. With jacalin showing 
affinities for hexose compounds such as galactose this was not entirely 
unexpected. However, the binding of such hexose molecules and the 
consequent potential inhibition of the binding of jacalin to the T-antigen will 
need to be investigated should this work be continued further. This will be 
269 
 
imperative to understand whether the jacalin conjugation will be a successful 
strategy for delivering a duocarmycin warhead to cancer tissue specifically. 
As a further expansion of the work presented here, it would also be desirable 
to understand the precipitation of the jacalin from the buffer upon 
conjugation. Such a phenomenon was observed during all of the conjugation 
chemistries presented within chapter 3 of this thesis. This precipitation was 
detrimental to the analysis of the resulting conjugates and as such, 
investigations to try and overcome the precipitation will be required to 
further this piece of work. Whilst some experiments were performed in order 
to adapt the concentrations of ligand and protein used in the conjugation 
reactions, a more thorough investigation of this type is likely to aid in 
overcoming this issue. Further, an investigation into the conjugation of more 
hydrophilic duocarmycin analogues may also aid in ensuring that jacalin 
remains in solution even after conjugation.   
Finally, should the above mentioned investigations aid in the provision of a 
jacalin conjugate suitable for biological analysis, it will be important to 
thoroughly investigate the interaction of this conjugate with the T-antigen 
surface on a variety of cell lines. Of course, in order to fully understand the 
behaviour of the conjugate, it will also be necessary to provide investigations 
into the interaction of the conjugate with cell lines which do not present the 
T-antigen on their surface. Such investigations will give a more complete 
picture on whether the duocarmycin warhead can be delivered to T-antigen 
expressing cancer cells specifically as opposed to healthy cells. As mentioned 
throughout this body of work, this may aid in providing a platform for the 
duocarmycin family of compounds to realise their clinical potential.  
6.3 Duocarmycin-peptide conjugates 
The work provided in chapter 4 of this thesis focused on the conjugation of a 
duocarmycin warhead to a peptide sequence which had been shown by other 
groups to specifically and selectively bind to the T-antigen.  
The T-antigen binding peptide was successfully synthesised using solid phase 
peptide chemistry and a variety of strategies were investigated to incorporate 
the duocarmycin warhead. Of these strategies, the most successful was 
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shown to be the incorporation of a cathepsin B cleavage sequence in between 
the duocarmycin warhead and the T-antigen binding peptide. The cleavage 
sequence utilised was a Cit-Val linker including a PABA spacer. The synthesis 
and subsequent testing of the duocarmycin-PABA-Cit-Val peptide 
demonstrated impressive biological potency, especially the duocarmycin-
PABA cleavage product (4.7 in chapter 4). The biological activity obtained in 
various cells lines provided promise that the conjugate formed in chapter 4 
would demonstrate activity within T-antigen expressing cell lines. Indeed, 
when the entire Peptide-drug conjugate construct was tested in vitro, IC50s 
in the low micromolar range were obtained which provides an ideal spring 
board for a continuation of this work. It is proposed that this potency could 
be improved through the incorporation of further duocarmycin warhead 
units into the peptide sequence. Due to the amino acid-like structure of the 
Fmoc-DSA-OH unit, the incorporation of further units into the peptide 
sequence should not present a significant hurdle. Furthermore, in other work 
conducted but not presented as part of this thesis, the additions of further 
duocarmycin alkylating subunits into peptide sequences resulted in an 
improvement to the biological potency of the resulting compounds.  
Whilst the work presented in chapter 4 provides a solid platform for further 
work into this area, it is acknowledged that a more thorough understanding 
of the interaction of the T-antigen binding peptide with the T-antigen is 
required. Specifically, whilst fluorescence studies allowed the postulation 
that the T-antigen binding peptide was able to bind and subsequently enter 
the T-antigen expressing cells lines used within this work, a more thorough 
analysis of this interaction must be established. Of particular importance 
here is providing data for all the relevant controls for the peptide conjugate 
and their interaction with the T-antigen expressing cells lines. Furthermore, 
future investigations will also be required to investigate whether 
duocarmycin incorporation into the peptide sequence has an effect on the 
interaction of the peptide with the T-antigen. For example, it will need to be 
established whether the duocarmycin unit inhibits the binding of the peptide 
to the T-antigen in any way. This could significantly impact the selectivity of 
the synthesised peptide. Additionally, further, more detailed fluorescence 
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microscopy studies will aid in providing more details on the behaviour of the 
peptide conjugates in terms of their uptake within various cell lines.  
In order to gain an understanding of the above considerations, further work 
could look into establishing a comparative data set incorporating a scrambled 
peptide sequence, wherein the proposed T-antigen binding region of the 
peptide is scrambled. The synthesis of such a conjugate and investigations 
into its resulting biological activity will certainly help in gaining an 
understanding of the selectivity of the peptide-conjugate synthesised in this 
work for T-antigen expressing cell lines. Additionally, since iodination of the 
tryptophan residues of the T-antigen binding peptide has previously been 
shown to be detrimental to the binding of the peptide to the T-antigen, 
experiments of this kind may also be helpful for investigating the activity of 
the peptide-duocarmycin conjugates. Furthermore, experiments could be 
designed which establish a comparison between the interaction of jacalin, the 
T-antigen binding peptide and the peptide–conjugates synthesised in this 
body of work with the T-antigen. It is possible that competitive binding 
studies in this regard could aid in establishing such a relationship. 
Finally, and as mentioned above in regards to the jacalin-duocarmycin 
conjugates, it is imperative that the interaction of the duocarmycin-peptide 
conjugates synthesised in chapter 4 with non-T-antigen expressing cells lines 
is established. Such data would provide a necessary insight into the 
underlying aim of this body of work, namely, how the selective delivery of a 
duocarmycin warhead to T-antigen expressing cancer cells rather than 
healthy cells can be achieved.  
6.4 Duocarmycin based Gold Nanoparticles  
In chapter 5 of this thesis, the synthesis of a gold nanoparticle functionalised 
with a duocarmycin warhead and a jacalin based directing moiety was 
detailed.  
The successful synthesis of a 4 nm gold nanoparticle with a duocarmycin-
based peptide comprising a cleavable sequence was presented. This 
nanoparticle construct was then successfully decorated with jacalin in an 
attempt to achieve targeted delivery of the nanoparticle. 
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Whilst best efforts were made to fully characterise the gold nanoparticle 
construct, one of the inherent issues associated with gold nanoparticle 
systems is trying to obtain a clear picture of how exactly the gold 
nanoparticle surface is functionalised. In this regard, should future work be 
pursued relating to the work presented in chapter 5, a thorough investigation 
into the functionalisation of the gold nanoparticle surface should be made. Of 
specific interest would be obtaining an understanding of the number of 
duocarmycin units present on the surface of the gold nanoparticle. In a 
similar manner, the number of jacalin units per gold nanoparticle would also 
be of interest. It is possible that elemental analysis of the gold nanoparticle 
constructs may be useful for obtaining this information. Previous work in the 
laboratory has shown that that this technique is useful in obtaining such 
information. By deciphering this information, a greater understanding and 
more thorough interpretation of the biological data collected as part of the 
work detailed in chapter 5 could be obtained. For example, the lack of activity 
in the gold nanoparticle could be a direct result of a lack of duocarmycin 
warheads functionalising the gold nanoparticle core. Alternatively, it could 
also be that over-functionalisation with jacalin may affect the activity of the 
resulting nanoparticle construct.  
Further to the above, a greater understanding of the interaction of the gold 
nanoparticle with the T-antigen expressed on certain cells would be ideal. 
Whilst fluorescence microscopy studies demonstrated the potential uptake of 
the gold nanoparticles into cell lines expressing the T-antigen, these studies 
need to be repeated with further controls to provide real evidence of this 
interaction. Whilst similar 4 nm gold nanoparticles functionalised with 
jacalin have been previously synthesised and shown to specifically and 
selectively target T-antigen expressing cell lines, it would be ideal to 
understand how this specific interaction may be affected when a 
duocarmycin warhead is introduced. This is since previous work utilised 
other non-duocarmycin based drug molecules. This interaction may be 
further studied through the use of confocal microscopy. Such methods have 
been fundamental in studying the distribution of gold nanoparticles within 
cells and would be of use for future work relating to this area.  
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As a further area of future work, it will be necessary to conduct experiments 
to investigate how the gold nanoparticle constructs synthesised in this work 
interact with a cathepsin B cleavage enzyme. This is since a cathepsin B 
cleavage sequence was employed in attempt to ensure detachment of the 
duocarmycin warhead from the nanoparticle upon internalisation into the 
cell. Specifically, an understanding of whether the duocarmycin unit can be 
successfully released from the gold nanoparticle by cathepsin B may aid in 
providing an explanation for the lack of activity in the gold nanoparticles 
synthesised in this work. This is since it has been postulated that the reason 
for a lack of activity in the synthesised gold nanoparticles may be due to the 
duocarmycin warhead not being able to reach the nucleus to exert its 
biological activity. In this regard, it is possible that the PEG chains used to 
functionalise the nanoparticle provide a barrier for the cathepsin B to 
interact with the Cit-Val sequence provided on the duocarmycin-peptide 
units. Should this be the case, different length PEG chains may provide an 
area of investigation for overcoming this issue. In particular, longer PEG 
chains may provide more space for the cathepsin B to contact the cleavage 
sequence.  
Finally, and as discussed in relation to the work presented in chapter 4, in 
order to gain a real understanding of the specificity of the gold nanoparticles 
synthesised, studies with cell lines which do not express the T-antigen will be 
fundamental. The results in these studies could be compared to those with 
cell lines which do express the T-antigen. It is hoped that the cytotoxicities of 
the nanoparticles within the cell lines which express the T-antigen will be 
greater than those which do not. This would indicate that the 
nanoparticle/jacalin constructs successfully aid in delivering the 
duocarmycin warhead to specific target sites. This is of course fundamental 
to the work in this thesis where the targeted delivery of duocarmycin to T-
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